{"PMC7306267": [["IntroductionIn December 2019, the first patients presenting with a pneumonia of unknown origin were reported in the Wuhan province of the People\u2019s Republic of China.", [["pneumonia", "DISEASE", 67, 76], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["a pneumonia", "PROBLEM", 65, 76], ["pneumonia", "OBSERVATION", 67, 76]]], ["Over the subsequent months, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe, resulting in the COVID-19 pandemic.", [["acute respiratory syndrome coronavirus", "DISEASE", 39, 77], ["SARS-CoV-2", "CHEMICAL", 81, 91], ["SARS-CoV-2", "ORGANISM", 81, 91], ["globe", "ORGAN", 123, 128], ["severe acute respiratory syndrome coronavirus", "SPECIES", 32, 77], ["SARS-CoV-2", "SPECIES", 81, 91], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 28, 77], ["SARS-CoV", "TEST", 81, 89], ["the COVID", "TEST", 143, 152], ["pandemic", "PROBLEM", 156, 164], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome coronavirus", "OBSERVATION", 45, 77], ["globe", "ANATOMY", 123, 128]]], ["As of 23 April 2020, there have been over 2.4 million confirmed cases worldwide in over 213 countries, areas or territories, resulting in 169 000 deaths.1", [["deaths", "DISEASE", 146, 152]]]], "67f9492971a30f560668065cf1ca704694b2757a": [["The conference was on track to be a great success: the week before the start, we had an outstanding lineup of speakers and a record number of registrations for both the symposium and ASM.", [["ASM", "CELL", 183, 186], ["ASM", "ANATOMY", 183, 186]]], ["The symposium was scheduled to have 17 speakers, and ASM would have 72 speakers and 15 moderators.Storm CloudsAs the conference approached, we followed with concern as the first cases of coronavirus disease 2019 (COVID-19) emerged in the USA (January 20) and New York (March 1) [1] [2] [3] .", [["coronavirus disease", "DISEASE", 187, 206], ["coronavirus", "ORGANISM", 187, 198], ["coronavirus disease", "PROBLEM", 187, 206], ["COVID", "TEST", 213, 218], ["coronavirus disease", "OBSERVATION", 187, 206]]], ["On March 3, we received notification from our first (and keynote) speaker that his institution would not allow him to attend in person.", [["person", "SPECIES", 128, 134]]], ["By the end of that day, 50% of speakers and 25% of registrants had notified us they could not attend in person.", [["person", "SPECIES", 104, 110]]], ["By the morning of March 11 (the day before the start of the conference), 90% of speakers and over 50% of conference registrants had notified us that they were unable to attend in person.Storm CloudsIn the week prior to the conference, we considered whether to cancel the live portion of the meeting.", [["person", "SPECIES", 179, 185]]], ["As COVID-19 spread, we looked for guidance from city officials and peer organizations.", [["19 spread", "OBSERVATION_MODIFIER", 9, 18]]], ["Recent conferences were known to be a potential source for disease spread; a Biogen corporate meeting had just been linked to approximately 80 coronavirus cases [4, 5] .", [["coronavirus", "DISEASE", 143, 154], ["disease spread", "PROBLEM", 59, 73]]], ["Other scientific groups had canceled live meetings that week, including a large HIV conference in Boston and an allergy conference in Philadelphia [6, 7] .", [["allergy", "DISEASE", 112, 119]]], ["However, NYC authorities had not yet announced any restrictions, businesses and schools were operating normally, and the large Council of Residency Directors in Emergency Medicine (CORD) meeting proceeded earlier that week in NYC.", [["CORD", "ANATOMY", 181, 185]]], ["There were several hundred known cases in NYC at that time, but no one yet fully appreciated the severity of COVID-19 in NYC [8] .", [["COVID-19", "CHEMICAL", 109, 117], ["COVID", "TEST", 109, 114]]], ["That afternoon during the symposium, the National Collegiate Athletic Association (NCAA) canceled its men's basketball tournament, and Broadway theaters announced they would close their doors that evening [2, 10] .", [["men", "ORGANISM", 102, 105], ["men", "SPECIES", 102, 105]]], ["These decisions by large national organizations signaled a far more serious situation was developing.Storm CloudsThe Board of Directors of ACMT convened an emergency meeting and concluded that the live portion of the meeting must be canceled to protect the health of attendees and show solidarity with public health efforts.", [["large", "OBSERVATION_MODIFIER", 19, 24]]], ["ACMT upgraded its membership with WebEx to accommodate more viewers per session, and the sessions were set up to be recorded.", [["ACMT", "PROTEIN", 0, 4]]], ["Moving online also posed scheduling challenges.", [["scheduling challenges", "TREATMENT", 25, 46]]], ["Simultaneous sessions had to be canceled or rescheduled, and multiple moderators had to be changed.Transition to VirtualThe time difference between the eastern and western USA also presented a dilemma.", [["dilemma", "OBSERVATION", 193, 200]]], ["We had no major technical issues, and all speakers successfully presented remotely.", [["no", "UNCERTAINTY", 7, 9], ["major", "OBSERVATION_MODIFIER", 10, 15]]], ["We always had at least one staff member on hand managing the technical aspects of the meeting.Transition to VirtualThe main areas of potential improvement that arose were related to the late cancelation of the meeting and the loss of the ability to network and see friends in person.", [["hand", "ANATOMY", 43, 47], ["hand", "ORGANISM_SUBDIVISION", 43, 47], ["person", "SPECIES", 276, 282], ["main", "OBSERVATION_MODIFIER", 119, 123], ["areas", "OBSERVATION_MODIFIER", 124, 129], ["potential", "OBSERVATION_MODIFIER", 133, 142], ["improvement", "OBSERVATION", 143, 154]]], ["In hindsight, cancelation was the correct decision.Transition to VirtualAlthough spread of COVID-19 occurred at other medical conferences in NYC that week, we did not receive any reports of the infection among individuals who had traveled to the city for our conference [11] .Potential Future DirectionsThe COVID-19 pandemic has caused nearly every industry to turn to virtual platforms for their day-to-day functioning.", [["infection", "DISEASE", 194, 203], ["COVID-19", "DNA", 91, 99], ["the infection", "PROBLEM", 190, 203], ["The COVID", "TREATMENT", 303, 312]]], ["As of publication of this commentary, multiple medical organizations have decided to transition their meetings to being fully virtual this fall including ACEP 2020, ACOEP 2020, NACCT 2020, ACMT Board Review Course, American Academy of Neurology, American Society of Regional Anesthesia and Pain Medicine, American Society of Clinical Oncology, and the American College of Surgeons Clinical Congress.Potential Future DirectionsWe do not anticipate that online medical meetings will replace in-person meetings when the pandemic subsides.", [["Pain", "DISEASE", 290, 294], ["Regional Anesthesia", "TREATMENT", 266, 285], ["Pain Medicine", "TREATMENT", 290, 303]]], ["People travel to meetings to take advantage of opportunities for tourism and reconnect with old friends and colleagues.", [["People", "SPECIES", 0, 6]]], ["For registrants, a virtual option is more affordable, as most of the costs of a live meeting are related to travel and lodging.Potential Future DirectionsHow to Optimize a Hybrid/Online Course Even Further?Potential Future DirectionsConsider time zone differences when scheduling sessions and speakers.", [["a virtual option", "TREATMENT", 17, 33], ["a Hybrid/Online Course", "TREATMENT", 170, 192]]], ["Consider a shorter conference day: the audience may not tolerate 8 hours in front of a screen.", [["a screen", "TEST", 85, 93]]], ["To substitute for the loss of interactivity from a speaker in the same room, the hybrid course may need to use more polling and chat functions to engage the audience.Potential Future DirectionsOur conference was rated as excellent by the audience.", [["the loss of interactivity", "PROBLEM", 18, 43]]], ["This suggests that behind the fa\u00e7ade of technology, the human aspect of the online meeting is still the most important for success.", [["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61]]], ["For planners, there is no shortcut in doing the work of finding engaging speakers who are interesting to your audience.", [["no", "UNCERTAINTY", 23, 25]]]], "34a942268ef93e2776d5074b3fb75879858712b6": [["INTRODUCTIONMiddle East respiratory syndrome (MERS) is a lethal respiratory disease caused by MERS-coronavirus (MERS-CoV) and occurs mostly in the Middle East, initially by camel-to-human transmission, and then by human-to-human transmission.", [["respiratory", "ANATOMY", 64, 75], ["INTRODUCTIONMiddle East respiratory syndrome", "DISEASE", 0, 44], ["MERS", "DISEASE", 46, 50], ["respiratory disease", "DISEASE", 64, 83], ["MERS-coronavirus", "DISEASE", 94, 110], ["MERS-coronavirus", "ORGANISM", 94, 110], ["MERS-CoV", "ORGANISM", 112, 120], ["human", "ORGANISM", 182, 187], ["human", "ORGANISM", 214, 219], ["human", "ORGANISM", 223, 228], ["MERS-coronavirus", "SPECIES", 94, 110], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 223, 228], ["MERS-coronavirus", "SPECIES", 94, 110], ["MERS-CoV", "SPECIES", 112, 120], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 223, 228], ["East respiratory syndrome", "PROBLEM", 19, 44], ["a lethal respiratory disease", "PROBLEM", 55, 83], ["MERS", "PROBLEM", 94, 98], ["coronavirus", "PROBLEM", 99, 110], ["respiratory syndrome", "OBSERVATION", 24, 44], ["respiratory disease", "OBSERVATION", 64, 83], ["Middle", "ANATOMY_MODIFIER", 147, 153]]], ["However, the disease was spread to other continents, probably by an index case, with subsequent pandemic outbreaks through human-to-human transmission through droplets and contact.", [["human", "ORGANISM", 123, 128], ["human", "ORGANISM", 132, 137], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 132, 137], ["the disease", "PROBLEM", 9, 20], ["disease", "OBSERVATION", 13, 20]]], ["During these respiratory viral outbreaks, pregnant women can be expected as highly vulnerable candidates for infection (1) .INTRODUCTIONA MERS outbreak occurred in Korea in 2015 with 186 infections, including 38 deaths (2, 3) .", [["respiratory viral outbreaks", "DISEASE", 13, 40], ["infection", "DISEASE", 109, 118], ["infections", "DISEASE", 187, 197], ["deaths", "DISEASE", 212, 218], ["women", "ORGANISM", 51, 56], ["women", "SPECIES", 51, 56], ["these respiratory viral outbreaks", "PROBLEM", 7, 40], ["infection", "PROBLEM", 109, 118], ["respiratory", "ANATOMY", 13, 24], ["viral outbreaks", "OBSERVATION", 25, 40], ["infection", "OBSERVATION", 109, 118]]], ["We experienced a case of a Korean pregnant woman who was confirmed for a MERS-CoV infection via a polymerase chain reaction (PCR) test.", [["MERS-CoV infection", "DISEASE", 73, 91], ["woman", "ORGANISM", 43, 48], ["MERS-CoV", "ORGANISM", 73, 81], ["woman", "SPECIES", 43, 48], ["MERS-CoV", "SPECIES", 73, 81], ["a MERS", "PROBLEM", 71, 77], ["CoV infection", "PROBLEM", 78, 91], ["a polymerase chain reaction", "PROBLEM", 96, 123], ["PCR) test", "TEST", 125, 134], ["infection", "OBSERVATION", 82, 91]]], ["This is the first case of a MERS-positive pregnancy reported outside the Middle East and is also the first case of having been exposed and confirmed on 3rd trimester of pregnancy with full-recovery and successful full-term delivery.CASE DESCRIPTIONOn May 27, 2015, the patient's mother was exposed to the 14th MERS patient, had a fever starting from June 3 and was diagnosed with MERS on June 7.", [["fever", "DISEASE", 330, 335], ["MERS", "DISEASE", 380, 384], ["patient", "ORGANISM", 269, 276], ["mother", "ORGANISM", 279, 285], ["patient", "ORGANISM", 315, 322], ["patient", "SPECIES", 269, 276], ["patient", "SPECIES", 315, 322], ["a MERS-positive pregnancy", "PROBLEM", 26, 51], ["successful full-term delivery", "TREATMENT", 202, 231], ["a fever", "PROBLEM", 328, 335], ["fever", "OBSERVATION", 330, 335]]], ["While febrile, she had been in close contact with her daughter, a 39-year-old pregnant woman (gravida 2 para 1).", [["febrile", "DISEASE", 6, 13], ["woman", "ORGANISM", 87, 92], ["woman", "SPECIES", 87, 92], ["febrile", "PROBLEM", 6, 13]]], ["On June 8 (35 weeks and 4 days of gestational age [GA]), this pregnant woman visited the emergency room complaining of mild myalgia.", [["myalgia", "DISEASE", 124, 131], ["woman", "ORGANISM", 71, 76], ["woman", "SPECIES", 71, 76], ["mild myalgia", "PROBLEM", 119, 131], ["mild", "OBSERVATION_MODIFIER", 119, 123], ["myalgia", "OBSERVATION", 124, 131]]], ["Based on this contact history with a MERS patient and her symptoms, a MERS-CoV PCR test was performed and the result was found to be positive on June 9.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["her symptoms", "PROBLEM", 54, 66], ["a MERS-CoV PCR test", "TEST", 68, 87]]], ["Starting from June 9, the patient developed dyspnea and sputum production.", [["sputum", "ANATOMY", 56, 62], ["dyspnea", "DISEASE", 44, 51], ["patient", "ORGANISM", 26, 33], ["sputum", "ORGANISM_SUBSTANCE", 56, 62], ["patient", "SPECIES", 26, 33], ["dyspnea", "PROBLEM", 44, 51], ["sputum production", "PROBLEM", 56, 73], ["dyspnea", "OBSERVATION", 44, 51], ["sputum", "OBSERVATION", 56, 62]]], ["Although chest auscultation was normal, the oxygen saturation (SpO2) was 95% in room air and chest radiography showed diffuse opacity in the left lower lung area compared to a previously obtained radiographic image.", [["chest", "ANATOMY", 9, 14], ["left lower lung area", "ANATOMY", 141, 161], ["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["chest", "ORGAN", 9, 14], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["lung", "ORGAN", 152, 156], ["chest auscultation", "TEST", 9, 27], ["the oxygen saturation", "TEST", 40, 61], ["SpO2", "TEST", 63, 67], ["chest radiography", "TEST", 93, 110], ["diffuse opacity in the left lower lung area", "PROBLEM", 118, 161], ["a previously obtained radiographic image", "TEST", 174, 214], ["chest", "ANATOMY", 9, 14], ["normal", "OBSERVATION", 32, 38], ["chest", "ANATOMY", 93, 98], ["diffuse", "OBSERVATION_MODIFIER", 118, 125], ["opacity", "OBSERVATION", 126, 133], ["left", "ANATOMY_MODIFIER", 141, 145], ["lower", "ANATOMY_MODIFIER", 146, 151], ["lung", "ANATOMY", 152, 156], ["area", "ANATOMY_MODIFIER", 157, 161]]], ["The laboratory findings included a leukocyte count of 5,570/mm 3 (normal range 4,000-10,000/mm 3 ), with a differential of 71.4% segmented neutrophils, 20.5% lymphocytes, and 7.9% monocytes; and C-reactive protein level of 1.95 mg/ dL (normal range 0-0.3 mg/dL).", [["leukocyte", "ANATOMY", 35, 44], ["neutrophils", "ANATOMY", 139, 150], ["lymphocytes", "ANATOMY", 158, 169], ["monocytes", "ANATOMY", 180, 189], ["leukocyte", "CELL", 35, 44], ["neutrophils", "CELL", 139, 150], ["lymphocytes", "CELL", 158, 169], ["monocytes", "CELL", 180, 189], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 195, 213], ["neutrophils", "CELL_TYPE", 139, 150], ["lymphocytes", "CELL_TYPE", 158, 169], ["monocytes", "CELL_TYPE", 180, 189], ["C-reactive protein", "PROTEIN", 195, 213], ["a leukocyte count", "TEST", 33, 50], ["a differential", "TEST", 105, 119], ["segmented neutrophils", "TEST", 129, 150], ["lymphocytes", "TEST", 158, 169], ["monocytes", "TEST", 180, 189], ["C-reactive protein level", "TEST", 195, 219]]], ["She was given supplemental oxygen for hypoxia and conservative treatment, with hydration and pain control.", [["oxygen", "CHEMICAL", 27, 33], ["hypoxia", "DISEASE", 38, 45], ["pain", "DISEASE", 93, 97], ["oxygen", "CHEMICAL", 27, 33], ["oxygen", "SIMPLE_CHEMICAL", 27, 33], ["supplemental oxygen", "TREATMENT", 14, 33], ["hypoxia", "PROBLEM", 38, 45], ["conservative treatment", "TREATMENT", 50, 72], ["hydration", "TREATMENT", 79, 88], ["pain control", "TREATMENT", 93, 105]]], ["The antiviral agents used in other severe MERS-CoV patients were not used in this patient, because her symptoms and laboratory findings were not severe.", [["MERS-CoV", "ORGANISM", 42, 50], ["patients", "ORGANISM", 51, 59], ["patient", "ORGANISM", 82, 89], ["patients", "SPECIES", 51, 59], ["patient", "SPECIES", 82, 89], ["MERS-CoV", "SPECIES", 42, 50], ["The antiviral agents", "TREATMENT", 0, 20], ["CoV patients", "TREATMENT", 47, 59], ["her symptoms", "PROBLEM", 99, 111], ["laboratory findings", "TEST", 116, 135]]], ["Also, there was no evidence of any potential harm to the fetus and pregnant woman related to those drugs.", [["fetus", "ANATOMY", 57, 62], ["fetus", "ORGANISM", 57, 62], ["woman", "ORGANISM", 76, 81], ["woman", "SPECIES", 76, 81], ["those drugs", "TREATMENT", 93, 104], ["no evidence of", "UNCERTAINTY", 16, 30], ["fetus", "ANATOMY", 57, 62]]], ["After several days, her dyspnea and myalgia improved.", [["dyspnea", "DISEASE", 24, 31], ["myalgia", "DISEASE", 36, 43], ["her dyspnea", "PROBLEM", 20, 31], ["myalgia", "PROBLEM", 36, 43], ["dyspnea", "OBSERVATION", 24, 31], ["myalgia", "OBSERVATION", 36, 43]]], ["The SpO2 was 98% in room air and chest radiography showed interval improvement.", [["The SpO2", "TEST", 0, 8], ["chest radiography", "TEST", 33, 50], ["chest", "ANATOMY", 33, 38], ["improvement", "OBSERVATION_MODIFIER", 67, 78]]], ["On June 19 and 21, MERS-CoV PCR was performed and the results were negative.", [["MERS-CoV PCR", "DNA", 19, 31], ["MERS-CoV PCR", "TEST", 19, 31], ["negative", "OBSERVATION", 67, 75]]], ["She had no symptoms related to MERS.CASE REPORTOn June 23, the patient manifested abrupt vaginal bleeding with rupture of membranes.", [["vaginal", "ANATOMY", 89, 96], ["membranes", "ANATOMY", 122, 131], ["MERS", "DISEASE", 31, 35], ["vaginal bleeding", "DISEASE", 89, 105], ["patient", "ORGANISM", 63, 70], ["vaginal", "ORGANISM_SUBDIVISION", 89, 96], ["membranes", "CELLULAR_COMPONENT", 122, 131], ["patient", "SPECIES", 63, 70], ["symptoms", "PROBLEM", 11, 19], ["MERS", "PROBLEM", 31, 35], ["abrupt vaginal bleeding", "PROBLEM", 82, 105], ["rupture of membranes", "PROBLEM", 111, 131], ["no", "UNCERTAINTY", 8, 10], ["abrupt", "OBSERVATION_MODIFIER", 82, 88], ["vaginal", "ANATOMY", 89, 96], ["bleeding", "OBSERVATION", 97, 105], ["rupture", "OBSERVATION", 111, 118]]], ["A fist-sized blood clot was found through speculum examination and she had abdominal pain.", [["blood clot", "ANATOMY", 13, 23], ["abdominal", "ANATOMY", 75, 84], ["abdominal pain", "DISEASE", 75, 89], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["clot", "ORGANISM_SUBSTANCE", 19, 23], ["abdominal", "ORGANISM_SUBDIVISION", 75, 84], ["A fist-sized blood clot", "PROBLEM", 0, 23], ["speculum examination", "TEST", 42, 62], ["abdominal pain", "PROBLEM", 75, 89], ["fist", "OBSERVATION_MODIFIER", 2, 6], ["sized", "OBSERVATION_MODIFIER", 7, 12], ["blood", "ANATOMY", 13, 18], ["clot", "OBSERVATION", 19, 23], ["abdominal", "ANATOMY", 75, 84], ["pain", "OBSERVATION", 85, 89]]], ["Fetal cardiotocography showed no deceleration, but a variability of fetal heart rate changed from moderate to minimal.", [["Fetal", "ANATOMY", 0, 5], ["fetal heart", "ANATOMY", 68, 79], ["Fetal", "ORGAN", 0, 5], ["fetal", "MULTI-TISSUE_STRUCTURE", 68, 73], ["heart", "ORGAN", 74, 79], ["Fetal cardiotocography", "TEST", 0, 22], ["deceleration", "PROBLEM", 33, 45], ["fetal heart rate", "TEST", 68, 84], ["no", "UNCERTAINTY", 30, 32], ["deceleration", "OBSERVATION", 33, 45], ["heart", "ANATOMY", 74, 79], ["moderate", "OBSERVATION_MODIFIER", 98, 106], ["minimal", "OBSERVATION_MODIFIER", 110, 117]]], ["With an impression of placental abruption, her obstetrical team decided on emergent cesarean delivery.", [["placental", "ANATOMY", 22, 31], ["placental abruption", "DISEASE", 22, 41], ["placental abruption", "MULTI-TISSUE_STRUCTURE", 22, 41], ["placental abruption", "PROBLEM", 22, 41], ["emergent cesarean delivery", "TREATMENT", 75, 101], ["placental", "ANATOMY", 22, 31], ["abruption", "OBSERVATION", 32, 41]]], ["A 3,140 g male newborn was delivered at 37 weeks and 5 days of gestation.", [["newborn", "ORGANISM", 15, 22]]], ["Apgar scores at 1 and 5 minutes were 9 and 9, respectively.", [["Apgar scores", "TEST", 0, 12]]], ["As expected, about 10% placental abruption was found (Fig. 1) .", [["placental", "ANATOMY", 23, 32], ["placental abruption", "DISEASE", 23, 42], ["placental", "ORGAN", 23, 32], ["10% placental abruption", "PROBLEM", 19, 42], ["abruption", "OBSERVATION", 33, 42]]], ["After delivery, the baby was immediately moved to the airborne infection isolation room (AIIR) and received an initial care with all health care personnel (HCP) completely protected according to the Centers for Disease Control and Prevention (CDC) guidelines (4).", [["infection", "DISEASE", 63, 72], ["baby", "ORGANISM", 20, 24], ["delivery", "TREATMENT", 6, 14], ["Disease Control", "TREATMENT", 211, 226]]], ["MERS-CoV PCR tests and antibody tests were performed with umbilical cord blood and placenta, and all results were negative.CASE REPORTA systematic testing procedure for coronavirus infection, including chest radiograph and serial reverse transcription (RT)-PCR assays with peripheral blood and nasopharyngeal swab, did not demonstrate the presence of MERS-CoV in the newborn.", [["umbilical cord blood", "ANATOMY", 58, 78], ["placenta", "ANATOMY", 83, 91], ["peripheral blood", "ANATOMY", 273, 289], ["nasopharyngeal swab", "ANATOMY", 294, 313], ["coronavirus infection", "DISEASE", 169, 190], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["cord blood", "ORGANISM_SUBSTANCE", 68, 78], ["placenta", "ORGAN", 83, 91], ["coronavirus", "ORGANISM", 169, 180], ["peripheral blood", "ORGANISM_SUBSTANCE", 273, 289], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 294, 313], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 351, 359], ["coronavirus", "SPECIES", 169, 180], ["MERS-CoV", "SPECIES", 351, 359], ["CoV PCR tests", "TEST", 5, 18], ["antibody tests", "TEST", 23, 37], ["umbilical cord blood", "TEST", 58, 78], ["systematic testing procedure", "TREATMENT", 136, 164], ["coronavirus infection", "PROBLEM", 169, 190], ["chest radiograph", "TEST", 202, 218], ["serial reverse transcription", "TEST", 223, 251], ["PCR assays", "TEST", 257, 267], ["peripheral blood and nasopharyngeal swab", "TEST", 273, 313], ["umbilical cord", "ANATOMY", 58, 72], ["placenta", "ANATOMY", 83, 91], ["negative", "OBSERVATION", 114, 122], ["chest", "ANATOMY", 202, 207], ["nasopharyngeal", "ANATOMY", 294, 308], ["MERS", "OBSERVATION", 351, 355], ["CoV", "OBSERVATION", 356, 359], ["newborn", "ANATOMY", 367, 374]]], ["MERS-CoV antibody tests were performed with mother and newborn sera on June 16 and June 28, respectively (5).", [["sera", "ANATOMY", 63, 67], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["sera", "ORGANISM_SUBSTANCE", 63, 67], ["MERS-CoV antibody", "PROTEIN", 0, 17], ["CoV antibody tests", "TEST", 5, 23]]], ["In the mother's serum, immunoglobulin G (IgG) was detected, albeit weakly, (0.302) via enzyme-linked immunosorbent assay (ELISA; Euroimmun AG, Luebeck, Germany), and via indirect immunofluorescence test (IIFT; Euroimmun AG) with a titer of 1:100.", [["serum", "ANATOMY", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 23, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 41, 44], ["immunoglobulin G", "PROTEIN", 23, 39], ["IgG", "PROTEIN", 41, 44], ["the mother's serum", "TEST", 3, 21], ["immunoglobulin G (IgG", "TEST", 23, 44], ["enzyme", "TEST", 87, 93], ["immunosorbent assay", "TEST", 101, 120], ["ELISA", "TEST", 122, 127], ["Euroimmun AG", "TEST", 129, 141], ["indirect immunofluorescence test", "TEST", 170, 202], ["a titer", "TEST", 229, 236]]], ["IgM and IgA were not detected through ELISA and the plaque reduction neutralization test (PRNT) result was below the cutoff value.", [["plaque", "ANATOMY", 52, 58], ["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgA", "GENE_OR_GENE_PRODUCT", 8, 11], ["IgM", "PROTEIN", 0, 3], ["IgA", "PROTEIN", 8, 11], ["IgM", "TEST", 0, 3], ["IgA", "TEST", 8, 11], ["ELISA", "TEST", 38, 43], ["the plaque reduction neutralization test", "TEST", 48, 88], ["IgA", "OBSERVATION", 8, 11], ["plaque", "OBSERVATION", 52, 58]]], ["However, MERS antibodies for IgG, IgM, and IgA were not detected in the newborn's blood samples ( Table 1) .CASE REPORTThe patient and her newborn baby were discharged in stable condition on June 30 with no clinical abnormalities on followup at the outpatient clinic.DISCUSSIONMERS-CoV was first isolated from a patient who died from a severe respiratory illness in Jeddah, Saudi Arabia in June 2012 (6) .", [["blood samples", "ANATOMY", 82, 95], ["respiratory", "ANATOMY", 343, 354], ["respiratory illness", "DISEASE", 343, 362], ["MERS antibodies", "GENE_OR_GENE_PRODUCT", 9, 24], ["IgG", "GENE_OR_GENE_PRODUCT", 29, 32], ["IgM", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgA", "GENE_OR_GENE_PRODUCT", 43, 46], ["blood samples", "ORGANISM_SUBSTANCE", 82, 95], ["patient", "ORGANISM", 123, 130], ["DISCUSSIONMERS-CoV", "ORGANISM", 267, 285], ["patient", "ORGANISM", 312, 319], ["MERS antibodies", "PROTEIN", 9, 24], ["IgG", "PROTEIN", 29, 32], ["IgM", "PROTEIN", 34, 37], ["IgA", "PROTEIN", 43, 46], ["patient", "SPECIES", 123, 130], ["patient", "SPECIES", 312, 319], ["DISCUSSIONMERS-CoV", "SPECIES", 267, 285], ["MERS antibodies", "TEST", 9, 24], ["IgG", "TEST", 29, 32], ["IgM", "TEST", 34, 37], ["IgA", "TEST", 43, 46], ["the newborn's blood samples", "TEST", 68, 95], ["clinical abnormalities", "PROBLEM", 207, 229], ["a severe respiratory illness", "PROBLEM", 334, 362], ["severe", "OBSERVATION_MODIFIER", 336, 342], ["respiratory", "ANATOMY", 343, 354], ["illness", "OBSERVATION", 355, 362]]], ["Clinical features of MERS are variable, and infected patients can be asymptomatic or have an acute febrile illness, upper respiratory tract disease, or even multiple organ failure resulting in death (7) (8) (9) (10) (11) .", [["upper respiratory tract", "ANATOMY", 116, 139], ["organ", "ANATOMY", 166, 171], ["MERS", "DISEASE", 21, 25], ["febrile illness", "DISEASE", 99, 114], ["upper respiratory tract disease", "DISEASE", 116, 147], ["organ failure", "DISEASE", 166, 179], ["death", "DISEASE", 193, 198], ["MERS", "CANCER", 21, 25], ["patients", "ORGANISM", 53, 61], ["upper", "ORGANISM_SUBDIVISION", 116, 121], ["respiratory tract", "ORGANISM_SUBDIVISION", 122, 139], ["organ", "ORGAN", 166, 171], ["patients", "SPECIES", 53, 61], ["MERS", "PROBLEM", 21, 25], ["an acute febrile illness", "PROBLEM", 90, 114], ["upper respiratory tract disease", "PROBLEM", 116, 147], ["multiple organ failure", "PROBLEM", 157, 179], ["death", "PROBLEM", 193, 198], ["MERS", "OBSERVATION", 21, 25], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["febrile", "OBSERVATION", 99, 106], ["upper", "ANATOMY_MODIFIER", 116, 121], ["respiratory tract", "ANATOMY", 122, 139], ["multiple", "OBSERVATION_MODIFIER", 157, 165], ["organ", "ANATOMY", 166, 171], ["failure", "OBSERVATION", 172, 179]]], ["However, there are limited data about the clinical features of MERS-CoV infection during pregnancy and the perinatal outcome of patients diagnosed with MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 63, 81], ["MERS-CoV infection", "DISEASE", 152, 170], ["MERS-CoV", "ORGANISM", 63, 71], ["patients", "ORGANISM", 128, 136], ["MERS-CoV", "ORGANISM", 152, 160], ["patients", "SPECIES", 128, 136], ["MERS-CoV", "SPECIES", 63, 71], ["MERS-CoV", "SPECIES", 152, 160], ["MERS", "PROBLEM", 63, 67], ["CoV infection", "PROBLEM", 68, 81], ["MERS", "PROBLEM", 152, 156], ["CoV infection", "PROBLEM", 157, 170], ["CoV", "OBSERVATION_MODIFIER", 68, 71], ["infection", "OBSERVATION", 72, 81], ["CoV infection", "OBSERVATION", 157, 170]]], ["To our best knowledge, there have been 9 reported cases in which pregnant patients had positive laboratory results for MERS-CoV including this case (12) (13) (14) (15) (Table 2) .", [["patients", "ORGANISM", 74, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 119, 127], ["patients", "SPECIES", 74, 82], ["MERS-CoV", "SPECIES", 119, 127], ["MERS", "PROBLEM", 119, 123]]], ["Unlike other cases, this case is not only the first MERS-CoV infection during pregnancy occurred outside of the Middle East, but also the first case of MERS confirmed on 3rd trimester of pregnancy showing good outcome of both mother and baby.DISCUSSIONCurrently, an exposure time to this virus during pregnancy and a severity of maternal disease could be expected to affect the perinatal outcome.", [["MERS-CoV infection", "DISEASE", 52, 70], ["MERS", "DISEASE", 152, 156], ["maternal disease", "DISEASE", 329, 345], ["MERS-CoV", "ORGANISM", 52, 60], ["baby", "ORGANISM_SUBDIVISION", 237, 241], ["MERS-CoV", "SPECIES", 52, 60], ["CoV infection", "PROBLEM", 57, 70], ["this virus", "PROBLEM", 283, 293], ["pregnancy", "PROBLEM", 301, 310], ["maternal disease", "PROBLEM", 329, 345], ["infection", "OBSERVATION", 61, 70], ["disease", "OBSERVATION", 338, 345]]], ["However, there is limited knowledge about the clinical implications of MERS-CoV infection on the maternal, fetal, and placental aspects of pregnancy.", [["fetal", "ANATOMY", 107, 112], ["placental", "ANATOMY", 118, 127], ["infection", "DISEASE", 80, 89], ["MERS-CoV", "ORGANISM", 71, 79], ["fetal", "ANATOMICAL_SYSTEM", 107, 112], ["placental", "ANATOMICAL_SYSTEM", 118, 127], ["MERS-CoV", "SPECIES", 71, 79], ["MERS", "PROBLEM", 71, 75], ["CoV infection", "PROBLEM", 76, 89], ["pregnancy", "PROBLEM", 139, 148], ["CoV", "OBSERVATION_MODIFIER", 76, 79], ["infection", "OBSERVATION", 80, 89]]], ["From the maternal aspect, there is no epidemiologic data regarding whether pregnant women are more susceptible to MERS.", [["MERS", "DISEASE", 114, 118], ["women", "ORGANISM", 84, 89], ["women", "SPECIES", 84, 89], ["no", "UNCERTAINTY", 35, 37]]], ["Also, it is unknown whether MERS-CoV infected pregnant women have a more severe disease course compared with the non-pregnant population.", [["MERS-CoV", "ORGANISM", 28, 36], ["women", "ORGANISM", 55, 60], ["women", "SPECIES", 55, 60], ["MERS-CoV", "SPECIES", 28, 36], ["a more severe disease course", "PROBLEM", 66, 94], ["CoV", "OBSERVATION_MODIFIER", 33, 36], ["infected", "OBSERVATION", 37, 45], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disease", "OBSERVATION", 80, 87]]], ["In our case, she showed a mild disease course.", [["a mild disease course", "PROBLEM", 24, 45], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["disease", "OBSERVATION", 31, 38]]], ["She had low level of IgG antibody by ELISA and IIFT but not detectable neutralization activity by PRNT.", [["She", "ORGANISM", 0, 3], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 21, 33], ["IgG antibody", "PROTEIN", 21, 33], ["PRNT", "PROTEIN", 98, 102], ["low level of IgG antibody", "PROBLEM", 8, 33], ["ELISA", "TEST", 37, 42], ["low level", "OBSERVATION_MODIFIER", 8, 17], ["neutralization activity", "OBSERVATION", 71, 94]]], ["It has been suggested that neutralizing antibodies are produced at low levels and are potentially short-lived after mild or asymptomatic MERS-CoV infection (16, 17) .", [["MERS-CoV infection", "DISEASE", 137, 155], ["MERS-CoV", "ORGANISM", 137, 145], ["neutralizing antibodies", "PROTEIN", 27, 50], ["MERS-CoV", "SPECIES", 137, 145], ["neutralizing antibodies", "TEST", 27, 50], ["mild or asymptomatic MERS", "PROBLEM", 116, 141], ["CoV infection", "PROBLEM", 142, 155], ["neutralizing antibodies", "OBSERVATION", 27, 50], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["asymptomatic", "OBSERVATION_MODIFIER", 124, 136], ["CoV", "OBSERVATION_MODIFIER", 142, 145], ["infection", "OBSERVATION", 146, 155]]], ["From the fetal aspect, it is unclear whether MERS was a causative factor in the stillbirth or preterm birth.", [["fetal", "ANATOMY", 9, 14], ["stillbirth", "DISEASE", 80, 90], ["preterm birth", "DISEASE", 94, 107], ["fetal", "ANATOMICAL_SYSTEM", 9, 14], ["MERS", "GENE_OR_GENE_PRODUCT", 45, 49], ["fetal", "ANATOMY", 9, 14]]], ["Fetal specimen and/or placenta were not available for evaluation in the previous cases.", [["Fetal specimen", "ANATOMY", 0, 14], ["placenta", "ANATOMY", 22, 30], ["Fetal specimen", "MULTI-TISSUE_STRUCTURE", 0, 14], ["placenta", "ORGAN", 22, 30], ["Fetal specimen", "TEST", 0, 14], ["evaluation", "TEST", 54, 64], ["placenta", "ANATOMY", 22, 30]]], ["As pregnancy alters maternal pulmonary function and consumes more oxygen, severe respiratory illness during pregnancy results in maternal hypoxemia.", [["pulmonary", "ANATOMY", 29, 38], ["respiratory", "ANATOMY", 81, 92], ["oxygen", "CHEMICAL", 66, 72], ["respiratory illness", "DISEASE", 81, 100], ["hypoxemia", "DISEASE", 138, 147], ["oxygen", "CHEMICAL", 66, 72], ["pulmonary", "ORGAN", 29, 38], ["oxygen", "SIMPLE_CHEMICAL", 66, 72], ["pregnancy alters", "PROBLEM", 3, 19], ["maternal pulmonary function", "PROBLEM", 20, 47], ["severe respiratory illness", "PROBLEM", 74, 100], ["pregnancy results", "PROBLEM", 108, 125], ["maternal hypoxemia", "PROBLEM", 129, 147], ["pulmonary", "ANATOMY", 29, 38], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["respiratory illness", "OBSERVATION", 81, 100], ["hypoxemia", "OBSERVATION", 138, 147]]], ["Maternal hypoxemia can be associated with poor fetal oxygenation, which eventually could lead to preterm birth or stillbirth.", [["fetal", "ANATOMY", 47, 52], ["hypoxemia", "DISEASE", 9, 18], ["preterm birth", "DISEASE", 97, 110], ["stillbirth", "DISEASE", 114, 124], ["fetal", "ANATOMICAL_SYSTEM", 47, 52], ["Maternal hypoxemia", "PROBLEM", 0, 18], ["poor fetal oxygenation", "PROBLEM", 42, 64], ["preterm birth", "PROBLEM", 97, 110], ["stillbirth", "PROBLEM", 114, 124], ["hypoxemia", "OBSERVATION", 9, 18], ["fetal oxygenation", "OBSERVATION", 47, 64]]], ["Also, altered immune responses during pregnancy could affect the fetal outcome (13) .", [["fetal", "ANATOMY", 65, 70], ["fetal", "ANATOMICAL_SYSTEM", 65, 70], ["altered immune responses", "PROBLEM", 6, 30], ["altered", "OBSERVATION_MODIFIER", 6, 13], ["immune responses", "OBSERVATION", 14, 30]]], ["From the placental aspect, there have been no reports of MERS causing pathology of the placenta including infarction, insufficiency, or villus placentitis.", [["placental", "ANATOMY", 9, 18], ["placenta", "ANATOMY", 87, 95], ["villus", "ANATOMY", 136, 142], ["infarction", "DISEASE", 106, 116], ["insufficiency", "DISEASE", 118, 131], ["villus placentitis", "DISEASE", 136, 154], ["placental", "ANATOMICAL_SYSTEM", 9, 18], ["placenta", "ORGAN", 87, 95], ["villus", "MULTI-TISSUE_STRUCTURE", 136, 142], ["the placenta", "PROBLEM", 83, 95], ["infarction", "PROBLEM", 106, 116], ["insufficiency", "PROBLEM", 118, 131], ["villus placentitis", "PROBLEM", 136, 154], ["placental", "ANATOMY", 9, 18], ["no reports of", "UNCERTAINTY", 43, 56], ["placenta", "ANATOMY", 87, 95], ["infarction", "OBSERVATION", 106, 116], ["insufficiency", "OBSERVATION", 118, 131], ["villus placentitis", "OBSERVATION", 136, 154]]], ["Our case showed placenta abruption clinically, which can be caused by maternal infection.", [["placenta", "ANATOMY", 16, 24], ["placenta abruption", "DISEASE", 16, 34], ["maternal infection", "DISEASE", 70, 88], ["placenta", "ORGAN", 16, 24], ["placenta abruption", "PROBLEM", 16, 34], ["maternal infection", "PROBLEM", 70, 88], ["placenta", "ANATOMY", 16, 24], ["abruption", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 79, 88]]], ["There is no evidence of a relationship between MERS-CoV and placenta disorder.", [["placenta", "ANATOMY", 60, 68], ["placenta disorder", "DISEASE", 60, 77], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 47, 55], ["placenta", "ORGAN", 60, 68], ["MERS-CoV", "SPECIES", 47, 55], ["a relationship between MERS", "PROBLEM", 24, 51], ["placenta disorder", "PROBLEM", 60, 77], ["no evidence of", "UNCERTAINTY", 9, 23], ["placenta", "ANATOMY", 60, 68]]], ["However, the possibility that this virus may be a cause of placenta abruption should be of concern.DISCUSSIONLastly, the remaining question was whether the virus could cross the placenta causing significant infection in the fetus, and whether MERS could cause vertical transmission.", [["placenta", "ANATOMY", 59, 67], ["placenta", "ANATOMY", 178, 186], ["fetus", "ANATOMY", 224, 229], ["placenta abruption", "DISEASE", 59, 77], ["infection", "DISEASE", 207, 216], ["placenta", "ORGAN", 59, 67], ["placenta", "ORGAN", 178, 186], ["fetus", "ORGAN", 224, 229], ["this virus", "PROBLEM", 30, 40], ["placenta abruption", "PROBLEM", 59, 77], ["the virus", "PROBLEM", 152, 161], ["significant infection in the fetus", "PROBLEM", 195, 229], ["vertical transmission", "PROBLEM", 260, 281], ["placenta", "ANATOMY", 59, 67], ["abruption", "OBSERVATION", 68, 77], ["significant", "OBSERVATION_MODIFIER", 195, 206], ["infection", "OBSERVATION", 207, 216], ["fetus", "ANATOMY", 224, 229]]], ["Camel-tohuman transmission, and human-to-human transmission via contact, droplet, and possibly airborne routes are the known modes of transmission (18, 19) .", [["human", "ORGANISM", 32, 37], ["human", "ORGANISM", 41, 46], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 41, 46]]], ["However, there are no data about perinatal transmission of MERS-CoV.", [["MERS-CoV", "ORGANISM", 59, 67], ["MERS-CoV", "SPECIES", 59, 67], ["no", "UNCERTAINTY", 19, 21]]], ["Moreover, if the mother mounts an appropriate immune response to produce enough neutralizing antibodies without serious conditions, passive antibodies transferred from mother to fetus may have a protective effect on the fetus.", [["fetus", "ANATOMY", 178, 183], ["fetus", "ANATOMY", 220, 225], ["fetus", "ORGANISM", 178, 183], ["fetus", "ORGAN", 220, 225], ["neutralizing antibodies", "PROTEIN", 80, 103], ["passive antibodies", "PROTEIN", 132, 150], ["neutralizing antibodies", "PROBLEM", 80, 103], ["serious conditions", "PROBLEM", 112, 130], ["passive antibodies", "TREATMENT", 132, 150], ["fetus", "ANATOMY", 220, 225]]], ["There is only one case reporting the mother's serologic data previously (15) , in which stillbirth occurred at approximately 5 months of gestation, although the mother had MERS-CoV antibody by ELISA (titer 1:1,600) , immunofluorescent antibody (IFA), and microneutralization titer assay (titer 1:80).", [["stillbirth", "DISEASE", 88, 98], ["MERS-CoV antibody", "GENE_OR_GENE_PRODUCT", 172, 189], ["MERS-CoV antibody", "PROTEIN", 172, 189], ["immunofluorescent antibody", "PROTEIN", 217, 243], ["IFA", "PROTEIN", 245, 248], ["MERS-CoV", "SPECIES", 172, 180], ["the mother's serologic data", "TEST", 33, 60], ["MERS", "TEST", 172, 176], ["CoV antibody", "TEST", 177, 189], ["ELISA", "TEST", 193, 198], ["immunofluorescent antibody", "TEST", 217, 243], ["IFA", "TEST", 245, 248], ["microneutralization titer assay", "TEST", 255, 286]]], ["In our case, although the mother had IgG antibody (titer 1:100 by IIFT), antibody was not detected in neonatal serum.", [["serum", "ANATOMY", 111, 116], ["mother", "ORGANISM", 26, 32], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 37, 49], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["IgG antibody", "PROTEIN", 37, 49], ["titer 1:100", "PROTEIN", 51, 62], ["IIFT", "PROTEIN", 66, 70], ["IgG antibody", "TEST", 37, 49], ["titer", "TEST", 51, 56], ["antibody", "TEST", 73, 81], ["neonatal serum", "TEST", 102, 116]]], ["This finding may provoke different interpretations in regard to the role of maternal antibodies in the fetus or to transmission of maternal antibodies, necessitating more data in the future.", [["fetus", "ANATOMY", 103, 108], ["fetus", "ORGAN", 103, 108], ["maternal antibodies", "PROTEIN", 76, 95], ["maternal antibodies", "PROTEIN", 131, 150], ["maternal antibodies", "PROBLEM", 76, 95], ["maternal antibodies", "PROBLEM", 131, 150]]], ["To know whether prenatal transmission of MERS-CoV can occur, collection of samples including amniotic fluid, placenta, and umbilical cord is needed from an infected pregnant patient.DISCUSSIONFurther studies with a larger sample size will help in understanding of the pathophysiology and perinatal outcome of MERS during pregnancy and the optimal mode of delivery.", [["samples", "ANATOMY", 75, 82], ["amniotic fluid", "ANATOMY", 93, 107], ["placenta", "ANATOMY", 109, 117], ["umbilical cord", "ANATOMY", 123, 137], ["MERS", "DISEASE", 309, 313], ["MERS-CoV", "ORGANISM", 41, 49], ["amniotic fluid", "MULTI-TISSUE_STRUCTURE", 93, 107], ["placenta", "TISSUE", 109, 117], ["umbilical cord", "ORGAN", 123, 137], ["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["MERS-CoV", "SPECIES", 41, 49], ["MERS", "PROBLEM", 41, 45], ["CoV", "PROBLEM", 46, 49], ["collection of samples including amniotic fluid", "TEST", 61, 107], ["placenta, and umbilical cord", "PROBLEM", 109, 137], ["a larger sample size", "PROBLEM", 213, 233], ["MERS during pregnancy", "PROBLEM", 309, 330], ["delivery", "TREATMENT", 355, 363], ["amniotic fluid", "OBSERVATION", 93, 107], ["placenta", "ANATOMY", 109, 117], ["umbilical cord", "ANATOMY", 123, 137], ["infected", "OBSERVATION", 156, 164]]]], "PMC7113860": [["IntroductionRespiratory and enteric diseases are the two most common and costly diseases in cattle industry worldwide.", [["IntroductionRespiratory and enteric diseases", "DISEASE", 0, 44], ["cattle", "ORGANISM", 92, 98], ["cattle", "SPECIES", 92, 98], ["cattle", "SPECIES", 92, 98], ["IntroductionRespiratory and enteric diseases", "PROBLEM", 0, 44], ["enteric diseases", "OBSERVATION", 28, 44]]], ["In the USA, respiratory ailments account for 40\u201350% of feedlot deaths (Hilton, 2014; Snowder et al., 2006).", [["respiratory", "ANATOMY", 12, 23], ["respiratory ailments", "DISEASE", 12, 32], ["deaths", "DISEASE", 63, 69], ["respiratory ailments", "PROBLEM", 12, 32], ["respiratory", "ANATOMY", 12, 23], ["ailments", "OBSERVATION", 24, 32]]], ["Based on a National Animal Health Monitoring System\u2019s (NAHMS) Beef Feedlot study conducted in 2011, approximately 2.29 million US beef cattle in feedlots are affected by respiratory diseases costing around 54.12 million US dollars annually for the treatments (USDA\u2013APHIS\u2013VS, 2013; Johnson and Pendell, 2017).", [["respiratory", "ANATOMY", 170, 181], ["respiratory diseases", "DISEASE", 170, 190], ["cattle", "ORGANISM", 135, 141], ["beef", "SPECIES", 130, 134], ["cattle", "SPECIES", 135, 141], ["beef", "SPECIES", 130, 134], ["cattle", "SPECIES", 135, 141], ["Feedlot study", "TEST", 67, 80], ["respiratory diseases", "PROBLEM", 170, 190], ["the treatments", "TREATMENT", 244, 258], ["respiratory diseases", "OBSERVATION", 170, 190]]], ["In the UK, an estimated 1.9 million animals are affected by bovine respiratory disease each year costing the UK beef industry approximately \u00a360 million (NADIS, 2007).", [["respiratory", "ANATOMY", 67, 78], ["bovine respiratory disease", "DISEASE", 60, 86], ["bovine", "ORGANISM", 60, 66], ["bovine", "SPECIES", 60, 66], ["bovine respiratory disease", "PROBLEM", 60, 86], ["bovine", "OBSERVATION_MODIFIER", 60, 66], ["respiratory disease", "OBSERVATION", 67, 86]]], ["Enteric diseases are responsible for more than a half of deaths among pre-weaned dairy calves in the USA and other countries (Gomez and Weese, 2017; Cho and Yoon, 2014; Hur et al., 2013; Azizzadeh et al., 2012).", [["Enteric diseases", "DISEASE", 0, 16], ["deaths", "DISEASE", 57, 63], ["calves", "ORGANISM", 87, 93], ["calves", "SPECIES", 87, 93], ["Enteric diseases", "PROBLEM", 0, 16], ["diseases", "OBSERVATION", 8, 16]]], ["Both respiratory and enteric diseases continue to be major health threats to the global cattle industry despite many intervention strategies such as vaccination, medications, and herd management.IntroductionBovine respiratory disease complex (BRDC) is multi-factorial in origin and involves a complex interaction between host, pathogen and environmental factors that makes its diagnosis, prevention and control a challenging task (Mosier, 2014).", [["respiratory", "ANATOMY", 5, 16], ["respiratory and enteric diseases", "DISEASE", 5, 37], ["IntroductionBovine respiratory disease", "DISEASE", 195, 233], ["IntroductionBovine respiratory disease complex", "GENE_OR_GENE_PRODUCT", 195, 241], ["cattle", "SPECIES", 88, 94], ["Both respiratory and enteric diseases", "PROBLEM", 0, 37], ["many intervention strategies", "TREATMENT", 112, 140], ["vaccination", "TREATMENT", 149, 160], ["medications", "TREATMENT", 162, 173], ["herd management", "TREATMENT", 179, 194], ["IntroductionBovine respiratory disease complex", "PROBLEM", 195, 241], ["a complex interaction between host, pathogen and environmental factors", "PROBLEM", 291, 361], ["respiratory", "ANATOMY", 5, 16], ["enteric", "ANATOMY", 21, 28], ["diseases", "OBSERVATION", 29, 37], ["respiratory disease", "OBSERVATION", 214, 233]]], ["Several viruses and bacteria, including mycoplasma are associated with BRDC.", [["mycoplasma", "DISEASE", 40, 50], ["BRDC", "CANCER", 71, 75], ["Several viruses", "PROBLEM", 0, 15], ["bacteria", "PROBLEM", 20, 28], ["mycoplasma", "PROBLEM", 40, 50], ["BRDC", "PROBLEM", 71, 75], ["viruses", "OBSERVATION", 8, 15], ["bacteria", "OBSERVATION_MODIFIER", 20, 28]]], ["The most common viral pathogens associated with BRDC are bovine respiratory syncytial virus (BRSV), bovine parainfluenza virus-3 (BPI-3), bovine viral diarrhea virus (BVDV), and bovine herpesvirus 1 (BoHV-1).", [["bovine respiratory syncytial virus", "DISEASE", 57, 91], ["bovine viral diarrhea virus (BVDV)", "DISEASE", 138, 172], ["bovine", "ORGANISM", 57, 63], ["respiratory syncytial virus", "ORGANISM", 64, 91], ["BRSV", "ORGANISM", 93, 97], ["bovine", "ORGANISM", 100, 106], ["parainfluenza virus-3", "ORGANISM", 107, 128], ["BPI-3", "ORGANISM", 130, 135], ["bovine viral diarrhea virus", "ORGANISM", 138, 165], ["BVDV", "ORGANISM", 167, 171], ["bovine herpesvirus 1", "ORGANISM", 178, 198], ["BoHV-1", "ORGANISM", 200, 206], ["bovine", "SPECIES", 57, 63], ["respiratory syncytial virus", "SPECIES", 64, 91], ["BRSV", "SPECIES", 93, 97], ["bovine", "SPECIES", 100, 106], ["parainfluenza virus-3", "SPECIES", 107, 128], ["bovine", "SPECIES", 138, 144], ["viral diarrhea virus", "SPECIES", 145, 165], ["BVDV", "SPECIES", 167, 171], ["bovine", "SPECIES", 178, 184], ["herpesvirus 1", "SPECIES", 185, 198], ["bovine respiratory syncytial virus", "SPECIES", 57, 91], ["BRSV", "SPECIES", 93, 97], ["bovine parainfluenza virus-3 (BPI-3", "SPECIES", 100, 135], ["bovine viral diarrhea virus", "SPECIES", 138, 165], ["BVDV", "SPECIES", 167, 171], ["bovine herpesvirus 1", "SPECIES", 178, 198], ["BoHV-1", "SPECIES", 200, 206], ["The most common viral pathogens", "PROBLEM", 0, 31], ["BRDC", "PROBLEM", 48, 52], ["bovine respiratory syncytial virus", "PROBLEM", 57, 91], ["BRSV", "TEST", 93, 97], ["bovine parainfluenza virus", "PROBLEM", 100, 126], ["BPI", "TEST", 130, 133], ["bovine viral diarrhea virus", "PROBLEM", 138, 165], ["BVDV", "PROBLEM", 167, 171], ["bovine herpesvirus", "TEST", 178, 196], ["BoHV", "TEST", 200, 204], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["syncytial virus", "OBSERVATION", 76, 91], ["parainfluenza virus", "OBSERVATION", 107, 126]]], ["The role of some viruses such as bovine coronavirus (BCoV) and bovine rhinitis A virus, in BRDC pathogenesis, is being increasingly recognized (Murray et al., 2016).", [["bovine coronavirus", "DISEASE", 33, 51], ["rhinitis A", "DISEASE", 70, 80], ["bovine coronavirus", "ORGANISM", 33, 51], ["BCoV", "GENE_OR_GENE_PRODUCT", 53, 57], ["bovine rhinitis A virus", "ORGANISM", 63, 86], ["BRDC", "CANCER", 91, 95], ["bovine", "SPECIES", 33, 39], ["coronavirus", "SPECIES", 40, 51], ["bovine", "SPECIES", 63, 69], ["A virus", "SPECIES", 79, 86], ["bovine coronavirus", "SPECIES", 33, 51], ["BCoV", "SPECIES", 53, 57], ["bovine rhinitis A virus", "SPECIES", 63, 86], ["some viruses", "PROBLEM", 12, 24], ["bovine coronavirus (BCoV)", "PROBLEM", 33, 58], ["bovine rhinitis A virus", "PROBLEM", 63, 86], ["viruses", "OBSERVATION", 17, 24], ["bovine rhinitis", "OBSERVATION", 63, 78]]], ["Some of these viral infections alone may not result in any clinical disease, but lead to secondary bacterial infections resulting in severe respiratory disease.", [["respiratory", "ANATOMY", 140, 151], ["viral infections", "DISEASE", 14, 30], ["bacterial infections", "DISEASE", 99, 119], ["respiratory disease", "DISEASE", 140, 159], ["these viral infections", "PROBLEM", 8, 30], ["any clinical disease", "PROBLEM", 55, 75], ["secondary bacterial infections", "PROBLEM", 89, 119], ["severe respiratory disease", "PROBLEM", 133, 159], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 20, 30], ["bacterial", "OBSERVATION_MODIFIER", 99, 108], ["infections", "OBSERVATION", 109, 119], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["respiratory disease", "OBSERVATION", 140, 159]]], ["Bacterial species that are commonly associated with BRDC are Mannheimia haemolytica, Mycoplasma bovis, Histophilus somni, and Pasteurella multocida (reviewed in Griffin et al., 2010).IntroductionLike BRDC, bovine enteric disease (BED) in neonatal calves is often caused by concurrent infection of multiple pathogens of viral, bacterial and/or protozoan origin (Foster and Smith, 2009).", [["Pasteurella multocida", "DISEASE", 126, 147], ["bovine enteric disease", "DISEASE", 206, 228], ["BED", "DISEASE", 230, 233], ["infection", "DISEASE", 284, 293], ["BRDC", "GENE_OR_GENE_PRODUCT", 52, 56], ["Mannheimia haemolytica", "ORGANISM", 61, 83], ["Mycoplasma bovis", "ORGANISM", 85, 101], ["Histophilus somni", "ORGANISM", 103, 120], ["Pasteurella multocida", "ORGANISM", 126, 147], ["bovine", "ORGANISM", 206, 212], ["calves", "ORGANISM", 247, 253], ["Mannheimia haemolytica", "SPECIES", 61, 83], ["Mycoplasma bovis", "SPECIES", 85, 101], ["Histophilus somni", "SPECIES", 103, 120], ["Pasteurella multocida", "SPECIES", 126, 147], ["bovine", "SPECIES", 206, 212], ["calves", "SPECIES", 247, 253], ["Mannheimia haemolytica", "SPECIES", 61, 83], ["Mycoplasma bovis", "SPECIES", 85, 101], ["Histophilus somni", "SPECIES", 103, 120], ["Pasteurella multocida", "SPECIES", 126, 147], ["bovine", "SPECIES", 206, 212], ["Bacterial species", "PROBLEM", 0, 17], ["BRDC", "PROBLEM", 52, 56], ["Mannheimia haemolytica", "PROBLEM", 61, 83], ["Mycoplasma bovis", "PROBLEM", 85, 101], ["Histophilus somni", "PROBLEM", 103, 120], ["Pasteurella multocida", "PROBLEM", 126, 147], ["bovine enteric disease", "PROBLEM", 206, 228], ["multiple pathogens of viral, bacterial and/or protozoan origin", "PROBLEM", 297, 359], ["species", "OBSERVATION", 10, 17], ["Mannheimia haemolytica", "OBSERVATION", 61, 83], ["Mycoplasma bovis", "OBSERVATION", 85, 101], ["bovine enteric disease", "OBSERVATION", 206, 228], ["infection", "OBSERVATION", 284, 293], ["multiple", "OBSERVATION_MODIFIER", 297, 305], ["pathogens", "OBSERVATION", 306, 315], ["viral", "OBSERVATION", 319, 324]]], ["Establishment of pathogenic infection in the alimentary epithelium leads to secretion, malabsorption or maldigestion leading to enteritis and scours.", [["alimentary epithelium", "ANATOMY", 45, 66], ["infection", "DISEASE", 28, 37], ["malabsorption", "DISEASE", 87, 100], ["maldigestion", "DISEASE", 104, 116], ["enteritis", "DISEASE", 128, 137], ["alimentary epithelium", "TISSUE", 45, 66], ["pathogenic infection", "PROBLEM", 17, 37], ["the alimentary epithelium", "PROBLEM", 41, 66], ["secretion", "PROBLEM", 76, 85], ["malabsorption", "PROBLEM", 87, 100], ["maldigestion", "PROBLEM", 104, 116], ["enteritis and scours", "PROBLEM", 128, 148], ["pathogenic", "OBSERVATION_MODIFIER", 17, 27], ["infection", "OBSERVATION", 28, 37], ["alimentary epithelium", "ANATOMY", 45, 66], ["enteritis", "OBSERVATION", 128, 137]]], ["Among viral agents, group A bovine rotaviruses (BRoV) and enteropathogenic BCoV are the leading causes of diarrhea in young calves (Dhama et al., 2009; Boileau and Kapil, 2010).", [["diarrhea", "DISEASE", 106, 114], ["bovine rotaviruses", "ORGANISM", 28, 46], ["BRoV", "ORGANISM", 48, 52], ["enteropathogenic BCoV", "ORGANISM", 58, 79], ["calves", "ORGANISM", 124, 130], ["bovine", "SPECIES", 28, 34], ["calves", "SPECIES", 124, 130], ["BRoV", "SPECIES", 48, 52], ["BCoV", "SPECIES", 75, 79], ["Among viral agents", "TREATMENT", 0, 18], ["group A bovine rotaviruses", "TREATMENT", 20, 46], ["enteropathogenic BCoV", "PROBLEM", 58, 79], ["diarrhea", "PROBLEM", 106, 114], ["diarrhea", "OBSERVATION", 106, 114]]], ["Additionally, BVDV and BRoV group B and C are also considered as causative agents of scours.", [["BVDV", "ORGANISM", 14, 18], ["BRoV group B", "ORGANISM", 23, 35], ["C", "CELL", 40, 41], ["BVDV", "SPECIES", 14, 18], ["BVDV", "SPECIES", 14, 18], ["BVDV", "PROBLEM", 14, 18], ["BVDV", "OBSERVATION", 14, 18]]], ["Besides viruses, several bacteria including pathogenic strains of Escherichia coli, Clostridium perfringens, and Salmonella are associated with BED.", [["Clostridium perfringens", "DISEASE", 84, 107], ["BED", "DISEASE", 144, 147], ["Escherichia coli", "ORGANISM", 66, 82], ["Clostridium perfringens", "ORGANISM", 84, 107], ["Escherichia coli", "SPECIES", 66, 82], ["Clostridium perfringens", "SPECIES", 84, 107], ["Escherichia coli", "SPECIES", 66, 82], ["Clostridium perfringens", "SPECIES", 84, 107], ["Salmonella", "SPECIES", 113, 123], ["viruses", "PROBLEM", 8, 15], ["several bacteria", "PROBLEM", 17, 33], ["Escherichia coli", "PROBLEM", 66, 82], ["Clostridium perfringens", "PROBLEM", 84, 107], ["Salmonella", "PROBLEM", 113, 123], ["viruses", "OBSERVATION", 8, 15], ["several", "OBSERVATION_MODIFIER", 17, 24], ["bacteria", "OBSERVATION_MODIFIER", 25, 33], ["Escherichia coli", "OBSERVATION", 66, 82], ["Clostridium perfringens", "OBSERVATION", 84, 107]]], ["Eimeria species and Cryptosporidium parvum are the major parasitic protozoans that cause diarrhea in young calves.IntroductionGiven the multiple etiological nature of BRDC and BED, accurate and rapid identification of pathogen(s) involved is crucial towards effective treatment and prevention of such diseases.", [["Cryptosporidium parvum", "DISEASE", 20, 42], ["parasitic protozoans", "DISEASE", 57, 77], ["diarrhea", "DISEASE", 89, 97], ["BRDC", "DISEASE", 167, 171], ["Eimeria species", "ORGANISM", 0, 15], ["Cryptosporidium parvum", "ORGANISM", 20, 42], ["calves", "ORGANISM", 107, 113], ["BRDC", "CANCER", 167, 171], ["Cryptosporidium parvum", "SPECIES", 20, 42], ["calves", "SPECIES", 107, 113], ["Cryptosporidium parvum", "SPECIES", 20, 42], ["Eimeria species", "PROBLEM", 0, 15], ["Cryptosporidium parvum", "PROBLEM", 20, 42], ["diarrhea in young calves", "PROBLEM", 89, 113], ["pathogen", "PROBLEM", 218, 226], ["effective treatment", "TREATMENT", 258, 277], ["such diseases", "PROBLEM", 296, 309], ["Cryptosporidium parvum", "OBSERVATION", 20, 42], ["parasitic protozoans", "OBSERVATION", 57, 77], ["diarrhea", "OBSERVATION", 89, 97], ["calves", "ANATOMY", 107, 113], ["multiple", "OBSERVATION_MODIFIER", 136, 144]]], ["The current diagnostic assays for BRDC and BED include pathogen isolation, serology and detection of pathogen-specific nucleic acids using polymerase chain reaction (PCR) based methods.", [["nucleic acids", "CHEMICAL", 119, 132], ["BRDC", "CANCER", 34, 38], ["The current diagnostic assays", "TEST", 0, 29], ["BRDC", "PROBLEM", 34, 38], ["pathogen isolation", "TREATMENT", 55, 73], ["serology", "TEST", 75, 83], ["pathogen", "PROBLEM", 101, 109], ["specific nucleic acids", "TEST", 110, 132], ["polymerase chain reaction", "PROBLEM", 139, 164]]], ["While many of such assays target single pathogens, few assays have been developed for simultaneous detection of multiple pathogens in a single reaction (Vilcek et al., 1994; Decaro et al., 2012; Angen et al., 1998).", [["such assays target single pathogens", "PROBLEM", 14, 49], ["few assays", "TEST", 51, 61], ["simultaneous detection", "TEST", 86, 108], ["multiple pathogens", "PROBLEM", 112, 130], ["a single reaction", "PROBLEM", 134, 151], ["multiple", "OBSERVATION_MODIFIER", 112, 120], ["pathogens", "OBSERVATION", 121, 130]]], ["These multiplex assays depend on pathogen differentiation based on the size of PCR amplicons, and therefore requires gel-electrophoresis following PCR amplification.", [["PCR amplicons", "DNA", 79, 92], ["These multiplex assays", "TEST", 0, 22], ["pathogen differentiation", "TEST", 33, 57], ["PCR amplicons", "TREATMENT", 79, 92], ["gel-electrophoresis", "TREATMENT", 117, 136], ["PCR amplification", "TREATMENT", 147, 164], ["size", "OBSERVATION_MODIFIER", 71, 75]]], ["Recently several multiplex real-time PCR assays have been developed to detect pathogens associated with BRDC and BED (Horwood and Mahony, 2011; Marley et al., 2008; Thonur et al., 2012; Cho et al., 2010).", [["BED", "DISEASE", 113, 116], ["PCR assays", "TEST", 37, 47], ["pathogens", "PROBLEM", 78, 87]]], ["Alternatively, a real-time PCR based system was described that includes multiple reactions in one-run with similar thermal cycling conditions for detection of BRDC and BED pathogens (Kishimoto et al., 2017; Tsuchiaka et al., 2016).", [["a real-time PCR based system", "TEST", 15, 43], ["multiple reactions", "PROBLEM", 72, 90], ["BRDC", "PROBLEM", 159, 163], ["BED pathogens", "PROBLEM", 168, 181], ["multiple", "OBSERVATION_MODIFIER", 72, 80]]], ["Although these real-time PCR assays are rapid and highly sensitive, their multiplexing capability at present is restricted by the availability of limited number of compatible fluorescent dyes.IntroductionThe DNA microarray platform is suitable for multiplex detection of many targets in a single sample and has been widely used for multiplex pathogen detection (Kostrzynska and Bachand, 2006; Yadav et al., 2015).", [["sample", "ANATOMY", 296, 302], ["fluorescent dyes", "SIMPLE_CHEMICAL", 175, 191], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["these real-time PCR assays", "TEST", 9, 35], ["compatible fluorescent dyes", "PROBLEM", 164, 191], ["The DNA microarray platform", "TEST", 204, 231], ["multiplex detection", "TEST", 248, 267], ["multiplex pathogen detection", "TEST", 332, 360], ["fluorescent dyes", "OBSERVATION", 175, 191]]], ["Conventional microarray requires a substantial amount of manual processing, multiple pieces of equipment for array preparation, and longer time for passive target-probe hybridization.", [["manual processing", "TREATMENT", 57, 74], ["array preparation", "TREATMENT", 109, 126], ["passive target-probe hybridization", "TREATMENT", 148, 182], ["substantial", "OBSERVATION_MODIFIER", 35, 46], ["amount", "OBSERVATION_MODIFIER", 47, 53]]], ["Meanwhile, the new automated electronic microarray platform is rapid, user-friendly, and automates all steps from microarray capture probe printing to all post-PCR processing steps including electronically driven hybridization, washing and reporting (Lung et al., 2012).", [["microarray capture probe", "TREATMENT", 114, 138], ["new", "OBSERVATION_MODIFIER", 15, 18], ["Lung", "ANATOMY", 251, 255]]], ["Each electronic microarray cartridge consists of 400 individually activated probe binding sites that allow the probe layout to be customizable during each run based on the needs of the end user, in contrast to conventional glass slide microarray, where changes to the array layout is not possible once the arrays are printed.", [["400 individually activated probe binding sites", "DNA", 49, 95], ["Each electronic microarray cartridge", "TREATMENT", 0, 36], ["activated probe binding sites", "TREATMENT", 66, 95], ["the probe layout", "TREATMENT", 107, 123], ["not possible", "UNCERTAINTY", 284, 296]]], ["This allows the user to make changes to the detection probe panel if necessary and eliminates anticipation of the future needs before finalizing the array layout, which is the case with conventional microarray slide production.", [["the detection probe panel", "TEST", 40, 65]]], ["Furthermore, depending on the number of samples to be tested, not all probe binding sites on an electronic microarray cartridge need to be used on the initial run, and unused sites can be used in subsequent sessions (up to 10 times per cartridge).", [["probe binding sites", "DNA", 70, 89], ["all probe binding sites", "PROBLEM", 66, 89], ["an electronic microarray cartridge", "TREATMENT", 93, 127]]], ["Electronic microarray based assays for detection of several avian, bovine, and swine viruses and bacteria have been described previously (Lung et al., 2012; Lung et al., 2015; Lung et al., 2016).IntroductionThis study describes the development and initial validation of multiplex PCR and oligonucleotide electronic microarray assays that can detect a total of seven respiratory pathogens, nine enteric pathogens and two pathogens that cause both respiratory and enteric diseases in a single run.Sequence databases ::: Materials and methodsSequence databases were created for selected target genomic regions of four BRDC-associated bacteria (M. haemolytica, H. somni, P. multocida, and M. bovis), three BRDC-associated viruses (BPI-3, BRSV, and BoHV-1), four BED-associated bacteria (C. perfringens, E. coli, S. e.", [["respiratory", "ANATOMY", 446, 457], ["respiratory pathogens", "DISEASE", 366, 387], ["enteric pathogens", "DISEASE", 394, 411], ["respiratory and enteric diseases", "DISEASE", 446, 478], ["BED", "CHEMICAL", 758, 761], ["avian", "ORGANISM", 60, 65], ["bovine", "ORGANISM", 67, 73], ["swine viruses", "ORGANISM", 79, 92], ["BRDC", "GENE_OR_GENE_PRODUCT", 615, 619], ["M. haemolytica", "ORGANISM", 641, 655], ["H. somni", "ORGANISM", 657, 665], ["P. multocida", "ORGANISM", 667, 679], ["M. bovis", "ORGANISM", 685, 693], ["BRDC-associated viruses", "ORGANISM", 702, 725], ["BPI-3", "GENE_OR_GENE_PRODUCT", 727, 732], ["BRSV", "ORGANISM", 734, 738], ["BoHV-1", "ORGANISM", 744, 750], ["C. perfringens", "ORGANISM", 783, 797], ["E. coli", "ORGANISM", 799, 806], ["target genomic regions", "DNA", 584, 606], ["avian", "SPECIES", 60, 65], ["bovine", "SPECIES", 67, 73], ["swine", "SPECIES", 79, 84], ["M. haemolytica", "SPECIES", 641, 655], ["H. somni", "SPECIES", 657, 665], ["P. multocida", "SPECIES", 667, 679], ["M. bovis", "SPECIES", 685, 693], ["BRSV", "SPECIES", 734, 738], ["C. perfringens", "SPECIES", 783, 797], ["E. coli", "SPECIES", 799, 806], ["bovine", "SPECIES", 67, 73], ["swine viruses", "SPECIES", 79, 92], ["M. haemolytica", "SPECIES", 641, 655], ["H. somni", "SPECIES", 657, 665], ["P. multocida", "SPECIES", 667, 679], ["M. bovis", "SPECIES", 685, 693], ["BRSV", "SPECIES", 734, 738], ["BoHV-1", "SPECIES", 744, 750], ["C. perfringens", "SPECIES", 783, 797], ["E. coli", "SPECIES", 799, 806], ["S. e.", "SPECIES", 808, 813], ["Electronic microarray based assays", "TEST", 0, 34], ["detection", "TEST", 39, 48], ["several avian, bovine, and swine viruses", "PROBLEM", 52, 92], ["bacteria", "PROBLEM", 97, 105], ["This study", "TEST", 207, 217], ["multiplex PCR", "TEST", 270, 283], ["oligonucleotide electronic microarray assays", "TEST", 288, 332], ["seven respiratory pathogens", "PROBLEM", 360, 387], ["nine enteric pathogens", "PROBLEM", 389, 411], ["two pathogens", "PROBLEM", 416, 429], ["both respiratory and enteric diseases", "PROBLEM", 441, 478], ["methodsSequence databases", "TEST", 532, 557], ["four BRDC-associated bacteria", "PROBLEM", 610, 639], ["haemolytica", "TEST", 644, 655], ["H. somni", "TEST", 657, 665], ["P. multocida", "TEST", 667, 679], ["M. bovis", "TEST", 685, 693], ["associated viruses", "PROBLEM", 707, 725], ["BPI", "TEST", 727, 730], ["BRSV", "TEST", 734, 738], ["BoHV", "TEST", 744, 748], ["four BED-associated bacteria", "PROBLEM", 753, 781], ["C. perfringens", "PROBLEM", 783, 797], ["E. coli", "PROBLEM", 799, 806], ["Lung", "ANATOMY", 138, 142], ["Lung", "ANATOMY", 157, 161], ["Lung", "ANATOMY", 176, 180], ["respiratory", "ANATOMY", 446, 457], ["enteric diseases", "OBSERVATION", 462, 478], ["viruses", "OBSERVATION", 718, 725], ["E. coli", "OBSERVATION", 799, 806]]], ["Typhimurium, and S. e.", [["Typhimurium", "ORGANISM", 0, 11], ["Typhimurium", "SPECIES", 0, 11], ["Typhimurium", "SPECIES", 0, 11], ["S. e.", "SPECIES", 17, 22], ["Typhimurium", "PROBLEM", 0, 11]]], ["Dublin), three BED-associated protozoa (E. zuernii, E. bovis, and C. parvum), two BED-associated viruses (BoRV and BoTV), and two viruses that are associated with both BRDC and BED (BVDV and BCoV) in cattle.", [["Dublin", "GENE_OR_GENE_PRODUCT", 0, 6], ["E. zuernii", "ORGANISM", 40, 50], ["E. bovis", "ORGANISM", 52, 60], ["C. parvum", "ORGANISM", 66, 75], ["BoRV", "ORGANISM", 106, 110], ["BVDV", "ORGANISM", 182, 186], ["BCoV", "CANCER", 191, 195], ["cattle", "ORGANISM", 200, 206], ["E. zuernii", "SPECIES", 40, 50], ["E. bovis", "SPECIES", 52, 60], ["C. parvum", "SPECIES", 66, 75], ["cattle", "SPECIES", 200, 206], ["E. zuernii", "SPECIES", 40, 50], ["E. bovis", "SPECIES", 52, 60], ["C. parvum", "SPECIES", 66, 75], ["BoRV", "SPECIES", 106, 110], ["BoTV", "SPECIES", 115, 119], ["BVDV", "SPECIES", 182, 186], ["BCoV", "SPECIES", 191, 195], ["cattle", "SPECIES", 200, 206], ["associated protozoa", "PROBLEM", 19, 38], ["E. zuernii, E. bovis", "TEST", 40, 60], ["C. parvum", "PROBLEM", 66, 75], ["two BED-associated viruses", "PROBLEM", 78, 104], ["two viruses", "PROBLEM", 126, 137], ["bovis", "ANATOMY", 55, 60], ["parvum", "ANATOMY", 69, 75], ["viruses", "OBSERVATION", 97, 104], ["viruses", "OBSERVATION", 130, 137]]], ["Highly conserved genomic regions of these pathogens were identified through literature search, and all available full and partial nucleic acid sequences for each target were downloaded from the nucleotide database of the National Center for Biotechnology Information (NCBI).", [["nucleic acid", "CHEMICAL", 130, 142], ["nucleotide", "CHEMICAL", 194, 204], ["these pathogens", "PROBLEM", 36, 51], ["partial nucleic acid sequences", "TEST", 122, 152], ["pathogens", "OBSERVATION", 42, 51]]], ["Upon removal of duplicated sequences with identical GenInfo identifiers (GI), multiple sequence alignments for each genetic target were created with MAFFT v.7.0 (Katoh and Standley, 2013) using default settings.", [["GenInfo identifiers", "DNA", 52, 71], ["multiple sequence alignments", "TEST", 78, 106], ["MAFFT", "TEST", 149, 154]]], ["Databases were maintained with BioEdit Sequence Alignment Editor v.7.1.9 (Hall, 1999).Primer design ::: Materials and methodsGenerated sequence databases were used to design four panels of multiplex PCR primers specific for BRDC viruses, BRDC bacteria, BED viruses, and BED bacteria and protozoa (Table 1).", [["BED viruses", "DISEASE", 253, 264], ["BRDC", "GENE_OR_GENE_PRODUCT", 224, 228], ["BRDC bacteria", "ORGANISM", 238, 251], ["BRDC viruses", "SPECIES", 224, 236], ["sequence databases", "TEST", 135, 153], ["four panels", "TEST", 174, 185], ["multiplex PCR primers", "TEST", 189, 210], ["BRDC viruses", "PROBLEM", 224, 236], ["BRDC bacteria", "PROBLEM", 238, 251], ["BED viruses", "PROBLEM", 253, 264], ["BED bacteria", "PROBLEM", 270, 282]]], ["When possible, primers were sourced from literature.", [["primers", "PROBLEM", 15, 22]]], ["New primers were designed using either AlleleID (Premier Biosoft International, Palo Alto, CA) or Primer3web version 4.0.0 (Koressaar and Remm, 2007; Untergasser et al., 2012).", [["New primers", "PROBLEM", 0, 11]]], ["Except for a few instances, a single gene from each pathogen was targeted for PCR amplification.", [["a few instances", "PROBLEM", 11, 26], ["a single gene from each pathogen", "PROBLEM", 28, 60], ["PCR amplification", "TREATMENT", 78, 95]]], ["For M. haemolytica, the leukotoxin A (lktA) gene was selected to detect all serotypes, nmaA and tbpB genes were targeted to differentiate pathogenic serotypes 1 and 6 from commensal serotypes.", [["M. haemolytica", "ORGANISM", 4, 18], ["leukotoxin A", "GENE_OR_GENE_PRODUCT", 24, 36], ["lktA", "GENE_OR_GENE_PRODUCT", 38, 42], ["nmaA", "GENE_OR_GENE_PRODUCT", 87, 91], ["tbpB", "GENE_OR_GENE_PRODUCT", 96, 100], ["leukotoxin A (lktA) gene", "DNA", 24, 48], ["serotypes, nmaA and tbpB genes", "DNA", 76, 106], ["M. haemolytica", "SPECIES", 4, 18], ["M. haemolytica", "SPECIES", 4, 18], ["M. haemolytica", "PROBLEM", 4, 18], ["the leukotoxin A (lktA) gene", "TEST", 20, 48], ["all serotypes", "TEST", 72, 85], ["pathogenic serotypes", "PROBLEM", 138, 158], ["commensal serotypes", "PROBLEM", 172, 191], ["haemolytica", "OBSERVATION", 7, 18]]], ["For E. coli, heat-labile toxin (Lt) genes for identification of enterotoxigenic (ETEC) strains, Intimin (eae) and Shiga-like toxin-1 (stx-1) genes for identification of enterohemorrhagic (EHEC) strains, and K99 gene for identification of enteropathogenic (EPEC) strains were selected.", [["E. coli", "ORGANISM", 4, 11], ["heat-labile toxin", "GENE_OR_GENE_PRODUCT", 13, 30], ["enterotoxigenic (ETEC) strains", "ORGANISM", 64, 94], ["Intimin (eae)", "GENE_OR_GENE_PRODUCT", 96, 109], ["Shiga-like toxin-1", "GENE_OR_GENE_PRODUCT", 114, 132], ["stx-1", "GENE_OR_GENE_PRODUCT", 134, 139], ["enterohemorrhagic (EHEC", "GENE_OR_GENE_PRODUCT", 169, 192], ["K99", "GENE_OR_GENE_PRODUCT", 207, 210], ["heat-labile toxin (Lt) genes", "DNA", 13, 41], ["Intimin (eae) and Shiga-like toxin-1 (stx-1) genes", "DNA", 96, 146], ["K99 gene", "DNA", 207, 215], ["E. coli", "SPECIES", 4, 11], ["E. coli", "SPECIES", 4, 11], ["ETEC", "SPECIES", 81, 85], ["EHEC", "SPECIES", 188, 192], ["EPEC", "SPECIES", 256, 260], ["E. coli", "PROBLEM", 4, 11], ["heat-labile toxin", "TEST", 13, 30], ["enterotoxigenic (ETEC) strains", "PROBLEM", 64, 94], ["Intimin (eae", "TEST", 96, 108], ["Shiga-like toxin", "TEST", 114, 130], ["stx", "TEST", 134, 137], ["enterohemorrhagic (EHEC) strains", "PROBLEM", 169, 201], ["enteropathogenic (EPEC) strains", "PROBLEM", 238, 269], ["coli", "OBSERVATION", 7, 11]]], ["One pair of primers (a forward and a reverse primer) was used for amplification of each target virus except for 5\u2032-untranslated region (5\u2032UTR) of bovine viral diarrhea virus (BVDV).", [["bovine viral diarrhea virus", "DISEASE", 146, 173], ["bovine viral diarrhea virus", "ORGANISM", 146, 173], ["BVDV", "ORGANISM", 175, 179], ["reverse primer", "DNA", 37, 51], ["5\u2032-untranslated region", "DNA", 112, 134], ["5\u2032UTR", "DNA", 136, 141], ["bovine", "SPECIES", 146, 152], ["viral diarrhea virus", "SPECIES", 153, 173], ["bovine viral diarrhea virus", "SPECIES", 146, 173], ["BVDV", "SPECIES", 175, 179], ["a reverse primer", "TREATMENT", 35, 51], ["each target virus", "PROBLEM", 83, 100], ["5\u2032-untranslated region", "TREATMENT", 112, 134], ["bovine viral diarrhea virus", "PROBLEM", 146, 173]]], ["To cover the sequence diversity in the 5\u2032 UTR region of BVDV and HoBi viruses, two forward primers and one reverse primer were used.", [["BVDV", "ORGANISM", 56, 60], ["HoBi viruses", "ORGANISM", 65, 77], ["5\u2032 UTR region", "DNA", 39, 52], ["forward primers", "DNA", 83, 98], ["reverse primer", "DNA", 107, 121], ["BVDV", "SPECIES", 56, 60], ["BVDV", "SPECIES", 56, 60], ["HoBi viruses", "SPECIES", 65, 77], ["the sequence diversity", "TEST", 9, 31], ["BVDV", "PROBLEM", 56, 60], ["HoBi viruses", "PROBLEM", 65, 77], ["two forward primers", "TREATMENT", 79, 98], ["one reverse primer", "TREATMENT", 103, 121], ["BVDV", "OBSERVATION", 56, 60], ["HoBi viruses", "OBSERVATION", 65, 77]]], ["All reverse primers were synthesized with the reverse complementary sequence of the red universal reporter probe at the 5\u2032 end (Huang et al., 2009).", [["reverse primers", "DNA", 4, 19], ["reverse complementary sequence", "DNA", 46, 76], ["red universal reporter probe", "DNA", 84, 112], ["5\u2032 end", "DNA", 120, 126], ["All reverse primers", "TREATMENT", 0, 19]]], ["In addition to pathogen-specific primers, each PCR primer panel contained primers for a selected 229 bp 3\u2032 untranslated region of dengue virus (DENV) that was used as the internal control.", [["dengue", "DISEASE", 130, 136], ["dengue virus", "ORGANISM", 130, 142], ["DENV", "ORGANISM", 144, 148], ["pathogen-specific primers", "DNA", 15, 40], ["PCR primer panel", "DNA", 47, 63], ["229 bp 3\u2032 untranslated region", "DNA", 97, 126], ["dengue virus", "SPECIES", 130, 142], ["dengue virus", "SPECIES", 130, 142], ["DENV", "SPECIES", 144, 148], ["pathogen", "PROBLEM", 15, 23], ["each PCR primer panel", "TEST", 42, 63], ["primers", "TEST", 74, 81], ["bp", "TEST", 101, 103], ["dengue virus (DENV", "PROBLEM", 130, 148], ["the internal control", "TREATMENT", 167, 187], ["dengue virus", "OBSERVATION", 130, 142]]], ["Primer lengths and melting temperatures ranged from 19\u201329 bp and 45\u00b0-60 \u00b0C, respectively (Table 1).", [["Primer lengths", "TEST", 0, 14], ["melting temperatures", "TEST", 19, 39], ["bp", "TEST", 58, 60], ["lengths", "OBSERVATION_MODIFIER", 7, 14]]], ["The best combination of primers for each multiplex panel was selected upon examining various combinations of primers using AlleleID with default settings.Probe design ::: Materials and methodsExcept for BVDV and pestivirus probes, which were adapted from previously published work, all microarray capture probes were newly designed using Primer3web version 4.0.0 (Table 2).", [["BVDV", "ORGANISM", 203, 207], ["BVDV and pestivirus probes", "DNA", 203, 229], ["BVDV", "SPECIES", 203, 207], ["pestivirus", "SPECIES", 212, 222], ["primers", "TREATMENT", 24, 31], ["each multiplex panel", "TEST", 36, 56], ["primers", "TREATMENT", 109, 116], ["AlleleID with default settings", "TREATMENT", 123, 153], ["methods", "TEST", 185, 192], ["BVDV", "PROBLEM", 203, 207], ["pestivirus probes", "TEST", 212, 229], ["all microarray capture probes", "TEST", 282, 311], ["Primer3web version", "TEST", 338, 356]]], ["The probes contained minimal secondary structures (dG \u2265 \u22128.0 kcal/mol) and their lengths, GC contents, and melting temperatures ranged from 20\u201345 bp, 22\u201359%, and 53\u00b0\u201372 \u00b0C, respectively.", [["minimal secondary structures", "PROBLEM", 21, 49], ["dG", "TEST", 51, 53], ["melting temperatures", "TEST", 107, 127], ["bp", "TEST", 146, 148], ["minimal", "OBSERVATION_MODIFIER", 21, 28], ["secondary structures", "OBSERVATION", 29, 49], ["GC contents", "OBSERVATION", 90, 101]]], ["Specificity of each designed primer and probe were evaluated in silico by Nucleotide Basic Local Alignment Search Tool (BLASTn) homology search.", [["each designed primer", "PROBLEM", 15, 35]]], ["Primers or probes that showed significant homology to any non-target species were excluded from further investigation.Laboratory isolates, synthetic constructs, and nucleic acid extraction ::: Materials and methodsA list of laboratory isolates and synthetic genetic materials used in the evaluation (specificity and sensitivity) and initial validation of these assays and their sources are listed in Table 3.", [["nucleic acid", "CHEMICAL", 165, 177], ["nucleic acid", "SIMPLE_CHEMICAL", 165, 177], ["Primers or probes", "TEST", 0, 17], ["significant homology to any non-target species", "PROBLEM", 30, 76], ["further investigation", "TEST", 96, 117], ["Laboratory isolates", "TEST", 118, 137], ["synthetic constructs", "TEST", 139, 159], ["nucleic acid extraction", "TEST", 165, 188], ["laboratory isolates", "TEST", 224, 243], ["synthetic genetic materials", "TREATMENT", 248, 275], ["the evaluation", "TEST", 284, 298], ["sensitivity", "TEST", 316, 327], ["these assays", "TEST", 355, 367]]], ["Specificity of each assay was further evaluated using nucleic acids from a comprehensive panel of non-target pathogens (Supplementary Table 1).", [["nucleic acids", "CHEMICAL", 54, 67], ["each assay", "TEST", 15, 25], ["nucleic acids", "TREATMENT", 54, 67], ["non-target pathogens", "PROBLEM", 98, 118]]], ["Target sequences of Breda virus, a BToV prevalent in North America or any other BToV strains or genomic RNA, were synthesized as gBlocks\u00ae gene fragments (IDT, Coralville, IA), cloned into pCR-Blunt II-TOPO vector (Life Technologies Inc., Carlsbad, CA, USA) and propagated in One Shot TOP10 chemically competent E. coli (Life Technologies Inc.) following the manufacturer\u2019s protocol.", [["Breda virus", "ORGANISM", 20, 31], ["E. coli", "ORGANISM", 311, 318], ["genomic RNA", "RNA", 96, 107], ["gBlocks\u00ae gene fragments", "DNA", 129, 152], ["IDT", "DNA", 154, 157], ["IA", "DNA", 171, 173], ["pCR", "DNA", 188, 191], ["Blunt II", "DNA", 192, 200], ["TOPO vector", "DNA", 201, 212], ["E. coli", "SPECIES", 311, 318], ["Breda virus", "SPECIES", 20, 31], ["E. coli", "SPECIES", 311, 318], ["Breda virus", "PROBLEM", 20, 31], ["any other BToV strains", "PROBLEM", 70, 92], ["genomic RNA", "PROBLEM", 96, 107], ["Blunt II-TOPO vector", "TREATMENT", 192, 212], ["the manufacturer\u2019s protocol", "TREATMENT", 354, 381], ["E. coli", "OBSERVATION", 311, 318]]], ["The plasmids were extracted from overnight liquid cultures using QIAprep Miniprep kit (Qiagen Inc., Hilden Germany) and the sequence information and the orientation of the insert were confirmed by DNA sequencing using the Eurofins sequencing services (Eurofins MWG, Louisville, KY).", [["plasmids", "ANATOMY", 4, 12], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["plasmids", "DNA", 4, 12], ["The plasmids", "TREATMENT", 0, 12], ["overnight liquid cultures", "TEST", 33, 58], ["the insert", "TREATMENT", 168, 178], ["plasmids", "OBSERVATION", 4, 12]]], ["Extracted plasmids were used as templates for PCR amplification of the T7 promoter and the cloned gene target using M13 forward and reverse primers.", [["plasmids", "ANATOMY", 10, 18], ["plasmids", "DNA", 10, 18], ["T7 promoter", "DNA", 71, 82], ["cloned gene target", "DNA", 91, 109], ["M13 forward and reverse primers", "DNA", 116, 147], ["Extracted plasmids", "TREATMENT", 0, 18], ["PCR amplification", "TEST", 46, 63], ["the T7 promoter", "TREATMENT", 67, 82], ["reverse primers", "TREATMENT", 132, 147], ["plasmids", "OBSERVATION", 10, 18]]], ["The amplicons were purified using QIAquick PCR purification kit (Qiagen Inc.) according to manufacturer\u2019s recommendations and subjected to in vitro RNA transcription using MEGAscript T7 Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA).", [["The amplicons", "TREATMENT", 0, 13], ["QIAquick PCR purification kit", "TREATMENT", 34, 63]]], ["The in vitro synthesized BToV RNA was treated with TURBO DNase (Life Technologies Inc.) to remove any template DNA, quantified using Qubit RNA BR Assay kit on Qubit 2.0 fluorometer, (both from Life Technologies Inc.) and used in multiplex PCR and microarray assay evaluation and validation.Laboratory isolates, synthetic constructs, and nucleic acid extraction ::: Materials and methodsQIAamp Viral RNA mini and DNeasy Blood and Tissue kits (both from Qiagen Inc.) were selected to extract nucleic acids from viral and bacterial pathogens respectively, based on the results from previous studies (Lung et al., 2015) following manufacturer\u2019s recommendations.Laboratory isolates, synthetic constructs, and nucleic acid extraction ::: Materials and methodsThe analytical sensitivity of each multiplex PCR assay was determined using nucleic acids extracted from serially diluted laboratory-amplified isolates of each pathogen with known titers, when available.", [["Blood", "ANATOMY", 419, 424], ["nucleic acid", "CHEMICAL", 337, 349], ["nucleic acids", "CHEMICAL", 490, 503], ["nucleic acid", "CHEMICAL", 704, 716], ["nucleic acids", "CHEMICAL", 829, 842], ["BToV", "ORGANISM", 25, 29], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["nucleic acid", "SIMPLE_CHEMICAL", 337, 349], ["Blood", "ORGANISM_SUBSTANCE", 419, 424], ["Tissue", "TISSUE", 429, 435], ["nucleic acid", "SIMPLE_CHEMICAL", 704, 716], ["BToV RNA", "RNA", 25, 33], ["DNase", "PROTEIN", 57, 62], ["template DNA", "DNA", 102, 114], ["TURBO DNase (Life Technologies", "TREATMENT", 51, 81], ["any template DNA", "TREATMENT", 98, 114], ["Qubit 2.0 fluorometer", "TREATMENT", 159, 180], ["multiplex PCR", "TEST", 229, 242], ["microarray assay evaluation", "TEST", 247, 274], ["validation", "TEST", 279, 289], ["Laboratory isolates", "TEST", 290, 309], ["synthetic constructs", "TEST", 311, 331], ["nucleic acid extraction", "TEST", 337, 360], ["Materials", "TEST", 365, 374], ["methodsQIAamp Viral RNA mini", "TREATMENT", 379, 407], ["Tissue kits", "TEST", 429, 440], ["Qiagen Inc.)", "TREATMENT", 452, 464], ["nucleic acids", "TEST", 490, 503], ["viral and bacterial pathogens", "PROBLEM", 509, 538], ["previous studies", "TEST", 579, 595], ["Laboratory isolates", "TEST", 657, 676], ["synthetic constructs", "TEST", 678, 698], ["nucleic acid extraction", "TEST", 704, 727], ["The analytical sensitivity", "TEST", 753, 779], ["each multiplex PCR assay", "TEST", 783, 807], ["nucleic acids", "TEST", 829, 842], ["bacterial pathogens", "OBSERVATION", 519, 538], ["Lung", "ANATOMY", 597, 601]]], ["Titrated virus stocks of BVDV 1 and 2, BoHV1, BRSV, and BPI3 were from Prairie Diagnostic Services, Saskatoon, SK, and bacterial cultures of S. enterica Dublin and Typhimurium strains, and E. coli O101, O111 and O149 strains were kindly provided by Dr. John Fairbrother, Faculty of Veterinary Medicine, University of Montreal, QC.", [["strains", "ANATOMY", 176, 183], ["SK", "CHEMICAL", 111, 113], ["BVDV 1", "ORGANISM", 25, 31], ["2", "GENE_OR_GENE_PRODUCT", 36, 37], ["BoHV1", "GENE_OR_GENE_PRODUCT", 39, 44], ["BRSV", "ORGANISM", 46, 50], ["BPI3", "GENE_OR_GENE_PRODUCT", 56, 60], ["S. enterica Dublin", "ORGANISM", 141, 159], ["Typhimurium strains", "ORGANISM", 164, 183], ["E. coli", "ORGANISM", 189, 196], ["O101", "ORGANISM", 197, 201], ["O111", "CELL", 203, 207], ["O149 strains", "CELL", 212, 224], ["BVDV", "SPECIES", 25, 29], ["BRSV", "SPECIES", 46, 50], ["S. enterica", "SPECIES", 141, 152], ["Typhimurium", "SPECIES", 164, 175], ["E. coli", "SPECIES", 189, 196], ["BVDV 1", "SPECIES", 25, 31], ["BoHV1", "SPECIES", 39, 44], ["BRSV", "SPECIES", 46, 50], ["S. enterica", "SPECIES", 141, 152], ["E. coli", "SPECIES", 189, 196], ["O111", "SPECIES", 203, 207], ["BVDV", "TEST", 25, 29], ["BoHV1", "TEST", 39, 44], ["BRSV", "TEST", 46, 50], ["bacterial cultures", "TEST", 119, 137], ["Typhimurium strains", "PROBLEM", 164, 183], ["E. coli", "PROBLEM", 189, 196], ["BRSV", "ANATOMY", 46, 50], ["SK", "ANATOMY", 111, 113]]], ["Cultures of M. haemolytica type 1, 2 and 6 were from the Lethbridge Research and Development Centre, Lethbridge, AB and P. multocida was from Manitoba Agriculture, Food and Rural Initiative, Winnipeg, MB.", [["M. haemolytica type 1", "ORGANISM", 12, 33], ["P. multocida", "ORGANISM", 120, 132], ["M. haemolytica", "SPECIES", 12, 26], ["P. multocida", "SPECIES", 120, 132], ["M. haemolytica type 1", "SPECIES", 12, 33], ["P. multocida", "SPECIES", 120, 132], ["Cultures", "TEST", 0, 8], ["M. haemolytica type", "TEST", 12, 31], ["Lethbridge", "TREATMENT", 101, 111]]], ["Titrated C. parvum oocysts were purchased from Creative Sciences, Scotland, UK.Laboratory isolates, synthetic constructs, and nucleic acid extraction ::: Materials and methodsNucleic acids from viruses were extracted from 10-fold dilutions of titrated virus stocks.", [["nucleic acid", "CHEMICAL", 126, 138], ["C. parvum", "ORGANISM", 9, 18], ["oocysts", "ORGANISM", 19, 26], ["nucleic acid", "SIMPLE_CHEMICAL", 126, 138], ["Nucleic acids", "SIMPLE_CHEMICAL", 175, 188], ["C. parvum", "SPECIES", 9, 18], ["C. parvum", "SPECIES", 9, 18], ["C. parvum oocysts", "PROBLEM", 9, 26], ["Laboratory isolates", "TEST", 79, 98], ["synthetic constructs", "TEST", 100, 120], ["nucleic acid extraction", "TEST", 126, 149], ["methodsNucleic acids", "TEST", 168, 188], ["viruses", "PROBLEM", 194, 201], ["titrated virus stocks", "TREATMENT", 243, 264], ["parvum oocysts", "OBSERVATION", 12, 26]]], ["With respect to bacteria, frozen stocks of M. haemolytica strains, S. e.", [["M. haemolytica", "ORGANISM", 43, 57], ["M. haemolytica", "SPECIES", 43, 57], ["M. haemolytica", "SPECIES", 43, 57], ["S. e.", "SPECIES", 67, 72], ["bacteria", "PROBLEM", 16, 24], ["haemolytica strains", "PROBLEM", 46, 65], ["bacteria", "OBSERVATION", 16, 24]]], ["Dublin, S. e.", [["S. e.", "SPECIES", 8, 13]]], ["Typhimurium, and E. coli strains were streaked onto LB agar plates and P. multocida onto 5% sheep blood agar plates.", [["blood", "ANATOMY", 98, 103], ["Typhimurium", "ORGANISM", 0, 11], ["E. coli", "ORGANISM", 17, 24], ["strains", "ORGANISM", 25, 32], ["P. multocida", "ORGANISM", 71, 83], ["sheep", "ORGANISM", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["Typhimurium", "SPECIES", 0, 11], ["E. coli", "SPECIES", 17, 24], ["P. multocida", "SPECIES", 71, 83], ["sheep", "SPECIES", 92, 97], ["Typhimurium", "SPECIES", 0, 11], ["E. coli", "SPECIES", 17, 24], ["P. multocida", "SPECIES", 71, 83], ["sheep", "SPECIES", 92, 97], ["Typhimurium", "PROBLEM", 0, 11], ["E. coli strains", "PROBLEM", 17, 32], ["LB agar plates", "TEST", 52, 66], ["P. multocida", "TEST", 71, 83], ["5% sheep blood agar plates", "TREATMENT", 89, 115], ["coli strains", "OBSERVATION", 20, 32], ["agar plates", "OBSERVATION", 104, 115]]], ["Following overnight incubation at 37 \u00b0C, single colonies of each bacterium was harvested and inoculated into 5 ml of Miller\u2019s LB broth and incubated overnight at 37 \u00b0C on a shaking incubator (150 rpm).", [["colonies", "ANATOMY", 48, 56], ["each bacterium", "PROBLEM", 60, 74], ["a shaking incubator", "TREATMENT", 171, 190]]], ["On the next day, the cultures were enumerated using viable plate count method (Miller, 1972).", [["the cultures", "TEST", 17, 29]]], ["The cultures were standardized to 3.33 \u00d7 10^6 cfu/ml so that a 30 \u03bcl aliquot of each 10x serial dilution for each pathogen yielded CFUs to the nearest power of base 10 (i.e. 1 \u00d7 106, 1 \u00d7 105, etc.).", [["The cultures", "TEST", 0, 12], ["each pathogen", "PROBLEM", 109, 122]]], ["Thirty microliters of each dilution were used for nucleic acid extraction.Laboratory isolates, synthetic constructs, and nucleic acid extraction ::: Materials and methodsTitrated stocks were not available for M. bovis, H. somni, E. bovis, E. zuernii, C. perfringens, BRoV A, B and C strains, and BCoV.", [["nucleic acid", "CHEMICAL", 50, 62], ["nucleic acid", "CHEMICAL", 121, 133], ["nucleic acid", "SIMPLE_CHEMICAL", 50, 62], ["nucleic acid", "SIMPLE_CHEMICAL", 121, 133], ["M. bovis", "ORGANISM", 209, 217], ["H. somni", "ORGANISM", 219, 227], ["E. bovis", "ORGANISM", 229, 237], ["E. zuernii", "ORGANISM", 239, 249], ["C. perfringens", "ORGANISM", 251, 265], ["BRoV A", "ORGANISM", 267, 273], ["B and C strains", "ORGANISM", 275, 290], ["M. bovis", "SPECIES", 209, 217], ["H. somni", "SPECIES", 219, 227], ["E. bovis", "SPECIES", 229, 237], ["E. zuernii", "SPECIES", 239, 249], ["C. perfringens", "SPECIES", 251, 265], ["M. bovis", "SPECIES", 209, 217], ["H. somni", "SPECIES", 219, 227], ["E. bovis", "SPECIES", 229, 237], ["E. zuernii", "SPECIES", 239, 249], ["C. perfringens", "SPECIES", 251, 265], ["BRoV A", "SPECIES", 267, 273], ["BCoV", "SPECIES", 296, 300], ["each dilution", "TREATMENT", 22, 35], ["nucleic acid extraction", "TREATMENT", 50, 73], ["Laboratory isolates", "TEST", 74, 93], ["synthetic constructs", "TEST", 95, 115], ["nucleic acid extraction", "TEST", 121, 144], ["methodsTitrated stocks", "TREATMENT", 163, 185], ["C. perfringens", "PROBLEM", 251, 265], ["B and C strains", "TREATMENT", 275, 290], ["bovis", "ANATOMY", 232, 237]]], ["Therefore synthetic gene fragments targeting the genes of interest of these pathogens were artificially synthesized and individually cloned into pBlueScript SK(+) expression vector (GenScript, Piscataway, NJ).", [["SK", "GENE_OR_GENE_PRODUCT", 157, 159], ["synthetic gene fragments", "DNA", 10, 34], ["pBlueScript SK(+) expression vector", "DNA", 145, 180], ["synthetic gene fragments", "PROBLEM", 10, 34], ["these pathogens", "PROBLEM", 70, 85], ["fragments", "OBSERVATION_MODIFIER", 25, 34]]], ["For DNA targets, cloned plasmids were amplified, quantified and directly used in limit-of-detection experiments.", [["plasmids", "ANATOMY", 24, 32], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA targets", "DNA", 4, 15], ["cloned plasmids", "DNA", 17, 32], ["DNA targets", "PROBLEM", 4, 15], ["cloned plasmids", "TREATMENT", 17, 32]]], ["For RNA targets, the plasmids with target sequences were subjected to in vitro RNA transcription using MEGAscript T7 transcription kit as described above (Thermo Fisher Scientific).", [["plasmids", "ANATOMY", 21, 29], ["RNA targets", "DNA", 4, 15], ["plasmids", "DNA", 21, 29], ["RNA targets", "PROBLEM", 4, 15], ["the plasmids", "TREATMENT", 17, 29], ["target sequences", "TEST", 35, 51], ["vitro RNA transcription", "TREATMENT", 73, 96], ["MEGAscript T7 transcription kit", "TREATMENT", 103, 134]]], ["Based on the DNA/RNA yield and the length of each target sequence, copy numbers were calculated using a copy number calculator (http://www.endmemo.com/bio/dnacopynum.php) and used to determine the analytical sensitivities of multiplex PCR assays.Clinical samples and nucleic acid extraction ::: Materials and methodsClinical samples (Table 4) used in validation of the assays were from Prairie Diagnostic Services, Saskatoon, SK and Animal Health Centre, Ministry of Agriculture, Abbotsford, BC.", [["samples", "ANATOMY", 255, 262], ["samples", "ANATOMY", 325, 332], ["nucleic acid", "CHEMICAL", 267, 279], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["nucleic acid", "SIMPLE_CHEMICAL", 267, 279], ["multiplex PCR assays", "TEST", 225, 245], ["Clinical samples", "TEST", 246, 262], ["nucleic acid extraction", "TEST", 267, 290]]], ["The clinical samples for BRDC-associated pathogens included nasal swabs (n = 12) and lung tissues (n = 2), whereas for BED-associated pathogens, the clinical sample were feces (n = 13), intestinal tissues (n = 1) and rectal swabs.", [["samples", "ANATOMY", 13, 20], ["nasal swabs", "ANATOMY", 60, 71], ["lung tissues", "ANATOMY", 85, 97], ["sample", "ANATOMY", 158, 164], ["feces", "ANATOMY", 170, 175], ["intestinal tissues", "ANATOMY", 186, 204], ["rectal swabs", "ANATOMY", 217, 229], ["BED", "CHEMICAL", 119, 122], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 60, 71], ["lung tissues", "TISSUE", 85, 97], ["feces", "ORGANISM_SUBSTANCE", 170, 175], ["intestinal tissues", "TISSUE", 186, 204], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 217, 229], ["The clinical samples", "TEST", 0, 20], ["BRDC-associated pathogens", "PROBLEM", 25, 50], ["nasal swabs", "TEST", 60, 71], ["lung tissues", "PROBLEM", 85, 97], ["BED-associated pathogens", "PROBLEM", 119, 143], ["the clinical sample", "TEST", 145, 164], ["intestinal tissues", "PROBLEM", 186, 204], ["rectal swabs", "TEST", 217, 229], ["lung tissues", "ANATOMY", 85, 97], ["intestinal tissues", "ANATOMY", 186, 204], ["rectal", "ANATOMY", 217, 223]]], ["Nasal swabs (n = 10) and fecal swabs (n = 8) from clinically healthy cattle were obtained from the herd at the Lethbridge Laboratory of the Canadian Food Inspection Agency.", [["Nasal swabs", "ANATOMY", 0, 11], ["fecal swabs", "ANATOMY", 25, 36], ["Nasal swabs", "MULTI-TISSUE_STRUCTURE", 0, 11], ["fecal swabs", "ORGANISM_SUBSTANCE", 25, 36], ["cattle", "ORGANISM", 69, 75], ["cattle", "SPECIES", 69, 75], ["cattle", "SPECIES", 69, 75], ["Nasal swabs", "TEST", 0, 11], ["fecal swabs", "TEST", 25, 36], ["fecal", "ANATOMY", 25, 30]]], ["DNeasy Blood & Tissue kit and QIAamp DNA Stool Mini kit (both from Qiagen inc.) were used to extract nucleic acid from BRDC clinical samples and BED clinical samples, respectively, according to the manufacturer\u2019s recommendations.PCR and RT-PCR conditions ::: Materials and methodsInitially, four pools of PCR primers were prepared (75 \u03bcM final concentration of each primer) to use in their respective multiplex PCR assays i.e. BRDC virus, BRDC bacteria, BED virus, and BED bacteria/protozoa assays.", [["samples", "ANATOMY", 133, 140], ["samples", "ANATOMY", 158, 165], ["nucleic acid", "CHEMICAL", 101, 113], ["DNeasy Blood", "ORGANISM_SUBSTANCE", 0, 12], ["Tissue kit", "ORGANISM_SUBSTANCE", 15, 25], ["nucleic acid", "SIMPLE_CHEMICAL", 101, 113], ["BRDC virus", "ORGANISM", 427, 437], ["BRDC bacteria", "ORGANISM", 439, 452], ["PCR primers", "DNA", 305, 316], ["BRDC virus", "SPECIES", 427, 437], ["BED virus", "SPECIES", 454, 463], ["DNeasy Blood", "TEST", 0, 12], ["Tissue kit", "TEST", 15, 25], ["QIAamp DNA", "TEST", 30, 40], ["Mini kit", "TEST", 47, 55], ["Qiagen inc.)", "TREATMENT", 67, 79], ["nucleic acid", "TEST", 101, 113], ["BED clinical samples", "TEST", 145, 165], ["PCR", "TEST", 229, 232], ["RT-PCR conditions", "TEST", 237, 254], ["PCR primers", "TREATMENT", 305, 316], ["each primer)", "TREATMENT", 361, 373], ["their respective multiplex PCR assays", "TEST", 384, 421], ["BRDC virus", "PROBLEM", 427, 437], ["BRDC bacteria", "PROBLEM", 439, 452], ["BED virus", "PROBLEM", 454, 463], ["BED bacteria", "PROBLEM", 469, 481], ["protozoa assays", "PROBLEM", 482, 497], ["Tissue", "ANATOMY", 15, 21], ["BED", "ANATOMY", 469, 472]]], ["As presented in Table 1, the BRDC virus primer panel consisted of 12 primers targeting various genomic regions of five viruses.", [["BRDC virus", "ORGANISM", 29, 39], ["genomic regions", "DNA", 95, 110], ["BRDC virus", "SPECIES", 29, 39], ["the BRDC virus primer panel", "TEST", 25, 52], ["five viruses", "OBSERVATION", 114, 126]]], ["The BRDC bacteria panel consisted of 14 primers targeting four pathogenic bacterial species.", [["The BRDC bacteria panel", "TEST", 0, 23], ["14 primers", "PROBLEM", 37, 47], ["four pathogenic bacterial species", "PROBLEM", 58, 91], ["pathogenic", "OBSERVATION_MODIFIER", 63, 73], ["bacterial species", "OBSERVATION", 74, 91]]], ["The BED virus primer panel contained 13 primers targeting four viruses, and the BED bacteria/protozoa panel contained 20 primers targeting various genomic regions in seven pathogenic bacteria and protozoa.", [["genomic regions", "DNA", 147, 162], ["The BED virus primer panel", "TEST", 0, 26], ["four viruses", "PROBLEM", 58, 70], ["the BED bacteria", "TEST", 76, 92], ["protozoa panel", "TEST", 93, 107], ["various genomic regions", "PROBLEM", 139, 162], ["seven pathogenic bacteria", "PROBLEM", 166, 191], ["protozoa", "PROBLEM", 196, 204], ["seven", "OBSERVATION_MODIFIER", 166, 171], ["pathogenic bacteria", "OBSERVATION", 172, 191]]], ["Forward and reverse primers for the DENV internal control were included in the total number of primers in each pool.PCR and RT-PCR conditions ::: Materials and methodsAll four multiplex PCR assays were optimized for buffer and magnesium concentration, annealing temperature, cycle number, and internal control concentration.", [["magnesium", "CHEMICAL", 227, 236], ["magnesium", "CHEMICAL", 227, 236], ["magnesium", "SIMPLE_CHEMICAL", 227, 236], ["Forward and reverse primers", "DNA", 0, 27], ["DENV", "SPECIES", 36, 40], ["Forward and reverse primers", "TREATMENT", 0, 27], ["the DENV internal control", "TREATMENT", 32, 57], ["PCR", "TEST", 116, 119], ["RT-PCR conditions", "TEST", 124, 141], ["All four multiplex PCR assays", "TEST", 167, 196], ["buffer and magnesium concentration", "TREATMENT", 216, 250], ["annealing temperature", "TEST", 252, 273], ["internal control concentration", "TREATMENT", 293, 323]]], ["All reactions were performed on a Veriti\u00ae 96-Well Fast Thermal Cycler (Applied Biosystems, Foster City, CA).", [["All reactions", "PROBLEM", 0, 13], ["a Veriti\u00ae", "TEST", 32, 41], ["Fast Thermal Cycler (Applied Biosystems", "TREATMENT", 50, 89]]], ["For virus targets, both singleplex and multiplex reverse transcription (RT)-PCR assays were performed using Superscript III One-step RT-PCR kit with Platinum Taq DNA polymerase (Thermo Fisher Scientific).", [["DNA", "CELLULAR_COMPONENT", 162, 165], ["Platinum Taq DNA polymerase", "PROTEIN", 149, 176], ["virus targets", "TREATMENT", 4, 17], ["both singleplex", "TREATMENT", 19, 34], ["multiplex reverse transcription", "TREATMENT", 39, 70], ["PCR assays", "TEST", 76, 86], ["Superscript III One-step RT-PCR kit", "TREATMENT", 108, 143], ["Platinum Taq DNA polymerase", "TREATMENT", 149, 176]]], ["The finalized RT-PCR mixtures consisted of 1 \u03bcl of nucleic acid, 0.001 pg of internal control, 1 \u03bcl of enzyme mix, 2 \u03bcl of pooled primers (0.25 \u03bcM final concentration) and 12.5 \u03bcl of 2 x reaction buffer in a final reaction volume of 25 \u03bcl.", [["nucleic acid", "CHEMICAL", 51, 63], ["nucleic acid", "SIMPLE_CHEMICAL", 51, 63], ["The finalized RT-PCR mixtures", "TEST", 0, 29], ["nucleic acid", "TREATMENT", 51, 63], ["internal control", "TREATMENT", 77, 93], ["enzyme mix", "TREATMENT", 103, 113], ["pooled primers", "TREATMENT", 123, 137], ["a final reaction volume", "TEST", 206, 229]]], ["For bacterial and protozoal targets, singleplex PCR assays were performed using Platinum Taq DNA Polymerase (Invitrogen) according to the manufacturer\u2019s instructions and multiplex PCR were performed using Platinum\u00ae Multiplex PCR Master Mix (Applied Biosystems).", [["DNA", "CELLULAR_COMPONENT", 93, 96], ["Platinum Taq DNA Polymerase", "PROTEIN", 80, 107], ["bacterial and protozoal targets", "PROBLEM", 4, 35], ["singleplex PCR assays", "TEST", 37, 58], ["Platinum Taq DNA Polymerase (Invitrogen)", "TREATMENT", 80, 120], ["multiplex PCR", "TEST", 170, 183], ["Platinum\u00ae Multiplex PCR Master Mix", "TREATMENT", 205, 239], ["protozoal targets", "OBSERVATION", 18, 35]]], ["Finalized multiplex PCR mixtures consisted of 1 \u03bcl of nucleic acid, 0.001 pg of internal control, 12.5 \u03bcl of 2x Platinum\u00ae Multiplex PCR Master Mix, and 2 \u03bcl of pooled primers to a final volume of 25 \u03bcl.", [["nucleic acid", "CHEMICAL", 54, 66], ["Platinum\u00ae", "CHEMICAL", 112, 121], ["nucleic acid", "SIMPLE_CHEMICAL", 54, 66], ["multiplex PCR mixtures", "TEST", 10, 32], ["nucleic acid", "TREATMENT", 54, 66], ["internal control", "TREATMENT", 80, 96], ["2x Platinum", "TREATMENT", 109, 120], ["pooled primers", "TREATMENT", 160, 174], ["a final volume", "TEST", 178, 192]]], ["PCR cycling conditions were 2 min of initial denaturation at 94 \u00b0C followed by 40 cycles of 30 s at 94 \u00b0C, 30 s at 55 \u00b0C, and 40 s at 68 \u00b0C, and 5 min at 68 \u00b0C for final extension.", [["PCR cycling conditions", "TEST", 0, 22], ["initial denaturation", "PROBLEM", 37, 57]]], ["The RT-PCR cycling conditions included an initial RT step of 30 min at 50 \u00b0C followed by the same cycling conditions described above.", [["The RT-PCR cycling conditions", "TEST", 0, 29], ["an initial RT step", "TREATMENT", 39, 57]]], ["Amplified products were visualized by gel electrophoresis using the QIAxcel Advanced System (Qiagen).", [["Amplified products", "TREATMENT", 0, 18], ["the QIAxcel Advanced System (Qiagen)", "TREATMENT", 64, 100]]], ["The minimum number of target copies in a sample that could produce a detectable band by electrophoresis upon PCR amplification was considered as the limit-of-detection (LOD) for each multiplex PCR.", [["sample", "ANATOMY", 41, 47], ["a detectable band by electrophoresis", "PROBLEM", 67, 103], ["PCR amplification", "TEST", 109, 126], ["each multiplex PCR", "TEST", 178, 196], ["minimum", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["Any loss of sensitivity due to multiplexing was evaluated by comparison of LODs between singleplex and multiplex PCRs for each target.Electronic microarray ::: Materials and methodsBased on the evaluation of 76 microarray capture probes, 58 probes were selected to generate the four microarray panels to detect the BRDC and BED pathogens (Table 2).", [["Any loss of sensitivity", "PROBLEM", 0, 23], ["LODs", "TEST", 75, 79], ["singleplex", "TREATMENT", 88, 98], ["multiplex PCRs", "TEST", 103, 117], ["the evaluation", "TEST", 190, 204], ["microarray capture probes", "TEST", 211, 236], ["the four microarray panels", "TEST", 274, 300], ["the BRDC and BED pathogens", "PROBLEM", 311, 337]]], ["In addition to the pathogen-specific probes, each panel also consisted of a probe specific for the DENV internal control.", [["DENV", "SPECIES", 99, 103], ["each panel", "TEST", 45, 55], ["the DENV internal control", "TREATMENT", 95, 120], ["DENV", "OBSERVATION", 99, 103]]], ["The selected probes were validated on the NanoChip\u00ae 400 (NC400) electronic microarray platform (Nanogen, San Diego, CA), which is an \u201camplicon-to-answer\u201d system that automates the post-PCR analytical steps i.e. array printing, electrophoretically-driven amplicon hybridization, washing, and reporting (Takahashi et al., 2008; Papatheodorou et al., 2010; Keen-Kim et al., 2006).", [["the NanoChip\u00ae", "TREATMENT", 38, 51], ["an \u201camplicon", "TREATMENT", 130, 142], ["amplicon hybridization", "TREATMENT", 254, 276]]], ["The NC400 microarray protocol was carried out as previously described by (Lung et al., 2012) with modifications as described by (Lung et al., 2015).", [["NC400", "DNA", 4, 9], ["The NC400 microarray protocol", "TREATMENT", 0, 29], ["Lung", "ANATOMY", 74, 78], ["Lung", "ANATOMY", 129, 133]]], ["Briefly, biotinylated capture probes (250 nM) prepared in 50 mM histidine buffer containing 0.05% Proclin, were electronically addressed (\u201cprinted\u201d) to selected electrodes (test sites) in duplicate on the NC 400 cartridge through the application of a positive 350 nA current for 30 s.", [["histidine", "CHEMICAL", 64, 73], ["histidine", "CHEMICAL", 64, 73], ["Proclin", "SIMPLE_CHEMICAL", 98, 105], ["biotinylated capture probes", "TREATMENT", 9, 36], ["50 mM histidine buffer", "TREATMENT", 58, 80], ["0.05% Proclin", "TREATMENT", 92, 105], ["the NC 400 cartridge", "TREATMENT", 201, 221]]], ["After five washes of the cartridge with histidine buffer, unpurified PCR amplicons, diluted 1:8 in Cap-Down A Buffer (Nexogen Inc., San Diego, CA), were electronically addressed to selected test sites (800 nA for 120 s).", [["histidine", "CHEMICAL", 40, 49], ["histidine", "CHEMICAL", 40, 49], ["unpurified PCR amplicons", "DNA", 58, 82], ["the cartridge", "TREATMENT", 21, 34], ["histidine buffer", "TREATMENT", 40, 56], ["unpurified PCR amplicons", "TREATMENT", 58, 82], ["A Buffer (Nexogen Inc.", "TREATMENT", 108, 130]]], ["After five more washes with histidine buffer, the cartridge was subsequently filled with low-salt buffer (LSB) (Nexogen Inc.).", [["histidine", "CHEMICAL", 28, 37], ["histidine", "CHEMICAL", 28, 37], ["histidine buffer", "TREATMENT", 28, 44], ["the cartridge", "TREATMENT", 46, 59], ["low-salt buffer (LSB", "TREATMENT", 89, 109]]], ["Hybridized amplicons were detected using 5\u2032-Alexa Fluor 647 modified locked nucleic acid (LNA) variant (5\u2032-/5Alex647 N/TGT + CA + AGCG + AT + AT + ACT + GC-3\u2032) (IDT).", [["nucleic acid", "CHEMICAL", 76, 88], ["LNA", "CHEMICAL", 90, 93], ["5\u2032-Alexa Fluor 647", "CHEMICAL", 41, 59], ["Alexa Fluor 647", "SIMPLE_CHEMICAL", 44, 59], ["locked nucleic acid", "SIMPLE_CHEMICAL", 69, 88], ["LNA", "SIMPLE_CHEMICAL", 90, 93], ["CA", "PROTEIN", 125, 127], ["AGCG", "PROTEIN", 130, 134], ["ACT", "PROTEIN", 147, 150], ["Hybridized amplicons", "TREATMENT", 0, 20], ["variant", "TEST", 95, 102], ["TGT", "TEST", 119, 122], ["CA", "TEST", 125, 127], ["AGCG", "TEST", 130, 134], ["ACT", "TEST", 147, 150], ["GC", "TEST", 153, 155]]], ["The reporting protocol included washing of the microarray cartridge with LSB at 2 \u00b0C temperature increments between 24 \u00b0C and 60 \u00b0C. An image was taken at each temperature increment, and the raw fluorescent intensity (FI) data from all utilized electrodes at each temperature increment were obtained and analyzed using Microsoft Excel.", [["the microarray cartridge", "TREATMENT", 43, 67], ["An image", "TEST", 133, 141]]], ["For each probe, positive-to-no-template control (P:N) ratios were calculated by dividing the FI value from each analyte by the FI value produced by the no template control (NTC).", [["each probe", "TEST", 4, 14]]], ["For each assay, samples that produced P:N ratios of 2.0 or greater were considered positive.", [["samples", "ANATOMY", 16, 23], ["each assay", "TEST", 4, 14], ["samples", "TEST", 16, 23], ["P:N ratios", "TEST", 38, 48]]], ["Average P:N data derived from the microarrays were visualized with a heat map generated using Microsoft Excel.", [["P:N data", "DNA", 8, 16], ["the microarrays", "TEST", 30, 45], ["a heat map", "TEST", 67, 77]]], ["Based on preliminary data, P:N ratios calculated using FI values at 50 \u00b0C were considered as optimum and used throughout this study.Electronic microarray ::: Materials and methodsAmplicons generated by multiplex PCR using 10-fold serial dilutions of each target were used to determine the detection limits of the microarray (Table 5).", [["preliminary data", "TEST", 9, 25], ["N ratios", "TEST", 29, 37], ["FI values", "TEST", 55, 64], ["this study", "TEST", 121, 131], ["methodsAmplicons", "TREATMENT", 172, 188], ["multiplex PCR", "TEST", 202, 215]]], ["The highest dilution of the target that resulted in P:N ratio of 2 or higher was considered as the LOD of the electronic microarray for that target.Multiplex RT-PCR for BRDC and BED viruses ::: ResultsAll respiratory and enteric viral pathogens targeted in this study are RNA viruses except for BoHV-1, which is a DNA virus.", [["respiratory", "ANATOMY", 205, 216], ["BoHV-1", "GENE_OR_GENE_PRODUCT", 295, 301], ["DNA", "CELLULAR_COMPONENT", 314, 317], ["BoHV", "PROTEIN", 295, 299], ["BoHV-1", "SPECIES", 295, 301], ["P:N ratio", "TEST", 52, 61], ["Multiplex RT-PCR", "TEST", 148, 164], ["BRDC", "PROBLEM", 169, 173], ["All respiratory and enteric viral pathogens", "PROBLEM", 201, 244], ["this study", "TEST", 257, 267], ["RNA viruses", "PROBLEM", 272, 283], ["BoHV", "TEST", 295, 299], ["a DNA virus", "PROBLEM", 312, 323], ["respiratory", "ANATOMY", 205, 216], ["enteric", "ANATOMY", 221, 228]]], ["RT-PCR was performed to amplify BRDC and BED viral targets using respective multiplex primer panel.", [["BRDC and BED viral targets", "DNA", 32, 58], ["RT-PCR", "TEST", 0, 6], ["BRDC", "TEST", 32, 36], ["BED viral targets", "TEST", 41, 58], ["respective multiplex primer panel", "TEST", 65, 98]]], ["Optimized five-plex RT-PCR assay targeting BRDC viruses could successfully amplify genetic targets from all three BRDC-specific viruses (BoHV-1, BRSV, and BPI-3) and two viruses that are associated with both respiratory and enteric diseases (BCoV and BVDV).", [["respiratory", "ANATOMY", 208, 219], ["respiratory and enteric diseases", "DISEASE", 208, 240], ["BRDC viruses", "ORGANISM", 43, 55], ["BRDC", "GENE_OR_GENE_PRODUCT", 114, 118], ["BoHV-1", "ORGANISM", 137, 143], ["BRSV", "ORGANISM", 145, 149], ["BPI-3", "GENE_OR_GENE_PRODUCT", 155, 160], ["BVDV", "ORGANISM", 251, 255], ["BRSV", "SPECIES", 145, 149], ["BRDC viruses", "SPECIES", 43, 55], ["BoHV-1", "SPECIES", 137, 143], ["BRSV", "SPECIES", 145, 149], ["BCoV", "SPECIES", 242, 246], ["BVDV", "SPECIES", 251, 255], ["PCR assay", "TEST", 23, 32], ["BRDC viruses", "PROBLEM", 43, 55], ["genetic targets", "TEST", 83, 98], ["all three BRDC", "TEST", 104, 118], ["BoHV", "TEST", 137, 141], ["BRSV", "TEST", 145, 149], ["BPI", "TEST", 155, 158], ["two viruses", "PROBLEM", 166, 177], ["both respiratory and enteric diseases", "PROBLEM", 203, 240], ["BVDV", "PROBLEM", 251, 255], ["viruses", "OBSERVATION", 170, 177], ["respiratory", "ANATOMY", 208, 219], ["enteric diseases", "OBSERVATION", 224, 240]]], ["Primers targeting BVDV were able to amplify \u223c280bp region of 5\u2032UTR sequence of type 1 and 2 strains of BVDV as well as HoBi virus (a.k.a.", [["BVDV", "ORGANISM", 18, 22], ["BVDV", "ORGANISM", 103, 107], ["HoBi virus", "ORGANISM", 119, 129], ["\u223c280bp region", "DNA", 44, 57], ["5\u2032UTR sequence", "DNA", 61, 75], ["BVDV", "SPECIES", 103, 107], ["BVDV", "SPECIES", 18, 22], ["BVDV", "SPECIES", 103, 107], ["HoBi virus", "SPECIES", 119, 129], ["Primers targeting BVDV", "PROBLEM", 0, 22], ["UTR sequence", "TEST", 63, 75], ["type 1", "PROBLEM", 79, 85], ["BVDV", "PROBLEM", 103, 107], ["HoBi virus", "PROBLEM", 119, 129], ["BVDV", "OBSERVATION", 103, 107]]], ["BVDV type 3).", [["BVDV", "ORGANISM", 0, 4], ["BVDV", "SPECIES", 0, 4]]], ["Differentiation of each type of BVDV upon PCR amplification was achieved by the subsequent use of type-specific microarray detection probes (see below).", [["BVDV", "ORGANISM", 32, 36], ["BVDV", "SPECIES", 32, 36], ["BVDV", "PROBLEM", 32, 36], ["PCR amplification", "TEST", 42, 59], ["type-specific microarray detection probes", "TEST", 98, 139], ["BVDV", "OBSERVATION", 32, 36]]], ["With respect to the BED virus assay, the optimized RT-PCR assay included primers specific for BToV and BRoV along with primers specific for BVDV and BCoV.", [["BToV", "GENE_OR_GENE_PRODUCT", 94, 98], ["BRoV", "GENE_OR_GENE_PRODUCT", 103, 107], ["BVDV", "ORGANISM", 140, 144], ["BCoV", "GENE_OR_GENE_PRODUCT", 149, 153], ["BToV", "DNA", 94, 98], ["BRoV", "DNA", 103, 107], ["BToV", "SPECIES", 94, 98], ["BRoV", "SPECIES", 103, 107], ["BVDV", "SPECIES", 140, 144], ["BCoV", "SPECIES", 149, 153], ["the BED virus assay", "TEST", 16, 35], ["the optimized RT-PCR assay", "TEST", 37, 63], ["BToV", "PROBLEM", 94, 98], ["primers", "TREATMENT", 119, 126], ["BVDV", "PROBLEM", 140, 144]]], ["The BED primer panel consisted of two sets of BRoV-specific primers, one set targeting 467bp segment of VP6 gene of BRoV type A and C and another set targeting a 584bp segment of the same gene of BRoV type B. As observed by using laboratory strains of target pathogens or transcribed RNA (Table 3), both the BRDC and BED assays generated PCR products of expected sizes without any detectable cross reaction (Fig. 1).Multiplex PCR for BRDC and BED bacteria/protozoa ::: ResultsMultiplex PCR assays for bacterial pathogens associated with BRDC and bacterial and protozoan pathogens associated with BED were successfully optimized and validated using laboratory isolates, when available, and synthetic genetic material (Table 3).", [["BRoV", "GENE_OR_GENE_PRODUCT", 46, 50], ["VP6", "GENE_OR_GENE_PRODUCT", 104, 107], ["BRoV type A", "GENE_OR_GENE_PRODUCT", 116, 127], ["C", "CANCER", 132, 133], ["BRoV type B.", "ORGANISM", 196, 208], ["BRoV", "DNA", 46, 50], ["467bp segment", "DNA", 87, 100], ["VP6 gene", "DNA", 104, 112], ["584bp segment", "DNA", 162, 175], ["transcribed RNA", "RNA", 272, 287], ["BRDC", "DNA", 308, 312], ["BRoV type B.", "SPECIES", 196, 208], ["The BED primer panel", "TEST", 0, 20], ["BRoV type B.", "PROBLEM", 196, 208], ["laboratory strains", "TEST", 230, 248], ["target pathogens", "PROBLEM", 252, 268], ["BED assays", "TEST", 317, 327], ["any detectable cross reaction", "PROBLEM", 377, 406], ["Multiplex PCR", "TEST", 416, 429], ["BRDC", "PROBLEM", 434, 438], ["BED bacteria", "PROBLEM", 443, 455], ["protozoa", "PROBLEM", 456, 464], ["ResultsMultiplex PCR assays", "TEST", 469, 496], ["bacterial pathogens", "PROBLEM", 501, 520], ["BRDC", "PROBLEM", 537, 541], ["bacterial and protozoan pathogens", "PROBLEM", 546, 579], ["laboratory isolates", "TEST", 648, 667], ["bacterial", "OBSERVATION_MODIFIER", 546, 555], ["protozoan pathogens", "OBSERVATION", 560, 579]]], ["With a view of potential simultaneous testing of a single sample for both RNA and DNA pathogens, PCR cycling conditions used for bacterial assays were the same as those used in the RT-PCR.", [["DNA", "CELLULAR_COMPONENT", 82, 85], ["potential simultaneous testing", "TEST", 15, 45], ["a single sample", "TEST", 49, 64], ["DNA pathogens", "PROBLEM", 82, 95], ["PCR cycling conditions", "TEST", 97, 119], ["bacterial assays", "TEST", 129, 145]]], ["The additional step of 50 \u00b0C for 30 min (i.e. conditions for RT step) before the PCR did not have any detectable negative impact on the amplification of DNA targets (data not shown).", [["DNA", "CELLULAR_COMPONENT", 153, 156], ["DNA targets", "DNA", 153, 164], ["the PCR", "TEST", 77, 84], ["DNA targets", "TEST", 153, 164]]], ["Optimized multiplex panels for both BRDC and BED pathogens targeted one gene from each pathogen except for M. haemolytica and E. coli.", [["BRDC", "CHEMICAL", 36, 40], ["BRDC", "CANCER", 36, 40], ["M. haemolytica", "ORGANISM", 107, 121], ["E. coli", "ORGANISM", 126, 133], ["M. haemolytica", "SPECIES", 107, 121], ["E. coli", "SPECIES", 126, 133], ["M. haemolytica", "SPECIES", 107, 121], ["E. coli", "SPECIES", 126, 133], ["Optimized multiplex panels", "TEST", 0, 26], ["both BRDC and BED pathogens", "PROBLEM", 31, 58], ["M. haemolytica", "PROBLEM", 107, 121], ["E. coli", "PROBLEM", 126, 133], ["E. coli", "OBSERVATION", 126, 133]]], ["With respect to M. haemolytica, the assay consisted of three sets of primers targeting lktA, nmaA, and tbpB genes (Table 1).", [["M. haemolytica", "ORGANISM", 16, 30], ["lktA", "GENE_OR_GENE_PRODUCT", 87, 91], ["nmaA", "GENE_OR_GENE_PRODUCT", 93, 97], ["tbpB", "GENE_OR_GENE_PRODUCT", 103, 107], ["lktA, nmaA, and tbpB genes", "DNA", 87, 113], ["M. haemolytica", "SPECIES", 16, 30], ["M. haemolytica", "SPECIES", 16, 30], ["M. haemolytica", "PROBLEM", 16, 30], ["the assay", "TEST", 32, 41], ["primers", "TEST", 69, 76], ["lktA", "TEST", 87, 91], ["nmaA", "TEST", 93, 97], ["haemolytica", "OBSERVATION", 19, 30]]], ["By doing so commensal M. haemolytica strain type 2 (lktA+, nmaA-, tbpB-) was successfully differentiated from potentially pathogenic type 1 and 6 strains (lktA+, nmaA+, tbpB+) (Klima et al., 2014a, b).", [["strains", "ANATOMY", 146, 153], ["commensal", "ORGANISM", 12, 21], ["M. haemolytica strain type 2", "ORGANISM", 22, 50], ["lktA", "GENE_OR_GENE_PRODUCT", 52, 56], ["nmaA", "GENE_OR_GENE_PRODUCT", 59, 63], ["lktA", "GENE_OR_GENE_PRODUCT", 155, 159], ["tbpB", "PROTEIN", 66, 70], ["M. haemolytica", "SPECIES", 22, 36], ["M. haemolytica", "SPECIES", 22, 36], ["commensal M. haemolytica strain type", "TEST", 12, 48], ["lktA", "TEST", 52, 56], ["nmaA", "TEST", 59, 63], ["tbpB", "TEST", 66, 70], ["strains", "TEST", 146, 153], ["lktA", "TEST", 155, 159], ["nmaA", "TEST", 162, 166], ["tbpB", "TEST", 169, 173]]], ["Similarly, genes encoding four virulence factors in various strains of E. coli were targeted in the BED bacteria/protozoa assay.", [["E. coli", "ORGANISM", 71, 78], ["virulence factors", "PROTEIN", 31, 48], ["E. coli", "SPECIES", 71, 78], ["E. coli", "SPECIES", 71, 78], ["genes encoding four virulence factors", "PROBLEM", 11, 48], ["E. coli", "PROBLEM", 71, 78], ["protozoa assay", "TEST", 113, 127], ["E. coli", "OBSERVATION", 71, 78]]], ["As expected, the assay could amplify respective target genes from each E. coli strain used, namely, O157:H7 and O111 (stx-1+, eaeA+, Lt-, K99-), O149:H10 (stx-1-, eaeA-, Lt+, K99-), and O101 (stx-1-, eaeA-, Lt-, K99+) (Fig. 1 and Table 3).Electronic microarray ::: ResultsA total of 58 microarray detection probes targeting BRDC and BED pathogens were selected based on their reactivity on the microarray through preliminary screening (Table 2) and successfully validated on NC400 electronic microarray platform using multiplex PCR amplified products generated using laboratory isolates or synthetic genetic material (Table 3 and Fig. 2a\u2013d).", [["E. coli", "ORGANISM", 71, 78], ["O157:H7", "ORGANISM", 100, 107], ["O111", "CELL", 112, 116], ["stx-1+", "CELL", 118, 124], ["eaeA", "GENE_OR_GENE_PRODUCT", 126, 130], ["stx-1", "GENE_OR_GENE_PRODUCT", 155, 160], ["stx-1", "GENE_OR_GENE_PRODUCT", 192, 197], ["BRDC", "GENE_OR_GENE_PRODUCT", 324, 328], ["target genes", "DNA", 48, 60], ["E. coli", "SPECIES", 71, 78], ["E. coli", "SPECIES", 71, 78], ["O157:H7", "SPECIES", 100, 107], ["the assay", "TEST", 13, 22], ["each E. coli strain", "PROBLEM", 66, 85], ["stx", "TEST", 118, 121], ["eaeA", "TEST", 126, 130], ["Lt-", "TEST", 133, 136], ["K99", "TEST", 138, 141], ["stx", "TEST", 155, 158], ["eaeA", "TEST", 163, 167], ["Lt+", "TEST", 170, 173], ["K99", "TEST", 175, 178], ["stx", "TEST", 192, 195], ["eaeA", "TEST", 200, 204], ["K99", "TEST", 212, 215], ["microarray detection", "TEST", 286, 306], ["BRDC and BED pathogens", "PROBLEM", 324, 346], ["the microarray", "TEST", 390, 404], ["preliminary screening", "TEST", 413, 434], ["multiplex PCR amplified products", "TREATMENT", 518, 550], ["laboratory isolates", "TEST", 567, 586]]], ["Panels specific for BRDC-associated pathogens (Fig. 2a and b) consisted of 32 probes targeting five viruses and four bacteria.", [["Panels", "TEST", 0, 6], ["BRDC", "PROBLEM", 20, 24], ["associated pathogens", "PROBLEM", 25, 45], ["32 probes targeting five viruses", "PROBLEM", 75, 107], ["four bacteria", "PROBLEM", 112, 125], ["pathogens", "OBSERVATION", 36, 45], ["bacteria", "OBSERVATION_MODIFIER", 117, 125]]], ["Meanwhile, there were 36 probes in the finalized BED panels (Fig. 2c and d) that were designed to detect four viruses, four bacteria and three protozoa that are associated with neonatal bovine diarrhea.", [["bovine diarrhea", "DISEASE", 186, 201], ["bovine", "ORGANISM", 186, 192], ["bovine", "SPECIES", 186, 192], ["bovine", "SPECIES", 186, 192], ["the finalized BED panels", "TEST", 35, 59], ["Fig", "TEST", 61, 64], ["four viruses", "PROBLEM", 105, 117], ["four bacteria", "PROBLEM", 119, 132], ["three protozoa", "PROBLEM", 137, 151], ["neonatal bovine diarrhea", "PROBLEM", 177, 201], ["bovine diarrhea", "OBSERVATION", 186, 201]]], ["As BCoV and BVDV are associated with both respiratory and enteric ailments in cattle, probes specific for BCoV and for different strains of BVDV were included in both BRDC and BED panels.", [["respiratory", "ANATOMY", 42, 53], ["respiratory and enteric ailments", "DISEASE", 42, 74], ["BCoV", "GENE_OR_GENE_PRODUCT", 3, 7], ["BVDV", "ORGANISM", 12, 16], ["cattle", "ORGANISM", 78, 84], ["BCoV", "GENE_OR_GENE_PRODUCT", 106, 110], ["BVDV", "ORGANISM", 140, 144], ["BVDV", "SPECIES", 12, 16], ["cattle", "SPECIES", 78, 84], ["BCoV", "SPECIES", 3, 7], ["BVDV", "SPECIES", 12, 16], ["cattle", "SPECIES", 78, 84], ["BCoV", "SPECIES", 106, 110], ["BVDV", "SPECIES", 140, 144], ["BVDV", "PROBLEM", 12, 16], ["both respiratory and enteric ailments", "PROBLEM", 37, 74], ["BCoV", "TEST", 106, 110], ["different strains of BVDV", "PROBLEM", 119, 144], ["BVDV", "OBSERVATION", 12, 16], ["respiratory", "ANATOMY", 42, 53], ["enteric", "ANATOMY", 58, 65], ["ailments", "OBSERVATION", 66, 74]]], ["In addition to the pathogen-specific probes, each panel consisted of two control probes, a negative probe and a probe specific for the dengue virus internal control.Electronic microarray ::: ResultsAll target pathogens were accurately detected by their respective probes without any cross reactivity.", [["dengue", "DISEASE", 135, 141], ["negative probe", "DNA", 91, 105], ["dengue virus", "SPECIES", 135, 147], ["the pathogen", "TEST", 15, 27], ["each panel", "TEST", 45, 55], ["the dengue virus internal control", "TREATMENT", 131, 164]]], ["In the BED viral assay, upon amplification of VP6 gene of BRoV A and C strains using the same set of PCR primers, two strain-specific detection probes for each strain could differentiate between them.", [["VP6", "GENE_OR_GENE_PRODUCT", 46, 49], ["BRoV A", "GENE_OR_GENE_PRODUCT", 58, 64], ["C strains", "ORGANISM", 69, 78], ["VP6 gene", "DNA", 46, 54], ["PCR primers", "DNA", 101, 112], ["BRoV", "SPECIES", 58, 62], ["the BED viral assay", "TEST", 3, 22], ["BRoV A and C strains", "PROBLEM", 58, 78], ["PCR primers", "TEST", 101, 112], ["each strain", "PROBLEM", 155, 166]]], ["Similarly, the Breda virus, a BToV found in North America (Hoet and Saif, 2004) was accurately differentiated from the other bovine toroviruses by using species-specific detection probes (Table 3).", [["Breda virus", "ORGANISM", 15, 26], ["bovine", "ORGANISM", 125, 131], ["toroviruses", "CANCER", 132, 143], ["bovine", "SPECIES", 125, 131], ["Breda virus", "SPECIES", 15, 26], ["bovine", "SPECIES", 125, 131], ["the Breda virus", "PROBLEM", 11, 26]]], ["In both the BRDC and BED viral assays, while BVDV 5\u2032UTR was amplified in multiplex RT-PCR using common primers, each strain, namely BVDV 1 and 2, and HoBi virus, was accurately differentiated in the electronic microarray using strain-specific probes alongside the BVDV common probes (Table 3).", [["BRDC", "CANCER", 12, 16], ["BVDV 5", "ORGANISM", 45, 51], ["BVDV 1", "ORGANISM", 132, 138], ["HoBi virus", "ORGANISM", 150, 160], ["BVDV", "ORGANISM", 264, 268], ["BVDV 5\u2032UTR", "DNA", 45, 55], ["BVDV common probes", "DNA", 264, 282], ["BVDV", "SPECIES", 45, 49], ["BVDV 1", "SPECIES", 132, 138], ["HoBi virus", "SPECIES", 150, 160], ["BVDV", "SPECIES", 264, 268], ["BED viral assays", "TEST", 21, 37], ["BVDV", "PROBLEM", 45, 49], ["UTR", "TEST", 52, 55], ["multiplex RT-PCR", "TEST", 73, 89], ["common primers", "PROBLEM", 96, 110], ["each strain", "PROBLEM", 112, 123], ["BVDV", "TEST", 132, 136], ["HoBi virus", "PROBLEM", 150, 160], ["BRDC", "ANATOMY", 12, 16]]], ["Two laboratory isolates of BCoV and BRSV produced an additional PCR product corresponding to the size of BVDV amplicon by RT-PCR and reacted with BVDV detection probes (Fig. 2a and c) suggesting a possible contamination of the original isolates with BVDV, which was confirmed by subsequent sequencing of PCR amplicons (data not shown).", [["BCoV", "CANCER", 27, 31], ["BRSV", "ORGANISM", 36, 40], ["BVDV", "ORGANISM", 105, 109], ["BVDV", "ORGANISM", 146, 150], ["BVDV", "ORGANISM", 250, 254], ["PCR amplicons", "DNA", 304, 317], ["BRSV", "SPECIES", 36, 40], ["BCoV", "SPECIES", 27, 31], ["BRSV", "SPECIES", 36, 40], ["BVDV", "SPECIES", 105, 109], ["BVDV", "SPECIES", 146, 150], ["BVDV", "SPECIES", 250, 254], ["Two laboratory isolates", "TEST", 0, 23], ["BCoV", "TEST", 27, 31], ["BRSV", "PROBLEM", 36, 40], ["an additional PCR product", "PROBLEM", 50, 75], ["BVDV amplicon", "PROBLEM", 105, 118], ["RT-PCR", "TEST", 122, 128], ["BVDV detection probes", "TEST", 146, 167], ["contamination of the original isolates", "PROBLEM", 206, 244], ["BVDV", "PROBLEM", 250, 254], ["PCR amplicons", "TEST", 304, 317], ["size", "OBSERVATION_MODIFIER", 97, 101], ["possible", "UNCERTAINTY", 197, 205], ["contamination", "OBSERVATION", 206, 219]]], ["In order to exclude potential contamination of the samples during the assay, the presence of BVDV genomes in the original BCoV and BRSV isolates was confirmed by PCR and sequencing.", [["samples", "ANATOMY", 51, 58], ["BVDV", "ORGANISM", 93, 97], ["BCoV", "CANCER", 122, 126], ["BRSV", "ORGANISM", 131, 135], ["BVDV genomes", "DNA", 93, 105], ["BRSV", "SPECIES", 131, 135], ["BVDV", "SPECIES", 93, 97], ["BCoV", "SPECIES", 122, 126], ["BRSV", "SPECIES", 131, 135], ["potential contamination of the samples", "PROBLEM", 20, 58], ["the assay", "TEST", 66, 75], ["BVDV genomes", "PROBLEM", 93, 105], ["BRSV isolates", "PROBLEM", 131, 144], ["PCR", "TEST", 162, 165], ["sequencing", "TEST", 170, 180], ["BVDV genomes", "OBSERVATION", 93, 105], ["BRSV isolates", "OBSERVATION", 131, 144]]], ["The source of BVDV contamination in these samples was not investigated but could be non-irradiated fetal bovine serum used in cell culture during virus isolation.Analytical sensitivity and specificity ::: ResultsAnalytical sensitivities of multiplex PCR and subsequent microarray detection for all 23 pathogens (27 gene targets) were determined using series of dilutions of each target (Table 5).", [["samples", "ANATOMY", 42, 49], ["fetal", "ANATOMY", 99, 104], ["serum", "ANATOMY", 112, 117], ["cell", "ANATOMY", 126, 130], ["BVDV", "ORGANISM", 14, 18], ["bovine", "ORGANISM", 105, 111], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["cell", "CELL", 126, 130], ["bovine", "SPECIES", 105, 111], ["BVDV", "SPECIES", 14, 18], ["bovine", "SPECIES", 105, 111], ["BVDV contamination", "PROBLEM", 14, 32], ["these samples", "TEST", 36, 49], ["fetal bovine serum", "TEST", 99, 117], ["cell culture", "TEST", 126, 138], ["virus isolation", "TREATMENT", 146, 161], ["Analytical sensitivity", "TEST", 162, 184], ["multiplex PCR", "TEST", 240, 253], ["subsequent microarray detection", "TEST", 258, 289], ["all 23 pathogens", "PROBLEM", 294, 310], ["BVDV contamination", "OBSERVATION", 14, 32]]], ["All multiplex PCR assays could detect as few as 1\u201310 copies of most target genes (n = 21).", [["target genes", "DNA", 68, 80], ["All multiplex PCR assays", "TEST", 0, 24]]], ["The lowest sensitivity, 1000 copies/reaction, was observed for the BToV N gene in vitro transcribed RNA.", [["BToV N", "GENE_OR_GENE_PRODUCT", 67, 73], ["BToV N gene in vitro transcribed RNA", "RNA", 67, 103], ["The lowest sensitivity", "TEST", 0, 22], ["transcribed RNA", "OBSERVATION", 88, 103]]], ["The analytical sensitivities of the microarray capture probes were comparable to those of the multiplex PCR assays for most targets.", [["The analytical sensitivities", "TEST", 0, 28], ["the microarray capture probes", "TEST", 32, 61], ["the multiplex PCR assays", "TEST", 90, 114]]], ["Several targets including BPI-3, BVDV-2, BRoV B, BRoV C, BToV, M. haemolytica (tbpB and lktA), E. zuernii, C. parvum, S.e.", [["BPI-3", "GENE_OR_GENE_PRODUCT", 26, 31], ["BVDV-2", "ORGANISM", 33, 39], ["BRoV B", "ORGANISM", 41, 47], ["BRoV C", "ORGANISM", 49, 55], ["BToV", "GENE_OR_GENE_PRODUCT", 57, 61], ["M. haemolytica", "ORGANISM", 63, 77], ["tbpB", "GENE_OR_GENE_PRODUCT", 79, 83], ["lktA", "GENE_OR_GENE_PRODUCT", 88, 92], ["E. zuernii", "ORGANISM", 95, 105], ["C. parvum", "ORGANISM", 107, 116], ["S.e.", "ORGANISM", 118, 122], ["BPI", "PROTEIN", 26, 29], ["M. haemolytica", "SPECIES", 63, 77], ["E. zuernii", "SPECIES", 95, 105], ["C. parvum", "SPECIES", 107, 116], ["M. haemolytica", "SPECIES", 63, 77], ["E. zuernii", "SPECIES", 95, 105], ["C. parvum", "SPECIES", 107, 116], ["BPI", "TEST", 26, 29], ["BVDV", "TEST", 33, 37], ["BToV", "TEST", 57, 61], ["haemolytica", "TEST", 66, 77], ["tbpB", "TEST", 79, 83], ["lktA", "TEST", 88, 92], ["M. haemolytica", "OBSERVATION", 63, 77], ["C. parvum", "ANATOMY", 107, 116]]], ["Dublin, and E. coli (stx-1, Lt, and K99), showed a 10-fold drop in microarray sensitivity as compared to the corresponding multiplex PCR assay (Table 5).Analytical sensitivity and specificity ::: ResultsThe specificity of each assay was demonstrated by testing a panel of related non-target pathogens including other bovine pathogens and coronaviruses, herpesviruses and pestiviruses from other species (Supplementary Table 1).", [["Dublin", "GENE_OR_GENE_PRODUCT", 0, 6], ["E. coli", "ORGANISM", 12, 19], ["stx-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["Lt", "GENE_OR_GENE_PRODUCT", 28, 30], ["K99", "GENE_OR_GENE_PRODUCT", 36, 39], ["bovine", "ORGANISM", 317, 323], ["coronaviruses", "ORGANISM", 338, 351], ["herpesviruses", "ORGANISM", 353, 366], ["E. coli", "SPECIES", 12, 19], ["bovine", "SPECIES", 317, 323], ["E. coli", "SPECIES", 12, 19], ["bovine", "SPECIES", 317, 323], ["E. coli", "TEST", 12, 19], ["stx", "TEST", 21, 24], ["Lt", "TEST", 28, 30], ["K99", "TEST", 36, 39], ["a 10-fold drop in microarray sensitivity", "PROBLEM", 49, 89], ["the corresponding multiplex PCR assay", "TEST", 105, 142], ["Analytical sensitivity", "TEST", 153, 175], ["each assay", "TEST", 222, 232], ["a panel", "TEST", 261, 268], ["non-target pathogens", "PROBLEM", 280, 300], ["other bovine pathogens", "PROBLEM", 311, 333], ["coronaviruses", "PROBLEM", 338, 351], ["herpesviruses", "PROBLEM", 353, 366], ["pestiviruses", "PROBLEM", 371, 383], ["coli", "ANATOMY", 15, 19], ["10-fold", "OBSERVATION_MODIFIER", 51, 58], ["drop", "OBSERVATION", 59, 63]]], ["As there was no detectable amplification with any of the related non-target pathogens by multiplex PCR, only a few randomly selected reactions were tested on the electronic microarray and observed no positive reactivity, as expected (data not shown).Clinical validation of the finalized multiplex PCR-electronic microarray assay ::: ResultsPerformance of the multiplex PCR-electronic microarray assay was evaluated using a panel of clinical samples collected from cattle with respiratory and/or enteric ailments (Table 4).", [["samples", "ANATOMY", 441, 448], ["respiratory", "ANATOMY", 476, 487], ["respiratory and/or enteric ailments", "DISEASE", 476, 511], ["cattle", "ORGANISM", 464, 470], ["cattle", "SPECIES", 464, 470], ["cattle", "SPECIES", 464, 470], ["detectable amplification", "PROBLEM", 16, 40], ["the related non-target pathogens", "PROBLEM", 53, 85], ["multiplex PCR", "TEST", 89, 102], ["the electronic microarray", "TEST", 158, 183], ["positive reactivity", "PROBLEM", 200, 219], ["Clinical validation", "TEST", 250, 269], ["multiplex PCR", "TEST", 287, 300], ["the multiplex PCR", "TEST", 355, 372], ["electronic microarray assay", "TEST", 373, 400], ["a panel", "TEST", 421, 428], ["clinical samples", "TEST", 432, 448], ["no", "UNCERTAINTY", 13, 15], ["few", "OBSERVATION_MODIFIER", 111, 114], ["no", "UNCERTAINTY", 197, 199], ["positive reactivity", "OBSERVATION", 200, 219]]], ["According to the diagnostic records from provincial laboratories, most of the samples had tested for a single pathogen only.", [["samples", "ANATOMY", 78, 85], ["samples", "CANCER", 78, 85], ["provincial laboratories", "TEST", 41, 64], ["the samples", "TEST", 74, 85], ["a single pathogen", "PROBLEM", 101, 118]]], ["However, while confirming the original detection, we could demonstrate the presence of multiple pathogens in most samples.", [["samples", "ANATOMY", 114, 121], ["the original detection", "TEST", 26, 48], ["multiple pathogens in most samples", "PROBLEM", 87, 121], ["multiple", "OBSERVATION_MODIFIER", 87, 95], ["pathogens", "OBSERVATION", 96, 105]]], ["Where multiple pathogens were detected, any false positive reactivity was ruled out by demonstrating amplicons of the respective sizes by singleplex PCR using pathogen-specific primers, followed by Sanger sequencing.", [["multiple pathogens", "PROBLEM", 6, 24], ["any false positive reactivity", "PROBLEM", 40, 69], ["singleplex PCR", "TEST", 138, 152], ["multiple", "OBSERVATION_MODIFIER", 6, 14], ["pathogens", "OBSERVATION", 15, 24], ["sizes", "OBSERVATION_MODIFIER", 129, 134]]], ["Among samples collected from clinically healthy animals, several produced faint non-specific bands of various sizes by multiplex PCR.", [["samples", "ANATOMY", 6, 13], ["Among samples", "TEST", 0, 13], ["faint non-specific bands of various sizes", "PROBLEM", 74, 115], ["multiplex PCR", "TEST", 119, 132], ["faint", "OBSERVATION_MODIFIER", 74, 79], ["non-specific bands", "OBSERVATION_MODIFIER", 80, 98], ["various sizes", "OBSERVATION_MODIFIER", 102, 115]]], ["However, such samples did not generate any positive signal on any target specific probe on the microarray (data not shown).DiscussionIdentification of causative pathogens by isolation is the gold standard in affirmative diagnoses of infectious diseases.", [["samples", "ANATOMY", 14, 21], ["infectious diseases", "DISEASE", 233, 252], ["such samples", "TEST", 9, 21], ["any positive signal", "PROBLEM", 39, 58], ["the microarray", "TEST", 91, 105], ["causative pathogens", "PROBLEM", 151, 170], ["infectious diseases", "PROBLEM", 233, 252], ["infectious", "OBSERVATION", 233, 243]]], ["However, isolation of pathogens is difficult in many routine diagnostics due to long turnaround times and for practical reasons such as the requirement of specialized facilities, culture conditions, and high level of technical expertise as well as sensitivity to sample degradation.", [["sample", "ANATOMY", 263, 269], ["pathogens", "PROBLEM", 22, 31], ["routine diagnostics", "TEST", 53, 72], ["culture conditions", "TEST", 179, 197], ["pathogens", "OBSERVATION", 22, 31]]], ["In contrast, detection of pathogen-specific nucleic acid by PCR-based assays is a rapid, highly sensitive and cost effective alternative method for detection of infectious agents in clinical samples.", [["samples", "ANATOMY", 191, 198], ["nucleic acid", "CHEMICAL", 44, 56], ["pathogen", "PROBLEM", 26, 34], ["specific nucleic acid", "TEST", 35, 56], ["PCR", "TEST", 60, 63], ["infectious agents", "TREATMENT", 161, 178], ["clinical samples", "TEST", 182, 198], ["infectious", "OBSERVATION", 161, 171]]], ["In many cases, PCR-based assays also show significantly higher sensitivity than conventional culture methods (Bell et al., 2014; Shanthalingam et al., 2014).DiscussionSeveral previous studies documented the development of PCR-based assays for detection of pathogens associated with bovine respiratory and enteric diseases.", [["respiratory", "ANATOMY", 289, 300], ["bovine respiratory and enteric diseases", "DISEASE", 282, 321], ["bovine", "ORGANISM", 282, 288], ["bovine", "SPECIES", 282, 288], ["bovine", "SPECIES", 282, 288], ["PCR", "TEST", 15, 18], ["based assays", "TEST", 19, 31], ["significantly higher sensitivity", "PROBLEM", 42, 74], ["conventional culture methods", "TEST", 80, 108], ["previous studies", "TEST", 175, 191], ["PCR", "TEST", 222, 225], ["pathogens", "PROBLEM", 256, 265], ["bovine respiratory and enteric diseases", "PROBLEM", 282, 321], ["pathogens", "OBSERVATION", 256, 265], ["respiratory", "ANATOMY", 289, 300], ["enteric diseases", "OBSERVATION", 305, 321]]], ["However, most studies target either a single or a limited number of pathogens.", [["pathogens", "PROBLEM", 68, 77], ["pathogens", "OBSERVATION", 68, 77]]], ["Given the multifactorial nature and frequent involvement of multiple pathogens, a comprehensive assay that could simultaneously detect multiple pathogens is essential for rapid diagnosis and effective control of these economically significant diseases.DiscussionThis study describes the development and initial validation of four highly sensitive multiplex PCR assays and their respective electronic microarray assays for detection and differentiation of a total of 22 important viral, bacterial, and protozoal pathogens associated with respiratory and enteric diseases in cattle.", [["respiratory", "ANATOMY", 537, 548], ["respiratory and enteric diseases", "DISEASE", 537, 569], ["cattle", "ORGANISM", 573, 579], ["cattle", "SPECIES", 573, 579], ["cattle", "SPECIES", 573, 579], ["multiple pathogens", "PROBLEM", 60, 78], ["a comprehensive assay", "TEST", 80, 101], ["multiple pathogens", "PROBLEM", 135, 153], ["these economically significant diseases", "PROBLEM", 212, 251], ["This study", "TEST", 262, 272], ["multiplex PCR assays", "TEST", 347, 367], ["bacterial", "PROBLEM", 486, 495], ["protozoal pathogens", "PROBLEM", 501, 520], ["respiratory and enteric diseases", "PROBLEM", 537, 569], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["pathogens", "OBSERVATION", 69, 78], ["economically", "OBSERVATION_MODIFIER", 218, 230], ["significant", "OBSERVATION_MODIFIER", 231, 242], ["diseases", "OBSERVATION", 243, 251], ["protozoal pathogens", "OBSERVATION", 501, 520], ["enteric diseases", "OBSERVATION", 553, 569]]], ["The newly developed BRDC assays could successfully detect and differentiate four bacteria and five viruses, while the BED assays could detect and differentiate six viruses, four bacteria, and three protozoa.", [["BRDC assays", "TEST", 20, 31], ["four bacteria and five viruses", "PROBLEM", 76, 106], ["the BED assays", "TEST", 114, 128], ["six viruses", "PROBLEM", 160, 171], ["four bacteria", "PROBLEM", 173, 186]]], ["As demonstrated with laboratory strains as well as clinical samples, both the BRDC and BED assays could simultaneously amplify and detect multiple pathogens present in a single sample.DiscussionAs demonstrated using a limited number of clinical samples collected from the field, both BRDC bacterial and viral assays could successfully detect and differentiate multiple pathogens in a single sample (Table 4) it is notable that the initial diagnosis of clinical samples by corresponding laboratory was reproduced in most cases by the current multiplex assay.", [["samples", "ANATOMY", 60, 67], ["samples", "ANATOMY", 461, 468], ["samples", "CANCER", 245, 252], ["laboratory strains", "PROBLEM", 21, 39], ["clinical samples", "TEST", 51, 67], ["the BRDC and BED assays", "TEST", 74, 97], ["multiple pathogens", "PROBLEM", 138, 156], ["a single sample", "TEST", 168, 183], ["clinical samples", "TEST", 236, 252], ["both BRDC bacterial and viral assays", "TEST", 279, 315], ["multiple pathogens", "PROBLEM", 360, 378], ["the current multiplex assay", "TEST", 529, 556], ["multiple", "OBSERVATION_MODIFIER", 360, 368], ["pathogens", "OBSERVATION", 369, 378]]], ["However, despite the demonstration of the presence of multiple pathogens, we were unable to reproduce the historically reported detections in a few cases, potentially due to possible sample degradation.", [["sample", "ANATOMY", 183, 189], ["multiple pathogens", "PROBLEM", 54, 72], ["sample degradation", "PROBLEM", 183, 201], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["pathogens", "OBSERVATION", 63, 72], ["potentially due to possible", "UNCERTAINTY", 155, 182]]], ["While limited access to clinical samples is a hurdle, this highlights the need for use of an adequate number of freshly collected samples for assay validation.", [["samples", "ANATOMY", 130, 137], ["assay validation", "TEST", 142, 158]]], ["BRDC-associated viruses such as BoHV-1, BVDV, and BPI-3 alone can be primary pathogens, and often lead to BRDC of multiple etiologies through immunosuppression and damage to the respiratory epithelium (Srikumaran et al., 2007).", [["respiratory epithelium", "ANATOMY", 178, 200], ["damage to the respiratory epithelium", "DISEASE", 164, 200], ["BRDC", "GENE_OR_GENE_PRODUCT", 0, 4], ["BoHV-1", "GENE_OR_GENE_PRODUCT", 32, 38], ["BVDV", "ORGANISM", 40, 44], ["BPI-3", "GENE_OR_GENE_PRODUCT", 50, 55], ["respiratory epithelium", "TISSUE", 178, 200], ["BoHV-1", "SPECIES", 32, 38], ["BVDV", "SPECIES", 40, 44], ["BRDC-associated viruses", "PROBLEM", 0, 23], ["BoHV", "TEST", 32, 36], ["BVDV", "PROBLEM", 40, 44], ["BPI", "TEST", 50, 53], ["primary pathogens", "PROBLEM", 69, 86], ["multiple etiologies", "PROBLEM", 114, 133], ["immunosuppression", "TREATMENT", 142, 159], ["damage to the respiratory epithelium", "PROBLEM", 164, 200], ["viruses", "OBSERVATION", 16, 23], ["primary", "OBSERVATION_MODIFIER", 69, 76], ["pathogens", "OBSERVATION", 77, 86], ["multiple", "OBSERVATION_MODIFIER", 114, 122], ["etiologies", "OBSERVATION", 123, 133], ["respiratory epithelium", "ANATOMY", 178, 200]]], ["Determination of the non-viral etiological organism(s) of BRDC is often challenging as many of the bacterial agents such as H. somni, P. multocida, M. bovis, M. haemolytica causing BRDC are part of the commensal flora of the upper respiratory tract of cattle (Angen et al., 2009).", [["upper respiratory tract", "ANATOMY", 225, 248], ["BRDC", "DISEASE", 58, 62], ["BRDC", "CANCER", 58, 62], ["H. somni", "ORGANISM", 124, 132], ["P. multocida", "ORGANISM", 134, 146], ["M. bovis", "ORGANISM", 148, 156], ["M. haemolytica", "ORGANISM", 158, 172], ["BRDC", "GENE_OR_GENE_PRODUCT", 181, 185], ["upper respiratory", "ORGANISM_SUBDIVISION", 225, 242], ["tract", "ORGANISM_SUBDIVISION", 243, 248], ["cattle", "ORGANISM", 252, 258], ["H. somni", "SPECIES", 124, 132], ["P. multocida", "SPECIES", 134, 146], ["M. bovis", "SPECIES", 148, 156], ["M. haemolytica", "SPECIES", 158, 172], ["cattle", "SPECIES", 252, 258], ["H. somni", "SPECIES", 124, 132], ["P. multocida", "SPECIES", 134, 146], ["M. bovis", "SPECIES", 148, 156], ["M. haemolytica", "SPECIES", 158, 172], ["cattle", "SPECIES", 252, 258], ["the non-viral etiological organism", "PROBLEM", 17, 51], ["BRDC", "PROBLEM", 58, 62], ["the bacterial agents", "TREATMENT", 95, 115], ["multocida", "PROBLEM", 137, 146], ["haemolytica", "PROBLEM", 161, 172], ["BRDC", "PROBLEM", 181, 185], ["commensal flora", "OBSERVATION", 202, 217], ["upper", "ANATOMY_MODIFIER", 225, 230], ["respiratory tract", "ANATOMY", 231, 248]]], ["These opportunistic microbes increase in numbers and/or migrate to the lower respiratory tract (trachea and lungs) when the host is stressed or immunocompromised due to concurrent viral infections.", [["lower respiratory tract", "ANATOMY", 71, 94], ["trachea", "ANATOMY", 96, 103], ["lungs", "ANATOMY", 108, 113], ["viral infections", "DISEASE", 180, 196], ["lower", "ORGANISM_SUBDIVISION", 71, 76], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["trachea", "ORGAN", 96, 103], ["lungs", "ORGAN", 108, 113], ["immunocompromised", "PROBLEM", 144, 161], ["concurrent viral infections", "PROBLEM", 169, 196], ["opportunistic", "OBSERVATION_MODIFIER", 6, 19], ["microbes", "OBSERVATION_MODIFIER", 20, 28], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["numbers", "OBSERVATION_MODIFIER", 41, 48], ["lower", "ANATOMY_MODIFIER", 71, 76], ["respiratory tract", "ANATOMY", 77, 94], ["trachea", "ANATOMY", 96, 103], ["lungs", "ANATOMY", 108, 113], ["viral", "OBSERVATION_MODIFIER", 180, 185], ["infections", "OBSERVATION", 186, 196]]], ["Although detection of these pathogens in nasal or oral swabs may have less diagnostic value, the presence of these bacteria in tracheal swabs or lung tissues is indicative of their role in BRDC.DiscussionAlthough several molecular assays have been developed to detect multiple BED pathogens (Fukuda et al., 2012; Asano et al., 2010; Loa et al., 2006; Tsuchiaka et al., 2016), to our knowledge, the viral and bacterial/protozoa assays described here are the most comprehensive assays published to date for detection and differentiation of BED causative pathogens in a single reaction.", [["nasal", "ANATOMY", 41, 46], ["oral swabs", "ANATOMY", 50, 60], ["tracheal swabs", "ANATOMY", 127, 141], ["lung tissues", "ANATOMY", 145, 157], ["nasal", "ORGANISM_SUBDIVISION", 41, 46], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["swabs", "ORGANISM_SUBSTANCE", 55, 60], ["tracheal swabs", "MULTI-TISSUE_STRUCTURE", 127, 141], ["lung tissues", "TISSUE", 145, 157], ["BRDC", "CANCER", 189, 193], ["these pathogens in nasal or oral swabs", "PROBLEM", 22, 60], ["these bacteria in tracheal swabs or lung tissues", "PROBLEM", 109, 157], ["several molecular assays", "TEST", 213, 237], ["multiple BED pathogens", "PROBLEM", 268, 290], ["the viral and bacterial/protozoa assays", "TEST", 394, 433], ["BED causative pathogens", "PROBLEM", 538, 561], ["a single reaction", "PROBLEM", 565, 582], ["pathogens", "OBSERVATION", 28, 37], ["nasal", "ANATOMY", 41, 46], ["bacteria", "OBSERVATION", 115, 123], ["tracheal", "ANATOMY", 127, 135], ["swabs", "OBSERVATION", 136, 141], ["lung", "ANATOMY", 145, 149]]], ["A multiplex PCR assay for detection of five BED-associated viruses, namely BCoV, BRoV (strains A, B, and C) and BToV has been described previously (Fukuda et al., 2012).", [["BCoV", "GENE_OR_GENE_PRODUCT", 75, 79], ["BRoV", "GENE_OR_GENE_PRODUCT", 81, 85], ["B", "GENE_OR_GENE_PRODUCT", 98, 99], ["C", "GENE_OR_GENE_PRODUCT", 105, 106], ["BToV", "GENE_OR_GENE_PRODUCT", 112, 116], ["BCoV", "SPECIES", 75, 79], ["BRoV", "SPECIES", 81, 85], ["A multiplex PCR assay", "TEST", 0, 21], ["detection", "TEST", 26, 35], ["five BED-associated viruses", "PROBLEM", 39, 66], ["BCoV", "TEST", 75, 79], ["BRoV (strains A, B, and C) and BToV", "PROBLEM", 81, 116], ["viruses", "OBSERVATION", 59, 66]]], ["In addition to those pathogens, the NC400 BED viral assay could detect and differentiate BVDV 1, 2, and HoBi virus and differentiate Breda virus, which is prevalent in the North America from other toroviruses.", [["NC400", "GENE_OR_GENE_PRODUCT", 36, 41], ["BVDV 1", "ORGANISM", 89, 95], ["2", "GENE_OR_GENE_PRODUCT", 97, 98], ["HoBi virus", "ORGANISM", 104, 114], ["Breda virus", "ORGANISM", 133, 144], ["toroviruses", "CANCER", 197, 208], ["BVDV 1", "SPECIES", 89, 95], ["HoBi virus", "SPECIES", 104, 114], ["Breda virus", "SPECIES", 133, 144], ["those pathogens", "PROBLEM", 15, 30], ["the NC400 BED viral assay", "TEST", 32, 57], ["BVDV", "TEST", 89, 93], ["HoBi virus", "PROBLEM", 104, 114], ["Breda virus", "PROBLEM", 133, 144], ["Breda virus", "OBSERVATION", 133, 144]]], ["E. coli is commensal bacteria in the gut.", [["gut", "ANATOMY", 37, 40], ["E. coli", "ORGANISM", 0, 7], ["gut", "ORGANISM_SUBDIVISION", 37, 40], ["E. coli", "SPECIES", 0, 7], ["E. coli", "SPECIES", 0, 7], ["E. coli", "PROBLEM", 0, 7], ["commensal bacteria in the gut", "PROBLEM", 11, 40], ["coli", "OBSERVATION", 3, 7], ["commensal bacteria", "OBSERVATION", 11, 29], ["gut", "ANATOMY", 37, 40]]], ["Therefore, virulence factors associated with pathogenic strains of E. coli have been used to differentiate commensal strains from those that cause disease in calves (West et al., 2007; Sharma and Dean-Nystrom, 2003; Sharma, 2006).", [["E. coli", "ORGANISM", 67, 74], ["calves", "ORGANISM", 158, 164], ["virulence factors", "PROTEIN", 11, 28], ["E. coli", "SPECIES", 67, 74], ["calves", "SPECIES", 158, 164], ["E. coli", "SPECIES", 67, 74], ["virulence factors", "PROBLEM", 11, 28], ["pathogenic strains of E. coli", "PROBLEM", 45, 74], ["commensal strains", "PROBLEM", 107, 124], ["disease in calves", "PROBLEM", 147, 164], ["E. coli", "OBSERVATION", 67, 74], ["calves", "ANATOMY", 158, 164]]], ["By including a combination of virulence genes that are associated with pathogenic E. coli strains, the NC400 BED viral assay could differentiate pathotypes such as enterohemorrhagic (stx-1+, eaeA+), Enterotoxigenic (Lt+), and enteropathogenic (K99+) E. coli strains from those which are commensal inhabitants of the normal gut microflora.DiscussionThe current assays showed an overall high level of sensitivity for the detection of target pathogens however, when field-derived clinical samples are used, potential PCR inhibitors in the samples may reduce the sensitivity of these assays.", [["gut microflora", "ANATOMY", 323, 337], ["samples", "ANATOMY", 486, 493], ["samples", "ANATOMY", 536, 543], ["E. coli", "ORGANISM", 82, 89], ["NC400", "GENE_OR_GENE_PRODUCT", 103, 108], ["stx-1", "GENE_OR_GENE_PRODUCT", 183, 188], ["E. coli", "ORGANISM", 250, 257], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 323, 337], ["virulence genes", "DNA", 30, 45], ["E. coli", "SPECIES", 82, 89], ["E. coli", "SPECIES", 250, 257], ["E. coli", "SPECIES", 82, 89], ["E. coli", "SPECIES", 250, 257], ["virulence genes", "PROBLEM", 30, 45], ["pathogenic E. coli strains", "PROBLEM", 71, 97], ["the NC400 BED viral assay", "TEST", 99, 124], ["pathotypes", "PROBLEM", 145, 155], ["enterohemorrhagic (stx", "TEST", 164, 186], ["eaeA", "PROBLEM", 191, 195], ["Enterotoxigenic", "PROBLEM", 199, 214], ["enteropathogenic", "PROBLEM", 226, 242], ["E. coli strains", "PROBLEM", 250, 265], ["The current assays", "TEST", 348, 366], ["target pathogens", "PROBLEM", 432, 448], ["potential PCR inhibitors", "TREATMENT", 504, 528], ["the samples", "TEST", 532, 543], ["these assays", "TEST", 574, 586], ["coli strains", "OBSERVATION", 85, 97], ["coli strains", "OBSERVATION", 253, 265], ["normal gut microflora", "OBSERVATION", 316, 337]]], ["When the multiplex assays were combined with microarray detection a slight reduction (1/10 drop) in sensitivity was observed for several targets.", [["the multiplex assays", "TEST", 5, 25], ["microarray detection", "TEST", 45, 65], ["a slight reduction", "TREATMENT", 66, 84], ["sensitivity", "TEST", 100, 111], ["slight", "OBSERVATION_MODIFIER", 68, 74], ["reduction", "OBSERVATION_MODIFIER", 75, 84]]], ["However, given the potential high number of target pathogen particles present in clinical samples, the reduced sensitivity observed may not have a significant impact on the performance of these assays.", [["samples", "ANATOMY", 90, 97], ["target pathogen particles", "PROBLEM", 44, 69], ["the reduced sensitivity", "PROBLEM", 99, 122], ["these assays", "TEST", 188, 200], ["pathogen particles", "OBSERVATION", 51, 69]]], ["Nevertheless, these assays should be further investigated through a comprehensive clinical validation, before applying to routine diagnostics.ConclusionsIn summary, new pathogen detection assays based on multiplex PCR and automated electronic microarray have been developed for comprehensive detection of bacterial, viral, and protozoal pathogens that are associated with BRDC and BED.", [["BED", "DISEASE", 381, 384], ["these assays", "TEST", 14, 26], ["routine diagnostics", "TEST", 122, 141], ["new pathogen detection assays", "TEST", 165, 194], ["multiplex PCR", "TEST", 204, 217], ["automated electronic microarray", "TEST", 222, 253], ["comprehensive detection", "TEST", 278, 301], ["bacterial, viral, and protozoal pathogens", "PROBLEM", 305, 346], ["bacterial", "OBSERVATION_MODIFIER", 305, 314], ["protozoal pathogens", "OBSERVATION", 327, 346]]], ["With further clinical validation and subsequent deployment to veterinary diagnostic laboratories, these assays could be used for the rapid identification of pathogens in disease outbreaks and facilitate quick and accurate decision making for the control and treatment of economically important diseases of cattle.", [["cattle", "ORGANISM", 306, 312], ["cattle", "SPECIES", 306, 312], ["cattle", "SPECIES", 306, 312], ["further clinical validation", "TEST", 5, 32], ["these assays", "TEST", 98, 110], ["pathogens", "PROBLEM", 157, 166], ["disease outbreaks", "PROBLEM", 170, 187], ["the control", "TREATMENT", 242, 253], ["treatment", "TREATMENT", 258, 267]]], ["Furthermore, these assays could be very effective tools in epidemiological studies as well as screening of healthy animals to identify carriers, and those that may potentially develop BRD or BED.", [["BRD", "DISEASE", 184, 187], ["BED", "DISEASE", 191, 194], ["these assays", "TEST", 13, 25], ["epidemiological studies", "TEST", 59, 82]]], ["These assays are currently being adapted for use on a fully-integrated and fully-automated \u201csample-to-answer\u201d system which reduces costs associated with labour, decreases turnaround time, and minimizes potential cross-contamination due to user intervention.", [["potential cross-contamination", "PROBLEM", 202, 231], ["user intervention", "TREATMENT", 239, 256]]]], "ca8028af0a5d4530763b324515e71978d00ae99f": [["IntroductionAsthma exacerbations, the majority of which are caused by respiratory viral infection, are a continuing problem in respiratory medicine worldwide.", [["IntroductionAsthma exacerbations", "DISEASE", 0, 32], ["respiratory viral infection", "DISEASE", 70, 97], ["IntroductionAsthma exacerbations", "PROBLEM", 0, 32], ["respiratory viral infection", "PROBLEM", 70, 97], ["respiratory medicine", "TREATMENT", 127, 147], ["respiratory", "OBSERVATION", 70, 81], ["viral infection", "OBSERVATION", 82, 97]]], ["Most viral exacerbations are due to either respiratory syncytial viruses (RSV), coronaviruses, influenza viruses or human rhinoviruses (RV), with RV being the most frequent causative agent.", [["viral exacerbations", "DISEASE", 5, 24], ["respiratory syncytial viruses", "DISEASE", 43, 72], ["RSV", "DISEASE", 74, 77], ["influenza viruses", "DISEASE", 95, 112], ["human rhinoviruses", "DISEASE", 116, 134], ["respiratory syncytial viruses", "ORGANISM", 43, 72], ["RSV", "ORGANISM", 74, 77], ["influenza viruses", "ORGANISM", 95, 112], ["human", "ORGANISM", 116, 121], ["rhinoviruses", "ORGANISM", 122, 134], ["RV", "ORGAN", 136, 138], ["human", "SPECIES", 116, 121], ["respiratory syncytial viruses", "SPECIES", 43, 72], ["RSV", "SPECIES", 74, 77], ["human rhinoviruses", "SPECIES", 116, 134], ["RV", "SPECIES", 136, 138], ["RV", "SPECIES", 146, 148], ["Most viral exacerbations", "PROBLEM", 0, 24], ["respiratory syncytial viruses (RSV)", "PROBLEM", 43, 78], ["coronaviruses", "PROBLEM", 80, 93], ["influenza viruses", "PROBLEM", 95, 112], ["human rhinoviruses", "PROBLEM", 116, 134], ["RV", "PROBLEM", 146, 148], ["respiratory", "ANATOMY", 43, 54], ["syncytial viruses", "OBSERVATION", 55, 72], ["RV", "ANATOMY", 146, 148]]], ["In vitro and in vivo, RV infects the bronchial epithelium and upregulates a range of pro-inflammatory cytokines, chemokines, adhesion molecules, mucins and growth factors, all of which are thought to contribute to loss of lung function and lower airway inflammation [1] [2] [3] [4] .", [["bronchial epithelium", "ANATOMY", 37, 57], ["lung", "ANATOMY", 222, 226], ["airway", "ANATOMY", 246, 252], ["loss of lung function", "DISEASE", 214, 235], ["bronchial epithelium", "TISSUE", 37, 57], ["mucins", "GENE_OR_GENE_PRODUCT", 145, 151], ["lung", "ORGAN", 222, 226], ["airway", "ORGAN", 246, 252], ["2] [3] [4]", "SIMPLE_CHEMICAL", 271, 281], ["pro-inflammatory cytokines", "PROTEIN", 85, 111], ["chemokines", "PROTEIN", 113, 123], ["adhesion molecules", "PROTEIN", 125, 143], ["mucins", "PROTEIN", 145, 151], ["growth factors", "PROTEIN", 156, 170], ["RV", "SPECIES", 22, 24], ["pro-inflammatory cytokines", "PROBLEM", 85, 111], ["adhesion molecules", "PROBLEM", 125, 143], ["mucins and growth factors", "PROBLEM", 145, 170], ["loss of lung function", "PROBLEM", 214, 235], ["lower airway inflammation", "PROBLEM", 240, 265], ["RV", "ANATOMY", 22, 24], ["infects", "OBSERVATION", 25, 32], ["bronchial epithelium", "ANATOMY", 37, 57], ["lung", "ANATOMY", 222, 226], ["lower", "ANATOMY_MODIFIER", 240, 245], ["airway", "ANATOMY", 246, 252], ["inflammation", "OBSERVATION", 253, 265]]], ["A large number of these mediators are upregulated solely, or in part, by the transcription factor NF-kB.", [["NF-kB.", "GENE_OR_GENE_PRODUCT", 98, 104], ["transcription factor", "PROTEIN", 77, 97], ["NF", "PROTEIN", 98, 100], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["This would suggest that inhibiting the functions of this transcription factor may alleviate symptoms associated with RV-induced exacerbations of asthma.", [["asthma", "DISEASE", 145, 151], ["transcription factor", "PROTEIN", 57, 77], ["this transcription factor", "PROBLEM", 52, 77], ["symptoms", "PROBLEM", 92, 100], ["RV-induced exacerbations", "PROBLEM", 117, 141], ["asthma", "PROBLEM", 145, 151], ["exacerbations", "OBSERVATION", 128, 141], ["asthma", "OBSERVATION", 145, 151]]], ["In virusinduced asthma, bronchial biopsies and sputum have neutrophilic and lymphocytic infiltrates [4, 5] , and these cell types are therefore implicated in exacerbation pathogenesis.", [["bronchial biopsies", "ANATOMY", 24, 42], ["sputum", "ANATOMY", 47, 53], ["neutrophilic", "ANATOMY", 59, 71], ["lymphocytic infiltrates", "ANATOMY", 76, 99], ["cell", "ANATOMY", 119, 123], ["asthma", "DISEASE", 16, 22], ["bronchial biopsies", "MULTI-TISSUE_STRUCTURE", 24, 42], ["sputum", "ORGANISM_SUBSTANCE", 47, 53], ["lymphocytic infiltrates", "PATHOLOGICAL_FORMATION", 76, 99], ["cell", "CELL", 119, 123], ["virusinduced asthma", "PROBLEM", 3, 22], ["bronchial biopsies", "TEST", 24, 42], ["sputum", "TEST", 47, 53], ["neutrophilic", "PROBLEM", 59, 71], ["lymphocytic infiltrates", "PROBLEM", 76, 99], ["exacerbation pathogenesis", "PROBLEM", 158, 183], ["asthma", "OBSERVATION", 16, 22], ["bronchial", "ANATOMY", 24, 33], ["biopsies", "OBSERVATION", 34, 42], ["neutrophilic", "OBSERVATION_MODIFIER", 59, 71], ["lymphocytic infiltrates", "OBSERVATION", 76, 99], ["cell types", "OBSERVATION", 119, 129], ["exacerbation", "OBSERVATION_MODIFIER", 158, 170]]], ["Due to the lack of a small animal model, there are many unclarified issues regarding the immunology of RV infection, and how this relates to exacerbations of asthma.IntroductionA recent study has estimated the economic impact of asthma in Germany to be in billions of Euros [6] .", [["RV infection", "DISEASE", 103, 115], ["asthma", "DISEASE", 158, 164], ["asthma", "DISEASE", 229, 235], ["RV", "ORGAN", 103, 105], ["RV", "SPECIES", 103, 105], ["a small animal model", "PROBLEM", 19, 39], ["RV infection", "PROBLEM", 103, 115], ["asthma", "PROBLEM", 158, 164], ["IntroductionA recent study", "TEST", 165, 191], ["asthma", "PROBLEM", 229, 235], ["small", "OBSERVATION_MODIFIER", 21, 26], ["RV", "ANATOMY", 103, 105], ["infection", "OBSERVATION", 106, 115], ["asthma", "OBSERVATION", 158, 164], ["asthma", "OBSERVATION", 229, 235]]], ["Although the actual costs of viral exacerbations are not known, it is arguable that they would contribute significantly to this cost, as viral infections account for about 80% of asthma exacerbations in children, and between 40% and 76% in adults [7] [8] [9] [10] [11] [12] .", [["viral exacerbations", "DISEASE", 29, 48], ["viral infections", "DISEASE", 137, 153], ["asthma", "DISEASE", 179, 185], ["children", "ORGANISM", 203, 211], ["[7] [8] [9] [10] [", "SIMPLE_CHEMICAL", 247, 265], ["children", "SPECIES", 203, 211], ["viral exacerbations", "PROBLEM", 29, 48], ["viral infections", "PROBLEM", 137, 153], ["asthma exacerbations", "PROBLEM", 179, 199], ["viral exacerbations", "OBSERVATION", 29, 48], ["asthma", "OBSERVATION", 179, 185]]], ["In the UK, one study has estimated the cost of asthma exacerbations to be approximately 3.5-fold higher per patient when compared to asthma patients that did not experience exacerbation [13] .", [["asthma", "DISEASE", 47, 53], ["asthma", "DISEASE", 133, 139], ["patient", "ORGANISM", 108, 115], ["patients", "ORGANISM", 140, 148], ["patient", "SPECIES", 108, 115], ["patients", "SPECIES", 140, 148], ["one study", "TEST", 11, 20], ["asthma exacerbations", "PROBLEM", 47, 67], ["asthma", "PROBLEM", 133, 139], ["exacerbation", "PROBLEM", 173, 185], ["asthma", "OBSERVATION", 47, 53]]], ["Currently, the medical needs of patients suffering from viral exacerbations of asthma are largely unmet.", [["asthma", "DISEASE", 79, 85], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["viral exacerbations", "PROBLEM", 56, 75], ["asthma", "PROBLEM", 79, 85], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["exacerbations", "OBSERVATION", 62, 75], ["asthma", "OBSERVATION", 79, 85]]], ["There is no vaccine for RV or RSV, and the use of influenza vaccines in reducing virus-induced exacerbations remain controversial [14] .", [["RSV", "DISEASE", 30, 33], ["exacerbations", "DISEASE", 95, 108], ["RSV", "ORGANISM", 30, 33], ["RV", "SPECIES", 24, 26], ["RSV", "SPECIES", 30, 33], ["vaccine", "TREATMENT", 12, 19], ["RV", "PROBLEM", 24, 26], ["RSV", "PROBLEM", 30, 33], ["influenza vaccines", "TREATMENT", 50, 68], ["reducing virus", "PROBLEM", 72, 86], ["induced exacerbations", "PROBLEM", 87, 108], ["no", "UNCERTAINTY", 9, 11], ["RSV", "OBSERVATION", 30, 33]]], ["Steroids so far have been disappointing in their ability to control symptoms in models of experimental RV challenge of asthmatics [15] [16] [17] [18] , and high-dose steroids remain only partially effective at controlling virus-induced exacerbations of asthma [19, 20] .", [["RV", "ANATOMY", 103, 105], ["[15] [16] [17] [18]", "CHEMICAL", 130, 149], ["steroids", "CHEMICAL", 166, 174], ["asthma", "DISEASE", 253, 259], ["Steroids", "CHEMICAL", 0, 8], ["steroids", "CHEMICAL", 166, 174], ["asthmatics [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 119, 149], ["high-dose steroids", "SIMPLE_CHEMICAL", 156, 174], ["Steroids", "TREATMENT", 0, 8], ["symptoms", "PROBLEM", 68, 76], ["experimental RV challenge of asthmatics", "TREATMENT", 90, 129], ["high-dose steroids", "TREATMENT", 156, 174], ["asthma", "PROBLEM", 253, 259], ["asthma", "OBSERVATION", 253, 259]]], ["A range of anti-viral, anti-RV compounds and combinations of the above have been used as therapies for RV infection, these have had variable efficacies in controlling RV-associated illnesses.", [["RV", "ANATOMY", 103, 105], ["RV infection", "DISEASE", 103, 115], ["anti-RV compounds", "SIMPLE_CHEMICAL", 23, 40], ["RV", "SPECIES", 103, 105], ["anti-viral, anti-RV compounds", "TREATMENT", 11, 40], ["therapies", "TREATMENT", 89, 98], ["RV infection", "PROBLEM", 103, 115], ["variable efficacies", "PROBLEM", 132, 151], ["associated illnesses", "PROBLEM", 170, 190], ["range", "OBSERVATION_MODIFIER", 2, 7], ["infection", "OBSERVATION", 106, 115], ["RV", "ANATOMY", 167, 169], ["illnesses", "OBSERVATION", 181, 190]]], ["This review will summarise the current understanding of virus-induced exacerbations of asthma, with a special focus on RV, including the epidemiology, host defence and immunology.", [["asthma", "DISEASE", 87, 93], ["virus", "PROBLEM", 56, 61], ["asthma", "PROBLEM", 87, 93], ["asthma", "OBSERVATION", 87, 93]]], ["Studies of treatments aimed at virus-induced exacerbations will also be discussed, with an emphasis on how better understanding the process of infection and upregulation of proinflammatory mediator gene expression may be useful in aiding the design of novel therapies for virus-induced asthma exacerbations.Respiratory virus infections as exacerbators of asthmaThere is now overwhelming evidence that respiratory viruses are associated with acute exacerbations of asthma, accounting for up to 80-85% of acute exacerbations [7, 10, 21, 22] .", [["infection", "DISEASE", 143, 152], ["asthma", "DISEASE", 286, 292], ["Respiratory virus infections", "DISEASE", 307, 335], ["asthmaThere", "DISEASE", 355, 366], ["respiratory viruses", "DISEASE", 401, 420], ["asthma", "DISEASE", 464, 470], ["Respiratory virus", "ORGANISM", 307, 324], ["Respiratory virus", "SPECIES", 307, 324], ["treatments", "TREATMENT", 11, 21], ["virus", "PROBLEM", 31, 36], ["exacerbations", "PROBLEM", 45, 58], ["infection", "PROBLEM", 143, 152], ["proinflammatory mediator gene expression", "TREATMENT", 173, 213], ["novel therapies", "TREATMENT", 252, 267], ["virus", "PROBLEM", 272, 277], ["asthma exacerbations", "PROBLEM", 286, 306], ["Respiratory virus infections", "PROBLEM", 307, 335], ["asthmaThere", "PROBLEM", 355, 366], ["respiratory viruses", "PROBLEM", 401, 420], ["acute exacerbations", "PROBLEM", 441, 460], ["asthma", "PROBLEM", 464, 470], ["acute exacerbations", "PROBLEM", 503, 522], ["infection", "OBSERVATION", 143, 152], ["asthma", "OBSERVATION", 286, 292], ["virus infections", "OBSERVATION", 319, 335], ["respiratory viruses", "OBSERVATION", 401, 420], ["associated with", "UNCERTAINTY", 425, 440], ["acute", "OBSERVATION_MODIFIER", 441, 446], ["exacerbations", "OBSERVATION", 447, 460], ["asthma", "OBSERVATION", 464, 470], ["acute", "OBSERVATION_MODIFIER", 503, 508], ["exacerbations", "OBSERVATION", 509, 522]]], ["Of the common respiratory viruses, RV have emerged as the most frequent.", [["the common respiratory viruses", "PROBLEM", 3, 33], ["common", "ANATOMY_MODIFIER", 7, 13], ["respiratory viruses", "OBSERVATION", 14, 33], ["RV", "ANATOMY", 35, 37]]], ["Other respiratory viruses such as RSV influenza viruses, parainfluenza viruses, coronaviruses, adenoviruses and the newly described metapneumoviruses, may also be associated with exacerbations of asthma.", [["respiratory viruses", "DISEASE", 6, 25], ["RSV influenza viruses", "DISEASE", 34, 55], ["parainfluenza viruses", "DISEASE", 57, 78], ["asthma", "DISEASE", 196, 202], ["RSV influenza viruses", "ORGANISM", 34, 55], ["parainfluenza viruses", "ORGANISM", 57, 78], ["coronaviruses", "ORGANISM", 80, 93], ["adenoviruses", "ORGANISM", 95, 107], ["RSV influenza viruses", "SPECIES", 34, 55], ["parainfluenza", "SPECIES", 57, 70], ["RSV influenza viruses", "SPECIES", 34, 55], ["Other respiratory viruses", "PROBLEM", 0, 25], ["RSV influenza viruses", "PROBLEM", 34, 55], ["parainfluenza viruses", "PROBLEM", 57, 78], ["coronaviruses", "PROBLEM", 80, 93], ["adenoviruses", "PROBLEM", 95, 107], ["the newly described metapneumoviruses", "PROBLEM", 112, 149], ["asthma", "PROBLEM", 196, 202], ["respiratory viruses", "OBSERVATION", 6, 25], ["RSV influenza viruses", "OBSERVATION", 34, 55], ["parainfluenza viruses", "OBSERVATION", 57, 78], ["may also be associated with", "UNCERTAINTY", 151, 178], ["asthma", "OBSERVATION", 196, 202]]], ["In children o2 years of age, RSV, infection is a common cause of significant morbidity in the form of wheeze or bronchiolitis [9, 10, 22, 23] .", [["RSV", "DISEASE", 29, 32], ["infection", "DISEASE", 34, 43], ["wheeze", "DISEASE", 102, 108], ["bronchiolitis", "DISEASE", 112, 125], ["children", "ORGANISM", 3, 11], ["RSV", "ORGANISM", 29, 32], ["children", "SPECIES", 3, 11], ["RSV", "SPECIES", 29, 32], ["RSV", "PROBLEM", 29, 32], ["infection", "PROBLEM", 34, 43], ["significant morbidity", "PROBLEM", 65, 86], ["wheeze", "PROBLEM", 102, 108], ["bronchiolitis", "PROBLEM", 112, 125], ["infection", "OBSERVATION", 34, 43], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["morbidity", "OBSERVATION", 77, 86], ["wheeze", "OBSERVATION", 102, 108], ["bronchiolitis", "OBSERVATION", 112, 125]]], ["In older children and adults, RSV is still implicated in exacerbations of acute asthma, but does not appear to be as important as RV [7, 10, 21] .", [["RSV", "DISEASE", 30, 33], ["asthma", "DISEASE", 80, 86], ["children", "ORGANISM", 9, 17], ["RSV", "ORGANISM", 30, 33], ["children", "SPECIES", 9, 17], ["RSV", "SPECIES", 30, 33], ["RSV", "PROBLEM", 30, 33], ["acute asthma", "PROBLEM", 74, 86], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["asthma", "OBSERVATION", 80, 86]]], ["Influenza is an important pathogen during winter epidemics [24] , but outside these periods it is not a major contributor to exacerbations of asthma.", [["Influenza", "DISEASE", 0, 9], ["asthma", "DISEASE", 142, 148], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["asthma", "PROBLEM", 142, 148], ["asthma", "OBSERVATION", 142, 148]]], ["Recent data [25] [26] [27] suggest that human metapneumovirus has a minor contribution (o12%) to virus-induced exacerbations of asthma.", [["human metapneumovirus", "DISEASE", 40, 61], ["asthma", "DISEASE", 128, 134], ["[25] [26] [27]", "SIMPLE_CHEMICAL", 12, 26], ["human", "ORGANISM", 40, 45], ["metapneumovirus", "ORGANISM", 46, 61], ["human", "SPECIES", 40, 45], ["human metapneumovirus", "SPECIES", 40, 61], ["Recent data", "TEST", 0, 11], ["human metapneumovirus", "PROBLEM", 40, 61], ["virus", "PROBLEM", 97, 102], ["asthma", "PROBLEM", 128, 134], ["metapneumovirus", "OBSERVATION", 46, 61], ["asthma", "OBSERVATION", 128, 134]]], ["The relative frequency of detection of each virus type in exacerbations of children 42 years and adults as found in previous studies [10, 21, 22] are summarised in Fig. 1 , and represent approximate estimates for the most common respiratory viruses identified.", [["respiratory viruses", "DISEASE", 229, 248], ["children", "ORGANISM", 75, 83], ["children", "SPECIES", 75, 83], ["previous studies", "TEST", 116, 132], ["the most common respiratory viruses", "PROBLEM", 213, 248], ["respiratory viruses", "OBSERVATION", 229, 248]]], ["Virus-induced exacerbations of asthma: similar and distinct pathology and mechanisms of action to persistent asthma Virus-induced exacerbations of asthma have both similar and distinct properties to persistent asthma.", [["asthma", "DISEASE", 31, 37], ["asthma", "DISEASE", 109, 115], ["asthma", "DISEASE", 147, 153], ["asthma", "DISEASE", 210, 216], ["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5], ["asthma", "PROBLEM", 31, 37], ["distinct pathology", "PROBLEM", 51, 69], ["persistent asthma Virus", "PROBLEM", 98, 121], ["asthma", "PROBLEM", 147, 153], ["persistent asthma", "PROBLEM", 199, 216], ["exacerbations", "OBSERVATION_MODIFIER", 14, 27], ["asthma", "OBSERVATION", 31, 37], ["distinct", "OBSERVATION_MODIFIER", 51, 59], ["pathology", "OBSERVATION", 60, 69], ["persistent", "OBSERVATION_MODIFIER", 98, 108], ["asthma", "OBSERVATION", 109, 115], ["asthma", "OBSERVATION", 147, 153], ["persistent", "OBSERVATION_MODIFIER", 199, 209], ["asthma", "OBSERVATION", 210, 216]]], ["Respiratory virus-induced exacerbations of asthma may occur in patients with phenotypes that differ from the atopic phenotype characteristic of allergen-induced asthma.", [["asthma", "DISEASE", 43, 49], ["atopic phenotype", "DISEASE", 109, 125], ["asthma", "DISEASE", 161, 167], ["Respiratory virus", "ORGANISM", 0, 17], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Respiratory virus", "PROBLEM", 0, 17], ["asthma", "PROBLEM", 43, 49], ["phenotypes", "PROBLEM", 77, 87], ["the atopic phenotype", "PROBLEM", 105, 125], ["asthma", "PROBLEM", 161, 167], ["virus", "OBSERVATION", 12, 17], ["asthma", "OBSERVATION", 43, 49], ["asthma", "OBSERVATION", 161, 167]]], ["Viral infection was measured in these studies using virus culture, RT-PCR or both.ARTICLE IN PRESSobvious difference between allergen-induced asthma and exacerbations is that inhaled corticosteroids, which are effective for the treatment of persistent asthma, do not work with the same efficacy in asthma exacerbations [19, 20] .", [["Viral infection", "DISEASE", 0, 15], ["asthma", "DISEASE", 142, 148], ["exacerbations", "DISEASE", 153, 166], ["corticosteroids", "CHEMICAL", 183, 198], ["asthma", "DISEASE", 252, 258], ["asthma", "DISEASE", 298, 304], ["corticosteroids", "CHEMICAL", 183, 198], ["Viral", "ORGANISM", 0, 5], ["Viral infection", "PROBLEM", 0, 15], ["these studies", "TEST", 32, 45], ["virus culture", "TEST", 52, 65], ["RT-PCR", "TEST", 67, 73], ["allergen", "PROBLEM", 125, 133], ["asthma", "PROBLEM", 142, 148], ["exacerbations", "PROBLEM", 153, 166], ["inhaled corticosteroids", "TREATMENT", 175, 198], ["persistent asthma", "PROBLEM", 241, 258], ["asthma exacerbations", "PROBLEM", 298, 318], ["infection", "OBSERVATION", 6, 15], ["asthma", "OBSERVATION", 142, 148], ["persistent", "OBSERVATION_MODIFIER", 241, 251], ["asthma", "OBSERVATION", 252, 258]]], ["Evidence for similar mechanisms of action is suggested by the fact that allergen exposure and virus infection may act in a synergistic or additive manner, increasing the risk of asthma exacerbations [28] .", [["infection", "DISEASE", 100, 109], ["asthma", "DISEASE", 178, 184], ["allergen exposure", "PROBLEM", 72, 89], ["virus infection", "PROBLEM", 94, 109], ["asthma exacerbations", "PROBLEM", 178, 198], ["asthma", "OBSERVATION", 178, 184]]], ["Pollutants such as nitrogen dioxide may also increase the risk of virusinduced exacerbations of asthma [29] .", [["nitrogen dioxide", "CHEMICAL", 19, 35], ["asthma", "DISEASE", 96, 102], ["nitrogen dioxide", "CHEMICAL", 19, 35], ["nitrogen dioxide", "SIMPLE_CHEMICAL", 19, 35], ["Pollutants", "TREATMENT", 0, 10], ["nitrogen dioxide", "TREATMENT", 19, 35], ["virusinduced exacerbations", "PROBLEM", 66, 92], ["asthma", "PROBLEM", 96, 102], ["asthma", "OBSERVATION", 96, 102]]], ["Some interesting differences between asthma exacerbations and persistent asthma are highlighted by the following observations.ARTICLE IN PRESSVirus-induced asthma exacerbations may differ from persistent or allergen-induced asthma in that neutrophils appear to play a more prominent role in exacerbations, while eosinophils predominate in the latter.", [["neutrophils", "ANATOMY", 239, 250], ["eosinophils", "ANATOMY", 312, 323], ["asthma", "DISEASE", 37, 43], ["asthma", "DISEASE", 73, 79], ["asthma exacerbations", "DISEASE", 156, 176], ["asthma", "DISEASE", 224, 230], ["neutrophils", "CELL", 239, 250], ["eosinophils", "CELL", 312, 323], ["neutrophils", "CELL_TYPE", 239, 250], ["eosinophils", "CELL_TYPE", 312, 323], ["asthma exacerbations", "PROBLEM", 37, 57], ["persistent asthma", "PROBLEM", 62, 79], ["asthma exacerbations", "PROBLEM", 156, 176], ["asthma", "PROBLEM", 224, 230], ["exacerbations", "PROBLEM", 291, 304], ["eosinophils", "TEST", 312, 323], ["asthma", "OBSERVATION", 37, 43], ["persistent", "OBSERVATION_MODIFIER", 62, 72], ["asthma", "OBSERVATION", 73, 79], ["asthma", "OBSERVATION", 156, 162], ["persistent", "OBSERVATION_MODIFIER", 193, 203], ["asthma", "OBSERVATION", 224, 230], ["more prominent", "OBSERVATION_MODIFIER", 268, 282]]], ["T lymphocytes appear important to both.", [["T lymphocytes", "ANATOMY", 0, 13], ["T lymphocytes", "CELL", 0, 13], ["T lymphocytes", "CELL_TYPE", 0, 13], ["T lymphocytes", "PROBLEM", 0, 13], ["lymphocytes", "OBSERVATION", 2, 13]]], ["The importance of neutrophils and CD4+ and CD8+ T lymphocytes in asthma exacerbations is supported by several studies [4, 5, 11, 15, [30] [31] [32] [33] [34] [35] .", [["neutrophils", "ANATOMY", 18, 29], ["CD4+ and CD8+ T lymphocytes", "ANATOMY", 34, 61], ["asthma", "DISEASE", 65, 71], ["neutrophils", "CELL", 18, 29], ["CD4", "GENE_OR_GENE_PRODUCT", 34, 37], ["CD8", "GENE_OR_GENE_PRODUCT", 43, 46], ["[30] [31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 133, 162], ["neutrophils", "CELL_TYPE", 18, 29], ["CD4+ and CD8+ T lymphocytes", "CELL_TYPE", 34, 61], ["neutrophils", "TEST", 18, 29], ["CD4", "TEST", 34, 37], ["CD8", "TEST", 43, 46], ["T lymphocytes", "PROBLEM", 48, 61], ["asthma exacerbations", "PROBLEM", 65, 85], ["neutrophils", "ANATOMY", 18, 29]]], ["In atopic asthmatics, eosinophils or eosinophil activation are also increased in virus-induced asthma.", [["eosinophils", "ANATOMY", 22, 33], ["eosinophil", "ANATOMY", 37, 47], ["atopic asthmatics", "DISEASE", 3, 20], ["asthma", "DISEASE", 95, 101], ["eosinophils", "CELL", 22, 33], ["eosinophil", "CELL", 37, 47], ["eosinophils", "CELL_TYPE", 22, 33], ["eosinophil", "CELL_TYPE", 37, 47], ["atopic asthmatics", "PROBLEM", 3, 20], ["eosinophils", "PROBLEM", 22, 33], ["eosinophil activation", "PROBLEM", 37, 58], ["virus", "PROBLEM", 81, 86], ["asthma", "PROBLEM", 95, 101], ["atopic", "OBSERVATION_MODIFIER", 3, 9], ["asthmatics", "OBSERVATION", 10, 20], ["eosinophil activation", "OBSERVATION", 37, 58], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["asthma", "OBSERVATION", 95, 101]]], ["Given that a mixed aetiology is likely very common [28, 36] , it is not surprising that there is much overlap in pathogenesis.", [["pathogenesis", "PROBLEM", 113, 125]]], ["Differences also exist in the way asthmatics respond to viral infection and may affect the outcome of infection and hence disease severity.", [["viral infection", "DISEASE", 56, 71], ["infection", "DISEASE", 102, 111], ["asthmatics", "ORGANISM", 34, 44], ["asthmatics", "PROBLEM", 34, 44], ["viral infection", "PROBLEM", 56, 71], ["infection", "PROBLEM", 102, 111], ["disease severity", "PROBLEM", 122, 138], ["asthmatics", "OBSERVATION", 34, 44], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infection", "OBSERVATION", 62, 71], ["infection", "OBSERVATION", 102, 111]]], ["Although asthmatics have the same incidence of viral infection as normals, they have increased severity and duration of lower airway symptoms and reduction in lung function than normals [37] .", [["airway", "ANATOMY", 126, 132], ["lung", "ANATOMY", 159, 163], ["viral infection", "DISEASE", 47, 62], ["asthmatics", "ORGANISM", 9, 19], ["airway", "MULTI-TISSUE_STRUCTURE", 126, 132], ["lung", "ORGAN", 159, 163], ["asthmatics", "PROBLEM", 9, 19], ["viral infection", "PROBLEM", 47, 62], ["increased severity", "PROBLEM", 85, 103], ["lower airway symptoms", "PROBLEM", 120, 141], ["lung function", "TEST", 159, 172], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["infection", "OBSERVATION", 53, 62], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["severity", "OBSERVATION_MODIFIER", 95, 103], ["lower", "ANATOMY_MODIFIER", 120, 125], ["airway", "ANATOMY", 126, 132], ["reduction", "OBSERVATION_MODIFIER", 146, 155], ["lung", "ANATOMY", 159, 163]]], ["A recent study has also reported persistence of RV in children suffering from exacerbations of asthma, with children showing RV persistence having more severe exacerbations [38] .", [["asthma", "DISEASE", 95, 101], ["exacerbations", "DISEASE", 159, 172], ["RV", "ORGAN", 48, 50], ["children", "ORGANISM", 54, 62], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 54, 62], ["children", "SPECIES", 108, 116], ["A recent study", "TEST", 0, 14], ["exacerbations", "PROBLEM", 78, 91], ["asthma", "PROBLEM", 95, 101], ["RV persistence", "PROBLEM", 125, 139], ["more severe exacerbations", "PROBLEM", 147, 172], ["RV", "ANATOMY", 48, 50], ["exacerbations", "OBSERVATION", 78, 91], ["asthma", "OBSERVATION", 95, 101], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["exacerbations", "OBSERVATION", 159, 172]]], ["Also, increased levels of RV replication have also been observed accompanied by lower levels of virus-induced interferon (IFN)-b expression and virus-induced apoptosis compared to normals [39] .", [["RV", "GENE_OR_GENE_PRODUCT", 26, 28], ["interferon (IFN)-b", "GENE_OR_GENE_PRODUCT", 110, 128], ["interferon (IFN)-b", "PROTEIN", 110, 128], ["increased levels of RV replication", "PROBLEM", 6, 40], ["lower levels of virus", "PROBLEM", 80, 101], ["interferon (IFN)", "TREATMENT", 110, 126], ["b expression", "PROBLEM", 127, 139], ["virus", "PROBLEM", 144, 149], ["induced apoptosis", "PROBLEM", 150, 167], ["increased", "OBSERVATION_MODIFIER", 6, 15], ["RV replication", "OBSERVATION", 26, 40]]], ["In certain studies, greater levels of proinflammatory cytokine elaboration and inflammatory cell recruitment are observed [4] .", [["inflammatory cell", "ANATOMY", 79, 96], ["cell", "CELL", 92, 96], ["proinflammatory cytokine", "PROTEIN", 38, 62], ["certain studies", "TEST", 3, 18], ["proinflammatory cytokine elaboration", "PROBLEM", 38, 74], ["inflammatory cell recruitment", "PROBLEM", 79, 108], ["greater", "OBSERVATION_MODIFIER", 20, 27], ["proinflammatory cytokine", "OBSERVATION", 38, 62], ["inflammatory cell recruitment", "OBSERVATION", 79, 108]]], ["Peripheral blood mononuclear cells from asthmatics when cultured with RV exhibiting lower levels of the T H 1 cytokines IFN-g and IL-12, suggesting that asthmatics may have a defective T H 1 response to viral infection [40] .", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["RV", "ANATOMY", 70, 72], ["viral infection", "DISEASE", 203, 218], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["asthmatics", "ORGANISM", 40, 50], ["T H 1", "GENE_OR_GENE_PRODUCT", 104, 109], ["IFN-g", "GENE_OR_GENE_PRODUCT", 120, 125], ["IL-12", "GENE_OR_GENE_PRODUCT", 130, 135], ["asthmatics", "ORGANISM", 153, 163], ["T H 1", "GENE_OR_GENE_PRODUCT", 185, 190], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["T H 1 cytokines", "PROTEIN", 104, 119], ["IFN", "PROTEIN", 120, 123], ["IL-12", "PROTEIN", 130, 135], ["T H 1", "SPECIES", 185, 190], ["Peripheral blood mononuclear cells", "PROBLEM", 0, 34], ["asthmatics", "PROBLEM", 40, 50], ["RV", "TEST", 70, 72], ["the T H", "TEST", 100, 107], ["cytokines IFN", "TEST", 110, 123], ["IL", "TEST", 130, 132], ["asthmatics", "PROBLEM", 153, 163], ["a defective T H", "PROBLEM", 173, 188], ["viral infection", "PROBLEM", 203, 218], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["asthmatics", "OBSERVATION", 40, 50], ["lower levels", "OBSERVATION_MODIFIER", 84, 96], ["asthmatics", "OBSERVATION", 153, 163], ["viral", "OBSERVATION_MODIFIER", 203, 208], ["infection", "OBSERVATION", 209, 218]]], ["These data support two important points; firstly virus exacerbations of asthma have different properties to persistent or allergen-induced asthma, and secondly, researchers are still defining the characteristics of viral exacerbations and the populations in the community that are at risk.", [["asthma", "DISEASE", 72, 78], ["asthma", "DISEASE", 139, 145], ["firstly virus exacerbations", "PROBLEM", 41, 68], ["asthma", "PROBLEM", 72, 78], ["persistent or allergen-induced asthma", "PROBLEM", 108, 145], ["viral exacerbations", "PROBLEM", 215, 234], ["asthma", "OBSERVATION", 72, 78], ["persistent", "OBSERVATION_MODIFIER", 108, 118], ["asthma", "OBSERVATION", 139, 145], ["viral", "OBSERVATION_MODIFIER", 215, 220], ["exacerbations", "OBSERVATION", 221, 234]]], ["These important points must be appreciated prior to discussing new treatments for virus-induced exacerbations of asthma.", [["asthma", "DISEASE", 113, 119], ["new treatments", "TREATMENT", 63, 77], ["virus", "PROBLEM", 82, 87], ["asthma", "PROBLEM", 113, 119], ["asthma", "OBSERVATION", 113, 119]]], ["Human RV-the most common virus associated with exacerbations of asthmaEpidemiologyRVs belong to the Picornaviridae family of viruses.", [["asthmaEpidemiology", "DISEASE", 64, 82], ["Human", "ORGANISM", 0, 5], ["RV", "CELL", 6, 8], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human RV", "TEST", 0, 8], ["exacerbations of asthmaEpidemiology", "PROBLEM", 47, 82], ["viruses", "OBSERVATION", 125, 132]]], ["These viruses have small RNA genomes (approximately 7 kb), [41, 42] , are non-enveloped and are stable in the environment.", [["small RNA genomes", "DNA", 19, 36], ["small RNA genomes", "PROBLEM", 19, 36], ["viruses", "OBSERVATION", 6, 13], ["small", "OBSERVATION_MODIFIER", 19, 24], ["RNA genomes", "OBSERVATION", 25, 36], ["non-enveloped", "OBSERVATION_MODIFIER", 74, 87], ["stable", "OBSERVATION_MODIFIER", 96, 102]]], ["There are at least 100 serotypes, which are divided into major or minor groups depending on receptor specificity.", [["receptor specificity", "TEST", 92, 112], ["at least", "OBSERVATION_MODIFIER", 10, 18], ["serotypes", "OBSERVATION", 23, 32]]], ["Most RV are major group RV, and bind human ICAM-1, minor group RV bind the LDL receptor [43] .", [["RV", "ANATOMY", 5, 7], ["human", "ORGANISM", 37, 42], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 43, 49], ["LDL receptor", "GENE_OR_GENE_PRODUCT", 75, 87], ["human ICAM-1", "PROTEIN", 37, 49], ["RV", "PROTEIN", 63, 65], ["LDL receptor", "PROTEIN", 75, 87], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["bind human ICAM", "TEST", 32, 47]]], ["The difference in receptor specificity appears to be explained by a charge difference of the H1 loop of structural protein VP1 [44] .", [["H1 loop", "PROTEIN", 93, 100], ["structural protein VP1", "TEST", 104, 126], ["appears to be explained", "UNCERTAINTY", 39, 62]]], ["RV can replicate efficiently in the upper airway and can be detected in the lower airway although replication remains to be proven in vivo [45, 46] .", [["upper airway", "ANATOMY", 36, 48], ["lower airway", "ANATOMY", 76, 88], ["RV", "ORGAN", 0, 2], ["upper airway", "ORGAN", 36, 48], ["lower airway", "ORGANISM_SUBDIVISION", 76, 88], ["upper", "ANATOMY_MODIFIER", 36, 41], ["airway", "ANATOMY", 42, 48], ["lower", "ANATOMY_MODIFIER", 76, 81], ["airway", "ANATOMY", 82, 88]]], ["RV infection can be readily observed in the bronchial epithelium [47] in vivo, and ex vivo, detected by sampling both the lower airway [48, 49] and upper airway [50, 51] .EpidemiologyRV are now well established as the major virus associated with exacerbations of asthma and also chronic obstructive pulmonary disease (COPD) [4, 8, 21, 37, [52] [53] [54] .", [["bronchial epithelium", "ANATOMY", 44, 64], ["lower airway", "ANATOMY", 122, 134], ["upper airway", "ANATOMY", 148, 160], ["pulmonary", "ANATOMY", 299, 308], ["RV infection", "DISEASE", 0, 12], ["asthma", "DISEASE", 263, 269], ["chronic obstructive pulmonary disease", "DISEASE", 279, 316], ["COPD", "DISEASE", 318, 322], ["RV", "ORGAN", 0, 2], ["bronchial epithelium", "TISSUE", 44, 64], ["airway", "MULTI-TISSUE_STRUCTURE", 128, 134], ["upper airway", "ORGANISM_SUBDIVISION", 148, 160], ["pulmonary", "ORGAN", 299, 308], ["RV infection", "PROBLEM", 0, 12], ["ex vivo", "TEST", 83, 90], ["asthma", "PROBLEM", 263, 269], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 279, 323], ["infection", "OBSERVATION", 3, 12], ["bronchial epithelium", "ANATOMY", 44, 64], ["lower", "ANATOMY_MODIFIER", 122, 127], ["airway", "ANATOMY", 128, 134], ["upper", "ANATOMY_MODIFIER", 148, 153], ["airway", "ANATOMY", 154, 160], ["asthma", "OBSERVATION", 263, 269], ["chronic", "OBSERVATION_MODIFIER", 279, 286], ["obstructive", "OBSERVATION_MODIFIER", 287, 298], ["pulmonary", "ANATOMY", 299, 308], ["disease", "OBSERVATION", 309, 316], ["COPD", "OBSERVATION", 318, 322]]], ["Using virus-specific RT-PCR and virus culture techniques, epidemiological studies have observed that RV has the highest incidence of all respiratory viruses in exacerbations of asthma in adults and children42 years of age; approximately 60-65% of viral exacerbations are due to RV infection [7, 8, 10, 22, 26] , as presented in Fig. 1 .", [["respiratory viruses", "DISEASE", 137, 156], ["asthma", "DISEASE", 177, 183], ["viral exacerbations", "DISEASE", 247, 266], ["RV infection", "DISEASE", 278, 290], ["RV", "SPECIES", 101, 103], ["RV", "SPECIES", 278, 280], ["virus", "TEST", 6, 11], ["specific RT-PCR", "TEST", 12, 27], ["virus culture techniques", "TEST", 32, 56], ["epidemiological studies", "TEST", 58, 81], ["all respiratory viruses", "PROBLEM", 133, 156], ["asthma", "PROBLEM", 177, 183], ["viral exacerbations", "PROBLEM", 247, 266], ["RV infection", "PROBLEM", 278, 290], ["highest", "OBSERVATION_MODIFIER", 112, 119], ["respiratory viruses", "OBSERVATION", 137, 156], ["asthma", "OBSERVATION", 177, 183], ["RV", "ANATOMY", 278, 280], ["infection", "OBSERVATION", 281, 290]]], ["RV infection appears to be prevalent in children returning to school, leading to significant epidemics, and increased hospital admissions in the month of September in the Northern Hemisphere [55] .", [["RV infection", "DISEASE", 0, 12], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["RV", "SPECIES", 0, 2], ["RV infection", "PROBLEM", 0, 12], ["significant epidemics", "PROBLEM", 81, 102], ["infection", "OBSERVATION", 3, 12], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["epidemics", "OBSERVATION", 93, 102], ["increased", "OBSERVATION_MODIFIER", 108, 117]]], ["A thorough review of the epidemiology of RV infection of the lower respiratory tract is available elsewhere [56] .Immunopathology and host defenceDue to the lack of a small animal model, many aspects of immunology and host defence against RV infection remain unelucidated.", [["RV", "ANATOMY", 41, 43], ["lower respiratory tract", "ANATOMY", 61, 84], ["RV infection", "DISEASE", 41, 53], ["Immunopathology", "DISEASE", 114, 129], ["RV infection", "DISEASE", 239, 251], ["RV", "ORGAN", 41, 43], ["lower", "ORGANISM_SUBDIVISION", 61, 66], ["respiratory tract", "ORGANISM_SUBDIVISION", 67, 84], ["RV", "ORGAN", 239, 241], ["RV", "SPECIES", 239, 241], ["RV infection of the lower respiratory tract", "PROBLEM", 41, 84], ["RV infection", "PROBLEM", 239, 251], ["RV", "ANATOMY", 41, 43], ["infection", "OBSERVATION", 44, 53], ["lower", "ANATOMY_MODIFIER", 61, 66], ["respiratory tract", "ANATOMY", 67, 84], ["infection", "OBSERVATION", 242, 251]]], ["Experimental and natural infections, and in vitro infection of lung epithelial cells have been useful in the study of RV-induced inflammation, in both asthma and COPD.", [["lung epithelial cells", "ANATOMY", 63, 84], ["infections", "DISEASE", 25, 35], ["infection", "DISEASE", 50, 59], ["inflammation", "DISEASE", 129, 141], ["asthma", "DISEASE", 151, 157], ["COPD", "DISEASE", 162, 166], ["lung epithelial cells", "CELL", 63, 84], ["lung epithelial cells", "CELL_TYPE", 63, 84], ["Experimental and natural infections", "PROBLEM", 0, 35], ["vitro infection of lung epithelial cells", "PROBLEM", 44, 84], ["the study", "TEST", 105, 114], ["RV", "PROBLEM", 118, 120], ["inflammation", "PROBLEM", 129, 141], ["asthma", "PROBLEM", 151, 157], ["COPD", "PROBLEM", 162, 166], ["natural", "OBSERVATION_MODIFIER", 17, 24], ["infections", "OBSERVATION", 25, 35], ["infection", "OBSERVATION", 50, 59], ["lung", "ANATOMY", 63, 67], ["epithelial cells", "OBSERVATION", 68, 84], ["RV", "ANATOMY", 118, 120], ["inflammation", "OBSERVATION", 129, 141], ["both", "OBSERVATION_MODIFIER", 146, 150], ["asthma", "OBSERVATION", 151, 157], ["COPD", "OBSERVATION", 162, 166]]], ["The immunology of RV infection is a rapidly expanding field, and has been thoroughly reviewed elsewhere.", [["RV infection", "DISEASE", 18, 30], ["RV", "ORGAN", 18, 20], ["RV", "SPECIES", 18, 20], ["RV infection", "PROBLEM", 18, 30], ["RV", "ANATOMY", 18, 20], ["infection", "OBSERVATION", 21, 30], ["rapidly", "OBSERVATION_MODIFIER", 36, 43]]], ["This review will highlight the main findings and discuss some of the unresolved issues; interested readers are directed to the following recent reviews for more information [57] [58] [59] [60] .", [["[57] [58] [59] [60]", "SIMPLE_CHEMICAL", 173, 192]]], ["RV upregulate the expression of a range of pro-inflammatory mediators from lung epithelium in vitro and in vivo including the chemokines IL-8/CXCL8 [61] [62] [63] [64] [65] , ENA78/CXCL5 [66] , eotaxin/CCL10 [67, 68] RANTES/ CCL5 [67, 69] , IP-10/CXCL10 [70] , growth and differentiation factors such as IL-6 [62, 64, 71] , GM-CSF [62, 64, 65, 72, 73] , IL-11 [74, 75] and also adhesion molecules ICAM-1 and VCAM [76] [77] [78] [79] [80] , and respiratory mucins [81, 82] .Immunopathology and host defenceVirus-induced exacerbations of both asthma and COPD are associated with lower airway infection [47, 83] , resulting in lower airway inflammatory responses characterised by infiltration of CD4+ and CD8+ T cells, neutrophils, eosinophils and activation of local macrophages and mast cells [5, [84] [85] [86] .", [["lung epithelium", "ANATOMY", 75, 90], ["lower airway", "ANATOMY", 577, 589], ["airway", "ANATOMY", 630, 636], ["CD4+ and CD8+ T cells", "ANATOMY", 693, 714], ["neutrophils", "ANATOMY", 716, 727], ["eosinophils", "ANATOMY", 729, 740], ["macrophages", "ANATOMY", 765, 776], ["mast cells", "ANATOMY", 781, 791], ["defenceVirus", "CHEMICAL", 498, 510], ["asthma", "DISEASE", 541, 547], ["COPD", "DISEASE", 552, 556], ["airway infection", "DISEASE", 583, 599], ["RV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["lung epithelium", "TISSUE", 75, 90], ["IL-8", "GENE_OR_GENE_PRODUCT", 137, 141], ["CXCL8", "GENE_OR_GENE_PRODUCT", 142, 147], ["ENA78", "GENE_OR_GENE_PRODUCT", 175, 180], ["CXCL5", "GENE_OR_GENE_PRODUCT", 181, 186], ["eotaxin", "GENE_OR_GENE_PRODUCT", 194, 201], ["CCL10", "GENE_OR_GENE_PRODUCT", 202, 207], ["RANTES", "GENE_OR_GENE_PRODUCT", 217, 223], ["CCL5", "GENE_OR_GENE_PRODUCT", 225, 229], ["IP-10", "GENE_OR_GENE_PRODUCT", 241, 246], ["CXCL10", "GENE_OR_GENE_PRODUCT", 247, 253], ["IL-6", "GENE_OR_GENE_PRODUCT", 304, 308], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 324, 330], ["IL-11", "GENE_OR_GENE_PRODUCT", 354, 359], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 397, 403], ["VCAM [76] [77] [78] [79] [80", "SIMPLE_CHEMICAL", 408, 436], ["mucins", "GENE_OR_GENE_PRODUCT", 456, 462], ["airway", "MULTI-TISSUE_STRUCTURE", 583, 589], ["airway", "MULTI-TISSUE_STRUCTURE", 630, 636], ["CD4", "GENE_OR_GENE_PRODUCT", 693, 696], ["CD8", "GENE_OR_GENE_PRODUCT", 702, 705], ["neutrophils", "CELL", 716, 727], ["eosinophils", "CELL", 729, 740], ["macrophages", "CELL", 765, 776], ["mast cells", "CELL", 781, 791], ["pro-inflammatory mediators", "PROTEIN", 43, 69], ["chemokines", "PROTEIN", 126, 136], ["CXCL8", "PROTEIN", 142, 147], ["CXCL5", "PROTEIN", 181, 186], ["eotaxin", "PROTEIN", 194, 201], ["CCL10", "PROTEIN", 202, 207], ["RANTES", "PROTEIN", 217, 223], ["CCL5", "PROTEIN", 225, 229], ["CXCL10", "PROTEIN", 247, 253], ["growth and differentiation factors", "PROTEIN", 261, 295], ["IL", "PROTEIN", 304, 306], ["CSF", "PROTEIN", 327, 330], ["adhesion molecules", "PROTEIN", 378, 396], ["ICAM", "PROTEIN", 397, 401], ["VCAM", "PROTEIN", 408, 412], ["CD4", "PROTEIN", 693, 696], ["CD8", "PROTEIN", 702, 705], ["T cells", "CELL_TYPE", 707, 714], ["neutrophils", "CELL_TYPE", 716, 727], ["eosinophils", "CELL_TYPE", 729, 740], ["local macrophages", "CELL_TYPE", 759, 776], ["mast cells", "CELL_TYPE", 781, 791], ["pro-inflammatory mediators", "PROBLEM", 43, 69], ["lung epithelium", "PROBLEM", 75, 90], ["the chemokines IL", "TEST", 122, 139], ["CXCL8", "TEST", 142, 147], ["ENA78", "TEST", 175, 180], ["CXCL5", "TEST", 181, 186], ["eotaxin", "TEST", 194, 201], ["CCL10", "TEST", 202, 207], ["RANTES", "TEST", 217, 223], ["CCL5", "TEST", 225, 229], ["IP", "TEST", 241, 243], ["CXCL10", "TEST", 247, 253], ["differentiation factors", "TEST", 272, 295], ["IL", "TEST", 304, 306], ["GM-CSF", "TEST", 324, 330], ["IL", "TEST", 354, 356], ["adhesion molecules ICAM", "TEST", 378, 401], ["VCAM", "TEST", 408, 412], ["respiratory mucins", "TEST", 444, 462], ["Immunopathology", "PROBLEM", 473, 488], ["host defenceVirus", "PROBLEM", 493, 510], ["both asthma", "PROBLEM", 536, 547], ["COPD", "PROBLEM", 552, 556], ["lower airway infection", "PROBLEM", 577, 599], ["lower airway inflammatory responses", "PROBLEM", 624, 659], ["infiltration", "PROBLEM", 677, 689], ["CD4", "TEST", 693, 696], ["CD8", "TEST", 702, 705], ["neutrophils", "TEST", 716, 727], ["eosinophils", "TEST", 729, 740], ["local macrophages", "TEST", 759, 776], ["mast cells", "TEST", 781, 791], ["lung", "ANATOMY", 75, 79], ["epithelium", "ANATOMY_MODIFIER", 80, 90], ["host defenceVirus", "OBSERVATION", 493, 510], ["both", "OBSERVATION_MODIFIER", 536, 540], ["asthma", "OBSERVATION", 541, 547], ["COPD", "OBSERVATION", 552, 556], ["lower", "ANATOMY_MODIFIER", 577, 582], ["airway", "ANATOMY", 583, 589], ["infection", "OBSERVATION", 590, 599], ["lower", "ANATOMY_MODIFIER", 624, 629], ["airway", "ANATOMY", 630, 636], ["inflammatory", "OBSERVATION", 637, 649], ["infiltration", "OBSERVATION", 677, 689], ["local macrophages", "OBSERVATION", 759, 776], ["mast cells", "OBSERVATION", 781, 791]]], ["Experimental and natural infections of human subjects have also shown that subjects infected with RV show an increased level of the above cytokines in nasal secretions and sputum [1] [2] [3] [4] .", [["nasal secretions", "ANATOMY", 151, 167], ["infections", "DISEASE", 25, 35], ["human", "ORGANISM", 39, 44], ["nasal secretions", "ORGANISM_SUBSTANCE", 151, 167], ["sputum [1] [2] [3] [4]", "SIMPLE_CHEMICAL", 172, 194], ["cytokines", "PROTEIN", 138, 147], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["RV", "SPECIES", 98, 100], ["Experimental and natural infections of human subjects", "PROBLEM", 0, 53], ["an increased level", "PROBLEM", 106, 124], ["the above cytokines", "TEST", 128, 147], ["nasal secretions", "TEST", 151, 167], ["sputum", "TEST", 172, 178], ["increased", "OBSERVATION", 109, 118], ["nasal", "ANATOMY", 151, 156], ["secretions", "OBSERVATION", 157, 167]]], ["In one study, the accumulation of inflammatory cells and molecules correlated with increased symptom scores [2] , and in another, decreased lung function of asthmatics [1] , giving support to the current hypothesis that the local inflammatory reaction contributes to exacerbations in asthmatics.", [["inflammatory cells", "ANATOMY", 34, 52], ["lung", "ANATOMY", 140, 144], ["inflammatory cells", "CELL", 34, 52], ["lung", "ORGAN", 140, 144], ["inflammatory cells", "CELL_TYPE", 34, 52], ["one study", "TEST", 3, 12], ["inflammatory cells", "PROBLEM", 34, 52], ["increased symptom scores", "PROBLEM", 83, 107], ["decreased lung function of asthmatics", "PROBLEM", 130, 167], ["the local inflammatory reaction", "PROBLEM", 220, 251], ["exacerbations in asthmatics", "PROBLEM", 267, 294], ["inflammatory cells", "OBSERVATION", 34, 52], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["decreased", "OBSERVATION_MODIFIER", 130, 139], ["lung", "ANATOMY", 140, 144], ["local", "OBSERVATION_MODIFIER", 224, 229], ["inflammatory", "OBSERVATION", 230, 242]]], ["Therefore, if the upregulation of inflammatory molecules and cells can be prevented, diseases may be prevented.", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["inflammatory molecules", "PROTEIN", 34, 56], ["inflammatory molecules and cells", "PROBLEM", 34, 66], ["diseases", "PROBLEM", 85, 93], ["inflammatory", "OBSERVATION", 34, 46]]], ["Inhibition of RVinduced inflammatory cytokine/chemokine production therefore represents an important therapeutic target for asthma.", [["asthma", "DISEASE", 124, 130], ["RVinduced inflammatory cytokine", "PROTEIN", 14, 45], ["chemokine", "PROTEIN", 46, 55], ["RVinduced inflammatory cytokine/chemokine production", "PROBLEM", 14, 66], ["asthma", "PROBLEM", 124, 130], ["RVinduced", "OBSERVATION_MODIFIER", 14, 23], ["inflammatory", "OBSERVATION_MODIFIER", 24, 36], ["chemokine production", "OBSERVATION", 46, 66], ["asthma", "OBSERVATION", 124, 130]]], ["Some inflammatory molecules induced by respiratory virus infection and the cells they attract are outlined in Fig. 2 .Importance of NF-kB signallingA striking observation is that all the pro-inflammatory molecules and growth factors upregulated by RV so far studied in detail require the transcription factor NF-kB (discussed below).", [["cells", "ANATOMY", 75, 80], ["respiratory virus infection", "DISEASE", 39, 66], ["respiratory virus", "ORGANISM", 39, 56], ["cells", "CELL", 75, 80], ["NF-kB", "GENE_OR_GENE_PRODUCT", 132, 137], ["NF-kB", "GENE_OR_GENE_PRODUCT", 309, 314], ["inflammatory molecules", "PROTEIN", 5, 27], ["NF-kB", "PROTEIN", 132, 137], ["pro-inflammatory molecules", "PROTEIN", 187, 213], ["growth factors", "PROTEIN", 218, 232], ["transcription factor", "PROTEIN", 288, 308], ["NF-kB", "PROTEIN", 309, 314], ["respiratory virus", "SPECIES", 39, 56], ["Some inflammatory molecules", "PROBLEM", 0, 27], ["respiratory virus infection", "PROBLEM", 39, 66], ["inflammatory molecules", "OBSERVATION", 5, 27], ["respiratory virus infection", "OBSERVATION", 39, 66]]], ["The NF-kB or Rel family of transcription factors (p65, p50, c-Rel) are implicated in the expression of over 100 pro-inflammatory genes (for a review see [87] [88] [89] ).", [["NF-kB", "GENE_OR_GENE_PRODUCT", 4, 9], ["Rel", "GENE_OR_GENE_PRODUCT", 13, 16], ["p65", "GENE_OR_GENE_PRODUCT", 50, 53], ["p50", "GENE_OR_GENE_PRODUCT", 55, 58], ["c-Rel", "GENE_OR_GENE_PRODUCT", 60, 65], ["NF-kB", "PROTEIN", 4, 9], ["Rel family", "PROTEIN", 13, 23], ["transcription factors", "PROTEIN", 27, 48], ["p65", "PROTEIN", 50, 53], ["p50", "PROTEIN", 55, 58], ["c", "PROTEIN", 60, 61], ["Rel", "PROTEIN", 62, 65], ["pro-inflammatory genes", "DNA", 112, 134], ["transcription factors", "TEST", 27, 48]]], ["NF-kB is sequestered in the cytoplasm by its specific inhibitor IkB, when phosphorylated by upstream kinases, IkB is ubiquitinated and degraded by the proteasome, allowing NF-kB to translocate to the nucleus.", [["cytoplasm", "ANATOMY", 28, 37], ["nucleus", "ANATOMY", 200, 207], ["NF-kB", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 28, 37], ["IkB", "GENE_OR_GENE_PRODUCT", 64, 67], ["IkB", "GENE_OR_GENE_PRODUCT", 110, 113], ["NF-kB", "GENE_OR_GENE_PRODUCT", 172, 177], ["nucleus", "CELLULAR_COMPONENT", 200, 207], ["NF-kB", "PROTEIN", 0, 5], ["IkB", "PROTEIN", 64, 67], ["upstream kinases", "PROTEIN", 92, 108], ["IkB", "PROTEIN", 110, 113], ["proteasome", "PROTEIN", 151, 161], ["NF-kB", "PROTEIN", 172, 177], ["upstream kinases", "TEST", 92, 108], ["the proteasome", "TREATMENT", 147, 161], ["-kB", "OBSERVATION_MODIFIER", 2, 5], ["nucleus", "ANATOMY", 200, 207]]], ["The upstream kinases responsible for relaying the signal include NF-kB inducing kinase (NIK) [90] and the IkB kinases (IKK)-aXb [91, 92] , and the more recently identified IKK-i/e [93, 94] and TANK binding kinase-1 (TBK-1) [95] [96] [97] .", [["NF-kB inducing kinase", "GENE_OR_GENE_PRODUCT", 65, 86], ["NIK", "GENE_OR_GENE_PRODUCT", 88, 91], ["IkB kinases", "GENE_OR_GENE_PRODUCT", 106, 117], ["IKK", "GENE_OR_GENE_PRODUCT", 119, 122], ["IKK", "GENE_OR_GENE_PRODUCT", 172, 175], ["TANK binding kinase-1", "GENE_OR_GENE_PRODUCT", 193, 214], ["TBK-1", "GENE_OR_GENE_PRODUCT", 216, 221], ["upstream kinases", "PROTEIN", 4, 20], ["NF-kB inducing kinase", "PROTEIN", 65, 86], ["NIK", "PROTEIN", 88, 91], ["IkB kinases", "PROTEIN", 106, 117], ["IKK", "PROTEIN", 119, 122], ["aXb", "PROTEIN", 124, 127], ["IKK", "PROTEIN", 172, 175], ["TANK binding kinase", "PROTEIN", 193, 212], ["The upstream kinases", "TEST", 0, 20], ["kinase", "TEST", 80, 86], ["the IkB kinases", "TEST", 102, 117], ["IKK", "TEST", 119, 122], ["aXb", "TEST", 124, 127], ["IKK", "TEST", 172, 175], ["TANK binding kinase", "TEST", 193, 212], ["TBK", "TEST", 216, 219]]], ["Once in the nucleus, NF-kB can bind to various cis-acting sites within the promoter of NF-kB responsive genes and promote transcription (depicted in Fig. 3) .Importance of NF-kB signallingThe promoters of GM-CSF, IL-6, CXCL8, CXCL10, ICAM-1 and VCAM all contain NF-kB binding sequences, and NF-kB is required for the expression of these genes following RV infection in vitro [62, 63, 70, 71, 76, 80] .", [["nucleus", "ANATOMY", 12, 19], ["RV", "ANATOMY", 353, 355], ["RV infection", "DISEASE", 353, 365], ["nucleus", "CELLULAR_COMPONENT", 12, 19], ["NF-kB", "GENE_OR_GENE_PRODUCT", 21, 26], ["NF-kB", "GENE_OR_GENE_PRODUCT", 87, 92], ["NF-kB", "GENE_OR_GENE_PRODUCT", 172, 177], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 205, 211], ["IL-6", "GENE_OR_GENE_PRODUCT", 213, 217], ["CXCL8", "GENE_OR_GENE_PRODUCT", 219, 224], ["CXCL10", "GENE_OR_GENE_PRODUCT", 226, 232], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 234, 240], ["VCAM", "GENE_OR_GENE_PRODUCT", 245, 249], ["NF-kB", "GENE_OR_GENE_PRODUCT", 262, 267], ["NF-kB", "GENE_OR_GENE_PRODUCT", 291, 296], ["NF-kB", "PROTEIN", 21, 26], ["cis-acting sites", "DNA", 47, 63], ["promoter", "DNA", 75, 83], ["NF-kB responsive genes", "DNA", 87, 109], ["NF-kB", "PROTEIN", 172, 177], ["promoters", "DNA", 192, 201], ["GM-CSF, IL-6", "PROTEIN", 205, 217], ["CXCL8", "PROTEIN", 219, 224], ["CXCL10", "PROTEIN", 226, 232], ["ICAM", "PROTEIN", 234, 238], ["VCAM", "PROTEIN", 245, 249], ["NF-kB binding sequences", "DNA", 262, 285], ["NF-kB", "PROTEIN", 291, 296], ["various cis-acting sites", "PROBLEM", 39, 63], ["GM", "TEST", 205, 207], ["CSF", "TEST", 208, 211], ["IL", "TEST", 213, 215], ["CXCL8", "TEST", 219, 224], ["CXCL10", "TEST", 226, 232], ["ICAM", "TEST", 234, 238], ["VCAM", "TEST", 245, 249], ["kB binding sequences", "TEST", 265, 285], ["RV infection", "PROBLEM", 353, 365], ["nucleus", "ANATOMY", 12, 19], ["CSF", "ANATOMY", 208, 211], ["RV", "ANATOMY", 353, 355], ["infection", "OBSERVATION", 356, 365]]], ["We have also extended this analysis for CXCL8 and IL-6 and have shown that NF-kB cis-acting sequences are absolutely required for RV-induced promoter activation for these genes in bronchial epithelial cells, and have identified a role for IKK-b, using the specific IKK-b inhibitor AS602868 (Serono, M.R. Edwards and S.L. Johnston, submitted).", [["bronchial epithelial cells", "ANATOMY", 180, 206], ["AS602868", "CHEMICAL", 281, 289], ["AS602868", "CHEMICAL", 281, 289], ["CXCL8", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-6", "GENE_OR_GENE_PRODUCT", 50, 54], ["NF-kB", "GENE_OR_GENE_PRODUCT", 75, 80], ["RV", "GENE_OR_GENE_PRODUCT", 130, 132], ["bronchial epithelial cells", "CELL", 180, 206], ["IKK-b", "GENE_OR_GENE_PRODUCT", 239, 244], ["IKK-b", "GENE_OR_GENE_PRODUCT", 265, 270], ["AS602868", "SIMPLE_CHEMICAL", 281, 289], ["CXCL8", "PROTEIN", 40, 45], ["IL-6", "PROTEIN", 50, 54], ["NF-kB cis-acting sequences", "DNA", 75, 101], ["bronchial epithelial cells", "CELL_TYPE", 180, 206], ["IKK", "PROTEIN", 239, 242], ["IKK", "PROTEIN", 265, 268], ["this analysis", "TEST", 22, 35], ["CXCL8", "TEST", 40, 45], ["NF-kB cis-acting sequences", "PROBLEM", 75, 101], ["RV-induced promoter activation", "TREATMENT", 130, 160], ["these genes in bronchial epithelial cells", "PROBLEM", 165, 206], ["the specific IKK", "TEST", 252, 268], ["bronchial", "ANATOMY", 180, 189], ["epithelial cells", "OBSERVATION", 190, 206]]], ["The role of NF-kB signalling in RV-induced CCL5 and IL-11 gene expression is not yet known, however seems likely to be implicated as both promoters contain NF-kB sequences, and these are important for gene expression following infection with other respiratory viruses [98, 99] .", [["infection", "DISEASE", 227, 236], ["respiratory viruses", "DISEASE", 248, 267], ["NF-kB", "GENE_OR_GENE_PRODUCT", 12, 17], ["RV", "MULTI-TISSUE_STRUCTURE", 32, 34], ["CCL5", "GENE_OR_GENE_PRODUCT", 43, 47], ["IL-11", "GENE_OR_GENE_PRODUCT", 52, 57], ["NF-kB", "GENE_OR_GENE_PRODUCT", 156, 161], ["NF-kB", "PROTEIN", 12, 17], ["CCL5", "PROTEIN", 43, 47], ["promoters", "DNA", 138, 147], ["NF-kB sequences", "DNA", 156, 171], ["RV", "TEST", 32, 34], ["IL", "TEST", 52, 54], ["NF-kB sequences", "TEST", 156, 171], ["infection", "PROBLEM", 227, 236], ["other respiratory viruses", "PROBLEM", 242, 267], ["RV", "ANATOMY", 32, 34]]], ["The role of NF-kB in RV-induced CCL10 and CXCL5 has not yet been studied; however, both genes also have NF-kB sites within their promoter, that are required for gene expression in various systems [100] [101] [102] .", [["NF-kB", "GENE_OR_GENE_PRODUCT", 12, 17], ["RV", "CELL", 21, 23], ["CCL10", "GENE_OR_GENE_PRODUCT", 32, 37], ["CXCL5", "GENE_OR_GENE_PRODUCT", 42, 47], ["NF-kB", "GENE_OR_GENE_PRODUCT", 104, 109], ["NF-kB", "PROTEIN", 12, 17], ["CCL10", "PROTEIN", 32, 37], ["CXCL5", "PROTEIN", 42, 47], ["NF-kB sites", "DNA", 104, 115], ["RV", "TEST", 21, 23], ["CXCL5", "TEST", 42, 47], ["NF-kB sites", "TREATMENT", 104, 115], ["gene expression in various systems", "PROBLEM", 161, 195], ["RV", "ANATOMY", 21, 23]]], ["Hence inhibition of NF-kB translocation, and NF-kB signalling represents a potential area of therapeutic intervention.Importance of NF-kB signallingOne unresolved question in RV biology is how NF-kB signalling is initiated by virus infection.", [["RV", "ANATOMY", 175, 177], ["infection", "DISEASE", 232, 241], ["NF-kB", "GENE_OR_GENE_PRODUCT", 20, 25], ["NF-kB", "GENE_OR_GENE_PRODUCT", 45, 50], ["NF-kB", "GENE_OR_GENE_PRODUCT", 132, 137], ["RV", "CANCER", 175, 177], ["NF-kB", "GENE_OR_GENE_PRODUCT", 193, 198], ["NF-kB", "PROTEIN", 20, 25], ["NF-kB", "PROTEIN", 45, 50], ["NF-kB", "PROTEIN", 132, 137], ["NF-kB", "PROTEIN", 193, 198], ["NF-kB translocation", "TREATMENT", 20, 39], ["therapeutic intervention", "TREATMENT", 93, 117], ["kB signalling", "PROBLEM", 135, 148], ["kB signalling", "PROBLEM", 196, 209], ["virus infection", "PROBLEM", 226, 241], ["therapeutic", "OBSERVATION", 93, 104], ["RV", "ANATOMY", 175, 177]]], ["The dsRNA binding anti-viral protein kinase (PKR) has been widely implicated in NF-kB signalling via interacting with IKK-a/ b, or by phosphorylating IkB directly [103] [104] [105] [106] .", [["dsRNA binding anti-viral protein kinase", "GENE_OR_GENE_PRODUCT", 4, 43], ["PKR", "GENE_OR_GENE_PRODUCT", 45, 48], ["NF-kB", "GENE_OR_GENE_PRODUCT", 80, 85], ["IKK", "GENE_OR_GENE_PRODUCT", 118, 121], ["b", "GENE_OR_GENE_PRODUCT", 125, 126], ["IkB", "GENE_OR_GENE_PRODUCT", 150, 153], ["dsRNA binding anti-viral protein kinase", "PROTEIN", 4, 43], ["PKR", "PROTEIN", 45, 48], ["NF-kB", "PROTEIN", 80, 85], ["IKK", "PROTEIN", 118, 121], ["IkB", "PROTEIN", 150, 153], ["The dsRNA binding anti-viral protein kinase", "TEST", 0, 43], ["PKR", "TEST", 45, 48], ["IKK", "TEST", 118, 121]]], ["Tolllike receptor 3 (TLR3) [107] , and the recently described retinoic acid inducible gene (RIG)-I [108] also activate NF-kB in response to viral infection or dsRNA.", [["retinoic acid", "CHEMICAL", 62, 75], ["viral infection", "DISEASE", 140, 155], ["retinoic acid", "CHEMICAL", 62, 75], ["Tolllike receptor 3", "GENE_OR_GENE_PRODUCT", 0, 19], ["TLR3", "GENE_OR_GENE_PRODUCT", 21, 25], ["retinoic acid inducible gene (RIG)-I", "GENE_OR_GENE_PRODUCT", 62, 98], ["NF-kB", "GENE_OR_GENE_PRODUCT", 119, 124], ["TLR3", "PROTEIN", 21, 25], ["retinoic acid inducible gene", "DNA", 62, 90], ["RIG", "DNA", 92, 95], ["NF-kB", "PROTEIN", 119, 124], ["retinoic acid inducible gene (RIG)", "TREATMENT", 62, 96], ["viral infection", "PROBLEM", 140, 155], ["dsRNA", "PROBLEM", 159, 164], ["viral infection", "OBSERVATION", 140, 155]]], ["Gern et al. [68] have demonstrated a role for PKR in RV-induced pro-inflammatory mediators from bronchial epithelial cells.", [["bronchial epithelial cells", "ANATOMY", 96, 122], ["PKR", "GENE_OR_GENE_PRODUCT", 46, 49], ["RV", "SIMPLE_CHEMICAL", 53, 55], ["bronchial epithelial cells", "CELL", 96, 122], ["PKR", "PROTEIN", 46, 49], ["pro-inflammatory mediators", "PROTEIN", 64, 90], ["bronchial epithelial cells", "CELL_TYPE", 96, 122], ["PKR", "PROBLEM", 46, 49], ["RV", "TEST", 53, 55], ["bronchial epithelial cells", "PROBLEM", 96, 122], ["RV", "ANATOMY", 53, 55], ["bronchial", "ANATOMY", 96, 105], ["epithelial cells", "OBSERVATION", 106, 122]]], ["PKR would thus seem a potential therapeutic target in RV exacerbations of asthma; however, PKR is also implicated in beneficial anti-viral host responses.", [["RV", "ANATOMY", 54, 56], ["asthma", "DISEASE", 74, 80], ["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["RV", "ORGAN", 54, 56], ["PKR", "GENE_OR_GENE_PRODUCT", 91, 94], ["PKR", "PROTEIN", 0, 3], ["PKR", "PROTEIN", 91, 94], ["PKR", "PROBLEM", 0, 3], ["RV exacerbations", "PROBLEM", 54, 70], ["asthma", "PROBLEM", 74, 80], ["PKR", "PROBLEM", 91, 94], ["RV", "ANATOMY", 54, 56], ["exacerbations", "OBSERVATION", 57, 70], ["asthma", "OBSERVATION", 74, 80]]], ["Through its ability to phosphorylate eukaryotic initiation factor-2a, PKR causes termination of host protein synthesis following viral infection [109] , in an attempt to limit viral replication.", [["viral infection", "DISEASE", 129, 144], ["eukaryotic initiation factor-2a", "GENE_OR_GENE_PRODUCT", 37, 68], ["PKR", "GENE_OR_GENE_PRODUCT", 70, 73], ["eukaryotic initiation factor-2a", "PROTEIN", 37, 68], ["PKR", "PROTEIN", 70, 73], ["PKR", "TREATMENT", 70, 73], ["host protein synthesis", "TREATMENT", 96, 118], ["viral infection", "PROBLEM", 129, 144], ["viral replication", "TREATMENT", 176, 193], ["viral replication", "OBSERVATION", 176, 193]]], ["PKR is also involved in type I IFN responses [110] .", [["PKR", "GENE_OR_GENE_PRODUCT", 0, 3], ["type I IFN", "GENE_OR_GENE_PRODUCT", 24, 34], ["PKR", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 31, 34]]], ["Hence, the possibility of beneficial and/or detrimental affects of PKR inhibition in RV exacerbations of asthma remains an open issue.Anti-rhinoviral compounds, RV 3C protease inhibitors and capsid bindersThe late 1980s and early 1990s saw great interest in antirhinoviral treatments, directed mainly at the control of clinical colds.", [["RV", "ANATOMY", 85, 87], ["asthma", "DISEASE", 105, 111], ["colds", "DISEASE", 328, 333], ["PKR", "GENE_OR_GENE_PRODUCT", 67, 70], ["RV", "MULTI-TISSUE_STRUCTURE", 85, 87], ["RV 3C", "GENE_OR_GENE_PRODUCT", 161, 166], ["PKR", "PROTEIN", 67, 70], ["capsid binders", "PROTEIN", 191, 205], ["PKR inhibition", "TREATMENT", 67, 81], ["RV exacerbations", "PROBLEM", 85, 101], ["asthma", "PROBLEM", 105, 111], ["Anti-rhinoviral compounds", "TREATMENT", 134, 159], ["RV 3C protease inhibitors", "TREATMENT", 161, 186], ["capsid binders", "TREATMENT", 191, 205], ["antirhinoviral treatments", "TREATMENT", 258, 283], ["clinical colds", "PROBLEM", 319, 333], ["RV", "ANATOMY", 85, 87], ["exacerbations", "OBSERVATION", 88, 101], ["asthma", "OBSERVATION", 105, 111]]], ["Compounds which interfere with viral attachment and uncoating by binding to the picornaviral capside protein VP1 were first investigated in the late 1980s [111] [112] [113] , and RV 3C protease inhibitors such as Ruprintrivir much later [114] .", [["Ruprintrivir", "CHEMICAL", 213, 225], ["Ruprintrivir", "CHEMICAL", 213, 225], ["VP1", "GENE_OR_GENE_PRODUCT", 109, 112], ["RV 3C", "GENE_OR_GENE_PRODUCT", 179, 184], ["picornaviral capside protein VP1", "PROTEIN", 80, 112], ["viral attachment", "PROBLEM", 31, 47], ["the picornaviral capside protein VP1", "TREATMENT", 76, 112], ["RV 3C protease inhibitors", "TREATMENT", 179, 204]]], ["These drugs showed a broad inhibition to RV infection in vitro [115] .", [["RV infection", "DISEASE", 41, 53], ["These drugs", "TREATMENT", 0, 11], ["a broad inhibition", "TREATMENT", 19, 37], ["RV infection", "PROBLEM", 41, 53], ["RV", "ANATOMY", 41, 43], ["infection", "OBSERVATION", 44, 53]]], ["The modes of action of all treatment options discussed in this review are shown in Fig. 4 .Anti-rhinoviral compounds, RV 3C protease inhibitors and capsid bindersThe viral capsid binder R61837 was first used in 1989, in a model of experimental infection with RV9.", [["R61837", "CHEMICAL", 186, 192], ["infection", "DISEASE", 244, 253], ["R61837", "CHEMICAL", 186, 192], ["RV 3C", "GENE_OR_GENE_PRODUCT", 118, 123], ["capsid binders", "PROTEIN", 148, 162], ["RV9", "SPECIES", 259, 262], ["all treatment options", "TREATMENT", 23, 44], ["Anti-rhinoviral compounds", "TREATMENT", 91, 116], ["RV 3C protease inhibitors", "TREATMENT", 118, 143], ["capsid binders", "TREATMENT", 148, 162], ["The viral capsid binder", "TEST", 162, 185], ["experimental infection", "PROBLEM", 231, 253], ["RV9", "TREATMENT", 259, 262], ["viral", "OBSERVATION_MODIFIER", 166, 171], ["capsid binder", "OBSERVATION", 172, 185], ["infection", "OBSERVATION", 244, 253]]], ["R61837 was given in a single dose (2.5 mg) intranasally either 28 or 4 h prior to challenge, and continued up to 4 or 6 days, respectively, post-challenge [112] .", [["R61837", "CHEMICAL", 0, 6], ["R61837", "CHEMICAL", 0, 6], ["R61837", "SIMPLE_CHEMICAL", 0, 6]]], ["Clinical colds were 3 .", [["colds", "DISEASE", 9, 14], ["Clinical colds", "PROBLEM", 0, 14]]], ["Activation of NF-kB p65, p50 by the IKK-a/b/g complex, or an alternative IKK complex consisting of IKK-i/e, TBK-1 and TANK.", [["NF-kB p65", "GENE_OR_GENE_PRODUCT", 14, 23], ["p50", "GENE_OR_GENE_PRODUCT", 25, 28], ["IKK", "GENE_OR_GENE_PRODUCT", 36, 39], ["b/g complex", "GENE_OR_GENE_PRODUCT", 42, 53], ["IKK", "GENE_OR_GENE_PRODUCT", 73, 76], ["IKK-i/e", "GENE_OR_GENE_PRODUCT", 99, 106], ["TBK-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["TANK", "GENE_OR_GENE_PRODUCT", 118, 122], ["NF-kB p65", "PROTEIN", 14, 23], ["p50", "PROTEIN", 25, 28], ["IKK-a/b/g complex", "PROTEIN", 36, 53], ["IKK complex", "PROTEIN", 73, 84], ["IKK-i/e, TBK-1", "PROTEIN", 99, 113], ["TANK", "PROTEIN", 118, 122], ["the IKK", "TEST", 32, 39], ["a/b/g complex", "TEST", 40, 53], ["an alternative IKK complex", "PROBLEM", 58, 84], ["IKK", "TEST", 99, 102], ["TBK", "TEST", 108, 111]]], ["Following viral infection, or dsRNA recognistion via PKR and/or TLR3, RIG-I, or cytokines, e.g. TNF-a or IL-1b (via NIK), IKK phosphorylates IkB leading to its degradation by the proteasome.", [["viral infection", "DISEASE", 10, 25], ["PKR", "GENE_OR_GENE_PRODUCT", 53, 56], ["TLR3", "GENE_OR_GENE_PRODUCT", 64, 68], ["RIG-I", "GENE_OR_GENE_PRODUCT", 70, 75], ["TNF-a", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL-1b", "GENE_OR_GENE_PRODUCT", 105, 110], ["NIK", "GENE_OR_GENE_PRODUCT", 116, 119], ["IKK", "GENE_OR_GENE_PRODUCT", 122, 125], ["IkB", "GENE_OR_GENE_PRODUCT", 141, 144], ["PKR", "PROTEIN", 53, 56], ["TLR3", "PROTEIN", 64, 68], ["RIG-I", "PROTEIN", 70, 75], ["cytokines", "PROTEIN", 80, 89], ["TNF", "PROTEIN", 96, 99], ["IL-1b", "PROTEIN", 105, 110], ["NIK", "PROTEIN", 116, 119], ["IKK", "PROTEIN", 122, 125], ["IkB", "PROTEIN", 141, 144], ["proteasome", "PROTEIN", 179, 189], ["viral infection", "PROBLEM", 10, 25], ["dsRNA recognistion", "TEST", 30, 48], ["PKR", "TEST", 53, 56], ["TLR3", "TEST", 64, 68], ["cytokines", "TEST", 80, 89], ["TNF", "TEST", 96, 99], ["IL", "TEST", 105, 107], ["IKK phosphorylates IkB", "PROBLEM", 122, 144], ["the proteasome", "TREATMENT", 175, 189], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 16, 25]]], ["Once free, NF-kB p65, p50 subunits translocate to the nucleus and upregulate NF-kB responsive genes, such as CXCL8, IL-6 and GM-CSF. defined on the basis of using 44 tissues over the baseline rate plus development of one other relevant symptom (sore throat, sneezing, etc.).", [["nucleus", "ANATOMY", 54, 61], ["tissues", "ANATOMY", 166, 173], ["sore throat", "DISEASE", 245, 256], ["sneezing", "DISEASE", 258, 266], ["NF-kB p65", "GENE_OR_GENE_PRODUCT", 11, 20], ["p50", "GENE_OR_GENE_PRODUCT", 22, 25], ["nucleus", "CELLULAR_COMPONENT", 54, 61], ["NF-kB", "GENE_OR_GENE_PRODUCT", 77, 82], ["CXCL8", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 125, 131], ["tissues", "TISSUE", 166, 173], ["NF-kB p65", "PROTEIN", 11, 20], ["p50 subunits", "PROTEIN", 22, 34], ["NF-kB responsive genes", "DNA", 77, 99], ["CXCL8", "PROTEIN", 109, 114], ["IL-6", "PROTEIN", 116, 120], ["GM-CSF", "DNA", 125, 131], ["kB responsive genes", "PROBLEM", 80, 99], ["CXCL8", "TEST", 109, 114], ["IL", "TEST", 116, 118], ["one other relevant symptom", "PROBLEM", 217, 243], ["sore throat", "PROBLEM", 245, 256], ["sneezing", "PROBLEM", 258, 266], ["nucleus", "ANATOMY", 54, 61], ["CSF", "ANATOMY", 128, 131]]], ["When given 4 h prior to challenge, and for 6 days duration, R61837 reduced the incidence of colds, mean total symptom score and weight of nasal secretions compared to a control group given placebo.", [["nasal secretions", "ANATOMY", 138, 154], ["R61837", "CHEMICAL", 60, 66], ["colds", "DISEASE", 92, 97], ["R61837", "CHEMICAL", 60, 66], ["R61837", "SIMPLE_CHEMICAL", 60, 66], ["nasal secretions", "ORGANISM_SUBDIVISION", 138, 154], ["colds", "PROBLEM", 92, 97], ["mean total symptom score", "PROBLEM", 99, 123], ["weight of nasal secretions", "PROBLEM", 128, 154], ["placebo", "TREATMENT", 189, 196], ["nasal", "ANATOMY", 138, 143], ["secretions", "OBSERVATION", 144, 154]]], ["The effects of R61837 on the duration of the clinical cold, or length of time spent exhibiting symptoms were not studied.Anti-rhinoviral compounds, RV 3C protease inhibitors and capsid bindersIn contrast, the oxazoline WIN54954 was tested in 1993, and showed poor efficacy in experimental models of RV39 and RV23 [111] .", [["R61837", "CHEMICAL", 15, 21], ["oxazoline", "CHEMICAL", 209, 218], ["WIN54954", "CHEMICAL", 219, 227], ["RV39", "CHEMICAL", 299, 303], ["R61837", "CHEMICAL", 15, 21], ["oxazoline", "CHEMICAL", 209, 218], ["WIN54954", "CHEMICAL", 219, 227], ["R61837", "SIMPLE_CHEMICAL", 15, 21], ["RV 3C", "GENE_OR_GENE_PRODUCT", 148, 153], ["oxazoline WIN54954", "SIMPLE_CHEMICAL", 209, 227], ["capsid binders", "PROTEIN", 178, 192], ["RV39", "SPECIES", 299, 303], ["symptoms", "PROBLEM", 95, 103], ["Anti-rhinoviral compounds", "TREATMENT", 121, 146], ["RV 3C protease inhibitors", "TREATMENT", 148, 173], ["capsid binders", "TREATMENT", 178, 192], ["the oxazoline", "TREATMENT", 205, 218]]], ["Dosing consisted of a 600 mg oral dose, every 8 h for 6 days.", [["oral", "ANATOMY", 29, 33], ["oral", "ORGANISM_SUBDIVISION", 29, 33]]], ["WIN54954 did not reduce any of the parameters tested when compared to placebo, including incidence of colds, mean total symptom score and viral titre.", [["WIN54954", "CHEMICAL", 0, 8], ["colds", "DISEASE", 102, 107], ["WIN54954", "CHEMICAL", 0, 8], ["WIN54954", "SIMPLE_CHEMICAL", 0, 8], ["the parameters", "TEST", 31, 45], ["placebo", "TREATMENT", 70, 77], ["colds", "PROBLEM", 102, 107], ["mean total symptom score", "PROBLEM", 109, 133], ["viral titre", "TEST", 138, 149], ["viral titre", "OBSERVATION", 138, 149]]], ["One explanation for the poor performance of WIN54954 was the low levels of drug recovered from saliva and nasal wash after treatment.", [["nasal", "ANATOMY", 106, 111], ["WIN54954", "CHEMICAL", 44, 52], ["WIN54954", "CHEMICAL", 44, 52], ["WIN54954", "SIMPLE_CHEMICAL", 44, 52], ["saliva", "ORGANISM_SUBSTANCE", 95, 101], ["nasal", "ORGANISM_SUBDIVISION", 106, 111], ["drug", "TREATMENT", 75, 79], ["saliva", "TREATMENT", 95, 101], ["nasal wash", "TREATMENT", 106, 116], ["treatment", "TREATMENT", 123, 132], ["nasal", "ANATOMY", 106, 111]]], ["Few patients had concentrations greater than the minimum inhibitory concentration (MIC) for the test virus.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["concentrations", "TREATMENT", 17, 31], ["the test virus", "PROBLEM", 92, 106]]], ["Pirodavir (R77, 975) when given as an intranasal therapy (2 mg), was also disappointing in a study of natural virus infection [113] .", [["Pirodavir", "CHEMICAL", 0, 9], ["R77, 975", "CHEMICAL", 11, 19], ["infection", "DISEASE", 116, 125], ["Pirodavir", "CHEMICAL", 0, 9], ["Pirodavir", "SIMPLE_CHEMICAL", 0, 9], ["natural virus", "ORGANISM", 102, 115], ["Pirodavir", "TREATMENT", 0, 9], ["an intranasal therapy", "TREATMENT", 35, 56], ["a study", "TEST", 91, 98], ["natural virus infection", "PROBLEM", 102, 125]]], ["Pirodavir reduced only viral titre when compared to control groups treated with placebo, the duration of colds and mean total symptom score were not reduced by Pirodavir.Anti-rhinoviral compounds, RV 3C protease inhibitors and capsid bindersThe anti-picornaviral agent Pleconaril has been used in randomised, placebo-controlled, phase II clinical trials as a treatment of the common cold [116] .", [["Pirodavir", "CHEMICAL", 0, 9], ["colds", "DISEASE", 105, 110], ["Pirodavir", "CHEMICAL", 160, 169], ["Pleconaril", "CHEMICAL", 269, 279], ["Pirodavir", "CHEMICAL", 0, 9], ["Pirodavir", "CHEMICAL", 160, 169], ["Pleconaril", "CHEMICAL", 269, 279], ["Pirodavir", "SIMPLE_CHEMICAL", 0, 9], ["Pirodavir", "SIMPLE_CHEMICAL", 160, 169], ["RV 3C", "GENE_OR_GENE_PRODUCT", 197, 202], ["Pleconaril", "SIMPLE_CHEMICAL", 269, 279], ["capsid binders", "PROTEIN", 227, 241], ["Pirodavir", "TREATMENT", 0, 9], ["viral titre", "TREATMENT", 23, 34], ["placebo", "TREATMENT", 80, 87], ["colds", "PROBLEM", 105, 110], ["mean total symptom score", "PROBLEM", 115, 139], ["Pirodavir", "TREATMENT", 160, 169], ["Anti-rhinoviral compounds", "TREATMENT", 170, 195], ["RV 3C protease inhibitors", "TREATMENT", 197, 222], ["capsid binders", "TREATMENT", 227, 241], ["The anti-picornaviral agent Pleconaril", "TREATMENT", 241, 279], ["phase II clinical trials", "TREATMENT", 329, 353], ["a treatment", "TREATMENT", 357, 368], ["viral titre", "OBSERVATION", 23, 34]]], ["Pleconaril acts by preventing uncoating of picornaviruses, including most serotypes of RVs tested in vitro [117] .", [["Pleconaril", "CHEMICAL", 0, 10], ["Pleconaril", "CHEMICAL", 0, 10], ["Pleconaril", "SIMPLE_CHEMICAL", 0, 10], ["Pleconaril acts", "TREATMENT", 0, 15], ["picornaviruses", "PROBLEM", 43, 57], ["picornaviruses", "OBSERVATION", 43, 57]]], ["Participating volunteers commenced treatment 1-1.5 days after a clinical picornavirus infection was established.", [["picornavirus infection", "DISEASE", 73, 95], ["volunteers", "ORGANISM", 14, 24], ["picornavirus", "ORGANISM", 73, 85], ["treatment", "TREATMENT", 35, 44], ["a clinical picornavirus infection", "PROBLEM", 62, 95], ["infection", "OBSERVATION", 86, 95]]], ["Individuals taking Pleconaril, when taken as a 400 mg dose in liquid form, or as a 400 mg tablet three times daily showed significant improvement in mean symptoms scores at days 2-5 after commencement of treatment, and decreases in mean duration of illness.", [["Pleconaril", "CHEMICAL", 19, 29], ["illness", "DISEASE", 249, 256], ["Pleconaril", "CHEMICAL", 19, 29], ["Pleconaril", "SIMPLE_CHEMICAL", 19, 29], ["Pleconaril", "TREATMENT", 19, 29], ["mean symptoms scores", "PROBLEM", 149, 169], ["treatment", "TREATMENT", 204, 213], ["illness", "PROBLEM", 249, 256], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["improvement", "OBSERVATION_MODIFIER", 134, 145]]], ["Despite promising initial results, Pleconaril has not yet been tested in the setting of RVinduced exacerbations of asthma.Anti-rhinoviral compounds, RV 3C protease inhibitors and capsid bindersThe RV 3C protease inhibitor Ruprintrivir (Agouron Pharmaceuticals, Inc.) has also been tested in a doubleblind, placebo-controlled phase II trial of experimental RV39 challenge [114] .", [["Pleconaril", "CHEMICAL", 35, 45], ["asthma", "DISEASE", 115, 121], ["Ruprintrivir", "CHEMICAL", 222, 234], ["RV39", "CHEMICAL", 356, 360], ["Pleconaril", "CHEMICAL", 35, 45], ["Ruprintrivir", "CHEMICAL", 222, 234], ["RV39", "CHEMICAL", 356, 360], ["Pleconaril", "SIMPLE_CHEMICAL", 35, 45], ["RV 3C", "GENE_OR_GENE_PRODUCT", 149, 154], ["RV 3C", "GENE_OR_GENE_PRODUCT", 197, 202], ["Ruprintrivir", "SIMPLE_CHEMICAL", 222, 234], ["capsid binders", "PROTEIN", 179, 193], ["Pleconaril", "TREATMENT", 35, 45], ["RVinduced exacerbations", "PROBLEM", 88, 111], ["asthma", "PROBLEM", 115, 121], ["Anti-rhinoviral compounds", "TREATMENT", 122, 147], ["RV 3C protease inhibitors", "TREATMENT", 149, 174], ["capsid binders", "TREATMENT", 179, 193], ["The RV 3C protease inhibitor Ruprintrivir (Agouron Pharmaceuticals", "TREATMENT", 193, 259], ["experimental RV39 challenge", "TREATMENT", 343, 370], ["exacerbations", "OBSERVATION", 98, 111], ["asthma", "OBSERVATION", 115, 121], ["RV", "ANATOMY", 197, 199]]], ["RV 3C protease is required for cleavage of the rhinoviral precursor polyprotein into individual components prior to viral assembly.", [["RV 3C", "GENE_OR_GENE_PRODUCT", 0, 5], ["RV 3C protease", "PROTEIN", 0, 14], ["rhinoviral precursor polyprotein", "PROTEIN", 47, 79], ["RV 3C protease", "TREATMENT", 0, 14], ["cleavage", "PROBLEM", 31, 39], ["the rhinoviral precursor polyprotein", "TREATMENT", 43, 79]]], ["Furthermore, RV 3C protease is required for generation of the RNA polymerase and hence viral RNA replication.", [["RV 3C", "GENE_OR_GENE_PRODUCT", 13, 18], ["RV 3C protease", "PROTEIN", 13, 27], ["RNA polymerase", "PROTEIN", 62, 76], ["RV 3C protease", "TREATMENT", 13, 27], ["the RNA polymerase", "TREATMENT", 58, 76], ["viral RNA replication", "TREATMENT", 87, 108]]], ["RV 3C protease has also been implicated in initiation of host cell signalling leading to pro-inflammatory cytokine production [65] .", [["cell", "ANATOMY", 62, 66], ["RV 3C", "GENE_OR_GENE_PRODUCT", 0, 5], ["host cell", "CELL", 57, 66], ["RV 3C protease", "PROTEIN", 0, 14], ["cytokine", "PROTEIN", 106, 114], ["RV 3C protease", "TREATMENT", 0, 14], ["host cell signalling", "TREATMENT", 57, 77], ["pro-inflammatory cytokine production", "PROBLEM", 89, 125], ["host cell", "OBSERVATION", 57, 66]]], ["Ruprintrivir was designed using solved X-ray crystal structures of the RV 3C protease, and was designed to bind irreversibly to the RV 3C active site [118] .", [["Ruprintrivir", "CHEMICAL", 0, 12], ["Ruprintrivir", "CHEMICAL", 0, 12], ["Ruprintrivir", "SIMPLE_CHEMICAL", 0, 12], ["RV 3C protease", "PROTEIN", 71, 85], ["RV 3C active site", "PROTEIN", 132, 149], ["Ruprintrivir", "TREATMENT", 0, 12], ["solved X-ray crystal structures", "TREATMENT", 32, 63], ["the RV 3C protease", "TREATMENT", 67, 85], ["RV", "ANATOMY", 71, 73], ["RV", "ANATOMY", 132, 134]]], ["Ruprintrivir demonstrated a broad anti-picornaviral spectrum in vitro, with an MIC of 0.023 mM [119] .", [["Ruprintrivir", "CHEMICAL", 0, 12], ["Ruprintrivir", "CHEMICAL", 0, 12], ["Ruprintrivir", "SIMPLE_CHEMICAL", 0, 12], ["broad", "OBSERVATION_MODIFIER", 28, 33]]], ["The above study utilised Ruprintrivir as either two or five times a day as prophylaxis, 6 h prior to infection, or as a treatment five times a day 24 h after infection.", [["Ruprintrivir", "CHEMICAL", 25, 37], ["infection", "DISEASE", 101, 110], ["infection", "DISEASE", 158, 167], ["Ruprintrivir", "CHEMICAL", 25, 37], ["Ruprintrivir", "SIMPLE_CHEMICAL", 25, 37], ["The above study", "TEST", 0, 15], ["Ruprintrivir", "TREATMENT", 25, 37], ["prophylaxis", "TREATMENT", 75, 86], ["infection", "PROBLEM", 101, 110], ["infection", "PROBLEM", 158, 167], ["infection", "OBSERVATION", 101, 110]]], ["As a prophylaxis, Ruprintrivir reduced mean total symptom score, viral titre, nasal secretions but not the incidence or frequency of clinical colds (as assessed by the number of infected subjects that developed clinical colds).", [["nasal secretions", "ANATOMY", 78, 94], ["Ruprintrivir", "CHEMICAL", 18, 30], ["colds", "DISEASE", 142, 147], ["colds", "DISEASE", 220, 225], ["Ruprintrivir", "CHEMICAL", 18, 30], ["Ruprintrivir", "SIMPLE_CHEMICAL", 18, 30], ["a prophylaxis", "TREATMENT", 3, 16], ["Ruprintrivir reduced mean total symptom score", "PROBLEM", 18, 63], ["viral titre", "TEST", 65, 76], ["nasal secretions", "PROBLEM", 78, 94], ["clinical colds", "PROBLEM", 133, 147], ["viral titre", "OBSERVATION", 65, 76], ["nasal", "ANATOMY", 78, 83], ["secretions", "OBSERVATION", 84, 94]]], ["As a therapeutic treatment, Ruprintrivir also reduced symptom scores, nasal secretions and viral titre.", [["nasal secretions", "ANATOMY", 70, 86], ["Ruprintrivir", "CHEMICAL", 28, 40], ["Ruprintrivir", "CHEMICAL", 28, 40], ["Ruprintrivir", "SIMPLE_CHEMICAL", 28, 40], ["nasal secretions", "ORGANISM_SUBSTANCE", 70, 86], ["a therapeutic treatment", "TREATMENT", 3, 26], ["Ruprintrivir", "TREATMENT", 28, 40], ["reduced symptom scores", "PROBLEM", 46, 68], ["nasal secretions", "PROBLEM", 70, 86], ["viral titre", "PROBLEM", 91, 102], ["nasal", "ANATOMY", 70, 75], ["secretions", "OBSERVATION", 76, 86], ["viral titre", "OBSERVATION", 91, 102]]], ["Ruprintrivir was generally well tolerated, despite this study requiring numerous deliveries via nasal spray.Anti-rhinoviral compounds, RV 3C protease inhibitors and capsid bindersThe above studies provide evidence that treatment of clinical colds with anti-rhinoviral therapies is useful.", [["nasal", "ANATOMY", 96, 101], ["Ruprintrivir", "CHEMICAL", 0, 12], ["colds", "DISEASE", 241, 246], ["Ruprintrivir", "CHEMICAL", 0, 12], ["Ruprintrivir", "SIMPLE_CHEMICAL", 0, 12], ["nasal", "ORGANISM_SUBDIVISION", 96, 101], ["RV 3C", "GENE_OR_GENE_PRODUCT", 135, 140], ["anti-rhinoviral", "SIMPLE_CHEMICAL", 252, 267], ["capsid binders", "PROTEIN", 165, 179], ["this study", "TEST", 51, 61], ["numerous deliveries via nasal spray", "TREATMENT", 72, 107], ["Anti-rhinoviral compounds", "TREATMENT", 108, 133], ["RV 3C protease inhibitors", "TREATMENT", 135, 160], ["capsid binders", "TREATMENT", 165, 179], ["The above studies", "TEST", 179, 196], ["clinical colds", "PROBLEM", 232, 246], ["anti-rhinoviral therapies", "TREATMENT", 252, 277]]], ["However, there are potential problems with these approaches, with respect to potential therapies for virusinduced asthma exacerbations.", [["asthma", "DISEASE", 114, 120], ["these approaches", "TREATMENT", 43, 59], ["potential therapies", "TREATMENT", 77, 96], ["virusinduced asthma exacerbations", "PROBLEM", 101, 134], ["asthma", "OBSERVATION", 114, 120]]], ["For example, therapy of capsid binding molecules has led to the development of escape mutants [117] .", [["capsid binding molecules", "PROTEIN", 24, 48], ["therapy of capsid binding molecules", "TREATMENT", 13, 48], ["escape mutants", "PROBLEM", 79, 93]]], ["It could also be argued for the RV 3C protease inhibitors, that virus binding, uncoating and entry could be a stimulus for cell signalling events, leading to initiation of pro-inflammatory mediator gene expression [61] , and future therapies should aim at preventing the early steps of virus uncoating and entry.", [["cell", "ANATOMY", 123, 127], ["RV 3C", "GENE_OR_GENE_PRODUCT", 32, 37], ["cell", "CELL", 123, 127], ["the RV 3C protease inhibitors", "TREATMENT", 28, 57], ["virus binding", "PROBLEM", 64, 77], ["cell signalling events", "PROBLEM", 123, 145], ["pro-inflammatory mediator gene expression", "TREATMENT", 172, 213], ["future therapies", "TREATMENT", 225, 241], ["virus uncoating", "PROBLEM", 286, 301]]], ["In support of this view, a study of Ruprintrivir to prevent RV14-induced IL-6 and CXCL8 suggested that this agent was not 100% effective at reducing mediator production, despite a high dose of 10 mM being used [120] .", [["Ruprintrivir", "CHEMICAL", 36, 48], ["RV14", "CHEMICAL", 60, 64], ["Ruprintrivir", "CHEMICAL", 36, 48], ["Ruprintrivir", "SIMPLE_CHEMICAL", 36, 48], ["RV14", "SIMPLE_CHEMICAL", 60, 64], ["IL-6", "GENE_OR_GENE_PRODUCT", 73, 77], ["CXCL8", "GENE_OR_GENE_PRODUCT", 82, 87], ["RV14", "PROTEIN", 60, 64], ["IL-6", "PROTEIN", 73, 77], ["CXCL8", "PROTEIN", 82, 87], ["a study", "TEST", 25, 32], ["Ruprintrivir", "TREATMENT", 36, 48], ["RV14", "TEST", 60, 64], ["CXCL8", "TEST", 82, 87], ["this agent", "TREATMENT", 103, 113]]], ["For therapies such as Ruprintrivir, which were administered via nasal spray, it can also be argued that delivery by this method may not be effective at treating the lower airway, where virus-induced asthma exacerbations are believed to be triggered.", [["nasal", "ANATOMY", 64, 69], ["lower airway", "ANATOMY", 165, 177], ["Ruprintrivir", "CHEMICAL", 22, 34], ["asthma", "DISEASE", 199, 205], ["Ruprintrivir", "CHEMICAL", 22, 34], ["Ruprintrivir", "SIMPLE_CHEMICAL", 22, 34], ["nasal", "ORGANISM_SUBDIVISION", 64, 69], ["lower airway", "ORGANISM_SUBDIVISION", 165, 177], ["therapies", "TREATMENT", 4, 13], ["Ruprintrivir", "TREATMENT", 22, 34], ["nasal spray", "TREATMENT", 64, 75], ["this method", "TREATMENT", 116, 127], ["virus", "PROBLEM", 185, 190], ["asthma exacerbations", "PROBLEM", 199, 219], ["lower", "ANATOMY_MODIFIER", 165, 170], ["airway", "ANATOMY", 171, 177], ["believed to be", "UNCERTAINTY", 224, 238]]], ["Furthermore, dosing regimes must also be suitable for children, as well as adults, in a setting of asthma exacerbations.", [["asthma", "DISEASE", 99, 105], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["dosing regimes", "TREATMENT", 13, 27], ["asthma exacerbations", "PROBLEM", 99, 119], ["asthma", "OBSERVATION", 99, 105]]], ["Perhaps a further criticism of many of these studies is that duration of clinical colds was not affected by most treatments.", [["colds", "DISEASE", 82, 87], ["these studies", "TEST", 39, 52], ["clinical colds", "PROBLEM", 73, 87]]], ["Pleconaril was the only treatment successful at reducing duration of clinical cold.", [["Pleconaril", "CHEMICAL", 0, 10], ["Pleconaril", "CHEMICAL", 0, 10], ["Pleconaril", "SIMPLE_CHEMICAL", 0, 10], ["Pleconaril", "TREATMENT", 0, 10], ["treatment", "TREATMENT", 24, 33], ["clinical cold", "PROBLEM", 69, 82]]], ["These therapies, although reducing symptoms may not necessarily affect duration of symptoms, and therefore may not improve the rate of general practitioner consultations, hospital admission rates, and school and work absenteeism for infected individuals with virus-induced exacerbations of asthma.Human or recombinant soluble ICAM-1 and derivativesSeveral versions of human ICAM-1 have been used in clinical studies, including soluble ICAM-1 (Tremacamra/ BIRR 4) [121] , antibodies to ICAM-1 [122] , and fusion proteins of ICAM-1 and IgA [123] .", [["asthma", "DISEASE", 290, 296], ["Human", "ORGANISM", 297, 302], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 326, 332], ["human", "ORGANISM", 368, 373], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 374, 380], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 435, 441], ["Tremacamra/ BIRR 4", "GENE_OR_GENE_PRODUCT", 443, 461], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 485, 491], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 523, 529], ["IgA", "GENE_OR_GENE_PRODUCT", 534, 537], ["Human or recombinant soluble ICAM-1", "PROTEIN", 297, 332], ["human ICAM-1", "PROTEIN", 368, 380], ["ICAM-1", "PROTEIN", 435, 441], ["Tremacamra", "PROTEIN", 443, 453], ["BIRR 4", "PROTEIN", 455, 461], ["antibodies", "PROTEIN", 471, 481], ["ICAM", "PROTEIN", 485, 489], ["fusion proteins", "PROTEIN", 504, 519], ["ICAM", "PROTEIN", 523, 527], ["IgA", "PROTEIN", 534, 537], ["Human", "SPECIES", 297, 302], ["human", "SPECIES", 368, 373], ["Human", "SPECIES", 297, 302], ["human", "SPECIES", 368, 373], ["These therapies", "TREATMENT", 0, 15], ["reducing symptoms", "PROBLEM", 26, 43], ["symptoms", "PROBLEM", 83, 91], ["infected individuals", "PROBLEM", 233, 253], ["virus", "PROBLEM", 259, 264], ["asthma", "PROBLEM", 290, 296], ["Human or recombinant soluble ICAM", "TREATMENT", 297, 330], ["derivatives", "TREATMENT", 337, 348], ["human ICAM", "TEST", 368, 378], ["clinical studies", "TEST", 399, 415], ["soluble ICAM", "TEST", 427, 439], ["Tremacamra", "TEST", 443, 453], ["BIRR", "TEST", 455, 459], ["antibodies", "TEST", 471, 481], ["ICAM", "TEST", 485, 489], ["fusion proteins", "TEST", 504, 519], ["ICAM", "TEST", 523, 527], ["IgA", "TEST", 534, 537], ["asthma", "OBSERVATION", 290, 296]]], ["In vitro, soluble ICAM-1 preparations have been shown to reduce titres of a large range of major group RVs [123, 124] .", [["ICAM-1", "GENE_OR_GENE_PRODUCT", 18, 24], ["ICAM", "PROTEIN", 18, 22], ["soluble ICAM-1 preparations", "TREATMENT", 10, 37]]], ["Tremacamra has been tested in randomised double-blind placebo-controlled studies both as a therapeutic and prophylactic intervention to RV39 challenge [121] .", [["Tremacamra", "CHEMICAL", 0, 10], ["RV39", "CHEMICAL", 136, 140], ["RV39", "CHEMICAL", 136, 140], ["Tremacamra", "SIMPLE_CHEMICAL", 0, 10], ["Tremacamra", "TREATMENT", 0, 10], ["blind placebo", "TREATMENT", 48, 61], ["prophylactic intervention", "TREATMENT", 107, 132]]], ["In these clinical studies, Tremacamra has shown promise as a therapy, reducing the proportion of clinical colds following experimental RV39 challenge, total symptom score, nasal mucus weight, and significantly lowering CXCL8 release on days 3 and 4 post-infection compared to placebo.", [["nasal mucus", "ANATOMY", 172, 183], ["Tremacamra", "CHEMICAL", 27, 37], ["colds", "DISEASE", 106, 111], ["RV39", "CHEMICAL", 135, 139], ["infection", "DISEASE", 254, 263], ["Tremacamra", "CHEMICAL", 27, 37], ["Tremacamra", "SIMPLE_CHEMICAL", 27, 37], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 172, 183], ["CXCL8", "GENE_OR_GENE_PRODUCT", 219, 224], ["CXCL8", "PROTEIN", 219, 224], ["RV39", "SPECIES", 135, 139], ["these clinical studies", "TEST", 3, 25], ["Tremacamra", "TREATMENT", 27, 37], ["a therapy", "TREATMENT", 59, 68], ["clinical colds", "PROBLEM", 97, 111], ["experimental RV39 challenge", "TREATMENT", 122, 149], ["total symptom score", "TEST", 151, 170], ["nasal mucus weight", "TEST", 172, 190], ["significantly lowering CXCL8 release", "PROBLEM", 196, 232], ["infection", "PROBLEM", 254, 263], ["placebo", "TREATMENT", 276, 283], ["nasal mucus", "ANATOMY", 172, 183], ["infection", "OBSERVATION", 254, 263]]], ["Tremacamra also significantly reduced RV39 replication on days 2-4 postinfection.", [["Tremacamra", "CHEMICAL", 0, 10], ["Tremacamra", "SIMPLE_CHEMICAL", 0, 10], ["RV39", "DNA", 38, 42], ["RV39", "SPECIES", 38, 42], ["Tremacamra", "TREATMENT", 0, 10], ["significantly", "OBSERVATION_MODIFIER", 16, 29], ["reduced", "OBSERVATION_MODIFIER", 30, 37]]], ["Also, Tremacamra was useful in controlling RVinduced symptoms if given prior to challenge, or after challenge but before establishment of symptoms.", [["Tremacamra", "CHEMICAL", 6, 16], ["Tremacamra", "SIMPLE_CHEMICAL", 6, 16], ["Tremacamra", "TREATMENT", 6, 16], ["RVinduced symptoms", "PROBLEM", 43, 61], ["symptoms", "PROBLEM", 138, 146]]], ["Tremacamra holds promise as a therapy for clinical colds, however, has not been tested in a context of exacerbations of asthma.Type I IFN therapyType I IFNs are potent anti-viral mediators having a range of effects that limit viral infection and dissemination.", [["Tremacamra", "CHEMICAL", 0, 10], ["colds", "DISEASE", 51, 56], ["asthma", "DISEASE", 120, 126], ["viral infection", "DISEASE", 226, 241], ["Tremacamra", "SIMPLE_CHEMICAL", 0, 10], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 127, 137], ["Type I IFNs", "GENE_OR_GENE_PRODUCT", 145, 156], ["Type I IFN", "PROTEIN", 127, 137], ["Type I IFNs", "PROTEIN", 145, 156], ["Tremacamra", "TREATMENT", 0, 10], ["a therapy", "TREATMENT", 28, 37], ["clinical colds", "PROBLEM", 42, 56], ["asthma", "PROBLEM", 120, 126], ["Type I IFN therapy", "TREATMENT", 127, 145], ["Type I IFNs", "PROBLEM", 145, 156], ["potent anti-viral mediators", "TREATMENT", 161, 188], ["viral infection", "PROBLEM", 226, 241], ["asthma", "OBSERVATION", 120, 126], ["IFN therapy", "OBSERVATION", 134, 145], ["viral", "OBSERVATION_MODIFIER", 226, 231], ["infection", "OBSERVATION", 232, 241]]], ["Type I IFNs include the numerous IFN-as, IFN-b and the newly identified IFN-ls [125] .", [["Type I IFNs", "GENE_OR_GENE_PRODUCT", 0, 11], ["IFN", "GENE_OR_GENE_PRODUCT", 33, 36], ["IFN-b", "GENE_OR_GENE_PRODUCT", 41, 46], ["Type I IFNs", "PROTEIN", 0, 11], ["IFN", "PROTEIN", 33, 36], ["IFN", "PROTEIN", 41, 44], ["IFN", "PROTEIN", 72, 75], ["Type I IFNs", "PROBLEM", 0, 11], ["the numerous IFN", "PROBLEM", 20, 36], ["IFN", "TEST", 41, 44], ["IFN", "TEST", 72, 75]]], ["Type I IFNs act on virally infected cells or uninfected cells and induce a well-ordered anti-viral programme, involving the upregulation and activation of a range of IFN inducible genes, such as PKR, which phosphorylate eIF-2a and hence blocks translation, also anti-viral RNase L and Mx proteins.", [["cells", "ANATOMY", 36, 41], ["cells", "ANATOMY", 56, 61], ["Type I IFNs", "GENE_OR_GENE_PRODUCT", 0, 11], ["cells", "CELL", 36, 41], ["cells", "CELL", 56, 61], ["IFN", "GENE_OR_GENE_PRODUCT", 166, 169], ["PKR", "GENE_OR_GENE_PRODUCT", 195, 198], ["eIF-2a", "GENE_OR_GENE_PRODUCT", 220, 226], ["RNase L", "GENE_OR_GENE_PRODUCT", 273, 280], ["Mx proteins", "GENE_OR_GENE_PRODUCT", 285, 296], ["Type I IFNs", "PROTEIN", 0, 11], ["virally infected cells", "CELL_TYPE", 19, 41], ["uninfected cells", "CELL_TYPE", 45, 61], ["IFN inducible genes", "DNA", 166, 185], ["PKR", "PROTEIN", 195, 198], ["eIF", "PROTEIN", 220, 223], ["anti-viral RNase L", "PROTEIN", 262, 280], ["Mx proteins", "PROTEIN", 285, 296], ["Type I IFNs", "PROBLEM", 0, 11], ["virally infected cells", "PROBLEM", 19, 41], ["uninfected cells", "PROBLEM", 45, 61], ["anti-viral programme", "TREATMENT", 88, 108], ["IFN inducible genes", "PROBLEM", 166, 185], ["PKR", "TEST", 195, 198], ["phosphorylate eIF", "TEST", 206, 223], ["hence blocks translation", "TREATMENT", 231, 255], ["anti-viral RNase L and Mx proteins", "TREATMENT", 262, 296], ["uninfected cells", "OBSERVATION", 45, 61]]], ["IFNs can induce apoptosis, or induce more IFN gene expression in an autocrine or paracrine manner.", [["IFNs", "GENE_OR_GENE_PRODUCT", 0, 4], ["IFN", "GENE_OR_GENE_PRODUCT", 42, 45], ["IFNs", "PROTEIN", 0, 4], ["IFN gene", "DNA", 42, 50], ["apoptosis", "PROBLEM", 16, 25]]], ["IFNs also activate NK cells and are required for NK cell survival, and may have other effects on both innate and adaptive immunity (for a review see [126, 127] ).Type I IFN therapyType 1 IFNs-a and b have been extensively studied in the prevention of clinical colds since the 1980s.", [["NK cells", "ANATOMY", 19, 27], ["NK cell", "ANATOMY", 49, 56], ["colds", "DISEASE", 260, 265], ["IFNs", "GENE_OR_GENE_PRODUCT", 0, 4], ["NK cells", "CELL", 19, 27], ["NK cell", "CELL", 49, 56], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 162, 172], ["Type 1 IFNs", "GENE_OR_GENE_PRODUCT", 180, 191], ["IFNs", "PROTEIN", 0, 4], ["NK cells", "CELL_TYPE", 19, 27], ["Type I IFN", "PROTEIN", 162, 172], ["IFNs", "PROTEIN", 187, 191], ["NK cell survival", "TREATMENT", 49, 65], ["Type I IFN therapy", "TREATMENT", 162, 180], ["clinical colds", "PROBLEM", 251, 265], ["NK cells", "OBSERVATION", 19, 27], ["IFN therapy", "OBSERVATION", 169, 180]]], ["The potential of IFN-a2 attracted wide interest, culminating in several reports in the early to mid-1980s.", [["IFN-a2", "GENE_OR_GENE_PRODUCT", 17, 23], ["IFN", "PROTEIN", 17, 20], ["IFN", "PROBLEM", 17, 20]]], ["In 1984, IFN-a2 was used as therapy for experimental RV39 infection [128] .", [["infection", "DISEASE", 58, 67], ["IFN-a2", "GENE_OR_GENE_PRODUCT", 9, 15], ["IFN", "PROTEIN", 9, 12], ["RV39", "SPECIES", 53, 57], ["IFN-a2", "TREATMENT", 9, 15], ["therapy", "TREATMENT", 28, 35], ["experimental RV39 infection", "PROBLEM", 40, 67]]], ["Previous studies had suggested that effectiveness of IFN-a2 was dose dependent, with high doses (2-4.5 \u00c2 10 7 IU per day) effective at reducing both RV infection and illness, and lower doses, 10 6 IU, effective at reducing illness (symptom scores), but not necessarily affecting the incidence of colds [129] [130] [131] .", [["IFN", "CHEMICAL", 53, 56], ["RV infection", "DISEASE", 149, 161], ["illness", "DISEASE", 166, 173], ["illness", "DISEASE", 223, 230], ["colds", "DISEASE", 296, 301], ["IFN-a2", "GENE_OR_GENE_PRODUCT", 53, 59], ["IFN", "PROTEIN", 53, 56], ["RV", "SPECIES", 149, 151], ["Previous studies", "TEST", 0, 16], ["IFN-a2", "TREATMENT", 53, 59], ["dose dependent", "PROBLEM", 64, 78], ["both RV infection", "PROBLEM", 144, 161], ["illness", "PROBLEM", 166, 173], ["symptom scores", "TEST", 232, 246], ["colds", "PROBLEM", 296, 301], ["RV", "ANATOMY", 149, 151], ["infection", "OBSERVATION", 152, 161]]], ["Despite the effectiveness of IFN-a2 in models of experimental RV infection at these high doses, significant side effects were observed, including blood-tinged mucus, and even mucosal histopathological abnormalities [131] .", [["RV", "ANATOMY", 62, 64], ["blood", "ANATOMY", 146, 151], ["mucus", "ANATOMY", 159, 164], ["mucosal", "ANATOMY", 175, 182], ["RV infection", "DISEASE", 62, 74], ["IFN-a2", "GENE_OR_GENE_PRODUCT", 29, 35], ["RV", "ORGAN", 62, 64], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["mucus", "ORGANISM_SUBSTANCE", 159, 164], ["mucosal", "PATHOLOGICAL_FORMATION", 175, 182], ["IFN-a2", "PROTEIN", 29, 35], ["RV", "SPECIES", 62, 64], ["IFN", "TREATMENT", 29, 32], ["experimental RV infection", "PROBLEM", 49, 74], ["significant side effects", "PROBLEM", 96, 120], ["blood-tinged mucus", "PROBLEM", 146, 164], ["even mucosal histopathological abnormalities", "PROBLEM", 170, 214], ["RV", "ANATOMY", 62, 64], ["infection", "OBSERVATION", 65, 74]]], ["This study sought to examine the efficacy of 10 6 IU IFN-a2 delivered three times daily for 5 days via nasal spray or drops.", [["nasal", "ANATOMY", 103, 108], ["IFN-a2", "CHEMICAL", 53, 59], ["IFN-a2", "GENE_OR_GENE_PRODUCT", 53, 59], ["nasal", "ORGANISM_SUBDIVISION", 103, 108], ["IFN", "PROTEIN", 53, 56], ["This study", "TEST", 0, 10], ["IFN-a2", "TREATMENT", 53, 59], ["nasal spray", "TREATMENT", 103, 114]]], ["Challenge with RV39 occurred 28 h later.", [["RV39", "CHEMICAL", 15, 19], ["RV39", "SPECIES", 15, 19]]], ["IFN-a2 reduced virus shedding, with the drops having a more potent effect.", [["IFN-a2", "GENE_OR_GENE_PRODUCT", 0, 6], ["virus", "ORGANISM", 15, 20], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROBLEM", 0, 3], ["a2 reduced virus shedding", "PROBLEM", 4, 29], ["a2 reduced", "OBSERVATION_MODIFIER", 4, 14], ["virus", "OBSERVATION", 15, 20]]], ["IFN-a2 delivered via drops also significantly reduced nasal mucus weights, but neither treatment reduced the frequency of clinical colds.Type I IFN therapyIFN-a2 has also been tested as a prophylactic treatment in natural viral infections.", [["nasal mucus", "ANATOMY", 54, 65], ["IFN", "CHEMICAL", 0, 3], ["colds", "DISEASE", 131, 136], ["Type I IFN therapyIFN-a2", "CHEMICAL", 137, 161], ["viral infections", "DISEASE", 222, 238], ["IFN-a2", "GENE_OR_GENE_PRODUCT", 0, 6], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 54, 65], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 137, 147], ["therapyIFN-a2", "GENE_OR_GENE_PRODUCT", 148, 161], ["IFN-a2", "PROTEIN", 0, 6], ["Type I IFN therapyIFN-a2", "PROTEIN", 137, 161], ["a2 delivered via drops", "TREATMENT", 4, 26], ["significantly reduced nasal mucus weights", "PROBLEM", 32, 73], ["clinical colds", "PROBLEM", 122, 136], ["Type I IFN therapyIFN", "TREATMENT", 137, 158], ["a prophylactic treatment", "TREATMENT", 186, 210], ["natural viral infections", "PROBLEM", 214, 238], ["nasal mucus", "ANATOMY", 54, 65], ["viral infections", "OBSERVATION", 222, 238]]], ["In one study, twice daily IFN-a2 at 10 6 IU for 28 days demonstrated less RV-associated colds, but was not significantly different to placebo [132] .", [["IFN", "CHEMICAL", 26, 29], ["colds", "DISEASE", 88, 93], ["IFN-a2", "GENE_OR_GENE_PRODUCT", 26, 32], ["IFN", "PROTEIN", 26, 29], ["one study", "TEST", 3, 12], ["less RV-associated colds", "PROBLEM", 69, 93], ["colds", "OBSERVATION", 88, 93]]], ["Another study utilised IFN-a2b at either 1.5 \u00c2 10 6 units twice daily or 2.5 \u00c2 10 6 once daily each for 4 weeks; control subjects were given dose-matched placebo [133] .", [["IFN-a2b", "CHEMICAL", 23, 30], ["IFN-a2b", "SIMPLE_CHEMICAL", 23, 30], ["IFN", "PROTEIN", 23, 26], ["Another study", "TEST", 0, 13], ["IFN", "TEST", 23, 26], ["a2b", "TREATMENT", 27, 30]]], ["During the medication period, twice daily IFN-a2b greatly reduced the number of RV-associated colds, but had no effect on parainfluenza-associated colds.", [["IFN-a2b", "CHEMICAL", 42, 49], ["colds", "DISEASE", 94, 99], ["parainfluenza", "DISEASE", 122, 135], ["colds", "DISEASE", 147, 152], ["IFN-a2b", "SIMPLE_CHEMICAL", 42, 49], ["parainfluenza", "ORGANISM", 122, 135], ["IFN", "PROTEIN", 42, 45], ["parainfluenza", "SPECIES", 122, 135], ["a2b", "PROBLEM", 46, 49], ["associated colds", "PROBLEM", 83, 99], ["parainfluenza", "PROBLEM", 122, 135], ["associated colds", "PROBLEM", 136, 152], ["RV", "ANATOMY", 80, 82], ["colds", "OBSERVATION", 94, 99], ["parainfluenza", "OBSERVATION", 122, 135], ["colds", "OBSERVATION", 147, 152]]], ["The effects of IFN were slowly lost after the treatment period, with frequencies of RV-associated colds being about equal after 8 days post-treatment.", [["IFN", "CHEMICAL", 15, 18], ["colds", "DISEASE", 98, 103], ["IFN", "GENE_OR_GENE_PRODUCT", 15, 18], ["IFN", "PROTEIN", 15, 18], ["IFN", "TREATMENT", 15, 18], ["the treatment period", "TREATMENT", 42, 62], ["RV-associated colds", "PROBLEM", 84, 103], ["RV", "ANATOMY", 84, 86], ["colds", "OBSERVATION", 98, 103]]], ["At both doses, IFN-a2b exhibited side effects, mostly in the form of nasal blood-tinged mucus.Type I IFN therapySeveral studies have investigated the potential of IFN-b in treatment of clinical colds.", [["nasal blood", "ANATOMY", 69, 80], ["mucus", "ANATOMY", 88, 93], ["IFN-a2b", "CHEMICAL", 15, 22], ["colds", "DISEASE", 194, 199], ["IFN-a2b", "SIMPLE_CHEMICAL", 15, 22], ["nasal blood", "ORGANISM_SUBSTANCE", 69, 80], ["mucus", "ORGANISM_SUBSTANCE", 88, 93], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 94, 104], ["IFN-b", "GENE_OR_GENE_PRODUCT", 163, 168], ["IFN", "PROTEIN", 15, 18], ["IFN", "PROTEIN", 101, 104], ["IFN", "PROTEIN", 163, 166], ["IFN", "TREATMENT", 15, 18], ["a2b", "PROBLEM", 19, 22], ["side effects", "PROBLEM", 33, 45], ["nasal blood-tinged mucus", "PROBLEM", 69, 93], ["Type I IFN therapySeveral studies", "PROBLEM", 94, 127], ["IFN", "TREATMENT", 163, 166], ["clinical colds", "PROBLEM", 185, 199], ["side effects", "OBSERVATION_MODIFIER", 33, 45], ["nasal", "ANATOMY", 69, 74], ["tinged mucus", "OBSERVATION", 81, 93]]], ["The first study of intranasally administered recombinant IFN-b (IFN-b Ser) involved 13 doses of 2 \u00c2 10 6 IU over 4 days.", [["IFN-b Ser", "CHEMICAL", 64, 73], ["Ser", "CHEMICAL", 70, 73], ["IFN-b", "GENE_OR_GENE_PRODUCT", 57, 62], ["IFN-b Ser", "SIMPLE_CHEMICAL", 64, 73], ["IFN", "PROTEIN", 57, 60], ["IFN", "PROTEIN", 64, 67], ["The first study", "TEST", 0, 15], ["intranasally administered recombinant IFN", "TREATMENT", 19, 60], ["b (IFN-b Ser)", "TREATMENT", 61, 74]]], ["This treatment showed promise in control of experimental RV9 or RV14 challenge [134] .", [["RV9", "CHEMICAL", 57, 60], ["RV14", "CHEMICAL", 64, 68], ["RV9", "SPECIES", 57, 60], ["This treatment", "TREATMENT", 0, 14], ["experimental RV9", "TREATMENT", 44, 60]]], ["This study involved RV challenge occurring after the fourth dose of IFN-b.", [["IFN", "CHEMICAL", 68, 71], ["IFN", "PROTEIN", 68, 71], ["This study", "TEST", 0, 10], ["RV challenge", "TREATMENT", 20, 32], ["IFN", "TREATMENT", 68, 71], ["RV", "ANATOMY", 20, 22]]], ["There were significantly lower symptom scores, nasal secretions and virus release compared with placebo.", [["nasal", "ANATOMY", 47, 52], ["significantly lower symptom scores", "PROBLEM", 11, 45], ["nasal secretions and virus release", "PROBLEM", 47, 81], ["placebo", "TREATMENT", 96, 103], ["significantly", "OBSERVATION_MODIFIER", 11, 24], ["lower", "OBSERVATION_MODIFIER", 25, 30], ["symptom", "OBSERVATION", 31, 38], ["nasal", "ANATOMY", 47, 52], ["secretions", "OBSERVATION", 53, 63]]], ["The next study with IFN-b Ser involved both a tolerance and efficacy study against experimental RV challenge.", [["IFN-b Ser", "CHEMICAL", 20, 29], ["Ser", "CHEMICAL", 26, 29], ["IFN-b Ser", "GENE_OR_GENE_PRODUCT", 20, 29], ["IFN", "PROTEIN", 20, 23], ["RV", "SPECIES", 96, 98], ["The next study", "TEST", 0, 14], ["IFN", "TREATMENT", 20, 23], ["efficacy study", "TEST", 60, 74], ["experimental RV challenge", "TREATMENT", 83, 108]]], ["Volunteers were pre-treated with either IFN-b Ser (12 \u00c2 10 6 , or 3 \u00c2 10 6 IU) 36 h before infection, and continued for 25 days [135] .", [["IFN-b Ser", "CHEMICAL", 40, 49], ["infection", "DISEASE", 91, 100], ["Ser", "CHEMICAL", 46, 49], ["Volunteers", "ORGANISM", 0, 10], ["IFN", "PROTEIN", 40, 43], ["IFN", "TEST", 40, 43], ["infection", "PROBLEM", 91, 100]]], ["The tolerance study demonstrated numerous side effects particularly with the high-dose regime, including blood-tinged mucus, and an increase in subepithelial lymphocytic infiltrates in nasal biopsies.", [["blood", "ANATOMY", 105, 110], ["mucus", "ANATOMY", 118, 123], ["subepithelial lymphocytic infiltrates", "ANATOMY", 144, 181], ["nasal biopsies", "ANATOMY", 185, 199], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["mucus", "ORGANISM_SUBSTANCE", 118, 123], ["subepithelial lymphocytic infiltrates", "TISSUE", 144, 181], ["nasal biopsies", "TISSUE", 185, 199], ["The tolerance study", "TEST", 0, 19], ["numerous side effects", "PROBLEM", 33, 54], ["the high-dose regime", "TREATMENT", 73, 93], ["blood-tinged mucus", "PROBLEM", 105, 123], ["subepithelial lymphocytic infiltrates", "PROBLEM", 144, 181], ["nasal biopsies", "TREATMENT", 185, 199], ["numerous", "OBSERVATION_MODIFIER", 33, 41], ["side effects", "OBSERVATION_MODIFIER", 42, 54], ["tinged mucus", "OBSERVATION", 111, 123], ["increase", "OBSERVATION_MODIFIER", 132, 140], ["subepithelial lymphocytic infiltrates", "OBSERVATION", 144, 181], ["nasal", "ANATOMY", 185, 190], ["biopsies", "OBSERVATION", 191, 199]]], ["The efficacy study also reported significant decreases in nasal mucus weights, less development or incidence of clinical colds, but not less viral shedding, and these differences were only significant with the high-dose regime.Type I IFN therapyA third study involving prophylaxis against natural infections reported quite disappointing results [136] .", [["nasal mucus", "ANATOMY", 58, 69], ["colds", "DISEASE", 121, 126], ["natural infections", "DISEASE", 289, 307], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 58, 69], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 227, 237], ["IFN", "PROTEIN", 234, 237], ["The efficacy study", "TEST", 0, 18], ["significant decreases in nasal mucus weights", "PROBLEM", 33, 77], ["clinical colds", "PROBLEM", 112, 126], ["less viral shedding", "PROBLEM", 136, 155], ["the high-dose regime", "TREATMENT", 206, 226], ["Type I IFN therapy", "TREATMENT", 227, 245], ["A third study", "TEST", 245, 258], ["prophylaxis", "TREATMENT", 269, 280], ["natural infections", "PROBLEM", 289, 307], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["decreases", "OBSERVATION_MODIFIER", 45, 54], ["nasal mucus", "ANATOMY", 58, 69]]], ["Two randomised placebo-controlled trials in 1986-87 utilised IFN-b Ser given either 6 days a week for 4 weeks (9 \u00c2 10 6 IU), or a higher dose (24 \u00c2 10 6 IU) for 24 consecutive days.", [["IFN-b Ser", "CHEMICAL", 61, 70], ["Ser", "CHEMICAL", 67, 70], ["IFN-b Ser", "SIMPLE_CHEMICAL", 61, 70], ["IFN", "PROTEIN", 61, 64], ["Two randomised placebo", "TREATMENT", 0, 22]]], ["Both studies failed to show a significant reduction in the incidence of clinical colds compared to placebo, and also in patients that received cold, the number of days of illness did not differ between IFN-b Ser treated groups and placebo.Type I IFN therapyThese studies provide a useful background to assess the potential of IFN therapy for viral exacerbations of asthma.", [["colds", "DISEASE", 81, 86], ["illness", "DISEASE", 171, 178], ["IFN-b", "CHEMICAL", 202, 207], ["Ser", "CHEMICAL", 208, 211], ["IFN", "CHEMICAL", 326, 329], ["asthma", "DISEASE", 365, 371], ["Ser", "CHEMICAL", 208, 211], ["patients", "ORGANISM", 120, 128], ["Ser", "AMINO_ACID", 208, 211], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 239, 249], ["IFN", "PROTEIN", 202, 205], ["Type I IFN", "PROTEIN", 239, 249], ["IFN", "PROTEIN", 326, 329], ["patients", "SPECIES", 120, 128], ["Both studies", "TEST", 0, 12], ["a significant reduction", "PROBLEM", 28, 51], ["clinical colds", "PROBLEM", 72, 86], ["placebo", "TREATMENT", 99, 106], ["illness", "PROBLEM", 171, 178], ["Ser treated groups", "TREATMENT", 208, 226], ["placebo", "TREATMENT", 231, 238], ["Type I IFN therapy", "TREATMENT", 239, 257], ["These studies", "TEST", 257, 270], ["IFN therapy", "TREATMENT", 326, 337], ["viral exacerbations", "PROBLEM", 342, 361], ["asthma", "PROBLEM", 365, 371], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["reduction", "OBSERVATION_MODIFIER", 42, 51], ["IFN therapy", "OBSERVATION", 246, 257], ["asthma", "OBSERVATION", 365, 371]]], ["An advantage that type I IFN therapy has over anti-RV therapies is that all exacerbations of asthma with viral agents could be controlled.", [["anti-RV", "ANATOMY", 46, 53], ["asthma", "DISEASE", 93, 99], ["type I IFN", "GENE_OR_GENE_PRODUCT", 18, 28], ["anti-RV", "CANCER", 46, 53], ["IFN", "PROTEIN", 25, 28], ["type I IFN therapy", "TREATMENT", 18, 36], ["anti-RV therapies", "TREATMENT", 46, 63], ["asthma", "PROBLEM", 93, 99], ["viral agents", "TREATMENT", 105, 117], ["asthma", "OBSERVATION", 93, 99]]], ["Specific RV therapies would treat 60-65% of virus-induced exacerbations; however, broad-spectrum therapies such as IFN would not have this disadvantage.", [["RV", "ANATOMY", 9, 11], ["exacerbations", "DISEASE", 58, 71], ["RV", "MULTI-TISSUE_STRUCTURE", 9, 11], ["IFN", "PROTEIN", 115, 118], ["Specific RV therapies", "TREATMENT", 0, 21], ["virus", "PROBLEM", 44, 49], ["induced exacerbations", "PROBLEM", 50, 71], ["broad-spectrum therapies", "TREATMENT", 82, 106], ["IFN", "TREATMENT", 115, 118], ["exacerbations", "OBSERVATION", 58, 71]]], ["In particular, the above studies suggest that IFN-a2 is effective when given prior to experimental RV infection, or as a prophylactic therapy in a context of natural RV infections.", [["RV", "ANATOMY", 99, 101], ["RV", "ANATOMY", 166, 168], ["RV infection", "DISEASE", 99, 111], ["RV infections", "DISEASE", 166, 179], ["IFN-a2", "GENE_OR_GENE_PRODUCT", 46, 52], ["RV", "ORGANISM_SUBDIVISION", 166, 168], ["IFN", "PROTEIN", 46, 49], ["RV", "SPECIES", 99, 101], ["the above studies", "TEST", 15, 32], ["IFN", "PROBLEM", 46, 49], ["experimental RV infection", "PROBLEM", 86, 111], ["a prophylactic therapy", "TREATMENT", 119, 141], ["natural RV infections", "PROBLEM", 158, 179], ["RV", "ANATOMY", 99, 101], ["infection", "OBSERVATION", 102, 111], ["RV", "ANATOMY", 166, 168], ["infections", "OBSERVATION", 169, 179]]], ["IFN-b has been less impressive, exhibiting some effect when given prior to experimental RV challenge, but no effect as a prophylactic in natural infections.", [["IFN", "CHEMICAL", 0, 3], ["infections", "DISEASE", 145, 155], ["IFN-b", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "PROTEIN", 0, 3], ["experimental RV challenge", "TREATMENT", 75, 100], ["natural infections", "PROBLEM", 137, 155], ["less impressive", "OBSERVATION_MODIFIER", 15, 30], ["infections", "OBSERVATION", 145, 155]]], ["It is believed that these differences are not due to differences in anti-viral activity, as both IFN-a2 and IFN-b have similar anti-rhinoviral activities in vitro [137] .", [["IFN-a2", "GENE_OR_GENE_PRODUCT", 97, 103], ["IFN-b", "GENE_OR_GENE_PRODUCT", 108, 113], ["anti-rhinoviral", "CANCER", 127, 142], ["IFN", "PROTEIN", 97, 100], ["IFN", "PROTEIN", 108, 111], ["IFN", "TREATMENT", 108, 111]]], ["The relative ineffectiveness of IFN-b has been thought to be due to instability as a nasal spray [136, 137] ; however, when used as drops, IFN-b also did not perform in a prophylactic study against natural RV infection [136] .Type I IFN therapyDelivery and dose appeared to be contentious issues in these studies, with the effectiveness of IFN-a dependent upon a high enough dose to prevent infection and clinical colds, but low enough to prevent unwanted side effects.Type I IFN therapyHowever, most studies reported side effects, even at lower doses of 10 6 IU given daily.", [["nasal", "ANATOMY", 85, 90], ["IFN", "CHEMICAL", 32, 35], ["RV infection", "DISEASE", 206, 218], ["IFN", "CHEMICAL", 340, 343], ["infection", "DISEASE", 391, 400], ["colds", "DISEASE", 414, 419], ["IFN-b", "GENE_OR_GENE_PRODUCT", 32, 37], ["IFN-b", "GENE_OR_GENE_PRODUCT", 139, 144], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 226, 236], ["IFN", "GENE_OR_GENE_PRODUCT", 340, 343], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 469, 479], ["IFN", "PROTEIN", 32, 35], ["IFN", "PROTEIN", 139, 142], ["IFN", "PROTEIN", 233, 236], ["IFN", "PROTEIN", 340, 343], ["Type I IFN", "PROTEIN", 469, 479], ["RV", "SPECIES", 206, 208], ["IFN-b", "PROBLEM", 32, 37], ["instability", "PROBLEM", 68, 79], ["a nasal spray", "TREATMENT", 83, 96], ["a prophylactic study", "TEST", 169, 189], ["natural RV infection", "PROBLEM", 198, 218], ["Type I IFN therapyDelivery", "TREATMENT", 226, 252], ["contentious issues", "PROBLEM", 277, 295], ["these studies", "TEST", 299, 312], ["IFN", "TREATMENT", 340, 343], ["a dependent", "PROBLEM", 344, 355], ["infection", "PROBLEM", 391, 400], ["clinical colds", "PROBLEM", 405, 419], ["unwanted side effects", "PROBLEM", 447, 468], ["Type I IFN therapyHowever", "TREATMENT", 469, 494], ["side effects", "PROBLEM", 518, 530], ["ineffectiveness", "OBSERVATION_MODIFIER", 13, 28], ["thought to be due to", "UNCERTAINTY", 47, 67], ["instability", "OBSERVATION", 68, 79], ["RV", "ANATOMY", 206, 208], ["infection", "OBSERVATION", 209, 218], ["infection", "OBSERVATION", 391, 400]]], ["It can be argued that such side effects would be even more problematic in asthmatics, particularly the increased inflammation of the nasal passage, which appeared to be a hallmark of intranasal IFN therapy.", [["nasal", "ANATOMY", 133, 138], ["IFN", "CHEMICAL", 194, 197], ["nasal", "ORGAN", 133, 138], ["IFN", "PROTEIN", 194, 197], ["asthmatics", "PROBLEM", 74, 84], ["the increased inflammation of the nasal passage", "PROBLEM", 99, 146], ["intranasal IFN therapy", "TREATMENT", 183, 205], ["asthmatics", "OBSERVATION", 74, 84], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["inflammation", "OBSERVATION", 113, 125], ["nasal passage", "ANATOMY", 133, 146]]], ["Another issue for asthmatics would be effective delivery to the upper versus lower airway.", [["lower airway", "ANATOMY", 77, 89], ["asthmatics", "ORGANISM", 18, 28], ["upper", "ORGANISM_SUBDIVISION", 64, 69], ["lower airway", "ORGANISM_SUBDIVISION", 77, 89], ["asthmatics", "PROBLEM", 18, 28], ["upper", "ANATOMY_MODIFIER", 64, 69], ["lower", "ANATOMY_MODIFIER", 77, 82], ["airway", "ANATOMY", 83, 89]]], ["While RV when administered by nasal spray can definitely be found in the lower airway during experimental infection, it is currently unknown whether intranasally applied IFN would act at a high enough concentration in the lower airway.", [["nasal", "ANATOMY", 30, 35], ["lower airway", "ANATOMY", 73, 85], ["lower airway", "ANATOMY", 222, 234], ["infection", "DISEASE", 106, 115], ["IFN", "CHEMICAL", 170, 173], ["RV", "MULTI-TISSUE_STRUCTURE", 6, 8], ["nasal", "ORGANISM_SUBDIVISION", 30, 35], ["lower airway", "ORGANISM_SUBDIVISION", 73, 85], ["lower airway", "ORGANISM_SUBDIVISION", 222, 234], ["IFN", "PROTEIN", 170, 173], ["nasal spray", "TREATMENT", 30, 41], ["experimental infection", "PROBLEM", 93, 115], ["lower", "ANATOMY_MODIFIER", 73, 78], ["airway", "ANATOMY", 79, 85], ["infection", "OBSERVATION", 106, 115], ["lower", "ANATOMY_MODIFIER", 222, 227], ["airway", "ANATOMY", 228, 234]]], ["An alternative could be IFN delivered via oral inhalation, similar to inhaled corticosteroids, thereby ensuring delivery to the lower airway.", [["oral", "ANATOMY", 42, 46], ["lower airway", "ANATOMY", 128, 140], ["IFN", "CHEMICAL", 24, 27], ["corticosteroids", "CHEMICAL", 78, 93], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["lower airway", "ORGANISM_SUBDIVISION", 128, 140], ["IFN", "PROTEIN", 24, 27], ["IFN", "TREATMENT", 24, 27], ["oral inhalation", "TREATMENT", 42, 57], ["inhaled corticosteroids", "TREATMENT", 70, 93], ["lower", "ANATOMY_MODIFIER", 128, 133], ["airway", "ANATOMY", 134, 140]]], ["The ultimate effectiveness of IFN therapy in RV-induced exacerbations of asthma has yet to be investigated.Type I IFN therapyIFN has also been tested in conjunction with other treatments such as non-steroidal anti-inflammatory agents.", [["non-steroidal", "ANATOMY", 195, 208], ["IFN", "CHEMICAL", 30, 33], ["asthma", "DISEASE", 73, 79], ["therapyIFN", "CHEMICAL", 118, 128], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 107, 117], ["non-steroidal anti-inflammatory agents", "SIMPLE_CHEMICAL", 195, 233], ["IFN", "PROTEIN", 30, 33], ["Type I IFN therapyIFN", "PROTEIN", 107, 128], ["IFN therapy", "TREATMENT", 30, 41], ["RV", "PROBLEM", 45, 47], ["asthma", "PROBLEM", 73, 79], ["Type I IFN therapyIFN", "TREATMENT", 107, 128], ["other treatments", "TREATMENT", 170, 186], ["non-steroidal anti-inflammatory agents", "TREATMENT", 195, 233], ["asthma", "OBSERVATION", 73, 79]]], ["This approach is based on the belief that no single molecule therapy has proved effect for RV-associated clinical colds, as no single therapy can block viral infection and replication, and the associated host response to infection, including the cellular, and humoral inflammatory reactions [138] .", [["RV", "ANATOMY", 91, 93], ["cellular", "ANATOMY", 246, 254], ["colds", "DISEASE", 114, 119], ["viral infection", "DISEASE", 152, 167], ["infection", "DISEASE", 221, 230], ["cellular", "CELL", 246, 254], ["single molecule therapy", "TREATMENT", 45, 68], ["RV-associated clinical colds", "PROBLEM", 91, 119], ["single therapy", "TREATMENT", 127, 141], ["viral infection", "PROBLEM", 152, 167], ["infection", "PROBLEM", 221, 230], ["the cellular, and humoral inflammatory reactions", "PROBLEM", 242, 290], ["viral", "OBSERVATION_MODIFIER", 152, 157], ["infection", "OBSERVATION", 158, 167], ["host response", "OBSERVATION", 204, 217], ["infection", "OBSERVATION", 221, 230], ["humoral", "ANATOMY", 260, 267], ["inflammatory", "OBSERVATION_MODIFIER", 268, 280]]], ["These studies aimed to treat the clinical colds with a combination of treatments in the early phase of infection, with the argument that this regime at this time would be effective in not only controlling infection, but the many symptoms associated with the host inflammatory response to infection.Type I IFN therapyIntranasal IFN-a2b was used along with ipratropium and oral naproxen in a model of experimental RV infection [139] .", [["oral", "ANATOMY", 371, 375], ["RV", "ANATOMY", 412, 414], ["colds", "DISEASE", 42, 47], ["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 205, 214], ["infection", "DISEASE", 288, 297], ["IFN-a2b", "CHEMICAL", 327, 334], ["ipratropium", "CHEMICAL", 355, 366], ["naproxen", "CHEMICAL", 376, 384], ["RV infection", "DISEASE", 412, 424], ["ipratropium", "CHEMICAL", 355, 366], ["naproxen", "CHEMICAL", 376, 384], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 298, 308], ["IFN-a2b", "GENE_OR_GENE_PRODUCT", 327, 334], ["ipratropium", "SIMPLE_CHEMICAL", 355, 366], ["oral", "ORGANISM_SUBDIVISION", 371, 375], ["naproxen", "SIMPLE_CHEMICAL", 376, 384], ["Type I IFN", "PROTEIN", 298, 308], ["IFN", "PROTEIN", 327, 330], ["RV", "SPECIES", 412, 414], ["These studies", "TEST", 0, 13], ["the clinical colds", "PROBLEM", 29, 47], ["treatments", "TREATMENT", 70, 80], ["infection", "PROBLEM", 103, 112], ["this regime", "TREATMENT", 137, 148], ["infection", "PROBLEM", 205, 214], ["the many symptoms", "PROBLEM", 220, 237], ["the host inflammatory response to infection", "PROBLEM", 254, 297], ["Type I IFN therapy", "TREATMENT", 298, 316], ["Intranasal IFN", "TREATMENT", 316, 330], ["a2b", "PROBLEM", 331, 334], ["ipratropium", "TREATMENT", 355, 366], ["oral naproxen", "TREATMENT", 371, 384], ["experimental RV infection", "PROBLEM", 399, 424], ["infection", "OBSERVATION", 103, 112], ["infection", "OBSERVATION", 205, 214], ["inflammatory", "OBSERVATION_MODIFIER", 263, 275], ["infection", "OBSERVATION", 288, 297], ["IFN therapy", "OBSERVATION", 305, 316], ["RV", "ANATOMY", 412, 414], ["infection", "OBSERVATION", 415, 424]]], ["The treatment was given 24 h post-infection, and continued for 4 days.", [["infection", "DISEASE", 34, 43], ["The treatment", "TREATMENT", 0, 13], ["infection", "PROBLEM", 34, 43], ["infection", "OBSERVATION", 34, 43]]], ["This treatment effectively reduced days of virus shedding and virus titre compared to placebo, and decreased nasal mucus weights on days 3-4 postinfection.", [["nasal mucus", "ANATOMY", 109, 120], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 109, 120], ["This treatment", "TREATMENT", 0, 14], ["virus shedding", "PROBLEM", 43, 57], ["virus titre", "TREATMENT", 62, 73], ["placebo", "TREATMENT", 86, 93], ["decreased nasal mucus weights", "PROBLEM", 99, 128], ["nasal mucus", "ANATOMY", 109, 120]]], ["Intranasal IFN-a2b has also been studied with oral chlorpheniramine and ibuprofen, versus treatments consisting of intranasal placebo with oral chlorpheniramine and ibuprofen, or both oral and intranasal placebos, in experimental RV39 infection [138] .", [["oral", "ANATOMY", 46, 50], ["oral", "ANATOMY", 139, 143], ["oral", "ANATOMY", 184, 188], ["IFN-a2b", "CHEMICAL", 11, 18], ["chlorpheniramine", "CHEMICAL", 51, 67], ["ibuprofen", "CHEMICAL", 72, 81], ["chlorpheniramine", "CHEMICAL", 144, 160], ["ibuprofen", "CHEMICAL", 165, 174], ["infection", "DISEASE", 235, 244], ["chlorpheniramine", "CHEMICAL", 51, 67], ["ibuprofen", "CHEMICAL", 72, 81], ["chlorpheniramine", "CHEMICAL", 144, 160], ["ibuprofen", "CHEMICAL", 165, 174], ["IFN-a2b", "GENE_OR_GENE_PRODUCT", 11, 18], ["oral", "ORGANISM_SUBDIVISION", 46, 50], ["chlorpheniramine", "SIMPLE_CHEMICAL", 51, 67], ["ibuprofen", "SIMPLE_CHEMICAL", 72, 81], ["oral", "ORGANISM_SUBDIVISION", 139, 143], ["chlorpheniramine", "SIMPLE_CHEMICAL", 144, 160], ["ibuprofen", "SIMPLE_CHEMICAL", 165, 174], ["oral", "ORGANISM_SUBDIVISION", 184, 188], ["IFN", "PROTEIN", 11, 14], ["RV39", "SPECIES", 230, 234], ["a2b", "PROBLEM", 15, 18], ["oral chlorpheniramine", "TREATMENT", 46, 67], ["ibuprofen", "TREATMENT", 72, 81], ["treatments", "TREATMENT", 90, 100], ["intranasal placebo", "TREATMENT", 115, 133], ["oral chlorpheniramine", "TREATMENT", 139, 160], ["ibuprofen", "TREATMENT", 165, 174], ["oral and intranasal placebos", "TREATMENT", 184, 212], ["experimental RV39 infection", "PROBLEM", 217, 244]]], ["The combination reduced the total symptom score by about 22%, compared to 27% with only oral chlorpheniramine and ibuprofen, or 19% achieved with placebos.", [["oral", "ANATOMY", 88, 92], ["chlorpheniramine", "CHEMICAL", 93, 109], ["ibuprofen", "CHEMICAL", 114, 123], ["chlorpheniramine", "CHEMICAL", 93, 109], ["ibuprofen", "CHEMICAL", 114, 123], ["oral", "ORGANISM_SUBDIVISION", 88, 92], ["chlorpheniramine", "SIMPLE_CHEMICAL", 93, 109], ["ibuprofen", "SIMPLE_CHEMICAL", 114, 123], ["the total symptom score", "PROBLEM", 24, 47], ["oral chlorpheniramine", "TREATMENT", 88, 109], ["ibuprofen", "TREATMENT", 114, 123], ["placebos", "TREATMENT", 146, 154], ["reduced", "OBSERVATION_MODIFIER", 16, 23], ["total", "OBSERVATION_MODIFIER", 28, 33]]], ["The combination also significantly reduced nasal mucus weights generated by clinical colds, and also reduced viral titres compared to the other groups on day 3 post-infection.", [["nasal mucus", "ANATOMY", 43, 54], ["colds", "DISEASE", 85, 90], ["infection", "DISEASE", 165, 174], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 43, 54], ["significantly reduced nasal mucus weights", "PROBLEM", 21, 62], ["clinical colds", "PROBLEM", 76, 90], ["reduced viral titres", "PROBLEM", 101, 121], ["post-infection", "PROBLEM", 160, 174], ["significantly", "OBSERVATION_MODIFIER", 21, 34], ["reduced", "OBSERVATION_MODIFIER", 35, 42], ["nasal mucus", "ANATOMY", 43, 54], ["viral titres", "OBSERVATION", 109, 121], ["infection", "OBSERVATION", 165, 174]]], ["The effects of these treatments on the duration of clinical colds were not studied however.", [["colds", "DISEASE", 60, 65], ["these treatments", "TREATMENT", 15, 31], ["clinical colds", "PROBLEM", 51, 65]]], ["There appeared to be significant side effects associated with the combination treatment regime.", [["significant side effects", "PROBLEM", 21, 45], ["the combination treatment regime", "TREATMENT", 62, 94], ["appeared to be", "UNCERTAINTY", 6, 20], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["side effects", "OBSERVATION_MODIFIER", 33, 45]]], ["One fifth of subjects having received the combination complained of blood-tinged nasal mucus.", [["blood", "ANATOMY", 68, 73], ["nasal mucus", "ANATOMY", 81, 92], ["subjects", "ORGANISM", 13, 21], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 81, 92], ["blood-tinged nasal mucus", "PROBLEM", 68, 92], ["nasal", "ANATOMY", 81, 86], ["mucus", "OBSERVATION", 87, 92]]], ["Drowsiness and nasal dryness were also common for all groups.Inhaled GC therapyGlucocorticosteroids (GC), are the mainstay of current asthma therapy.", [["nasal", "ANATOMY", 15, 20], ["Drowsiness", "DISEASE", 0, 10], ["nasal dryness", "DISEASE", 15, 28], ["GC therapyGlucocorticosteroids", "CHEMICAL", 69, 99], ["GC", "CHEMICAL", 101, 103], ["asthma", "DISEASE", 134, 140], ["therapyGlucocorticosteroids", "CHEMICAL", 72, 99], ["nasal", "ORGAN", 15, 20], ["GC therapyGlucocorticosteroids", "SIMPLE_CHEMICAL", 69, 99], ["GC", "SIMPLE_CHEMICAL", 101, 103], ["Drowsiness", "PROBLEM", 0, 10], ["nasal dryness", "PROBLEM", 15, 28], ["Inhaled GC therapyGlucocorticosteroids", "TREATMENT", 61, 99], ["current asthma therapy", "TREATMENT", 126, 148], ["nasal", "ANATOMY", 15, 20], ["dryness", "OBSERVATION", 21, 28], ["asthma therapy", "OBSERVATION", 134, 148]]], ["Steroids when administered topically are potent inflammatory agents, acting to help reduce proinflammatory molecule gene expression operating largely at the level of pre-transcription (for a review, see [140] ).", [["Steroids", "CHEMICAL", 0, 8], ["proinflammatory molecule", "PROTEIN", 91, 115], ["Steroids", "TREATMENT", 0, 8], ["potent inflammatory agents", "TREATMENT", 41, 67]]], ["Steroids can reduce inflammation through glucocorticoid receptor (GR)-DNA interactions, GR-transcription factor interactions, inducing histone deacetylation, and therefore reducing DNA unwinding and hence transcription of inflammatory genes, and finally by inducing anti-inflammatory agents.Inhaled GC therapyDespite evidence that steroids attenuate RV-associated inflammatory responses in vitro [75, 77] , the use of steroids in virus-induced exacerbations of asthma remains controversial.", [["RV", "ANATOMY", 350, 352], ["inflammation", "DISEASE", 20, 32], ["steroids", "CHEMICAL", 331, 339], ["steroids", "CHEMICAL", 418, 426], ["exacerbations", "DISEASE", 444, 457], ["asthma", "DISEASE", 461, 467], ["Steroids", "CHEMICAL", 0, 8], ["steroids", "CHEMICAL", 331, 339], ["steroids", "CHEMICAL", 418, 426], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 41, 64], ["GR", "GENE_OR_GENE_PRODUCT", 66, 68], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["GR", "GENE_OR_GENE_PRODUCT", 88, 90], ["histone", "GENE_OR_GENE_PRODUCT", 135, 142], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["steroids", "SIMPLE_CHEMICAL", 331, 339], ["steroids", "SIMPLE_CHEMICAL", 418, 426], ["glucocorticoid receptor", "PROTEIN", 41, 64], ["GR", "PROTEIN", 66, 68], ["GR", "PROTEIN", 88, 90], ["transcription factor", "PROTEIN", 91, 111], ["histone", "PROTEIN", 135, 142], ["inflammatory genes", "DNA", 222, 240], ["Steroids", "TREATMENT", 0, 8], ["inflammation", "PROBLEM", 20, 32], ["glucocorticoid receptor", "TREATMENT", 41, 64], ["DNA interactions", "PROBLEM", 70, 86], ["histone deacetylation", "TREATMENT", 135, 156], ["DNA unwinding", "PROBLEM", 181, 194], ["inflammatory genes", "PROBLEM", 222, 240], ["anti-inflammatory agents", "TREATMENT", 266, 290], ["Inhaled GC therapyDespite", "TREATMENT", 291, 316], ["steroids", "TREATMENT", 331, 339], ["inflammatory responses", "PROBLEM", 364, 386], ["steroids in virus", "TREATMENT", 418, 435], ["asthma", "PROBLEM", 461, 467], ["inflammation", "OBSERVATION", 20, 32], ["inflammatory genes", "OBSERVATION", 222, 240], ["inflammatory", "OBSERVATION_MODIFIER", 364, 376], ["asthma", "OBSERVATION", 461, 467]]], ["Several in vivo studies report poor efficacy of steroids in preventing inflammation and reduction of lung function in models of experimental RV infection [15] [16] [17] [18] .Inhaled GC therapyFarr et al. [18] examined the potential use of prednisone (30 mg twice daily), or intranasal beclomethasone (168 micrograms twice a day), given 3-4 days prior to challenge as a prophylactic treatment in a model of experimental RV infection.", [["lung", "ANATOMY", 101, 105], ["RV", "ANATOMY", 420, 422], ["steroids", "CHEMICAL", 48, 56], ["inflammation", "DISEASE", 71, 83], ["reduction of lung function", "DISEASE", 88, 114], ["RV infection", "DISEASE", 141, 153], ["prednisone", "CHEMICAL", 240, 250], ["beclomethasone", "CHEMICAL", 286, 300], ["RV infection", "DISEASE", 420, 432], ["steroids", "CHEMICAL", 48, 56], ["prednisone", "CHEMICAL", 240, 250], ["beclomethasone", "CHEMICAL", 286, 300], ["steroids", "SIMPLE_CHEMICAL", 48, 56], ["lung", "ORGAN", 101, 105], ["[15] [16] [17] [18]", "SIMPLE_CHEMICAL", 154, 173], ["prednisone", "SIMPLE_CHEMICAL", 240, 250], ["beclomethasone", "SIMPLE_CHEMICAL", 286, 300], ["RV", "SPECIES", 141, 143], ["RV", "SPECIES", 420, 422], ["vivo studies", "TEST", 11, 23], ["steroids", "TREATMENT", 48, 56], ["inflammation", "PROBLEM", 71, 83], ["lung function", "PROBLEM", 101, 114], ["experimental RV infection", "PROBLEM", 128, 153], ["Inhaled GC therapy", "TREATMENT", 175, 193], ["prednisone", "TREATMENT", 240, 250], ["intranasal beclomethasone", "TREATMENT", 275, 300], ["a prophylactic treatment", "TREATMENT", 368, 392], ["experimental RV infection", "PROBLEM", 407, 432], ["inflammation", "OBSERVATION", 71, 83], ["lung", "ANATOMY", 101, 105], ["RV", "ANATOMY", 141, 143], ["infection", "OBSERVATION", 144, 153], ["RV", "ANATOMY", 420, 422], ["infection", "OBSERVATION", 423, 432]]], ["Up to 48 h, this treatment appeared affective at reducing nasal obstruction, nasal mucus weights, and nasal kinin concentrations; however, this effect was lost when steroid treatment ceased.", [["nasal", "ANATOMY", 58, 63], ["nasal mucus", "ANATOMY", 77, 88], ["nasal", "ANATOMY", 102, 107], ["nasal obstruction", "DISEASE", 58, 75], ["steroid", "CHEMICAL", 165, 172], ["steroid", "CHEMICAL", 165, 172], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 58, 75], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 77, 88], ["kinin", "GENE_OR_GENE_PRODUCT", 108, 113], ["steroid", "SIMPLE_CHEMICAL", 165, 172], ["this treatment", "TREATMENT", 12, 26], ["affective", "PROBLEM", 36, 45], ["nasal obstruction", "PROBLEM", 58, 75], ["nasal mucus weights", "TREATMENT", 77, 96], ["nasal kinin concentrations", "TREATMENT", 102, 128], ["steroid treatment", "TREATMENT", 165, 182], ["nasal", "ANATOMY", 58, 63], ["obstruction", "OBSERVATION", 64, 75], ["nasal mucus", "ANATOMY", 77, 88], ["nasal", "ANATOMY", 102, 107], ["kinin concentrations", "OBSERVATION", 108, 128]]], ["Another study also examined prednisone (20 mg) given three times daily for 5 days, with treatment commencing 11 h prior to RV infection [141] .", [["RV", "ANATOMY", 123, 125], ["prednisone", "CHEMICAL", 28, 38], ["RV infection", "DISEASE", 123, 135], ["prednisone", "CHEMICAL", 28, 38], ["prednisone", "SIMPLE_CHEMICAL", 28, 38], ["Another study", "TEST", 0, 13], ["prednisone", "TREATMENT", 28, 38], ["treatment", "TREATMENT", 88, 97], ["RV infection", "PROBLEM", 123, 135], ["RV", "ANATOMY", 123, 125], ["infection", "OBSERVATION", 126, 135]]], ["The steroids reduced nasal kinin and mucus concentrations but had little effect on other symptoms.", [["nasal", "ANATOMY", 21, 26], ["mucus", "ANATOMY", 37, 42], ["steroids", "CHEMICAL", 4, 12], ["steroids", "CHEMICAL", 4, 12], ["steroids", "SIMPLE_CHEMICAL", 4, 12], ["nasal kinin", "GENE_OR_GENE_PRODUCT", 21, 32], ["mucus", "ORGANISM_SUBSTANCE", 37, 42], ["The steroids", "TREATMENT", 0, 12], ["nasal kinin", "TREATMENT", 21, 32], ["mucus concentrations", "PROBLEM", 37, 57], ["other symptoms", "PROBLEM", 83, 97], ["steroids", "OBSERVATION_MODIFIER", 4, 12], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["nasal kinin", "OBSERVATION", 21, 32], ["mucus concentrations", "OBSERVATION", 37, 57]]], ["Virus load was higher in the steroid-treated group, with significant differences on days 3 and 4 post-infection.", [["steroid", "CHEMICAL", 29, 36], ["infection", "DISEASE", 102, 111], ["steroid", "CHEMICAL", 29, 36], ["Virus", "ORGANISM", 0, 5], ["steroid", "SIMPLE_CHEMICAL", 29, 36], ["Virus load", "PROBLEM", 0, 10], ["the steroid", "TREATMENT", 25, 36], ["infection", "PROBLEM", 102, 111], ["higher", "OBSERVATION_MODIFIER", 15, 21], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["differences", "OBSERVATION_MODIFIER", 69, 80], ["infection", "OBSERVATION", 102, 111]]], ["The data suggest that an adverse effect of steroids may be suppression of antiviral mediators that are required for the natural defence against viral infection in vivo.", [["steroids", "CHEMICAL", 43, 51], ["viral infection", "DISEASE", 144, 159], ["steroids", "CHEMICAL", 43, 51], ["steroids", "SIMPLE_CHEMICAL", 43, 51], ["antiviral mediators", "PROTEIN", 74, 93], ["The data", "TEST", 0, 8], ["steroids", "TREATMENT", 43, 51], ["antiviral mediators", "TREATMENT", 74, 93], ["viral infection", "PROBLEM", 144, 159], ["infection", "OBSERVATION", 150, 159]]], ["No support for this has yet been observed in vitro; however, the relative effects of steroids on type I IFNs, defensins (for enveloped viruses), or other anti-viral components remains largely unexplored.Inhaled GC therapyGrunberg et al. [15] examined the possible benefits of inhaled budesonide (800 mg, twice daily) treatment in mild asthmatics during experimental RV infection.", [["RV", "ANATOMY", 366, 368], ["steroids", "CHEMICAL", 85, 93], ["budesonide", "CHEMICAL", 284, 294], ["RV infection", "DISEASE", 366, 378], ["steroids", "CHEMICAL", 85, 93], ["budesonide", "CHEMICAL", 284, 294], ["steroids", "SIMPLE_CHEMICAL", 85, 93], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 97, 108], ["defensins", "GENE_OR_GENE_PRODUCT", 110, 119], ["enveloped viruses", "ORGANISM", 125, 142], ["budesonide", "SIMPLE_CHEMICAL", 284, 294], ["type I IFNs", "PROTEIN", 97, 108], ["defensins", "PROTEIN", 110, 119], ["RV", "SPECIES", 366, 368], ["support", "TREATMENT", 3, 10], ["steroids", "TREATMENT", 85, 93], ["type I IFNs", "TREATMENT", 97, 108], ["defensins", "TREATMENT", 110, 119], ["enveloped viruses", "PROBLEM", 125, 142], ["other anti-viral components", "PROBLEM", 148, 175], ["Inhaled GC therapy", "TREATMENT", 203, 221], ["inhaled budesonide", "TREATMENT", 276, 294], ["treatment", "TREATMENT", 317, 326], ["mild asthmatics", "PROBLEM", 330, 345], ["experimental RV infection", "PROBLEM", 353, 378], ["GC therapy", "OBSERVATION", 211, 221], ["mild", "OBSERVATION_MODIFIER", 330, 334], ["asthmatics", "OBSERVATION", 335, 345], ["RV", "ANATOMY", 366, 368], ["infection", "OBSERVATION", 369, 378]]], ["Treatment commenced 2 weeks prior to challenge and was maintained throughout the study period (until 2 weeks post-challenge).", [["Treatment", "TREATMENT", 0, 9]]], ["Budesonide improved lung function in the asthmatics, and decreased eosinophil numbers, but did not reduce total inflammatory cell numbers in the lung.", [["lung", "ANATOMY", 20, 24], ["eosinophil", "ANATOMY", 67, 77], ["inflammatory cell", "ANATOMY", 112, 129], ["lung", "ANATOMY", 145, 149], ["Budesonide", "CHEMICAL", 0, 10], ["Budesonide", "CHEMICAL", 0, 10], ["Budesonide", "SIMPLE_CHEMICAL", 0, 10], ["lung", "ORGAN", 20, 24], ["eosinophil", "CELL", 67, 77], ["cell", "CELL", 125, 129], ["lung", "ORGAN", 145, 149], ["Budesonide", "TREATMENT", 0, 10], ["the asthmatics", "PROBLEM", 37, 51], ["decreased eosinophil numbers", "PROBLEM", 57, 85], ["total inflammatory cell numbers in the lung", "PROBLEM", 106, 149], ["lung", "ANATOMY", 20, 24], ["function", "OBSERVATION", 25, 33], ["asthmatics", "OBSERVATION", 41, 51], ["decreased", "OBSERVATION_MODIFIER", 57, 66], ["eosinophil numbers", "OBSERVATION", 67, 85], ["inflammatory cell numbers", "OBSERVATION", 112, 137], ["lung", "ANATOMY", 145, 149]]], ["The authors concluded that steroids only gave partial protection in RV-associated inflammation of asthma.", [["steroids", "CHEMICAL", 27, 35], ["inflammation", "DISEASE", 82, 94], ["asthma", "DISEASE", 98, 104], ["steroids", "CHEMICAL", 27, 35], ["steroids", "SIMPLE_CHEMICAL", 27, 35], ["steroids", "TREATMENT", 27, 35], ["asthma", "PROBLEM", 98, 104], ["RV", "ANATOMY", 68, 70], ["inflammation", "OBSERVATION", 82, 94], ["asthma", "OBSERVATION", 98, 104]]], ["In another study, it was observed that budesonide treatment caused a small but significant increase in the soluble IL-1R antagonist in nasal secretions.", [["nasal secretions", "ANATOMY", 135, 151], ["budesonide", "CHEMICAL", 39, 49], ["budesonide", "CHEMICAL", 39, 49], ["budesonide", "SIMPLE_CHEMICAL", 39, 49], ["IL-1R antagonist", "GENE_OR_GENE_PRODUCT", 115, 131], ["nasal secretions", "ORGANISM_SUBSTANCE", 135, 151], ["another study", "TEST", 3, 16], ["budesonide treatment", "TREATMENT", 39, 59], ["the soluble IL-1R antagonist", "TREATMENT", 103, 131], ["nasal secretions", "PROBLEM", 135, 151], ["small", "OBSERVATION_MODIFIER", 69, 74], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["nasal", "ANATOMY", 135, 140], ["secretions", "OBSERVATION", 141, 151]]], ["There was no significant difference between CXCL8 and IL-1b levels between asthmatics treated with budesonide and control asthmatics treated with placebo [16] .", [["budesonide", "CHEMICAL", 99, 109], ["budesonide", "CHEMICAL", 99, 109], ["CXCL8", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL-1b", "GENE_OR_GENE_PRODUCT", 54, 59], ["asthmatics", "ORGANISM", 75, 85], ["budesonide", "SIMPLE_CHEMICAL", 99, 109], ["CXCL8", "PROTEIN", 44, 49], ["IL", "PROTEIN", 54, 56], ["significant difference", "PROBLEM", 13, 35], ["CXCL8", "TEST", 44, 49], ["IL", "TEST", 54, 56], ["asthmatics", "PROBLEM", 75, 85], ["budesonide", "TREATMENT", 99, 109], ["control asthmatics", "TREATMENT", 114, 132], ["placebo", "TREATMENT", 146, 153], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["These data support the idea that steroids may have benefits in RV-associated exacerbations by increasing the level of anti-inflammatory mediators within the airway, rather than having a direct effect on proinflammatory mediator expression.Inhaled GC therapyThe use of GCs in treating virus-induced wheeze in children under 17 years of age has also been carefully examined.", [["RV", "ANATOMY", 63, 65], ["airway", "ANATOMY", 157, 163], ["steroids", "CHEMICAL", 33, 41], ["GCs", "CHEMICAL", 268, 271], ["wheeze", "DISEASE", 298, 304], ["steroids", "CHEMICAL", 33, 41], ["steroids", "SIMPLE_CHEMICAL", 33, 41], ["airway", "MULTI-TISSUE_STRUCTURE", 157, 163], ["GCs", "CELL", 268, 271], ["children", "ORGANISM", 308, 316], ["anti-inflammatory mediators", "PROTEIN", 118, 145], ["children", "SPECIES", 308, 316], ["steroids", "TREATMENT", 33, 41], ["RV", "PROBLEM", 63, 65], ["associated exacerbations", "PROBLEM", 66, 90], ["anti-inflammatory mediators", "TREATMENT", 118, 145], ["proinflammatory mediator expression", "PROBLEM", 203, 238], ["Inhaled GC therapy", "TREATMENT", 239, 257], ["GCs in treating virus", "TREATMENT", 268, 289], ["wheeze", "PROBLEM", 298, 304], ["exacerbations", "OBSERVATION", 77, 90], ["anti-inflammatory mediators", "OBSERVATION", 118, 145], ["airway", "ANATOMY", 157, 163], ["GC therapy", "OBSERVATION", 247, 257]]], ["A meta-analysis of compiled data from several studies showed that maintenance low-dose inhaled GCs did not demonstrate any clear reduction over placebo in the proportion of hospital admissions due to viral wheeze, and this treatment did not affect the prescription rate of oral GCs as treatment when these individuals were admitted to hospital [142] .", [["oral", "ANATOMY", 273, 277], ["viral wheeze", "DISEASE", 200, 212], ["oral", "ORGANISM_SUBDIVISION", 273, 277], ["GCs", "SIMPLE_CHEMICAL", 278, 281], ["individuals", "ORGANISM", 306, 317], ["compiled data", "TEST", 19, 32], ["several studies", "TEST", 38, 53], ["maintenance low-dose inhaled GCs", "TREATMENT", 66, 98], ["placebo", "TREATMENT", 144, 151], ["viral wheeze", "PROBLEM", 200, 212], ["oral GCs", "TREATMENT", 273, 281], ["treatment", "TREATMENT", 285, 294], ["reduction", "OBSERVATION_MODIFIER", 129, 138], ["viral wheeze", "OBSERVATION", 200, 212]]], ["Several other studies report similar findings [143] [144] [145] .", [["Several other studies", "TEST", 0, 21]]], ["In contrast, a study investigating emergency room hospital admissions and community cases of viral infection in autumn in Canada revealed that in children, patients admitted to hospital with exacerbations are less likely to have been given prior treatment in the form of inhaled GCs or leukotriene receptor antagonists [55] .", [["viral infection", "DISEASE", 93, 108], ["leukotriene", "CHEMICAL", 286, 297], ["children", "ORGANISM", 146, 154], ["patients", "ORGANISM", 156, 164], ["GCs", "SIMPLE_CHEMICAL", 279, 282], ["leukotriene receptor antagonists", "GENE_OR_GENE_PRODUCT", 286, 318], ["children", "SPECIES", 146, 154], ["patients", "SPECIES", 156, 164], ["a study", "TEST", 13, 20], ["viral infection", "PROBLEM", 93, 108], ["exacerbations", "PROBLEM", 191, 204], ["prior treatment", "TREATMENT", 240, 255], ["inhaled GCs", "TREATMENT", 271, 282], ["leukotriene receptor antagonists", "TREATMENT", 286, 318], ["viral", "OBSERVATION_MODIFIER", 93, 98], ["infection", "OBSERVATION", 99, 108]]], ["Also, two clinical studies consisting of older children (413 years) and adults have shown that GCs alone have failed to reduce asthma exacerbation rates.", [["asthma", "DISEASE", 127, 133], ["children", "ORGANISM", 47, 55], ["GCs", "CELL", 95, 98], ["children", "SPECIES", 47, 55], ["two clinical studies", "TEST", 6, 26], ["asthma exacerbation rates", "PROBLEM", 127, 152]]], ["In these studies, increasing the GC dose did not reduce the rate of asthma exacerbations [19, 20] , Currently, there is much evidence suggesting that the use of GCs alone is only partially protective against virus-induced exacerbations of asthma, and that preventive therapy can be improved.", [["asthma", "DISEASE", 68, 74], ["GCs", "CHEMICAL", 161, 164], ["asthma", "DISEASE", 239, 245], ["GCs", "SIMPLE_CHEMICAL", 161, 164], ["these studies", "TEST", 3, 16], ["asthma exacerbations", "PROBLEM", 68, 88], ["virus", "PROBLEM", 208, 213], ["asthma", "PROBLEM", 239, 245], ["preventive therapy", "TREATMENT", 256, 274], ["increasing", "OBSERVATION_MODIFIER", 18, 28], ["asthma", "OBSERVATION", 68, 74], ["much evidence suggesting", "UNCERTAINTY", 120, 144], ["asthma", "OBSERVATION", 239, 245]]], ["Again these data indirectly support the idea that exacerbations of asthma may involve processes that are different to persistent asthma.GCs in combination with b 2 agonistsGCs may act in concert with other therapeutics, for example, long-acting b 2 agonists (LABA) in combination therapy.", [["asthma", "DISEASE", 67, 73], ["asthma", "DISEASE", 129, 135], ["LABA", "CHEMICAL", 259, 263], ["GCs", "CELL", 136, 139], ["b 2 agonistsGCs", "SIMPLE_CHEMICAL", 160, 175], ["long-acting b 2 agonists", "SIMPLE_CHEMICAL", 233, 257], ["LABA", "SIMPLE_CHEMICAL", 259, 263], ["asthma", "PROBLEM", 67, 73], ["persistent asthma", "PROBLEM", 118, 135], ["GCs", "TEST", 136, 139], ["long-acting b 2 agonists (LABA", "TREATMENT", 233, 263], ["combination therapy", "TREATMENT", 268, 287], ["asthma", "OBSERVATION", 67, 73], ["persistent", "OBSERVATION_MODIFIER", 118, 128], ["asthma", "OBSERVATION", 129, 135]]], ["LABAs act via a G protein coupled receptor, activate adenylate cyclase and through the second messenger cAMP, induce intracellular signalling events affecting a broad range of physiological processes, alone and in combination with GCs, such as smooth muscle growth and differentiation [146] , inflammation [147] [148] [149] [150] [151] [152] [153] and response to bacterial infection [154, 155] .", [["intracellular", "ANATOMY", 117, 130], ["GCs", "ANATOMY", 231, 234], ["smooth muscle", "ANATOMY", 244, 257], ["cAMP", "CHEMICAL", 104, 108], ["inflammation", "DISEASE", 293, 305], ["bacterial infection", "DISEASE", 364, 383], ["adenylate", "CHEMICAL", 53, 62], ["cAMP", "CHEMICAL", 104, 108], ["LABAs", "SIMPLE_CHEMICAL", 0, 5], ["G protein coupled receptor", "GENE_OR_GENE_PRODUCT", 16, 42], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 53, 70], ["cAMP", "SIMPLE_CHEMICAL", 104, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["GCs", "CELL", 231, 234], ["smooth muscle", "TISSUE", 244, 257], ["LABAs", "PROTEIN", 0, 5], ["G protein coupled receptor", "PROTEIN", 16, 42], ["adenylate cyclase", "PROTEIN", 53, 70], ["LABAs", "TEST", 0, 5], ["a G protein coupled receptor", "TREATMENT", 14, 42], ["activate adenylate cyclase", "TREATMENT", 44, 70], ["the second messenger cAMP", "TREATMENT", 83, 108], ["intracellular signalling events", "PROBLEM", 117, 148], ["GCs", "TEST", 231, 234], ["inflammation", "PROBLEM", 293, 305], ["bacterial infection", "PROBLEM", 364, 383], ["muscle", "ANATOMY", 251, 257], ["bacterial", "OBSERVATION_MODIFIER", 364, 373], ["infection", "OBSERVATION", 374, 383]]], ["In severe or persistent asthma, several studies in vitro and in vivo have shown that the combined use of GCs and LABA has advantages over the use of GCs alone, in terms of alleviating inflammation, controlling smooth muscle remodelling and improving lung function [146, [156] [157] [158] [159] [160] .GCs in combination with b 2 agonistsConsidering the ability of LABA to enhance the antiinflammatory properties of GCs, and exert some antiinflammatory effects themselves in vitro [147, 152, 161] , an important question is whether or not combination therapy of LABA and GCs can reduce asthma exacerbation rates.", [["smooth muscle", "ANATOMY", 210, 223], ["lung", "ANATOMY", 250, 254], ["asthma", "DISEASE", 24, 30], ["LABA", "CHEMICAL", 113, 117], ["inflammation", "DISEASE", 184, 196], ["LABA", "CHEMICAL", 364, 368], ["LABA", "CHEMICAL", 561, 565], ["GCs", "CHEMICAL", 570, 573], ["asthma", "DISEASE", 585, 591], ["LABA", "CHEMICAL", 113, 117], ["LABA", "CHEMICAL", 364, 368], ["LABA", "CHEMICAL", 561, 565], ["GCs", "CELL", 105, 108], ["LABA", "SIMPLE_CHEMICAL", 113, 117], ["GCs", "CELL", 149, 152], ["smooth muscle", "TISSUE", 210, 223], ["lung", "ORGAN", 250, 254], ["GCs", "CELL", 301, 304], ["b 2 agonists", "GENE_OR_GENE_PRODUCT", 325, 337], ["LABA", "SIMPLE_CHEMICAL", 364, 368], ["GCs", "CELL", 415, 418], ["LABA", "SIMPLE_CHEMICAL", 561, 565], ["GCs", "SIMPLE_CHEMICAL", 570, 573], ["persistent asthma", "PROBLEM", 13, 30], ["several studies", "TEST", 32, 47], ["GCs", "TEST", 105, 108], ["LABA", "TREATMENT", 113, 117], ["GCs", "TEST", 149, 152], ["alleviating inflammation", "PROBLEM", 172, 196], ["smooth muscle remodelling", "PROBLEM", 210, 235], ["GCs", "TEST", 301, 304], ["b 2 agonists", "TREATMENT", 325, 337], ["LABA", "TREATMENT", 364, 368], ["GCs", "TEST", 415, 418], ["LABA", "TREATMENT", 561, 565], ["GCs", "TREATMENT", 570, 573], ["asthma exacerbation rates", "PROBLEM", 585, 610], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["persistent", "OBSERVATION_MODIFIER", 13, 23], ["asthma", "OBSERVATION", 24, 30], ["inflammation", "OBSERVATION", 184, 196], ["smooth muscle", "ANATOMY", 210, 223], ["lung", "ANATOMY", 250, 254]]], ["Studies completed thus far suggest a positive effect of b 2 agonists when combined with GCs, in reducing frequencies of asthma exacerbations [162, 163] ; however, further evidence is required before the use of GCs in this way is generally accepted.", [["asthma exacerbations", "DISEASE", 120, 140], ["b 2 agonists", "GENE_OR_GENE_PRODUCT", 56, 68], ["GCs", "CELL", 210, 213], ["Studies", "TEST", 0, 7], ["b 2 agonists", "TREATMENT", 56, 68], ["GCs", "TEST", 88, 91], ["asthma exacerbations", "PROBLEM", 120, 140], ["GCs", "TEST", 210, 213], ["positive", "OBSERVATION", 37, 45], ["asthma", "OBSERVATION", 120, 126]]], ["These studies may also be of mixed aetiology, as exacerbations in general were investigated, and not specifically virus-induced exacerbations.", [["exacerbations", "DISEASE", 128, 141], ["These studies", "TEST", 0, 13], ["mixed aetiology", "PROBLEM", 29, 44], ["exacerbations", "PROBLEM", 49, 62], ["induced exacerbations", "PROBLEM", 120, 141], ["may also be of", "UNCERTAINTY", 14, 28], ["mixed", "OBSERVATION_MODIFIER", 29, 34]]], ["It is also unclear whether the enhanced effect produced by b 2 agonists in the above studies was due to bronchodilation, or by decreasing inflammation, or both.GCs in combination with b 2 agonistsThere are yet to be clinical studies using combination therapy in models of experimental or natural RV infection in asthma.", [["RV", "ANATOMY", 296, 298], ["inflammation", "DISEASE", 138, 150], ["RV infection", "DISEASE", 296, 308], ["asthma", "DISEASE", 312, 318], ["b 2 agonists", "GENE_OR_GENE_PRODUCT", 59, 71], ["GCs", "CELL", 160, 163], ["b 2 agonists", "GENE_OR_GENE_PRODUCT", 184, 196], ["RV", "ORGAN", 296, 298], ["RV", "SPECIES", 296, 298], ["b 2 agonists", "TREATMENT", 59, 71], ["the above studies", "TEST", 75, 92], ["bronchodilation", "PROBLEM", 104, 119], ["decreasing inflammation", "PROBLEM", 127, 150], ["GCs", "TEST", 160, 163], ["b 2 agonists", "TREATMENT", 184, 196], ["clinical studies", "TEST", 216, 232], ["combination therapy", "TREATMENT", 239, 258], ["natural RV infection", "PROBLEM", 288, 308], ["asthma", "PROBLEM", 312, 318], ["bronchodilation", "OBSERVATION", 104, 119], ["decreasing", "OBSERVATION_MODIFIER", 127, 137], ["inflammation", "OBSERVATION", 138, 150], ["RV", "ANATOMY", 296, 298], ["infection", "OBSERVATION", 299, 308], ["asthma", "OBSERVATION", 312, 318]]], ["Until such studies are performed, the potential role of combination therapy in the treatment of RVinduced asthma exacerbations remains open.", [["asthma", "DISEASE", 106, 112], ["such studies", "TEST", 6, 18], ["combination therapy", "TREATMENT", 56, 75], ["the treatment", "TREATMENT", 79, 92], ["RVinduced asthma exacerbations", "PROBLEM", 96, 126], ["asthma", "OBSERVATION", 106, 112]]], ["One caveat to this idea is the general observation that virus-induced exacerbations of asthma involve not only eosinophils, but recruitment of both neutrophils, and activated T cells into the inflamed airway, and also activation of local macrophages [5, [84] [85] [86] .", [["eosinophils", "ANATOMY", 111, 122], ["neutrophils", "ANATOMY", 148, 159], ["T cells", "ANATOMY", 175, 182], ["airway", "ANATOMY", 201, 207], ["macrophages", "ANATOMY", 238, 249], ["asthma", "DISEASE", 87, 93], ["eosinophils", "CELL", 111, 122], ["neutrophils", "CELL", 148, 159], ["T cells", "CELL", 175, 182], ["airway", "MULTI-TISSUE_STRUCTURE", 201, 207], ["macrophages", "CELL", 238, 249], ["eosinophils", "CELL_TYPE", 111, 122], ["neutrophils", "CELL_TYPE", 148, 159], ["activated T cells", "CELL_TYPE", 165, 182], ["local macrophages", "CELL_TYPE", 232, 249], ["virus", "PROBLEM", 56, 61], ["asthma", "PROBLEM", 87, 93], ["eosinophils", "TEST", 111, 122], ["neutrophils", "TEST", 148, 159], ["local macrophages", "TEST", 232, 249], ["asthma", "OBSERVATION", 87, 93], ["inflamed airway", "ANATOMY", 192, 207]]], ["The ability of combination therapy to control neutrophilic and lymphocytic-induced inflammation is yet to be investigated experimentally.Inhibitors of NF-kB signallingAs NF-kB is involved in induction of the majority of pro-inflammatory mediators studied so far in RV infection (see section above), NF-kB signalling components represent possible therapeutic targets.", [["neutrophilic", "ANATOMY", 46, 58], ["lymphocytic", "ANATOMY", 63, 74], ["RV", "ANATOMY", 265, 267], ["inflammation", "DISEASE", 83, 95], ["RV infection", "DISEASE", 265, 277], ["neutrophilic", "CELL", 46, 58], ["lymphocytic", "CELL", 63, 74], ["NF-kB", "GENE_OR_GENE_PRODUCT", 151, 156], ["NF-kB", "GENE_OR_GENE_PRODUCT", 170, 175], ["RV", "ORGAN", 265, 267], ["NF-kB", "GENE_OR_GENE_PRODUCT", 299, 304], ["NF-kB", "PROTEIN", 151, 156], ["NF-kB", "PROTEIN", 170, 175], ["pro-inflammatory mediators", "PROTEIN", 220, 246], ["NF-kB", "PROTEIN", 299, 304], ["combination therapy", "TREATMENT", 15, 34], ["neutrophilic", "PROBLEM", 46, 58], ["lymphocytic-induced inflammation", "PROBLEM", 63, 95], ["Inhibitors", "TREATMENT", 137, 147], ["NF", "TREATMENT", 151, 153], ["pro-inflammatory mediators", "TEST", 220, 246], ["RV infection", "PROBLEM", 265, 277], ["neutrophilic", "OBSERVATION_MODIFIER", 46, 58], ["lymphocytic", "OBSERVATION", 63, 74], ["inflammation", "OBSERVATION", 83, 95], ["RV", "ANATOMY", 265, 267], ["infection", "OBSERVATION", 268, 277], ["possible", "UNCERTAINTY", 337, 345], ["therapeutic targets", "OBSERVATION", 346, 365]]], ["In murine models of allergic asthma, there has been some success with NF-kB inhibition.", [["allergic asthma", "DISEASE", 20, 35], ["murine", "ORGANISM", 3, 9], ["NF-kB", "GENE_OR_GENE_PRODUCT", 70, 75], ["NF-kB", "PROTEIN", 70, 75], ["murine", "SPECIES", 3, 9], ["allergic asthma", "PROBLEM", 20, 35], ["NF-kB inhibition", "TREATMENT", 70, 86], ["allergic asthma", "OBSERVATION", 20, 35], ["some", "OBSERVATION_MODIFIER", 52, 56], ["success", "OBSERVATION_MODIFIER", 57, 64]]], ["The redox inhibitor MOL294 and NF-kB decoy oligodeoxynucleotides have been successful in reducing pro-inflammatory molecule expression, lung inflammation and airway hyper-responsiveness to metacholine [164, 165] .Inhibitors of NF-kB signallingRecent studies have shown that the RV induction of CXCL8 and IL-6 from bronchial epithelial cells is an IKKb dependent process, and is sensitive to inhibition with AS602868 (Serono International, [166] ), a selective IKK-b inhibitor (M.R. Edwards and S.L. Johnston, unpublished observations), suggesting that IKK-b inhibition may be a useful therapeutic option.", [["lung", "ANATOMY", 136, 140], ["airway", "ANATOMY", 158, 164], ["bronchial epithelial cells", "ANATOMY", 314, 340], ["inflammation", "DISEASE", 141, 153], ["metacholine", "CHEMICAL", 189, 200], ["AS602868", "CHEMICAL", 407, 415], ["metacholine", "CHEMICAL", 189, 200], ["AS602868", "CHEMICAL", 407, 415], ["MOL294", "SIMPLE_CHEMICAL", 20, 26], ["NF-kB", "GENE_OR_GENE_PRODUCT", 31, 36], ["lung", "ORGAN", 136, 140], ["airway", "MULTI-TISSUE_STRUCTURE", 158, 164], ["metacholine", "SIMPLE_CHEMICAL", 189, 200], ["NF-kB", "GENE_OR_GENE_PRODUCT", 227, 232], ["CXCL8", "GENE_OR_GENE_PRODUCT", 294, 299], ["IL-6", "GENE_OR_GENE_PRODUCT", 304, 308], ["bronchial epithelial cells", "CELL", 314, 340], ["IKKb", "GENE_OR_GENE_PRODUCT", 347, 351], ["AS602868", "SIMPLE_CHEMICAL", 407, 415], ["Serono", "SIMPLE_CHEMICAL", 417, 423], ["[166]", "SIMPLE_CHEMICAL", 439, 444], ["IKK-b", "GENE_OR_GENE_PRODUCT", 460, 465], ["IKK-b", "GENE_OR_GENE_PRODUCT", 552, 557], ["pro-inflammatory molecule", "PROTEIN", 98, 123], ["NF-kB", "PROTEIN", 227, 232], ["CXCL8", "PROTEIN", 294, 299], ["IL-6", "PROTEIN", 304, 308], ["bronchial epithelial cells", "CELL_TYPE", 314, 340], ["IKK", "PROTEIN", 460, 463], ["IKK", "PROTEIN", 552, 555], ["The redox inhibitor MOL294", "TREATMENT", 0, 26], ["NF-kB decoy oligodeoxynucleotides", "TREATMENT", 31, 64], ["reducing pro-inflammatory molecule expression", "TREATMENT", 89, 134], ["lung inflammation", "PROBLEM", 136, 153], ["airway hyper-responsiveness", "PROBLEM", 158, 185], ["Inhibitors", "TREATMENT", 213, 223], ["Recent studies", "TEST", 243, 257], ["the RV induction", "TEST", 274, 290], ["CXCL8", "TEST", 294, 299], ["IL", "TEST", 304, 306], ["bronchial epithelial cells", "PROBLEM", 314, 340], ["an IKKb dependent process", "PROBLEM", 344, 369], ["a selective IKK-b inhibitor", "TREATMENT", 448, 475], ["IKK", "TEST", 552, 555], ["pro-inflammatory molecule", "OBSERVATION", 98, 123], ["lung", "ANATOMY", 136, 140], ["inflammation", "OBSERVATION", 141, 153], ["airway", "ANATOMY", 158, 164], ["RV", "ANATOMY", 278, 280], ["bronchial", "ANATOMY", 314, 323], ["epithelial cells", "OBSERVATION", 324, 340], ["IKKb dependent", "OBSERVATION_MODIFIER", 347, 361]]], ["A recent review has given a thorough summary of the current range of selective IKK inhibitors available, including both organic-based and small molecule inhibitors [88] ; therefore, they will not be discussed in detail here.", [["IKK", "GENE_OR_GENE_PRODUCT", 79, 82], ["IKK", "PROTEIN", 79, 82], ["selective IKK inhibitors", "TREATMENT", 69, 93], ["small molecule inhibitors", "TREATMENT", 138, 163]]], ["Importantly, the current range of selective IKK inhibitors have just begun to find their way into clinical trials, after showing promise in cell-based assays and murine models of disease.", [["cell", "ANATOMY", 140, 144], ["IKK", "GENE_OR_GENE_PRODUCT", 44, 47], ["cell", "CELL", 140, 144], ["murine", "ORGANISM", 162, 168], ["IKK", "PROTEIN", 44, 47], ["murine", "SPECIES", 162, 168], ["selective IKK inhibitors", "TREATMENT", 34, 58], ["disease", "PROBLEM", 179, 186], ["disease", "OBSERVATION", 179, 186]]], ["Inhibitors of these types have not yet been tested in human models of experimental virus infection, or asthma.Inhibitors of NF-kB signallingConcerning virus exacerbations of asthma, one caveat to the idea of NF-kB inhibition is that protective, anti-viral mediators may also be induced in an NF-kB dependent manner.", [["experimental virus infection", "DISEASE", 70, 98], ["asthma", "DISEASE", 103, 109], ["asthma", "DISEASE", 174, 180], ["human", "ORGANISM", 54, 59], ["NF-kB", "GENE_OR_GENE_PRODUCT", 124, 129], ["NF-kB", "GENE_OR_GENE_PRODUCT", 208, 213], ["NF-kB", "GENE_OR_GENE_PRODUCT", 292, 297], ["NF-kB", "PROTEIN", 124, 129], ["NF-kB", "PROTEIN", 208, 213], ["anti-viral mediators", "PROTEIN", 245, 265], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["Inhibitors", "TREATMENT", 0, 10], ["experimental virus infection", "PROBLEM", 70, 98], ["asthma", "PROBLEM", 103, 109], ["Inhibitors", "TREATMENT", 110, 120], ["NF", "TREATMENT", 124, 126], ["virus exacerbations", "PROBLEM", 151, 170], ["asthma", "PROBLEM", 174, 180], ["anti-viral mediators", "TREATMENT", 245, 265], ["experimental virus infection", "OBSERVATION", 70, 98], ["asthma", "OBSERVATION", 103, 109], ["asthma", "OBSERVATION", 174, 180], ["kB dependent", "OBSERVATION_MODIFIER", 295, 307]]], ["The obvious example of this is IFN-b, which in many systems, is made initially on viral infection in an NF-kB dependent manner [167] [168] [169] [170] .", [["viral infection", "DISEASE", 82, 97], ["IFN-b", "GENE_OR_GENE_PRODUCT", 31, 36], ["NF-kB", "GENE_OR_GENE_PRODUCT", 104, 109], ["IFN", "PROTEIN", 31, 34], ["viral infection", "PROBLEM", 82, 97], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97]]], ["Clearly, the potential role of NF-kB in the expression of mediators that are beneficial to the host response to infection needs to be carefully considered before NF-kB intervention becomes a serious therapeutic option.", [["infection", "DISEASE", 112, 121], ["NF-kB", "GENE_OR_GENE_PRODUCT", 31, 36], ["NF-kB", "GENE_OR_GENE_PRODUCT", 162, 167], ["NF-kB", "PROTEIN", 31, 36], ["infection", "PROBLEM", 112, 121], ["NF-kB intervention", "TREATMENT", 162, 180], ["a serious therapeutic option", "TREATMENT", 189, 217]]], ["With the discovery of alternate NF-kB signalling intermediates such as IKK-i/e and TBK-1, the proposition of NF-kB inhibition has become more complex (see Fig. 3 ).", [["NF-kB", "GENE_OR_GENE_PRODUCT", 32, 37], ["IKK-i/e", "GENE_OR_GENE_PRODUCT", 71, 78], ["TBK-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["NF-kB", "GENE_OR_GENE_PRODUCT", 109, 114], ["NF-kB", "PROTEIN", 32, 37], ["IKK-i/e and TBK-1", "PROTEIN", 71, 88], ["NF-kB", "PROTEIN", 109, 114], ["IKK", "TEST", 71, 74], ["TBK", "TEST", 83, 86], ["kB inhibition", "PROBLEM", 112, 125], ["more complex", "OBSERVATION_MODIFIER", 137, 149]]], ["However, the role of individual NF-kB signalling intermediates in both harmful pro-inflammatory mediator gene expression as well as in useful anti-viral mediator gene expression, is a much understudied field, and whether distinct signalling intermediates exist for IFN expression versus pro-inflammatory cytokine expression is currently unclear.", [["NF-kB", "GENE_OR_GENE_PRODUCT", 32, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 265, 268], ["NF-kB", "PROTEIN", 32, 37], ["IFN", "PROTEIN", 265, 268], ["pro-inflammatory cytokine", "PROTEIN", 287, 312], ["distinct signalling intermediates", "PROBLEM", 221, 254], ["IFN expression", "PROBLEM", 265, 279], ["pro-inflammatory cytokine expression", "PROBLEM", 287, 323]]], ["Further research efforts are required before the role of this important transcription factor and its signalling pathways can be fully understood.Summary and conclusionsMany respiratory viruses, in particular RV, cause exacerbations of asthma, and this is a healthcare concern worldwide.", [["respiratory viruses", "DISEASE", 173, 192], ["asthma", "DISEASE", 235, 241], ["transcription factor", "PROTEIN", 72, 92], ["Many respiratory viruses", "PROBLEM", 168, 192], ["exacerbations", "PROBLEM", 218, 231], ["asthma", "PROBLEM", 235, 241], ["respiratory viruses", "OBSERVATION", 173, 192], ["RV", "ANATOMY", 208, 210], ["asthma", "OBSERVATION", 235, 241]]], ["RVs upregulate pro-inflammatory mediators and cause local inflammation in the lower airway, and this may precipitate exacerbations of asthma in certain individuals.", [["lower airway", "ANATOMY", 78, 90], ["inflammation", "DISEASE", 58, 70], ["asthma", "DISEASE", 134, 140], ["lower airway", "ORGANISM_SUBDIVISION", 78, 90], ["pro-inflammatory mediators", "PROTEIN", 15, 41], ["pro-inflammatory mediators", "PROBLEM", 15, 41], ["local inflammation in the lower airway", "PROBLEM", 52, 90], ["asthma", "PROBLEM", 134, 140], ["pro-inflammatory mediators", "OBSERVATION", 15, 41], ["local", "OBSERVATION_MODIFIER", 52, 57], ["inflammation", "OBSERVATION", 58, 70], ["lower", "ANATOMY_MODIFIER", 78, 83], ["airway", "ANATOMY", 84, 90], ["asthma", "OBSERVATION", 134, 140]]], ["Individuals suffering from viral exacerbations of asthma are yet to be treated effectively, and there is wide interest in a range of treatment options for these unmet medical needs.", [["viral exacerbations", "DISEASE", 27, 46], ["asthma", "DISEASE", 50, 56], ["viral exacerbations", "PROBLEM", 27, 46], ["asthma", "PROBLEM", 50, 56], ["treatment options", "TREATMENT", 133, 150], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["exacerbations", "OBSERVATION", 33, 46], ["asthma", "OBSERVATION", 50, 56]]], ["Specific anti-rhinoviral therapy, IFN therapy, and steroid-based therapies have all been studied in the past with mixed successes.", [["IFN", "CHEMICAL", 34, 37], ["steroid", "CHEMICAL", 51, 58], ["steroid", "CHEMICAL", 51, 58], ["steroid", "SIMPLE_CHEMICAL", 51, 58], ["IFN", "PROTEIN", 34, 37], ["Specific anti-rhinoviral therapy", "TREATMENT", 0, 32], ["IFN therapy", "TREATMENT", 34, 45], ["steroid-based therapies", "TREATMENT", 51, 74], ["anti-rhinoviral therapy", "OBSERVATION", 9, 32]]], ["Anti-viral therapies have been classically applied in the context of clinical colds (Table 1) ; however, they have not yet been studied in exacerbations of asthma.", [["colds", "DISEASE", 78, 83], ["asthma", "DISEASE", 156, 162], ["Anti-viral therapies", "TREATMENT", 0, 20], ["clinical colds", "PROBLEM", 69, 83], ["asthma", "PROBLEM", 156, 162], ["asthma", "OBSERVATION", 156, 162]]], ["With the link between RV and asthma exacerbations now more established, the antirhinoviral treatments Pleconaril and Tremacamra should be regarded as serious therapeutic options.", [["asthma exacerbations", "DISEASE", 29, 49], ["Pleconaril", "CHEMICAL", 102, 112], ["Tremacamra", "CHEMICAL", 117, 127], ["RV", "MULTI-TISSUE_STRUCTURE", 22, 24], ["Pleconaril", "SIMPLE_CHEMICAL", 102, 112], ["Tremacamra", "SIMPLE_CHEMICAL", 117, 127], ["asthma exacerbations", "PROBLEM", 29, 49], ["the antirhinoviral treatments Pleconaril", "TREATMENT", 72, 112], ["Tremacamra", "TREATMENT", 117, 127], ["RV", "ANATOMY", 22, 24], ["asthma", "OBSERVATION", 29, 35]]], ["The study of type I IFN therapy in clinical colds has highlighted many problems with this treatment.", [["colds", "DISEASE", 44, 49], ["type I IFN", "GENE_OR_GENE_PRODUCT", 13, 23], ["type I IFN", "PROTEIN", 13, 23], ["The study", "TEST", 0, 9], ["type I IFN therapy", "TREATMENT", 13, 31], ["clinical colds", "PROBLEM", 35, 49], ["this treatment", "TREATMENT", 85, 99]]], ["Dose, delivery and safety all remain important issues for viral exacerbations of asthma.", [["asthma", "DISEASE", 81, 87], ["delivery", "TREATMENT", 6, 14], ["viral exacerbations", "PROBLEM", 58, 77], ["asthma", "PROBLEM", 81, 87], ["asthma", "OBSERVATION", 81, 87]]], ["As a deficiency in IFN-b expression has been recently described in asthmatics [39] , type I IFN therapy remains a candidate treatment however.", [["IFN-b", "GENE_OR_GENE_PRODUCT", 19, 24], ["type I IFN", "GENE_OR_GENE_PRODUCT", 85, 95], ["IFN", "PROTEIN", 19, 22], ["IFN", "PROTEIN", 92, 95], ["a deficiency in IFN", "PROBLEM", 3, 22], ["asthmatics", "PROBLEM", 67, 77], ["type I IFN therapy", "TREATMENT", 85, 103], ["a candidate treatment", "TREATMENT", 112, 133], ["deficiency", "OBSERVATION", 5, 15]]], ["One potential area of further research is combined anti-viral, anti-inflammatory therapy, which may inhibit viral replication as well as treating upper and lower airway inflammation.", [["lower airway", "ANATOMY", 156, 168], ["inflammation", "DISEASE", 169, 181], ["upper", "ORGANISM_SUBDIVISION", 146, 151], ["airway", "ORGANISM_SUBDIVISION", 162, 168], ["combined anti-viral", "TREATMENT", 42, 61], ["anti-inflammatory therapy", "TREATMENT", 63, 88], ["viral replication", "TREATMENT", 108, 125], ["upper and lower airway inflammation", "PROBLEM", 146, 181], ["area", "OBSERVATION_MODIFIER", 14, 18], ["anti-viral", "OBSERVATION_MODIFIER", 51, 61], ["anti-inflammatory therapy", "OBSERVATION", 63, 88], ["viral replication", "OBSERVATION", 108, 125], ["upper", "ANATOMY_MODIFIER", 146, 151], ["lower", "ANATOMY_MODIFIER", 156, 161], ["airway", "ANATOMY", 162, 168], ["inflammation", "OBSERVATION", 169, 181]]], ["Another area that has yet to be tested formally is NF-kB inhibition, as many RVinduced inflammatory mediators are NF-kB dependent.", [["NF-kB", "GENE_OR_GENE_PRODUCT", 51, 56], ["NF-kB", "GENE_OR_GENE_PRODUCT", 114, 119], ["NF-kB", "PROTEIN", 51, 56], ["RVinduced inflammatory mediators", "PROTEIN", 77, 109], ["NF-kB", "PROTEIN", 114, 119], ["many RVinduced inflammatory mediators", "PROBLEM", 72, 109], ["kB dependent", "PROBLEM", 117, 129], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99]]], ["The wealth of literature so far reported on RV-induced exacerbations of asthma suggests that the relationship of infection and asthma exacerbation, in particular the cellular and molecular immunological aspects of pathogenesis, is still unclear, and further experimental infection studies are required to better understand these important processes.", [["cellular", "ANATOMY", 166, 174], ["asthma", "DISEASE", 72, 78], ["infection", "DISEASE", 113, 122], ["asthma", "DISEASE", 127, 133], ["infection", "DISEASE", 271, 280], ["cellular", "CELL", 166, 174], ["RV", "PROBLEM", 44, 46], ["asthma", "PROBLEM", 72, 78], ["infection", "PROBLEM", 113, 122], ["asthma exacerbation", "PROBLEM", 127, 146], ["pathogenesis", "PROBLEM", 214, 226], ["further experimental infection studies", "TEST", 250, 288], ["exacerbations", "OBSERVATION", 55, 68], ["asthma", "OBSERVATION", 72, 78], ["infection", "OBSERVATION", 113, 122], ["asthma", "OBSERVATION", 127, 133]]], ["In particular, how asthmatics may differ from normal individuals who do not suffer from lower airway disease is a priority.", [["lower airway", "ANATOMY", 88, 100], ["lower airway disease", "DISEASE", 88, 108], ["asthmatics", "ORGANISM", 19, 29], ["lower airway", "MULTI-TISSUE_STRUCTURE", 88, 100], ["lower airway disease", "PROBLEM", 88, 108], ["lower", "ANATOMY_MODIFIER", 88, 93], ["airway", "ANATOMY", 94, 100], ["disease", "OBSERVATION", 101, 108]]], ["There is also a need for further vigorous pursuit of the molecular mechanisms of infection and pro-inflammatory mediator induction, for example, the development of small animal models that will be invaluable for testing these ideas and providing future therapeutic targets.", [["infection", "DISEASE", 81, 90], ["infection", "PROBLEM", 81, 90], ["pro-inflammatory mediator induction", "TREATMENT", 95, 130], ["small animal models", "PROBLEM", 164, 183], ["testing", "TEST", 212, 219], ["infection", "OBSERVATION", 81, 90], ["small", "OBSERVATION_MODIFIER", 164, 169]]], ["[134] [135] [136] a Refers to the symptoms studied by the authors.", [["the symptoms", "PROBLEM", 30, 42]]], ["O refers to successful control of the symptom being studied. p refers to unsuccessful control of that particular symptom.", [["the symptom", "PROBLEM", 34, 45], ["that particular symptom", "PROBLEM", 97, 120]]], ["NS refers to the symptom not being studied. b Limitations are those as suggested by the authors in each study.", [["NS", "TREATMENT", 0, 2], ["the symptom", "PROBLEM", 13, 24], ["each study", "TEST", 99, 109]]]], "PMC4102100": [["INTRODUCTIONHealthcare workers (HCWs) are at increased risk of healthcare-associated infections due to the front-line nature of their work.", [["infections", "DISEASE", 85, 95], ["healthcare-associated infections", "PROBLEM", 63, 95], ["infections", "OBSERVATION", 85, 95]]], ["Transmission of highly infectious diseases from infected patient to other patients and HCWs occurs constantly in hospitals and healthcare centres and has been well documented [1\u20133].", [["infectious diseases from infected", "DISEASE", 23, 56], ["patient", "ORGANISM", 57, 64], ["patients", "ORGANISM", 74, 82], ["patient", "SPECIES", 57, 64], ["patients", "SPECIES", 74, 82], ["highly infectious diseases", "PROBLEM", 16, 42], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["infectious", "OBSERVATION", 23, 33]]], ["Although HCWs are aware of infection control measures, low levels of compliance with standard precautions by this group are frequent [4, 5].", [["infection", "DISEASE", 27, 36], ["infection control measures", "TREATMENT", 27, 53], ["standard precautions", "TREATMENT", 85, 105]]], ["HCWs are less willing to adhere to infection-control practices when they work for extended hours [6], with probable reasons for low compliance being insufficient time, scarcity of equipment, lack of knowledge and low perception of risk [5].INTRODUCTIONThe three principal routes of transmission of respiratory pathogens are contact transmission (direct and indirect), droplet transmission, and airborne transmission.", [["respiratory", "ANATOMY", 298, 309], ["infection", "DISEASE", 35, 44], ["respiratory pathogens", "DISEASE", 298, 319], ["infection", "PROBLEM", 35, 44], ["respiratory pathogens", "PROBLEM", 298, 319], ["respiratory pathogens", "OBSERVATION", 298, 319], ["airborne transmission", "OBSERVATION", 394, 415]]], ["For any pathogen, more than one transmission route may occur, but many pathogens are known to be transmitted by one predominant mode.", [["any pathogen", "PROBLEM", 4, 16], ["many pathogens", "PROBLEM", 66, 80], ["pathogen", "OBSERVATION", 8, 16]]], ["In droplet transmission, pathogens or droplets which are larger than 5 \u03bcm, such as influenza virus and Bordetella pertussis are transmitted from an infected patient to HCWs through breathing, talking, coughing, sneezing, as well as through performing high-risk procedures (HRPs) [2, 7, 8].", [["droplets", "ANATOMY", 38, 46], ["influenza virus", "DISEASE", 83, 98], ["Bordetella pertussis", "DISEASE", 103, 123], ["coughing", "DISEASE", 201, 209], ["sneezing", "DISEASE", 211, 219], ["influenza virus", "ORGANISM", 83, 98], ["Bordetella pertussis", "ORGANISM", 103, 123], ["patient", "ORGANISM", 157, 164], ["influenza virus", "SPECIES", 83, 98], ["Bordetella pertussis", "SPECIES", 103, 123], ["patient", "SPECIES", 157, 164], ["influenza virus", "SPECIES", 83, 98], ["Bordetella pertussis", "SPECIES", 103, 123], ["pathogens", "PROBLEM", 25, 34], ["droplets", "PROBLEM", 38, 46], ["influenza virus", "PROBLEM", 83, 98], ["Bordetella pertussis", "PROBLEM", 103, 123], ["coughing", "PROBLEM", 201, 209], ["sneezing", "PROBLEM", 211, 219], ["larger", "OBSERVATION_MODIFIER", 57, 63], ["influenza virus", "OBSERVATION", 83, 98]]], ["However, influenza virus has also been documented to be transmitted by the airborne route, which results in infectious particles being present in the air for longer periods of time [9\u201312].INTRODUCTIONRespiratory infectious diseases, even those with limited airborne transmission, are more likely to be transmitted from patients to HCWs during HRPs such as suctioning and intubation which generate respiratory aerosols [13].", [["influenza virus", "DISEASE", 9, 24], ["infectious diseases", "DISEASE", 212, 231], ["influenza virus", "ORGANISM", 9, 24], ["patients", "ORGANISM", 319, 327], ["influenza virus", "SPECIES", 9, 24], ["patients", "SPECIES", 319, 327], ["influenza virus", "SPECIES", 9, 24], ["influenza virus", "PROBLEM", 9, 24], ["infectious particles", "PROBLEM", 108, 128], ["HRPs", "TREATMENT", 343, 347], ["suctioning", "TREATMENT", 356, 366], ["intubation", "TREATMENT", 371, 381], ["influenza virus", "OBSERVATION", 9, 24], ["infectious", "OBSERVATION", 108, 118], ["air", "ANATOMY", 150, 153], ["infectious", "OBSERVATION", 212, 222]]], ["Many studies suggest that both invasive and non-invasive procedures are likely to increase the probability of HCWs being infected [13, 14].", [["Many studies", "TEST", 0, 12], ["non-invasive procedures", "TREATMENT", 44, 67], ["HCWs", "PROBLEM", 110, 114]]], ["Some studies have reported that non-invasive positive pressure ventilation (NPPV) can be a risk of severe acute respiratory syndrome (SARS) transmission to HCWs [15\u201317].", [["acute respiratory syndrome", "DISEASE", 106, 132], ["SARS", "DISEASE", 134, 138], ["Some studies", "TEST", 0, 12], ["non-invasive positive pressure ventilation", "TREATMENT", 32, 74], ["NPPV", "TREATMENT", 76, 80], ["severe acute respiratory syndrome", "PROBLEM", 99, 132], ["pressure ventilation", "OBSERVATION", 54, 74], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["respiratory syndrome", "OBSERVATION", 112, 132]]], ["Cardiopulmonary resuscitation, manual ventilation, bronchoscopy and suctioning have also been documented to increase the risk of HCWs being infected with SARS and tuberculosis (TB) [18\u201321], while tracheal intubation has been significantly associated with risk of SARS transmission to HCWs [17].", [["tracheal", "ANATOMY", 196, 204], ["SARS", "DISEASE", 154, 158], ["tuberculosis", "DISEASE", 163, 175], ["TB", "DISEASE", 177, 179], ["SARS", "DISEASE", 263, 267], ["tracheal", "ORGAN", 196, 204], ["Cardiopulmonary resuscitation", "TREATMENT", 0, 29], ["manual ventilation", "TREATMENT", 31, 49], ["bronchoscopy", "TREATMENT", 51, 63], ["suctioning", "TREATMENT", 68, 78], ["HCWs", "PROBLEM", 129, 133], ["SARS", "PROBLEM", 154, 158], ["tuberculosis", "PROBLEM", 163, 175], ["tracheal intubation", "TREATMENT", 196, 215], ["resuscitation", "OBSERVATION", 16, 29], ["tracheal", "ANATOMY", 196, 204]]], ["While it has been well documented that TB and SARS can be transmitted to HCWs during aerosol-generating procedures, there are some data suggesting H1N1 can transmit via such procedures [13].", [["TB", "DISEASE", 39, 41], ["SARS", "DISEASE", 46, 50], ["H1N1", "ORGANISM", 147, 151], ["TB", "PROBLEM", 39, 41], ["aerosol-generating procedures", "TREATMENT", 85, 114], ["H1N1", "PROBLEM", 147, 151]]], ["Seasonal influenza also causes outbreaks in healthcare settings [22].", [["influenza", "DISEASE", 9, 18], ["Seasonal influenza", "PROBLEM", 0, 18]]], ["HCWs are one of the most vulnerable groups likely to be infected with influenza infection in acute-care facilities due to the high exposure rates in such settings [23].", [["influenza infection", "DISEASE", 70, 89], ["influenza infection", "PROBLEM", 70, 89], ["the high exposure rates", "PROBLEM", 122, 145], ["likely to be", "UNCERTAINTY", 43, 55], ["infected", "OBSERVATION", 56, 64], ["influenza", "OBSERVATION", 70, 79]]], ["An attack rate of nosocomial influenza could reach 11\u201359% in HCWs in a healthcare environment [24].", [["influenza", "DISEASE", 29, 38], ["nosocomial influenza", "PROBLEM", 18, 38], ["nosocomial influenza", "OBSERVATION", 18, 38]]], ["As such, HCWs are a priority group for preventive strategies such as influenza vaccination [25, 26].INTRODUCTIONAlthough various guidelines and policies for infection control measures are implemented in healthcare settings worldwide, the risk of transmission of infectious diseases while performing HRPs has not been well quantified.", [["influenza", "DISEASE", 69, 78], ["infection", "DISEASE", 157, 166], ["infectious diseases", "DISEASE", 262, 281], ["HRPs", "GENE_OR_GENE_PRODUCT", 299, 303], ["HRPs", "PROTEIN", 299, 303], ["preventive strategies", "TREATMENT", 39, 60], ["influenza vaccination", "TREATMENT", 69, 90], ["infection control measures", "TREATMENT", 157, 183], ["infectious diseases", "PROBLEM", 262, 281], ["infectious", "OBSERVATION", 262, 272]]], ["This study aims to describe the range of exposure to HRPs in HCWs and to quantify the risk of respiratory infections occurring in HCWs who perform HRPs.METHODSWe prospectively studied 481 hospital HCWs from wards including emergency and respiratory wards from nine hospitals in Beijing, China over a 5-week period from 1 December 2008 to 15 January 2009.", [["respiratory", "ANATOMY", 94, 105], ["HRPs", "CHEMICAL", 53, 57], ["respiratory infections", "DISEASE", 94, 116], ["HRPs", "SIMPLE_CHEMICAL", 53, 57], ["This study", "TEST", 0, 10], ["respiratory infections", "PROBLEM", 94, 116], ["HRPs", "TEST", 147, 151], ["respiratory", "ANATOMY", 94, 105], ["infections", "OBSERVATION", 106, 116]]], ["These 481 subjects were a control group in a larger study [27].METHODSThe hospital wards were selected as high-risk settings in which repeated and multiple exposures to respiratory infections are expected.", [["respiratory", "ANATOMY", 169, 180], ["respiratory infections", "DISEASE", 169, 191], ["a larger study", "TEST", 43, 57], ["respiratory infections", "PROBLEM", 169, 191], ["respiratory", "ANATOMY", 169, 180], ["infections", "OBSERVATION", 181, 191]]], ["Participants were hospital HCWs aged \u2a7e18 years and who were provided with written information about the study.", [["Participants", "SPECIES", 0, 12], ["the study", "TEST", 100, 109]]], ["Staff who agreed to participate provided informed consent and a copy of the information sheet with the participants' initials was retained as documentation [27].", [["participants", "SPECIES", 103, 115]]], ["The study protocol was approved by the Institutional Review Board and Human Research Ethics Committee of the Beijing Ministry for Health.METHODSParticipants were asked to record on a daily basis whether they had performed one of the following: provision of nebulizer medications, suctioning, intubation, aerosol-generating procedures and chest physiotherapy.", [["chest", "ANATOMY", 338, 343], ["Human", "ORGANISM", 70, 75], ["chest", "ORGANISM_SUBDIVISION", 338, 343], ["Human", "SPECIES", 70, 75], ["The study protocol", "TEST", 0, 18], ["nebulizer medications", "TREATMENT", 257, 278], ["suctioning", "TREATMENT", 280, 290], ["intubation", "TREATMENT", 292, 302], ["aerosol", "TREATMENT", 304, 311], ["generating procedures", "TREATMENT", 312, 333], ["chest physiotherapy", "TREATMENT", 338, 357], ["chest", "ANATOMY", 338, 343]]], ["The following information was also collected: number of hours worked, estimated number of daily contacts with patients, number of daily contacts with influenza-like illness (ILI) patients, and hand-washing adherence.", [["hand", "ANATOMY", 193, 197], ["influenza-like illness", "DISEASE", 150, 172], ["ILI", "DISEASE", 174, 177], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 179, 187], ["influenza", "PROBLEM", 150, 159], ["hand-washing adherence", "TREATMENT", 193, 215]]], ["The use of personal protective equipment such as gloves, gowns, eye shields, foot/hair covers was documented by study participants in a daily self-report diary, and details of clinical and demographics were also recorded.", [["eye", "ANATOMY", 64, 67], ["foot", "ANATOMY", 77, 81], ["hair", "ANATOMY", 82, 86], ["eye", "ORGANISM_SUBDIVISION", 64, 67], ["foot", "ORGANISM_SUBDIVISION", 77, 81], ["hair", "ORGANISM_SUBDIVISION", 82, 86], ["participants", "SPECIES", 118, 130], ["personal protective equipment", "TREATMENT", 11, 40], ["gloves", "TREATMENT", 49, 55], ["gowns", "TREATMENT", 57, 62], ["eye shields", "TREATMENT", 64, 75], ["foot/hair covers", "TREATMENT", 77, 93], ["eye", "ANATOMY", 64, 67], ["foot", "ANATOMY", 77, 81], ["hair", "ANATOMY", 82, 86]]], ["All study participants were followed up for a period of 31 days and monitored daily for the onset of respiratory symptoms.METHODSIf any symptom developed, combined nasal and throat swabs (double rayon-tipped, plastic-shafted swab) were taken and tested for respiratory viral or bacterial infection (Fig. 1).", [["respiratory", "ANATOMY", 101, 112], ["nasal", "ANATOMY", 164, 169], ["throat swabs", "ANATOMY", 174, 186], ["swab", "ANATOMY", 225, 229], ["respiratory symptoms", "DISEASE", 101, 121], ["respiratory viral or bacterial infection", "DISEASE", 257, 297], ["participants", "ORGANISM", 10, 22], ["nasal", "ORGANISM_SUBDIVISION", 164, 169], ["participants", "SPECIES", 10, 22], ["All study", "TEST", 0, 9], ["respiratory symptoms", "PROBLEM", 101, 121], ["any symptom", "PROBLEM", 132, 143], ["combined nasal and throat swabs", "PROBLEM", 155, 186], ["double rayon-tipped, plastic-shafted swab", "TREATMENT", 188, 229], ["respiratory viral or bacterial infection", "PROBLEM", 257, 297], ["respiratory", "ANATOMY", 101, 112], ["symptoms", "OBSERVATION", 113, 121], ["nasal", "ANATOMY", 164, 169], ["throat", "ANATOMY", 174, 180], ["bacterial", "OBSERVATION_MODIFIER", 278, 287], ["infection", "OBSERVATION", 288, 297]]], ["The nose and throat swabs were tested at the Laboratories of the Beijing Centres for Disease Control and Prevention.", [["nose", "ANATOMY", 4, 8], ["throat swabs", "ANATOMY", 13, 25], ["nose", "ORGANISM_SUBDIVISION", 4, 8], ["The nose and throat swabs", "TEST", 0, 25], ["Disease Control", "TREATMENT", 85, 100], ["nose", "ANATOMY", 4, 8], ["throat", "ANATOMY", 13, 19]]], ["Viral DNA\u2044RNA was extracted from 300\u03bcl of each respiratory specimen using the Viral Gene-spin\u2122 kit (iNtRON Biotechnology Inc., Korea) according to the manufacturer's instructions [27].", [["respiratory specimen", "ANATOMY", 47, 67], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["Viral DNA\u2044RNA", "RNA", 0, 13], ["Viral DNA\u2044RNA", "PROBLEM", 0, 13], ["each respiratory specimen", "TEST", 42, 67], ["the Viral Gene", "TREATMENT", 74, 88]]], ["We tested nose and throat swabs for the following: adenoviruses, human metapneumovirus (HMP), coronaviruses 229E/NL63 and OC43/HKU1, parainfluenza viruses 1, 2 and 3, influenza viruses A and B, respiratory syncytial virus (RSV) A and B, and rhinovirus A/B by nucleic acid testing using a commercial multiplex polymerase chain reaction (PCR), with the Seeplex\u00ae RV12 Detection kit (Seegen Inc., Korea).", [["nose", "ANATOMY", 10, 14], ["throat swabs", "ANATOMY", 19, 31], ["human metapneumovirus", "DISEASE", 65, 86], ["parainfluenza viruses", "DISEASE", 133, 154], ["influenza viruses", "DISEASE", 167, 184], ["respiratory syncytial virus", "DISEASE", 194, 221], ["nucleic acid", "CHEMICAL", 259, 271], ["nose", "ORGANISM_SUBDIVISION", 10, 14], ["throat swabs", "ORGANISM_SUBSTANCE", 19, 31], ["adenoviruses", "ORGANISM", 51, 63], ["human metapneumovirus", "ORGANISM", 65, 86], ["HMP", "CANCER", 88, 91], ["coronaviruses 229E/NL63", "ORGANISM", 94, 117], ["OC43", "GENE_OR_GENE_PRODUCT", 122, 126], ["HKU1", "GENE_OR_GENE_PRODUCT", 127, 131], ["parainfluenza viruses 1", "ORGANISM", 133, 156], ["2", "GENE_OR_GENE_PRODUCT", 158, 159], ["3", "GENE_OR_GENE_PRODUCT", 164, 165], ["influenza viruses A and B, respiratory syncytial virus", "ORGANISM", 167, 221], ["RSV", "ORGANISM", 223, 226], ["B", "GENE_OR_GENE_PRODUCT", 234, 235], ["rhinovirus A/B", "ORGANISM", 241, 255], ["human", "SPECIES", 65, 70], ["metapneumovirus", "SPECIES", 71, 86], ["parainfluenza", "SPECIES", 133, 146], ["respiratory syncytial virus (RSV", "SPECIES", 194, 226], ["human metapneumovirus", "SPECIES", 65, 86], ["respiratory syncytial virus", "SPECIES", 194, 221], ["RSV", "SPECIES", 223, 226], ["rhinovirus A/B", "SPECIES", 241, 255], ["throat swabs", "TEST", 19, 31], ["adenoviruses", "PROBLEM", 51, 63], ["human metapneumovirus", "PROBLEM", 65, 86], ["HMP", "TEST", 88, 91], ["coronaviruses", "TEST", 94, 107], ["NL63", "TEST", 113, 117], ["OC43", "TEST", 122, 126], ["HKU1", "TEST", 127, 131], ["parainfluenza viruses", "PROBLEM", 133, 154], ["influenza viruses A and B, respiratory syncytial virus", "PROBLEM", 167, 221], ["rhinovirus", "PROBLEM", 241, 251], ["nucleic acid testing", "TEST", 259, 279], ["a commercial multiplex polymerase chain reaction", "PROBLEM", 286, 334], ["PCR", "TEST", 336, 339], ["the Seeplex\u00ae", "TEST", 347, 359], ["nose", "ANATOMY", 10, 14], ["throat", "ANATOMY", 19, 25], ["parainfluenza viruses", "OBSERVATION", 133, 154], ["respiratory syncytial", "ANATOMY", 194, 215]]], ["We also tested for bacterial colonization.", [["bacterial colonization", "PROBLEM", 19, 41], ["bacterial", "OBSERVATION_MODIFIER", 19, 28], ["colonization", "OBSERVATION", 29, 41]]], ["A multiplex PCR (Seegen Inc.) was used to detect Streptococcus pneumoniae, Mycoplasma pneumoniae, B. pertussis, Legionella spp, Chlamydophilia and Haemophilus influenza type B. After preheating at 95 \u00b0C for 15 min, 40 amplification cycles were performed under the following conditions in a thermal cycler (GeneAmp PCR system 9700, Applied Biosystems, USA): 94\u00b0C for 30 s, 60\u00b0C for 1\u00b75 min, and 72\u00b0C for 1\u00b75 min.", [["Streptococcus pneumoniae", "DISEASE", 49, 73], ["Mycoplasma pneumoniae", "DISEASE", 75, 96], ["Legionella spp", "DISEASE", 112, 126], ["Haemophilus influenza type", "DISEASE", 147, 173], ["Streptococcus pneumoniae", "ORGANISM", 49, 73], ["Mycoplasma pneumoniae", "ORGANISM", 75, 96], ["B. pertussis", "ORGANISM", 98, 110], ["Legionella spp", "ORGANISM", 112, 126], ["Chlamydophilia", "ORGANISM", 128, 142], ["Haemophilus influenza type B.", "ORGANISM", 147, 176], ["Streptococcus pneumoniae", "SPECIES", 49, 73], ["Mycoplasma pneumoniae", "SPECIES", 75, 96], ["B. pertussis", "SPECIES", 98, 110], ["Legionella spp", "SPECIES", 112, 126], ["Haemophilus influenza", "SPECIES", 147, 168], ["Streptococcus pneumoniae", "SPECIES", 49, 73], ["Mycoplasma pneumoniae", "SPECIES", 75, 96], ["B. pertussis", "SPECIES", 98, 110], ["Legionella spp", "SPECIES", 112, 126], ["Haemophilus influenza type B.", "SPECIES", 147, 176], ["A multiplex PCR", "TEST", 0, 15], ["Streptococcus pneumoniae", "PROBLEM", 49, 73], ["Mycoplasma pneumoniae", "PROBLEM", 75, 96], ["B. pertussis", "PROBLEM", 98, 110], ["Legionella spp", "PROBLEM", 112, 126], ["Chlamydophilia", "PROBLEM", 128, 142], ["Haemophilus influenza type B.", "PROBLEM", 147, 176], ["a thermal cycler", "TREATMENT", 288, 304], ["Streptococcus pneumoniae", "OBSERVATION", 49, 73], ["Mycoplasma pneumoniae", "OBSERVATION", 75, 96], ["Haemophilus influenza", "OBSERVATION", 147, 168]]], ["The multiplex PCR products were visualized by electrophoresis on an ethidium bromide-stained 2% agarose gel.", [["ethidium bromide", "CHEMICAL", 68, 84], ["ethidium bromide", "CHEMICAL", 68, 84], ["ethidium bromide", "SIMPLE_CHEMICAL", 68, 84], ["agarose", "SIMPLE_CHEMICAL", 96, 103], ["The multiplex PCR products", "TREATMENT", 0, 26], ["electrophoresis", "TEST", 46, 61], ["an ethidium bromide", "TREATMENT", 65, 84], ["stained 2% agarose gel", "TREATMENT", 85, 107]]]], "de7f443485cd6fd6f7b640ded2c9a8203694eed3": [["Coronavirus disease 2019 (COVID-19) can progress to severe respiratory failure requiring intubation and mechanical ventilation, with a grim prognosis in this subset of patients [1] [2] [3] [4] .", [["respiratory", "ANATOMY", 59, 70], ["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["respiratory failure", "DISEASE", 59, 78], ["patients", "ORGANISM", 168, 176], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 177, 192], ["patients", "SPECIES", 168, 176], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["severe respiratory failure", "PROBLEM", 52, 78], ["intubation", "TREATMENT", 89, 99], ["mechanical ventilation", "TREATMENT", 104, 126], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["respiratory", "ANATOMY", 59, 70], ["failure", "OBSERVATION", 71, 78]]], ["Despite the perceived increased risk from aerosol-generating procedures, data from prior severe acute respiratory syndrome suggests no increased transmission from bronchoscopy [5] .", [["acute respiratory syndrome", "DISEASE", 96, 122], ["aerosol-generating procedures", "TREATMENT", 42, 71], ["prior severe acute respiratory syndrome", "PROBLEM", 83, 122], ["increased transmission", "PROBLEM", 135, 157], ["bronchoscopy", "TEST", 163, 175], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory syndrome", "OBSERVATION", 102, 122], ["no", "UNCERTAINTY", 132, 134], ["increased", "OBSERVATION_MODIFIER", 135, 144]]], ["There is a paucity of data regarding the actual risk and benefit of bronchoscopy for patients with COVID-19, leading to uncertainty regarding recommendations.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["bronchoscopy", "TEST", 68, 80], ["COVID", "TEST", 99, 104]]]], "f0cac80a7f161e02d317b22ec1d8ee5da127c80e": [["All of this leads to the question of where JGIM can have the most impact.", [["JGIM", "CHEMICAL", 43, 47]]], ["We have expedited some heartfelt pieces in healing arts and some perspectives which as always do not necessarily represent the opinions of the editors-in-chief-though we are not shy in sharing our opinions.", [["some heartfelt pieces", "TREATMENT", 18, 39], ["healing arts", "TREATMENT", 43, 55]]]], "PMC4522128": [["BackgroundPorcine epidemic diarrhea virus (PEDV) was first described in Europe in the 1970s with more recent and severe outbreaks in Asia [1, 2].", [["BackgroundPorcine epidemic diarrhea", "DISEASE", 0, 35], ["BackgroundPorcine epidemic diarrhea virus", "ORGANISM", 0, 41], ["BackgroundPorcine epidemic diarrhea virus", "SPECIES", 0, 41], ["BackgroundPorcine epidemic diarrhea virus", "SPECIES", 0, 41], ["PEDV", "SPECIES", 43, 47], ["BackgroundPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 0, 47], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["outbreaks", "OBSERVATION", 120, 129]]], ["The virus was identified in the United States in May 2013, causing severe diarrhea and vomiting in pigs across age groups, with high mortality of up to 90\u221295 % in suckling pigs [3].", [["diarrhea", "DISEASE", 74, 82], ["vomiting", "DISEASE", 87, 95], ["pigs", "ORGANISM", 99, 103], ["pigs", "ORGANISM", 172, 176], ["pigs", "SPECIES", 99, 103], ["pigs", "SPECIES", 172, 176], ["pigs", "SPECIES", 99, 103], ["pigs", "SPECIES", 172, 176], ["The virus", "PROBLEM", 0, 9], ["severe diarrhea", "PROBLEM", 67, 82], ["vomiting", "PROBLEM", 87, 95], ["virus", "OBSERVATION", 4, 9], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["diarrhea", "OBSERVATION", 74, 82]]], ["PEDV is an enveloped, single stranded RNA virus belonging to the Coronaviridae family.", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 65, 78], ["PEDV", "DNA", 0, 4], ["Coronaviridae family", "PROTEIN", 65, 85], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["single stranded RNA virus", "PROBLEM", 22, 47], ["enveloped", "OBSERVATION_MODIFIER", 11, 20]]], ["The coronaviruses taxonomically form a subfamily (Coronavirinae) within the order Nidovirales.", [["coronaviruses", "ORGANISM", 4, 17], ["Coronavirinae", "CANCER", 50, 63], ["coronaviruses", "OBSERVATION", 4, 17]]], ["Recently, the International Committee on Taxonomy of Viruses (ICTV) recognized four genera within the Coronavirinae subfamily: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus [4].", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 102, 115], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 127, 143], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 145, 160], ["Coronavirinae subfamily", "PROTEIN", 102, 125], ["ICTV", "SPECIES", 62, 66], ["Viruses (ICTV)", "TREATMENT", 53, 67], ["Alphacoronavirus", "PROBLEM", 127, 143], ["Betacoronavirus", "TREATMENT", 145, 160], ["Gammacoronavirus", "TREATMENT", 162, 178], ["Deltacoronavirus", "TREATMENT", 184, 200]]], ["PEDV belongs to the genus Alphacoronavirus along with other swine viruses including transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV).BackgroundThe genome is composed of a large ~28 Kb molecule consisting of a 5\u2032 untranslated region (UTR), a 3\u2032 UTR, and at least seven open reading frames (ORFs) encoding three nonstructural proteins: ORF1ab (pp1a and pp1ab) and ORF3, an accessory protein.", [["PEDV", "CHEMICAL", 0, 4], ["swine viruses", "DISEASE", 60, 73], ["transmissible gastroenteritis virus", "DISEASE", 84, 119], ["porcine respiratory coronavirus", "DISEASE", 131, 162], ["PRCV", "DISEASE", 164, 168], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 26, 42], ["swine viruses", "ORGANISM", 60, 73], ["transmissible gastroenteritis virus", "ORGANISM", 84, 119], ["TGEV", "ORGANISM", 121, 125], ["porcine respiratory coronavirus", "ORGANISM", 131, 162], ["PRCV", "CANCER", 164, 168], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 371, 377], ["pp1a", "GENE_OR_GENE_PRODUCT", 379, 383], ["pp1ab", "GENE_OR_GENE_PRODUCT", 388, 393], ["ORF3", "GENE_OR_GENE_PRODUCT", 399, 403], ["PEDV", "PROTEIN", 0, 4], ["5\u2032 untranslated region", "DNA", 246, 268], ["UTR", "DNA", 270, 273], ["UTR", "DNA", 281, 284], ["open reading frames", "DNA", 305, 324], ["ORFs", "DNA", 326, 330], ["nonstructural proteins", "PROTEIN", 347, 369], ["ORF1ab", "PROTEIN", 371, 377], ["pp1a", "PROTEIN", 379, 383], ["pp1ab", "PROTEIN", 388, 393], ["ORF3", "PROTEIN", 399, 403], ["accessory protein", "PROTEIN", 408, 425], ["swine", "SPECIES", 60, 65], ["transmissible gastroenteritis virus", "SPECIES", 84, 119], ["TGEV", "SPECIES", 121, 125], ["porcine respiratory coronavirus", "SPECIES", 131, 162], ["PEDV", "SPECIES", 0, 4], ["swine viruses", "SPECIES", 60, 73], ["transmissible gastroenteritis virus", "SPECIES", 84, 119], ["TGEV", "SPECIES", 121, 125], ["porcine respiratory coronavirus", "SPECIES", 131, 162], ["PRCV", "SPECIES", 164, 168], ["PEDV", "PROBLEM", 0, 4], ["other swine viruses", "PROBLEM", 54, 73], ["transmissible gastroenteritis virus", "PROBLEM", 84, 119], ["porcine respiratory coronavirus (PRCV", "TREATMENT", 131, 168], ["a large ~28 Kb molecule", "PROBLEM", 206, 229], ["a 5\u2032 untranslated region (UTR)", "PROBLEM", 244, 274], ["UTR", "PROBLEM", 281, 284], ["ORF1ab", "TEST", 371, 377], ["pp1a", "TEST", 379, 383], ["ORF3", "TEST", 399, 403], ["genus Alphacoronavirus", "ANATOMY", 20, 42], ["respiratory coronavirus", "OBSERVATION", 139, 162], ["genome", "OBSERVATION", 184, 190], ["large", "OBSERVATION_MODIFIER", 208, 213], ["28 Kb", "OBSERVATION_MODIFIER", 215, 220], ["accessory protein", "OBSERVATION", 408, 425]]], ["The four major structural proteins of the mature virion include the spike (S) glycoprotein (Mr 150\u2013220 kDa), the nucleoprotein (NP) (Mr 45\u201357 kDa) that is associated with the positive stranded RNA providing integral support for its helical structure, the glycosylated membrane protein (M) (Mr 20\u201330 kDa), and the glycosylated envelope protein (E) (Mr 7 kDa) [5\u20137].BackgroundCoronaviruses are taxonomically assigned to different genera based on their rooted phylogeny and calculated evolutionary distance for seven highly conserved genomic domains within ORF 1ab [8].", [["membrane", "ANATOMY", 268, 276], ["spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 68, 90], ["Mr 150\u2013220 kDa", "GENE_OR_GENE_PRODUCT", 92, 106], ["Mr 45\u201357 kDa", "GENE_OR_GENE_PRODUCT", 133, 145], ["membrane", "CELLULAR_COMPONENT", 268, 276], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 374, 387], ["structural proteins", "PROTEIN", 15, 34], ["mature virion", "PROTEIN", 42, 55], ["spike (S) glycoprotein", "PROTEIN", 68, 90], ["Mr 150\u2013220 kDa", "PROTEIN", 92, 106], ["nucleoprotein", "PROTEIN", 113, 126], ["NP", "PROTEIN", 128, 130], ["Mr 45\u201357 kDa", "PROTEIN", 133, 145], ["positive stranded RNA", "RNA", 175, 196], ["helical structure", "PROTEIN", 232, 249], ["glycosylated membrane protein", "PROTEIN", 255, 284], ["M", "PROTEIN", 286, 287], ["Mr 20\u201330 kDa", "PROTEIN", 290, 302], ["glycosylated envelope protein", "PROTEIN", 313, 342], ["E", "PROTEIN", 344, 345], ["Mr 7 kDa", "PROTEIN", 348, 356], ["genomic domains", "DNA", 531, 546], ["ORF 1", "DNA", 554, 559], ["the mature virion", "TREATMENT", 38, 55], ["glycoprotein (Mr", "TREATMENT", 78, 94], ["the nucleoprotein (NP) (Mr", "TREATMENT", 109, 135], ["the positive stranded RNA", "PROBLEM", 171, 196], ["integral support", "TREATMENT", 207, 223], ["the glycosylated membrane protein", "TEST", 251, 284], ["Mr", "TEST", 290, 292], ["the glycosylated envelope protein", "TEST", 309, 342], ["Mr", "TEST", 348, 350], ["BackgroundCoronaviruses", "PROBLEM", 364, 387], ["mature virion", "OBSERVATION", 42, 55], ["Coronaviruses", "OBSERVATION", 374, 387]]], ["The genetic diversity of coronaviruses may be due to their high frequency of recombination [9].", [["coronaviruses", "ORGANISM", 25, 38], ["coronaviruses", "PROBLEM", 25, 38], ["coronaviruses", "OBSERVATION", 25, 38]]], ["The heterogeneity among coronavirus subfamilies is well documented [7], and the factors that contribute to PEDV\u2019s ability to gain or lose parts of its transcriptome are believed to have contributed to quasispecies with novel traits that are able to adapt to new hosts, ecological niches and zoonotic events.", [["coronavirus", "ORGANISM", 24, 35], ["PEDV", "GENE_OR_GENE_PRODUCT", 107, 111], ["PEDV", "PROTEIN", 107, 111], ["PEDV", "SPECIES", 107, 111], ["The heterogeneity among coronavirus subfamilies", "PROBLEM", 0, 47], ["PEDV", "PROBLEM", 107, 111], ["quasispecies", "PROBLEM", 201, 213], ["novel traits", "PROBLEM", 219, 231], ["heterogeneity", "OBSERVATION_MODIFIER", 4, 17], ["coronavirus subfamilies", "OBSERVATION", 24, 47]]], ["The exact origin of PEDV in North America is not entirely clear, but there is evidence of genetic similarities to Chinese PEDV strains [10].BackgroundRecently, a novel NA PEDV recombinant strain was identified (S INDEL) containing both insertions and deletions within the N-terminal domain of the ORF 3 and S1 genes.", [["NA", "CHEMICAL", 168, 170], ["N", "CHEMICAL", 272, 273], ["PEDV", "GENE_OR_GENE_PRODUCT", 20, 24], ["ORF 3", "GENE_OR_GENE_PRODUCT", 297, 302], ["S1", "GENE_OR_GENE_PRODUCT", 307, 309], ["N-terminal domain", "DNA", 272, 289], ["ORF 3 and S1 genes", "DNA", 297, 315], ["Chinese PEDV", "SPECIES", 114, 126], ["PEDV", "PROBLEM", 20, 24], ["Chinese PEDV strains", "PROBLEM", 114, 134], ["a novel NA PEDV recombinant strain", "PROBLEM", 160, 194], ["S INDEL) containing both insertions and deletions", "PROBLEM", 211, 260], ["PEDV", "OBSERVATION", 20, 24], ["not entirely", "UNCERTAINTY", 45, 57], ["clear", "OBSERVATION", 58, 63], ["both", "OBSERVATION_MODIFIER", 231, 235], ["insertions", "OBSERVATION_MODIFIER", 236, 246], ["S1", "ANATOMY", 307, 309]]], ["Specifically, sequence alignment indicated spike gene nucleotide deletions at positions 164\u2013169 that correspond to amino acid deletions at positions 55 and 56 in addition to substitutions at positions 23 (I), 31 (H), 57 (K), and 59 (E) as compared to the CV777strain [10, 11].BackgroundThe relatedness of several PEDV strains circulating in China was evaluated by Li et al. [5] using phylogenic analysis of the NP gene and no insertions or deletions were noted.", [["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 54, 64], ["amino acid", "CHEMICAL", 115, 125], ["\u2013169", "AMINO_ACID", 91, 95], ["amino acid", "AMINO_ACID", 115, 125], ["PEDV", "GENE_OR_GENE_PRODUCT", 313, 317], ["NP gene", "DNA", 411, 418], ["PEDV", "SPECIES", 313, 317], ["sequence alignment", "TEST", 14, 32], ["spike gene nucleotide deletions", "PROBLEM", 43, 74], ["amino acid deletions", "TEST", 115, 135], ["K", "TEST", 221, 222], ["the CV777strain", "TEST", 251, 266], ["several PEDV strains", "PROBLEM", 305, 325], ["phylogenic analysis", "TEST", 384, 403], ["the NP gene", "TREATMENT", 407, 418], ["insertions", "PROBLEM", 426, 436], ["deletions", "PROBLEM", 440, 449], ["several", "OBSERVATION_MODIFIER", 305, 312], ["PEDV", "OBSERVATION_MODIFIER", 313, 317], ["strains", "OBSERVATION_MODIFIER", 318, 325]]], ["Sequence comparison with other European and Korean PEDV strains obtained from GenBank indicated that the NP genes were highly conserved (94.7\u221297.7 %) even though these strains originated from different geographic regions [5].", [["NP", "GENE_OR_GENE_PRODUCT", 105, 107], ["NP genes", "DNA", 105, 113], ["Korean PEDV strains", "TEST", 44, 63], ["the NP genes", "TEST", 101, 113], ["these strains", "PROBLEM", 162, 175]]], ["In addition to being highly conserved among PEDV variants, the NP is the most abundant viral protein expressed in PEDV infected cells [12, 13].", [["cells", "ANATOMY", 128, 133], ["PEDV", "GENE_OR_GENE_PRODUCT", 44, 48], ["NP", "GENE_OR_GENE_PRODUCT", 63, 65], ["PEDV", "CELL", 114, 118], ["cells", "CELL", 128, 133], ["PEDV variants", "DNA", 44, 57], ["NP", "DNA", 63, 65], ["viral protein", "PROTEIN", 87, 100], ["PEDV infected cells", "CELL_TYPE", 114, 133], ["PEDV", "SPECIES", 114, 118], ["PEDV variants", "PROBLEM", 44, 57], ["PEDV infected cells", "PROBLEM", 114, 133], ["infected cells", "OBSERVATION", 119, 133]]], ["In contrast, the spike protein is presented on the viral surface and subject to various host immune pressures, which predisposes it to a greater range of genetic heterogeneity including insertions and deletions.", [["surface", "ANATOMY", 57, 64], ["spike protein", "PROTEIN", 17, 30], ["the spike protein", "PROBLEM", 13, 30], ["genetic heterogeneity including insertions and deletions", "PROBLEM", 154, 210], ["viral surface", "OBSERVATION_MODIFIER", 51, 64], ["host immune pressures", "OBSERVATION", 88, 109], ["genetic heterogeneity", "OBSERVATION", 154, 175]]], ["Because the NP protein is highly abundant in virus infected cells, it provides an attractive target for the development of antigen-based serological assays.", [["cells", "ANATOMY", 60, 65], ["cells", "CELL", 60, 65], ["NP protein", "PROTEIN", 12, 22], ["virus infected cells", "CELL_TYPE", 45, 65], ["the NP protein", "TEST", 8, 22], ["virus infected cells", "PROBLEM", 45, 65], ["serological assays", "TEST", 137, 155], ["virus infected cells", "OBSERVATION", 45, 65]]], ["Taken together, this evidence provided rationale for using it as our antigen of choice for the iELISA, bELISA and FMIA.BackgroundIn response to the recent outbreaks of highly virulent PEDV in North America (NA), PCR assays were quickly developed to detect the presence of PEDV RNA in intestine or fecal material.", [["intestine", "ANATOMY", 284, 293], ["fecal material", "ANATOMY", 297, 311], ["PEDV", "CHEMICAL", 184, 188], ["PEDV", "GENE_OR_GENE_PRODUCT", 272, 276], ["intestine", "ORGAN", 284, 293], ["fecal material", "MULTI-TISSUE_STRUCTURE", 297, 311], ["PEDV RNA", "RNA", 272, 280], ["PEDV", "SPECIES", 184, 188], ["PEDV", "SPECIES", 272, 276], ["PCR assays", "TEST", 212, 222], ["PEDV RNA in intestine", "PROBLEM", 272, 293], ["fecal material", "PROBLEM", 297, 311], ["highly", "OBSERVATION_MODIFIER", 168, 174], ["virulent", "OBSERVATION_MODIFIER", 175, 183], ["PEDV", "OBSERVATION", 184, 188], ["PEDV", "OBSERVATION", 272, 276], ["intestine", "ANATOMY", 284, 293], ["fecal", "ANATOMY", 297, 302]]], ["These assays provide an important tool in control of the virus; however, well-validated, high-throughput assays to detect antibodies following infection would provide additional valuable diagnostic tools for the swine industry.", [["infection", "DISEASE", 143, 152], ["antibodies", "PROTEIN", 122, 132], ["swine", "SPECIES", 212, 217], ["These assays", "TEST", 0, 12], ["the virus", "PROBLEM", 53, 62], ["infection", "PROBLEM", 143, 152]]], ["The ability to detect and evaluate antibody responses using serologic tests is important in efforts to answer basic production related questions.", [["antibody responses", "TEST", 35, 53], ["serologic tests", "TEST", 60, 75]]], ["These questions may include whether a production site is na\u00efve or has historically experienced a PEDV exposure, even though a producer has not seen obvious clinical signs; the level of immune response sows may have in relation to vaccination, initial wild-type virus infection or intentional feedback exposure; and whether sow immunity is inadequate when clinical infection occurs in individual litters after initial PEDV exposure in a herd.BackgroundOne of the most pressing issues of PEDV disease is maintaining herd site biosecurity through exclusion measures to prevent viral entrance into swine units.", [["PEDV", "CHEMICAL", 97, 101], ["infection", "DISEASE", 267, 276], ["infection", "DISEASE", 364, 373], ["PEDV", "CHEMICAL", 417, 421], ["PEDV", "CHEMICAL", 486, 490], ["sows", "ORGANISM", 201, 205], ["wild-type virus", "ORGANISM", 251, 266], ["PEDV", "SPECIES", 417, 421], ["PEDV", "SPECIES", 486, 490], ["swine", "SPECIES", 594, 599], ["a production site", "PROBLEM", 36, 53], ["a PEDV exposure", "PROBLEM", 95, 110], ["obvious clinical signs", "PROBLEM", 148, 170], ["immune response", "PROBLEM", 185, 200], ["vaccination", "TREATMENT", 230, 241], ["type virus infection", "PROBLEM", 256, 276], ["intentional feedback exposure", "PROBLEM", 280, 309], ["clinical infection", "PROBLEM", 355, 373], ["initial PEDV exposure", "PROBLEM", 409, 430], ["PEDV disease", "PROBLEM", 486, 498], ["exclusion measures", "TREATMENT", 544, 562], ["viral entrance into swine units", "TREATMENT", 574, 605], ["PEDV", "OBSERVATION", 97, 101], ["PEDV disease", "OBSERVATION", 486, 498]]], ["However, PEDV infection may not always be obvious in finishing pigs so the widespread transport of these animals may represent additional risks.", [["infection", "DISEASE", 14, 23], ["pigs", "ORGANISM", 63, 67], ["pigs", "SPECIES", 63, 67], ["PEDV", "SPECIES", 9, 13], ["pigs", "SPECIES", 63, 67], ["PEDV infection", "PROBLEM", 9, 23], ["infection", "OBSERVATION", 14, 23], ["may not always be", "UNCERTAINTY", 24, 41]]], ["Thus, sensitive serological tests provide a valuable tool in the detection of recent infection to avoid the introduction of these animals into na\u00efve herds.BackgroundSince PEDV was widespread in Europe in the 1970s and 1990s and more recently in Asia, various serologic tests have been developed and subjected to varying degrees of validation [14\u201320].", [["infection", "DISEASE", 85, 94], ["sensitive serological tests", "TEST", 6, 33], ["recent infection", "PROBLEM", 78, 94], ["PEDV", "PROBLEM", 171, 175], ["various serologic tests", "TEST", 251, 274], ["validation", "TEST", 331, 341], ["infection", "OBSERVATION", 85, 94], ["widespread", "OBSERVATION_MODIFIER", 180, 190]]], ["However, few assays have been developed using antigens associated with contemporary strains currently circulating across NA.", [["NA", "MULTI-TISSUE_STRUCTURE", 121, 123], ["antigens", "PROTEIN", 46, 54], ["few assays", "TEST", 9, 19], ["contemporary strains", "PROBLEM", 71, 91]]], ["The need to develop more sensitive serological assays has become paramount in order to address questions regarding PEDV infections and epidemiological transmission patterns, as well as to analyze disease progression.BackgroundCurrently, serum virus neutralization (SVN) tests are the most widely employed serological assays used to detect PEDV antibodies.", [["serum", "ANATOMY", 237, 242], ["infections", "DISEASE", 120, 130], ["PEDV", "ORGANISM", 115, 119], ["serum", "ORGANISM_SUBSTANCE", 237, 242], ["virus", "ORGANISM", 243, 248], ["PEDV antibodies", "GENE_OR_GENE_PRODUCT", 339, 354], ["PEDV antibodies", "PROTEIN", 339, 354], ["PEDV", "SPECIES", 115, 119], ["PEDV", "SPECIES", 339, 343], ["sensitive serological assays", "TEST", 25, 53], ["PEDV infections", "PROBLEM", 115, 130], ["epidemiological transmission patterns", "TEST", 135, 172], ["disease progression", "PROBLEM", 196, 215], ["serum virus neutralization (SVN) tests", "TEST", 237, 275], ["serological assays", "TEST", 305, 323], ["PEDV antibodies", "PROBLEM", 339, 354]]], ["It is a test that is highly specific and useful for screening of antibody titer post vaccination [1, 16].", [["screening of antibody titer", "TEST", 52, 79]]], ["However, the test is expensive and labor intensive, requiring manual reading and interpretation of virus induced cytopathic effect (CPE) endpoints.", [["the test", "TEST", 9, 17], ["labor intensive", "PROBLEM", 35, 50], ["manual reading", "TEST", 62, 76], ["virus induced cytopathic effect (CPE) endpoints", "PROBLEM", 99, 146]]], ["Moreover, serum cytotoxicity can be mistaken for viral CPE, giving rise to false interpretations at lower serum dilutions.BackgroundSeveral laboratories have generated in-house indirect ELISAs using either virus derived antigen or recombinant structural proteins.", [["serum", "ANATOMY", 10, 15], ["serum", "ANATOMY", 106, 111], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["virus derived antigen", "PROTEIN", 206, 227], ["recombinant structural proteins", "PROTEIN", 231, 262], ["serum cytotoxicity", "TEST", 10, 28], ["viral CPE", "PROBLEM", 49, 58], ["false interpretations", "TEST", 75, 96], ["BackgroundSeveral laboratories", "TEST", 122, 152], ["recombinant structural proteins", "PROBLEM", 231, 262]]], ["Early indirect ELISAs were developed using Vero cell derived, whole virus preparations [15, 21] or Vero cell expressed viral proteins [16].", [["Vero cell", "ANATOMY", 43, 52], ["Vero cell", "ANATOMY", 99, 108], ["Vero cell", "CELL", 43, 52], ["Vero cell", "CELL", 99, 108], ["Vero cell", "CELL_LINE", 43, 52], ["Vero cell expressed viral proteins", "PROTEIN", 99, 133], ["Early indirect ELISAs", "TEST", 0, 21], ["Vero cell", "TREATMENT", 43, 52], ["whole virus preparations", "TREATMENT", 62, 86], ["Vero cell expressed viral proteins", "TEST", 99, 133]]], ["These methods may be problematic because serum from animals vaccinated with cell culture derived PEDV may cross-react with cellular components of ELISA antigen, causing low specificity and high background.", [["serum", "ANATOMY", 41, 46], ["cell", "ANATOMY", 76, 80], ["cellular", "ANATOMY", 123, 131], ["PEDV", "CHEMICAL", 97, 101], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["cell", "CELL", 76, 80], ["PEDV", "CELL", 97, 101], ["cellular", "CELL", 123, 131], ["ELISA antigen", "GENE_OR_GENE_PRODUCT", 146, 159], ["ELISA antigen", "PROTEIN", 146, 159], ["PEDV", "SPECIES", 97, 101], ["cell culture", "TEST", 76, 88], ["PEDV", "PROBLEM", 97, 101], ["ELISA antigen", "TEST", 146, 159], ["low specificity and high background", "PROBLEM", 169, 204], ["low specificity", "OBSERVATION_MODIFIER", 169, 184], ["high", "OBSERVATION_MODIFIER", 189, 193]]], ["Other groups have used recombinantly expressed, purified, structural S and NP proteins for iELISA serodiagnosis, but because low numbers of experimentally derived samples were used to evaluate the performance of the assay, full validation of the diagnostic sensitivities and specificities could not be assessed [19, 20].BackgroundBoth the iELISA and bELISA formats have proven useful for the serodiagnosis of experimental and natural infections.", [["samples", "ANATOMY", 163, 170], ["infections", "DISEASE", 434, 444], ["samples", "CANCER", 163, 170], ["recombinantly expressed, purified, structural S and NP proteins", "PROTEIN", 23, 86], ["iELISA", "DNA", 339, 345], ["iELISA serodiagnosis", "TEST", 91, 111], ["the assay", "TEST", 212, 221], ["the diagnostic sensitivities", "TEST", 242, 270], ["the serodiagnosis", "TEST", 388, 405], ["experimental and natural infections", "PROBLEM", 409, 444], ["natural", "OBSERVATION_MODIFIER", 426, 433], ["infections", "OBSERVATION", 434, 444]]], ["Blocking or competitive ELISAs have been shown to be especially useful where a higher level of specificity is required.", [["Blocking or competitive ELISAs", "PROBLEM", 0, 30]]], ["The increased specificity has been shown to be dependent on both the isotype and on the target specificity of the monoclonal or polyclonal antibodies [6, 17, 22].", [["monoclonal or polyclonal antibodies", "PROTEIN", 114, 149], ["The increased specificity", "PROBLEM", 0, 25], ["the monoclonal or polyclonal antibodies", "PROBLEM", 110, 149], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["dependent", "OBSERVATION_MODIFIER", 47, 56]]], ["Various laboratories have developed sensitive blocking ELISAs, and Carvajal et al. [17] demonstrated their bELISA was able to detect an antibody response 3 to 5 days earlier than IFA, which suggested higher sensitivity of the bELISA.", [["bELISA", "PROTEIN", 107, 113], ["Various laboratories", "TEST", 0, 20], ["blocking ELISAs", "TEST", 46, 61], ["an antibody response", "TEST", 133, 153], ["IFA", "TEST", 179, 182], ["higher sensitivity of the bELISA", "PROBLEM", 200, 232]]], ["In addition, the bELISA is valuable as a confirmatory test where unexpected positive results appear in presumably negative herds.BackgroundThe fluorescent microsphere immunoassay is based on fluidic, particle array technology (Luminex Corp., Austin, TX) and has become increasingly standardized and accepted in applications involving the serologic diagnosis of autoimmune and animal infectious diseases [23, 24].", [["autoimmune and animal infectious diseases", "DISEASE", 361, 402], ["bELISA", "DNA", 17, 23], ["a confirmatory test", "TEST", 39, 58], ["The fluorescent microsphere immunoassay", "TEST", 139, 178], ["TX", "TREATMENT", 250, 252], ["autoimmune", "PROBLEM", 361, 371], ["animal infectious diseases", "PROBLEM", 376, 402], ["infectious", "OBSERVATION_MODIFIER", 383, 393]]], ["There are distinct advantages of the FMIA over the ELISA, which include higher sensitivity, higher sample throughput analysis, and the ability to multiplex and monitor exposure to multiple pathogens simultaneously in a single sample.", [["FMIA", "SIMPLE_CHEMICAL", 37, 41], ["the ELISA", "TEST", 47, 56], ["higher sensitivity", "PROBLEM", 72, 90], ["higher sample throughput analysis", "TEST", 92, 125], ["multiplex", "TEST", 146, 155], ["multiple pathogens", "PROBLEM", 180, 198], ["a single sample", "TEST", 217, 232], ["distinct", "OBSERVATION_MODIFIER", 10, 18], ["advantages", "OBSERVATION_MODIFIER", 19, 29]]], ["In addition, multiple bead sets in the FMIA could be added to a standardized assay against newer virus subtypes that continue to emerge in the field or to assess antigenic/phylogenetic differences between genera of coronaviruses.BackgroundIn this study, we report the adaptation of a recombinant, highly purified, NA PEDV-NP antigen to the development of iELISA, bELISA and FMIA platforms for the detection of PEDV antibodies in serum.", [["serum", "ANATOMY", 429, 434], ["FMIA", "SIMPLE_CHEMICAL", 39, 43], ["coronaviruses", "ORGANISM", 215, 228], ["PEDV antibodies", "GENE_OR_GENE_PRODUCT", 410, 425], ["serum", "ORGANISM_SUBSTANCE", 429, 434], ["FMIA", "DNA", 39, 43], ["NA PEDV-NP antigen", "PROTEIN", 314, 332], ["PEDV antibodies", "PROTEIN", 410, 425], ["PEDV", "SPECIES", 410, 414], ["multiple bead sets", "TREATMENT", 13, 31], ["a standardized assay", "TEST", 62, 82], ["newer virus subtypes", "PROBLEM", 91, 111], ["antigenic/phylogenetic differences", "PROBLEM", 162, 196], ["coronaviruses", "PROBLEM", 215, 228], ["this study", "TEST", 242, 252], ["NA PEDV", "TEST", 314, 321], ["the detection", "TEST", 393, 406], ["PEDV antibodies in serum", "PROBLEM", 410, 434], ["multiple", "OBSERVATION_MODIFIER", 13, 21], ["bead", "OBSERVATION_MODIFIER", 22, 26]]], ["These assays provide high throughput serological tests designed to address PEDV disease diagnostics.", [["PEDV", "SPECIES", 75, 79], ["These assays", "TEST", 0, 12], ["serological tests", "TEST", 37, 54], ["PEDV disease diagnostics", "PROBLEM", 75, 99]]], ["They were fully validated using a large number of serum samples of known status, and validation of the tests was detailed using methods for the validation of serological assays for the diagnosis of infectious diseases previously described by Jacobson for the Office International des Epizooties [25].", [["serum samples", "ANATOMY", 50, 63], ["infectious diseases", "DISEASE", 198, 217], ["serum samples", "ORGANISM_SUBSTANCE", 50, 63], ["serum samples", "TEST", 50, 63], ["the tests", "TEST", 99, 108], ["serological assays", "TEST", 158, 176], ["infectious diseases", "PROBLEM", 198, 217], ["large", "OBSERVATION_MODIFIER", 34, 39], ["infectious", "OBSERVATION", 198, 208]]], ["In addition, a fluorescent focus neutralization (FFN) assay was developed for the rapid evaluation of neutralizing antibody responses.Animal samples for assay validation and time-course serological evaluation ::: Ethics Statement ::: MethodsFor time course studies, serum samples from experimentally infected animals were obtained courtesy of Dr. Richard Hesse (Kansas State University Veterinary Diagnostic Laboratory, National Pork Board Grant #13-228).", [["samples", "ANATOMY", 141, 148], ["serum samples", "ANATOMY", 266, 279], ["serum samples", "ORGANISM_SUBSTANCE", 266, 279], ["animals", "ORGANISM", 309, 316], ["a fluorescent focus neutralization (FFN) assay", "TEST", 13, 59], ["the rapid evaluation", "TEST", 78, 98], ["neutralizing antibody responses", "PROBLEM", 102, 133], ["Animal samples", "TEST", 134, 148], ["assay validation", "TEST", 153, 169], ["serological evaluation", "TEST", 186, 208], ["time course studies", "TEST", 245, 264], ["serum samples", "TEST", 266, 279]]], ["Thirty-three PEDV na\u00efve 3-week-old feeder pigs were obtained from a private, high-health status swine production farm. .", [["pigs", "ORGANISM", 42, 46], ["swine", "ORGANISM", 96, 101], ["pigs", "SPECIES", 42, 46], ["swine", "SPECIES", 96, 101], ["PEDV", "SPECIES", 13, 17], ["pigs", "SPECIES", 42, 46], ["swine", "SPECIES", 96, 101]]], ["Of the 33 pigs, 23 were inoculated with PEDV at 4 weeks of age via intranasal and oral routes with a pool of gut derived intestinal contents that had been used as \u201cfeedback\u201d inocula for controlled exposure of a sow herd.", [["oral", "ANATOMY", 82, 86], ["gut", "ANATOMY", 109, 112], ["intestinal", "ANATOMY", 121, 131], ["PEDV", "CHEMICAL", 40, 44], ["pigs", "ORGANISM", 10, 14], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["gut", "ORGANISM_SUBDIVISION", 109, 112], ["intestinal", "ORGAN", 121, 131], ["pigs", "SPECIES", 10, 14], ["pigs", "SPECIES", 10, 14], ["PEDV", "SPECIES", 40, 44], ["PEDV", "TREATMENT", 40, 44], ["intranasal", "TREATMENT", 67, 77], ["feedback\u201d inocula", "TREATMENT", 164, 181], ["intestinal", "ANATOMY", 121, 131]]], ["Serum was collected prior to challenge and at days 0, 6, 9, 14, 21, 28, 35 and 43 days post-infection (DPI).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5]]], ["Multiple aliquots of all samples collected were shared with requesting laboratories to expand diagnostic testing and vaccine development capabilities.Animal samples for assay validation and time-course serological evaluation ::: Ethics Statement ::: MethodsTo accurately assess the diagnostic sensitivity and specificity of the assays, samples of known serostatus for PEDV were used.", [["samples", "ANATOMY", 25, 32], ["samples", "ANATOMY", 157, 164], ["samples", "ANATOMY", 336, 343], ["PEDV", "ORGANISM", 368, 372], ["PEDV", "PROTEIN", 368, 372], ["PEDV", "SPECIES", 368, 372], ["all samples", "TEST", 21, 32], ["diagnostic testing", "TEST", 94, 112], ["Animal samples", "TEST", 150, 164], ["assay validation", "TEST", 169, 185], ["serological evaluation", "TEST", 202, 224], ["Methods", "TREATMENT", 250, 257], ["the diagnostic sensitivity", "TEST", 278, 304], ["the assays", "TEST", 324, 334], ["PEDV", "PROBLEM", 368, 372]]], ["This included sera from multiple animal populations including experimentally infected animals and serum samples from animals with known historical exposure to PEDV that were submitted to the South Dakota Animal Disease Research and Diagnostic Laboratory (ADRDL).", [["sera", "ANATOMY", 14, 18], ["serum samples", "ANATOMY", 98, 111], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["animals", "ORGANISM", 86, 93], ["serum samples", "ORGANISM_SUBSTANCE", 98, 111], ["PEDV", "SPECIES", 159, 163], ["multiple animal populations", "PROBLEM", 24, 51], ["experimentally infected animals", "PROBLEM", 62, 93], ["serum samples", "TEST", 98, 111], ["PEDV", "PROBLEM", 159, 163], ["infected", "OBSERVATION", 77, 85]]], ["PEDV negative sample sets included samples from PEDV negative control pigs used in experimental studies and selected high biosecurity herds with no history of PEDV.", [["samples", "ANATOMY", 35, 42], ["PEDV", "CHEMICAL", 159, 163], ["pigs", "ORGANISM", 70, 74], ["pigs", "SPECIES", 70, 74], ["pigs", "SPECIES", 70, 74], ["PEDV", "SPECIES", 159, 163], ["PEDV", "TEST", 0, 4], ["sample sets", "TEST", 14, 25], ["PEDV", "TEST", 48, 52], ["experimental studies", "TEST", 83, 103], ["PEDV", "PROBLEM", 159, 163], ["PEDV", "OBSERVATION", 159, 163]]], ["In addition, archived serum samples collected prior to the emergence of PEDV in the U.S., including samples testing positive for the related swine coronaviruses TGEV and PRCV (n= > 50), were used.", [["serum samples", "ANATOMY", 22, 35], ["samples", "ANATOMY", 100, 107], ["PEDV", "CHEMICAL", 72, 76], ["serum samples", "ORGANISM_SUBSTANCE", 22, 35], ["swine", "ORGANISM", 141, 146], ["coronaviruses", "ORGANISM", 147, 160], ["TGEV", "ORGANISM", 161, 165], ["swine coronaviruses TGEV", "SPECIES", 141, 165], ["PEDV", "SPECIES", 72, 76], ["swine coronaviruses TGEV", "SPECIES", 141, 165], ["archived serum samples", "TEST", 13, 35], ["PEDV", "PROBLEM", 72, 76], ["samples testing", "TEST", 100, 115], ["the related swine coronaviruses TGEV", "PROBLEM", 129, 165], ["PRCV", "TEST", 170, 174]]], ["The exact number of positive and negative sera used for sensitivity and specificity calculations per assay with statistical testing agreement calculations based on serum numbers is listed in Table 1.", [["sera", "ANATOMY", 42, 46], ["serum", "ANATOMY", 164, 169], ["sera", "ORGANISM_SUBSTANCE", 42, 46], ["serum", "ORGANISM_SUBSTANCE", 164, 169], ["sensitivity", "TEST", 56, 67], ["specificity calculations", "TEST", 72, 96], ["statistical testing agreement calculations", "TEST", 112, 154], ["serum numbers", "TEST", 164, 177]]], ["The majority of these sera were identical among assays, but limited serum volume did not allow for use of all sera samples among all assays.Antigen production, expression of recombinant PEDV-NP protein ::: Ethics Statement ::: MethodsThe development and validation of the iELISA and bELISA made use of a recombinantly expressed full length NA PEDV-NP.", [["sera", "ANATOMY", 22, 26], ["serum", "ANATOMY", 68, 73], ["sera samples", "ANATOMY", 110, 122], ["sera", "ORGANISM_SUBSTANCE", 22, 26], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["sera", "ORGANISM", 110, 114], ["PEDV-NP", "GENE_OR_GENE_PRODUCT", 186, 193], ["PEDV", "PROTEIN", 186, 190], ["NP protein", "PROTEIN", 191, 201], ["iELISA", "DNA", 272, 278], ["bELISA", "DNA", 283, 289], ["these sera", "TEST", 16, 26], ["limited serum volume", "PROBLEM", 60, 80], ["all sera samples", "TEST", 106, 122], ["Antigen production", "PROBLEM", 140, 158], ["Methods", "TREATMENT", 227, 234]]], ["The NP open reading frame (ORF) of PEDV was amplified from RNA extracted directly from intestinal contents by RT-PCR from a case submitted to the South Dakota ADRDL.", [["intestinal", "ANATOMY", 87, 97], ["PEDV", "GENE_OR_GENE_PRODUCT", 35, 39], ["intestinal", "ORGAN", 87, 97], ["NP open reading frame", "DNA", 4, 25], ["ORF", "DNA", 27, 30], ["PEDV", "DNA", 35, 39], ["PEDV", "SPECIES", 35, 39], ["The NP open", "TREATMENT", 0, 11], ["PEDV", "PROBLEM", 35, 39], ["intestinal", "ANATOMY", 87, 97]]], ["It was subsequently directionally cloned into the E. coli, pET 28a(+), plasmid expression vector (Novagen, Madison, WI), then transformed into BL21-Codon Plus (DE3)-RP competent cells (Stratagene, La Jolla, CA) for protein expression.", [["plasmid", "ANATOMY", 71, 78], ["cells", "ANATOMY", 178, 183], ["E. coli", "ORGANISM", 50, 57], ["pET 28a", "GENE_OR_GENE_PRODUCT", 59, 66], ["Novagen", "GENE_OR_GENE_PRODUCT", 98, 105], ["Madison", "GENE_OR_GENE_PRODUCT", 107, 114], ["WI", "GENE_OR_GENE_PRODUCT", 116, 118], ["BL21-Codon Plus", "GENE_OR_GENE_PRODUCT", 143, 158], ["cells", "CELL", 178, 183], ["CA", "GENE_OR_GENE_PRODUCT", 207, 209], ["pET 28a(+), plasmid expression vector", "DNA", 59, 96], ["Novagen", "DNA", 98, 105], ["BL21", "DNA", 143, 147], ["Codon Plus (DE3)-RP competent cells", "CELL_LINE", 148, 183], ["E. coli", "SPECIES", 50, 57], ["E. coli", "SPECIES", 50, 57], ["the E. coli", "TEST", 46, 57], ["pET", "TEST", 59, 62], ["plasmid expression vector", "TREATMENT", 71, 96], ["RP competent cells", "PROBLEM", 165, 183], ["Stratagene", "TEST", 185, 195], ["protein expression", "PROBLEM", 215, 233], ["E. coli", "OBSERVATION", 50, 57]]], ["Primers used for the amplification of the full length (1323 bp) nucleoprotein were: PEDV-NP-fwd (5\u2032-CGCGGATCCATGGCTTCTGTCAGTTTTCAG-3\u2032); PEDV-NP-rev (5\u2032- CACACTCGAGATTTCCTGTGTCGAAGATCTC-3\u2032).", [["PEDV", "PROTEIN", 84, 88], ["PEDV", "DNA", 136, 140], ["NP", "DNA", 141, 143], ["rev", "DNA", 144, 147], ["bp", "TEST", 60, 62], ["nucleoprotein", "TEST", 64, 77], ["PEDV", "TEST", 84, 88]]], ["Next, 20 \u03bcl of transformed cells were plated onto Luria-Bertani agar plates containing 50 \u03bcg of kanamycin/ml and incubated overnight.", [["cells", "ANATOMY", 27, 32], ["kanamycin", "CHEMICAL", 96, 105], ["kanamycin", "CHEMICAL", 96, 105], ["cells", "CELL", 27, 32], ["kanamycin", "SIMPLE_CHEMICAL", 96, 105], ["transformed cells", "CELL_LINE", 15, 32], ["transformed cells", "TREATMENT", 15, 32], ["Luria", "TEST", 50, 55], ["Bertani agar plates", "TREATMENT", 56, 75], ["kanamycin/ml", "TREATMENT", 96, 108]]], ["The following morning, colonies from the agar plates were added to 1 L of pre-warmed 2X yeast extract tryptone (YT) culture medium containing 50 \u03bcg kanamycin/ml and allowed to grow to an OD600 of 0.5 at 37 \u00b0C. PEDV-NP expression was induced using isopropyl \u03b2-D-1-thiogalactopyranoside (IPTG) at a final concentration of 1.0 mM to induce transcription of the Lac operon, and the E. coli was allowed to incubate for an additional 8 h at 37 \u00b0C with shaking at 200 RPM.", [["colonies", "ANATOMY", 23, 31], ["2X yeast extract tryptone", "CHEMICAL", 85, 110], ["kanamycin", "CHEMICAL", 148, 157], ["PEDV", "CHEMICAL", 210, 214], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 247, 284], ["IPTG", "CHEMICAL", 286, 290], ["kanamycin", "CHEMICAL", 148, 157], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 247, 284], ["IPTG", "CHEMICAL", 286, 290], ["kanamycin", "SIMPLE_CHEMICAL", 148, 157], ["isopropyl \u03b2-D-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 247, 284], ["IPTG", "SIMPLE_CHEMICAL", 286, 290], ["Lac", "GENE_OR_GENE_PRODUCT", 358, 361], ["E. coli", "ORGANISM", 378, 385], ["Lac operon", "DNA", 358, 368], ["yeast", "SPECIES", 88, 93], ["E. coli", "SPECIES", 378, 385], ["yeast", "SPECIES", 88, 93], ["PEDV", "SPECIES", 210, 214], ["E. coli", "SPECIES", 378, 385], ["the agar plates", "TEST", 37, 52], ["2X yeast extract tryptone", "TREATMENT", 85, 110], ["culture medium", "TEST", 116, 130], ["kanamycin", "TREATMENT", 148, 157], ["PEDV", "PROBLEM", 210, 214], ["isopropyl \u03b2-D-", "TREATMENT", 247, 261], ["thiogalactopyranoside (IPTG", "TREATMENT", 263, 290], ["the Lac operon", "TREATMENT", 354, 368], ["the E. coli", "PROBLEM", 374, 385], ["shaking", "PROBLEM", 446, 453]]], ["The agar was strained out and bacteria pelleted by centrifugation at 12,000 g for 10 min at 4 \u00b0C. The pellet was resuspended in 40 ml of lysis buffer solution (B-PER, Pierce, Rockford, IL), incubated for 15 min at 20\u201322 \u00b0C, then centrifuged at 12,000 g to separate the soluble from insoluble proteins.", [["pellet", "ANATOMY", 102, 108], ["insoluble proteins", "PROTEIN", 282, 300], ["bacteria", "PROBLEM", 30, 38], ["lysis buffer solution", "TREATMENT", 137, 158]]], ["The PEDV-NP recombinant protein was expressed as insoluble periplasmic inclusion bodies.", [["PEDV", "GENE_OR_GENE_PRODUCT", 4, 8], ["PEDV-NP recombinant protein", "PROTEIN", 4, 31], ["The PEDV", "TEST", 0, 8], ["NP recombinant protein", "TREATMENT", 9, 31], ["insoluble periplasmic inclusion bodies", "PROBLEM", 49, 87], ["inclusion bodies", "OBSERVATION", 71, 87]]], ["The resulting 441 amino acid recombinant protein was denatured using 8 M urea, subsequently purified three times using nickel-NTA affinity column chromatography and refolded back to its native conformational state.", [["amino acid", "CHEMICAL", 18, 28], ["urea", "CHEMICAL", 73, 77], ["nickel", "CHEMICAL", 119, 125], ["NTA", "CHEMICAL", 126, 129], ["amino acid", "CHEMICAL", 18, 28], ["urea", "CHEMICAL", 73, 77], ["nickel-NTA", "CHEMICAL", 119, 129], ["amino acid", "AMINO_ACID", 18, 28], ["urea", "SIMPLE_CHEMICAL", 73, 77], ["nickel-NTA", "SIMPLE_CHEMICAL", 119, 129], ["441 amino acid recombinant protein", "PROTEIN", 14, 48], ["amino acid recombinant protein", "TEST", 18, 48], ["8 M urea", "TREATMENT", 69, 77], ["nickel-NTA affinity column chromatography", "TREATMENT", 119, 160]]], ["Individual affinity column elutions were collected, pooled and confirmed by SDS-PAGE, then aliquoted/frozen at \u221280 \u00b0C. The correct nucleotide sequence was confirmed by sequence and restriction endonuclease analysis.", [["nucleotide", "CHEMICAL", 131, 141], ["Individual affinity column elutions", "PROBLEM", 0, 35], ["The correct nucleotide sequence", "TEST", 119, 150], ["restriction endonuclease analysis", "TEST", 181, 214], ["affinity column", "OBSERVATION", 11, 26]]], ["The average protein yield produced by the pET28a-PEDV-NP plasmid construct was calculated to be 11 mg PEDV-NP per liter of 2XYT under the aforementioned conditions.", [["PEDV-NP", "CHEMICAL", 102, 109], ["2XYT", "SIMPLE_CHEMICAL", 123, 127], ["pET28a-PEDV-NP plasmid construct", "DNA", 42, 74], ["the pET28a-PEDV", "TREATMENT", 38, 53], ["NP plasmid construct", "TREATMENT", 54, 74], ["2XYT", "TREATMENT", 123, 127]]], ["The recombinant protein was detected and a predicted molecular weight of 51 kDa was confirmed via Western Blotting using convalescent sera, a 6X histidine-specific mAb (Novagen, Madison, WI) and a PEDV-NP specific mAb (Figs.", [["sera", "ANATOMY", 134, 138], ["histidine", "CHEMICAL", 145, 154], ["histidine", "CHEMICAL", 145, 154], ["sera", "ORGANISM_SUBSTANCE", 134, 138], ["Novagen", "GENE_OR_GENE_PRODUCT", 169, 176], ["mAb", "GENE_OR_GENE_PRODUCT", 214, 217], ["recombinant protein", "PROTEIN", 4, 23], ["6X histidine-specific mAb", "PROTEIN", 142, 167], ["Novagen", "PROTEIN", 169, 176], ["PEDV", "PROTEIN", 197, 201], ["NP specific mAb", "PROTEIN", 202, 217], ["The recombinant protein", "TEST", 0, 23], ["convalescent sera", "TEST", 121, 138], ["a 6X histidine", "TREATMENT", 140, 154], ["a PEDV", "TREATMENT", 195, 201]]], ["1 and 2).mAb production and biotinylation ::: Ethics Statement ::: MethodsTwo separate mAbs were developed in our laboratory (SD6-29 and SD17-103) that recognize both the native conformation of the PEDV-NP and the full length, linear, recombinant protein used in all antibody capture assays.", [["mAb", "GENE_OR_GENE_PRODUCT", 9, 12], ["SD6-29", "CELL", 126, 132], ["SD17-103", "CELL", 137, 145], ["mAb", "PROTEIN", 9, 12], ["mAbs", "PROTEIN", 87, 91], ["PEDV", "PROTEIN", 198, 202], ["NP", "PROTEIN", 203, 205], ["recombinant protein", "PROTEIN", 235, 254], ["MethodsTwo separate mAbs", "TREATMENT", 67, 91], ["SD6", "TEST", 126, 129], ["SD17", "TEST", 137, 141], ["linear, recombinant protein", "TREATMENT", 227, 254], ["all antibody capture assays", "TEST", 263, 290], ["mAbs", "OBSERVATION", 87, 91], ["PEDV", "OBSERVATION", 198, 202]]], ["Hybridomas were produced as previously described [26, 27].", [["Hybridomas", "GENE_OR_GENE_PRODUCT", 0, 10], ["Hybridomas", "TEST", 0, 10]]], ["Immunoglobulin isotyping of the resulting mAbs was performed using a commercial lateral flow assay (Serotec, Raleigh, NC).", [["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 0, 14], ["mAbs", "PROTEIN", 42, 46], ["Immunoglobulin isotyping", "TREATMENT", 0, 24], ["a commercial lateral flow assay", "TEST", 67, 98]]], ["Subsequently, mouse ascites fluid was produced in pristane-primed mice, and the antibodies were purified and biotinylated for use as the detection moiety for the bELISA [23].", [["ascites fluid", "ANATOMY", 20, 33], ["ascites", "DISEASE", 20, 27], ["pristane", "CHEMICAL", 50, 58], ["pristane", "CHEMICAL", 50, 58], ["mouse", "ORGANISM", 14, 19], ["ascites fluid", "ORGANISM_SUBSTANCE", 20, 33], ["pristane", "SIMPLE_CHEMICAL", 50, 58], ["mice", "ORGANISM", 66, 70], ["antibodies", "PROTEIN", 80, 90], ["mouse", "SPECIES", 14, 19], ["mice", "SPECIES", 66, 70], ["mouse", "SPECIES", 14, 19], ["mice", "SPECIES", 66, 70], ["mouse ascites fluid", "PROBLEM", 14, 33], ["the antibodies", "TEST", 76, 90], ["the detection moiety", "TEST", 133, 153], ["the bELISA", "TEST", 158, 168], ["ascites", "OBSERVATION", 20, 27]]], ["The conjugated antibody solution was quantified via the Lowry protein method, and carrier BSA was added to a final concentration of 10 mg/ml, then aliquoted and stored at \u221220 \u00b0C.IFA ::: Ethics Statement ::: MethodsVero-76 cells (ATCC CRL-1587) were cultured with MEM + 10 % FBS for 48\u201372 h until fully confluent in 96-well plates, then washed twice with MEM.", [["MethodsVero-76 cells", "ANATOMY", 207, 227], ["ATCC CRL-1587", "ANATOMY", 229, 242], ["FBS", "ANATOMY", 274, 277], ["BSA", "CHEMICAL", 90, 93], ["CRL-1587", "CHEMICAL", 234, 242], ["MEM", "CHEMICAL", 263, 266], ["BSA", "SIMPLE_CHEMICAL", 90, 93], ["MethodsVero-76 cells", "CELL", 207, 227], ["ATCC CRL-1587", "CELL", 229, 242], ["FBS", "ORGANISM_SUBSTANCE", 274, 277], ["MethodsVero-76 cells", "CELL_LINE", 207, 227], ["ATCC CRL-1587", "SPECIES", 229, 242], ["The conjugated antibody solution", "TREATMENT", 0, 32], ["the Lowry protein method", "TREATMENT", 52, 76], ["carrier BSA", "TREATMENT", 82, 93], ["MethodsVero", "TEST", 207, 218], ["ATCC CRL", "TEST", 229, 237], ["conjugated antibody", "OBSERVATION", 4, 23], ["confluent", "OBSERVATION_MODIFIER", 302, 311]]], ["Subsequently, alternating rows of 96-well plates were inoculated with the cell culture adapted PEDV NVSL-CO strain of PEDV (PEDV USA/Colorado/2013, GenBank accession number KF272920) at a multiplicity of infection (MOI) of 0.05 with MEM supplemented with 1.5 \u03bcg/ml trypsin (TPCK treated, bovine derived (Sigma, St. Louis, MO)).", [["cell", "ANATOMY", 74, 78], ["PEDV", "CHEMICAL", 118, 122], ["infection", "DISEASE", 204, 213], ["MEM", "CHEMICAL", 233, 236], ["TPCK", "CHEMICAL", 274, 278], ["TPCK", "CHEMICAL", 274, 278], ["cell", "CELL", 74, 78], ["PEDV", "ORGANISM", 95, 99], ["PEDV", "ORGANISM", 118, 122], ["trypsin", "GENE_OR_GENE_PRODUCT", 265, 272], ["TPCK", "SIMPLE_CHEMICAL", 274, 278], ["bovine", "ORGANISM", 288, 294], ["St. Louis, MO", "ORGANISM", 311, 324], ["trypsin", "PROTEIN", 265, 272], ["bovine", "SPECIES", 288, 294], ["PEDV", "SPECIES", 118, 122], ["PEDV", "SPECIES", 124, 128], ["alternating rows", "TEST", 14, 30], ["the cell culture", "TEST", 70, 86], ["PEDV", "TEST", 95, 99], ["PEDV", "PROBLEM", 118, 122], ["infection", "PROBLEM", 204, 213], ["TPCK", "TREATMENT", 274, 278], ["infection", "OBSERVATION", 204, 213]]], ["After incubation at 37 \u00b0C for 20\u201324 h, monolayers were fixed with 80 % acetone for 20 min.", [["monolayers", "ANATOMY", 39, 49], ["acetone", "CHEMICAL", 71, 78], ["acetone", "CHEMICAL", 71, 78], ["monolayers", "CELL", 39, 49], ["acetone", "SIMPLE_CHEMICAL", 71, 78], ["80 % acetone", "TREATMENT", 66, 78]]], ["Serum samples were initially serially diluted from 1:40 to 1:320 with PBS in duplicate wells, and 100 \u03bcls of the diluted serum were added to each well.", [["Serum samples", "ANATOMY", 0, 13], ["serum", "ANATOMY", 121, 126], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["Serum samples", "TEST", 0, 13], ["PBS", "TEST", 70, 73], ["the diluted serum", "TEST", 109, 126]]], ["The plates were incubated at 37 \u00b0C for 1 h and then rinsed 3X with PBS.", [["PBS", "TREATMENT", 67, 70], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["Next, fluorescein isothiocyanate (FITC)-conjugated goat anti-swine IgG (KPL, West Chester, PA) was prepared at a dilution of 1:15 with PBS and 50 \u03bcl added to each well.", [["fluorescein isothiocyanate", "CHEMICAL", 6, 32], ["fluorescein isothiocyanate", "CHEMICAL", 6, 32], ["FITC", "CHEMICAL", 34, 38], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 6, 32], ["FITC", "SIMPLE_CHEMICAL", 34, 38], ["goat", "ORGANISM", 51, 55], ["anti-swine IgG", "SIMPLE_CHEMICAL", 56, 70], ["KPL", "SIMPLE_CHEMICAL", 72, 75], ["goat anti-swine IgG", "PROTEIN", 51, 70], ["goat", "SPECIES", 51, 55], ["goat", "SPECIES", 51, 55], ["fluorescein isothiocyanate (FITC)", "TREATMENT", 6, 39], ["PBS", "TREATMENT", 135, 138]]], ["After 1 h of incubation at 37 \u00b0C, plates were rinsed 3X with PBS and examined using fluorescent microscopy.", [["incubation", "TREATMENT", 13, 23], ["PBS", "TREATMENT", 61, 64], ["fluorescent microscopy", "TEST", 84, 106]]], ["For each individual test, each PEDV infected well was compared to its respective uninfected partner well, and a positive sample was indicated if a PEDV specific fluorescent signal was observed at a serum dilution of 1:40 or greater.", [["sample", "ANATOMY", 121, 127], ["serum", "ANATOMY", 198, 203], ["PEDV", "ORGANISM", 31, 35], ["PEDV", "SIMPLE_CHEMICAL", 147, 151], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["PEDV", "SPECIES", 31, 35], ["PEDV", "SPECIES", 147, 151], ["each individual test", "TEST", 4, 24], ["each PEDV infected", "PROBLEM", 26, 44], ["a positive sample", "PROBLEM", 110, 127], ["a PEDV specific fluorescent signal", "PROBLEM", 145, 179], ["a serum dilution", "TEST", 196, 212]]], ["All samples were tested in duplicate, and the antibody titer was expressed as the mean of all replicates.iELISA ::: Ethics Statement ::: MethodsThe serological PEDV-NP indirect ELISA was performed by coating alternate wells of Immulon 1B, 96-well, microtiter plates (Thermo Labsystems, Franklin, MA) with 250 ng/well of purified, recombinantly expressed PEDV-NP antigen.", [["samples", "ANATOMY", 4, 11], ["PEDV-NP antigen", "GENE_OR_GENE_PRODUCT", 354, 369], ["PEDV", "PROTEIN", 354, 358], ["NP antigen", "PROTEIN", 359, 369], ["All samples", "TEST", 0, 11], ["the antibody titer", "TEST", 42, 60], ["Methods", "TREATMENT", 137, 144], ["The serological PEDV", "TEST", 144, 164], ["Immulon", "TEST", 227, 234], ["microtiter plates", "TEST", 248, 265], ["PEDV", "OBSERVATION", 354, 358]]], ["The optimal dilution of the recombinant protein and secondary detection antibody was determined by a checkerboard titration that gave the highest signal to noise ratio.", [["recombinant protein", "PROTEIN", 28, 47], ["secondary detection antibody", "PROTEIN", 52, 80], ["the recombinant protein", "TEST", 24, 47], ["secondary detection antibody", "TEST", 52, 80], ["a checkerboard titration", "TEST", 99, 123]]], ["In addition, a single lot of pooled convalescent serum from PEDV infected pigs was used to generate quality control standards that gave high and low optical density (high OD = 2.0 to 2.5; low OD = 0.5 to 1.0; and negative OD < 0.2).", [["serum", "ANATOMY", 49, 54], ["convalescent", "ORGANISM", 36, 48], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["pigs", "ORGANISM", 74, 78], ["pigs", "SPECIES", 74, 78], ["PEDV", "SPECIES", 60, 64], ["pigs", "SPECIES", 74, 78], ["pooled convalescent serum", "PROBLEM", 29, 54], ["PEDV infected pigs", "TREATMENT", 60, 78], ["high and low optical density", "PROBLEM", 136, 164], ["high", "OBSERVATION_MODIFIER", 136, 140], ["low optical density", "OBSERVATION_MODIFIER", 145, 164]]], ["PEDV-NP recombinant protein was diluted to 2.5 \u03bcg/ml in 15 mM sodium carbonate-35 mM sodium bicarbonate- antigen coating buffer (ACB) pH 9.6.", [["PEDV", "CHEMICAL", 0, 4], ["sodium carbonate", "CHEMICAL", 62, 78], ["sodium bicarbonate", "CHEMICAL", 85, 103], ["sodium carbonate", "CHEMICAL", 62, 78], ["sodium bicarbonate", "CHEMICAL", 85, 103], ["sodium carbonate", "SIMPLE_CHEMICAL", 62, 78], ["sodium bicarbonate- antigen", "SIMPLE_CHEMICAL", 85, 112], ["PEDV-NP recombinant protein", "PROTEIN", 0, 27], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["NP recombinant protein", "TREATMENT", 5, 27], ["15 mM sodium carbonate", "TREATMENT", 56, 78], ["35 mM sodium bicarbonate", "TREATMENT", 79, 103], ["antigen coating buffer", "TREATMENT", 105, 127], ["pH", "TEST", 134, 136]]], ["Odd-numbered columns were coated with 100 \u03bcl of ACB plus antigen, while the even-numbered columns were coated with ACB without antigen, serving as background control.", [["ACB", "SIMPLE_CHEMICAL", 48, 51], ["ACB", "SIMPLE_CHEMICAL", 115, 118], ["ACB", "PROTEIN", 48, 51], ["ACB", "PROTEIN", 115, 118], ["Odd-numbered columns", "PROBLEM", 0, 20], ["ACB plus antigen", "TREATMENT", 48, 64]]], ["The plates were incubated for one hour at 37 \u00b0C, then washed 3X with PBS plus 0.05 % tween20 (PBST).", [["PBS", "TREATMENT", 69, 72], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["Each well was then blocked with 200 \u03bcl of sample milk diluent (PBST plus 5 % nonfat dry milk, (SMD)) and allowed to incubate overnight at 4 \u00b0C. The following day, the plates were washed 3X with 300 \u03bcl of PBST.", [["sample milk", "ANATOMY", 42, 53], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["milk", "ORGANISM_SUBSTANCE", 88, 92], ["sample milk diluent", "TREATMENT", 42, 61], ["the plates", "TREATMENT", 163, 173], ["PBST", "TREATMENT", 204, 208]]], ["Test and control sera were diluted 1/50 in SMD, mixed, and 100 \u03bcl of the solution was added to each well.", [["sera", "ANATOMY", 17, 21], ["sera", "ORGANISM_SUBSTANCE", 17, 21], ["Test", "TEST", 0, 4], ["the solution", "TREATMENT", 69, 81]]], ["The plates were incubated for 1 h at 20\u201322 \u00b0C. Next, 100 \u03bcl of biotinylated, goat anti-swine detection antibody (Bethyl Laboratories, TX) was added at a concentration of 200 ng/ml of PBST and allowed to incubate at 20\u201322 \u00b0C for 1 h.", [["goat", "ORGANISM", 77, 81], ["TX", "SIMPLE_CHEMICAL", 134, 136], ["goat anti-swine detection antibody", "PROTEIN", 77, 111], ["goat", "SPECIES", 77, 81], ["goat", "SPECIES", 77, 81], ["TX)", "TREATMENT", 134, 137], ["PBST", "TREATMENT", 183, 187], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The plate was washed 3X with 300 \u03bcl of PBST, then 100 \u03bcl of streptavidin-HRP conjugate (Pierce, Rockford, IL) was added and incubated for another hour at 20\u201322 \u00b0C, then washed and developed with 3,3\u2032,5,5\u2032- tetramethylbenzidine, peroxidase substrate (TMB) (Surmodics, Eden Prairie, MN).", [["3,3\u2032,5,5\u2032- tetramethylbenzidine", "CHEMICAL", 195, 226], ["3,3\u2032,5,5\u2032- tetramethylbenzidine", "CHEMICAL", 195, 226], ["TMB", "CHEMICAL", 250, 253], ["streptavidin-HRP conjugate", "SIMPLE_CHEMICAL", 60, 86], ["Pierce", "SIMPLE_CHEMICAL", 88, 94], ["IL", "GENE_OR_GENE_PRODUCT", 106, 108], ["3,3\u2032,5,5\u2032- tetramethylbenzidine", "SIMPLE_CHEMICAL", 195, 226], ["peroxidase substrate", "SIMPLE_CHEMICAL", 228, 248], ["TMB", "SIMPLE_CHEMICAL", 250, 253], ["HRP conjugate", "PROTEIN", 73, 86], ["The plate", "TREATMENT", 0, 9], ["PBST", "TREATMENT", 39, 43], ["streptavidin-HRP conjugate (Pierce, Rockford, IL)", "TREATMENT", 60, 109], ["tetramethylbenzidine", "TREATMENT", 206, 226], ["peroxidase substrate", "TREATMENT", 228, 248], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["Color development progressed until the positive control attained a standard OD and was stopped using 2 N H2SO4.", [["N H2SO4", "CHEMICAL", 103, 110], ["H2SO4", "CHEMICAL", 105, 110], ["a standard OD", "TREATMENT", 65, 78], ["2 N H2SO4", "TREATMENT", 101, 110], ["progressed", "OBSERVATION_MODIFIER", 18, 28]]], ["Colorimetric development was quantified spectrophotometrically at 450 nm with a ELx800 microplate reader (BioTek Instruments Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories, Westbrook, ME).", [["a ELx800 microplate reader (BioTek Instruments", "TREATMENT", 78, 124]]], ["The raw data was normalized and transformed into an Excel spreadsheet.", [["The raw data", "TEST", 0, 12]]], ["Sample to Positive (S/P) ratios were calculated using the following formula: S/P = optical density (OD) of sample - OD of buffer/OD of positive control - OD of buffer.bELISA ::: Ethics Statement ::: MethodsThe serological bELISA was performed using Immulon 1B, 96-well microtiter plates (Thermo Labsystems, Franklin, MA).", [["Sample", "TEST", 0, 6], ["ratios", "TEST", 25, 31], ["sample", "TEST", 107, 113], ["buffer", "TREATMENT", 122, 128], ["positive control", "TREATMENT", 135, 151], ["Methods", "TREATMENT", 199, 206], ["The serological bELISA", "TEST", 206, 228], ["Immulon", "TEST", 249, 256]]], ["Alternate wells of each plate were coated with 500 ng per well of expressed PEDV-NP antigen.", [["PEDV-NP antigen", "GENE_OR_GENE_PRODUCT", 76, 91], ["PEDV", "PROTEIN", 76, 80], ["NP antigen", "PROTEIN", 81, 91], ["Alternate wells of each plate", "TREATMENT", 0, 29]]], ["The optimal dilution of the recombinant protein and mAb antibody was determined by a checkerboard titration that gave the highest signal to noise ratio with an OD reading of approximately 2.0, in the absence of swine serum/competitor antibody.", [["serum", "ANATOMY", 217, 222], ["mAb antibody", "GENE_OR_GENE_PRODUCT", 52, 64], ["swine", "ORGANISM", 211, 216], ["serum", "ORGANISM_SUBSTANCE", 217, 222], ["recombinant protein", "PROTEIN", 28, 47], ["mAb antibody", "PROTEIN", 52, 64], ["swine serum/competitor antibody", "PROTEIN", 211, 242], ["swine", "SPECIES", 211, 216], ["swine", "SPECIES", 211, 216], ["the recombinant protein", "TEST", 24, 47], ["mAb antibody", "TEST", 52, 64], ["a checkerboard titration", "TEST", 83, 107], ["an OD reading", "TEST", 157, 170], ["swine serum/competitor antibody", "TEST", 211, 242]]], ["First, PEDV-NP recombinant protein was diluted to 2.5 \u03bcg/ml of ACB.", [["PEDV", "GENE_OR_GENE_PRODUCT", 7, 11], ["PEDV", "PROTEIN", 7, 11], ["NP recombinant protein", "PROTEIN", 12, 34], ["NP recombinant protein", "TREATMENT", 12, 34], ["ACB", "TREATMENT", 63, 66]]], ["Odd-numbered columns were coated with 100 \u03bcl of ACB plus antigen, while the even-numbered columns were coated with ACB without antigen serving as background control.", [["ACB", "SIMPLE_CHEMICAL", 48, 51], ["ACB", "SIMPLE_CHEMICAL", 115, 118], ["ACB", "PROTEIN", 48, 51], ["ACB", "PROTEIN", 115, 118], ["Odd-numbered columns", "PROBLEM", 0, 20], ["ACB plus antigen", "TREATMENT", 48, 64], ["ACB", "TREATMENT", 115, 118]]], ["The plates were incubated for 1 h at 37 \u00b0C, washed 3 times with PBST, then placed at 4 \u00b0C overnight.", [["PBST", "TREATMENT", 64, 68]]], ["The following day, each well was blocked with 300 \u03bcl of SMD and incubated one hour at 37 \u00b0C. Plates were washed 3 times with PBST, and 100 \u03bcl of test and control sera were diluted 1/3 with PBST + 0.1 % nonfat dry milk and added to each of the duplicate wells.", [["sera", "ANATOMY", 162, 166], ["milk", "ANATOMY", 213, 217], ["sera", "ORGANISM_SUBSTANCE", 162, 166], ["milk", "ORGANISM_SUBSTANCE", 213, 217], ["Plates", "TEST", 93, 99], ["PBST", "TEST", 125, 129], ["test", "TEST", 145, 149], ["control sera", "TEST", 154, 166], ["PBST", "TEST", 189, 193]]], ["Plates were incubated 1 h at 37 \u00b0C. During sample incubation, PEDV-NP specific biotinylated, mAbs (SD6-29 and SD17-103) were adjusted to equal titers and mixed together in a 1:1 ratio.", [["sample", "ANATOMY", 43, 49], ["PEDV", "CHEMICAL", 62, 66], ["PEDV", "SIMPLE_CHEMICAL", 62, 66], ["PEDV", "PROTEIN", 62, 66], ["mAbs", "PROTEIN", 93, 97], ["SD6", "PROTEIN", 99, 102], ["SD17", "PROTEIN", 110, 114], ["PEDV", "SPECIES", 62, 66], ["sample incubation", "TEST", 43, 60], ["PEDV", "TEST", 62, 66], ["mAbs", "TEST", 93, 97], ["SD6", "TEST", 99, 102], ["SD17", "TEST", 110, 114]]], ["Next, 100 \u03bcl of a 1:40,000 dilution of the antibody detection mixture was added to the microtiter plate containing the competitive swine antibody, then swirled and incubated for an additional 30 min at 37 \u00b0C. The plates were washed 3 times, and 100 \u03bcl of high sensitivity, streptavidin-horseradish peroxidase conjugate (Pierce, Rockford, IL) was added to all wells of the microtiter plate for 1 h at 37 \u00b0C.bELISA ::: Ethics Statement ::: MethodsPlates were washed 4 times with PBST, and 100 \u03bcl of TMB was added to all wells and gently swirled.", [["TMB", "CHEMICAL", 497, 500], ["TMB", "CHEMICAL", 497, 500], ["swine", "ORGANISM", 131, 136], ["streptavidin", "SIMPLE_CHEMICAL", 273, 285], ["horseradish peroxidase conjugate", "SIMPLE_CHEMICAL", 286, 318], ["Pierce", "SIMPLE_CHEMICAL", 320, 326], ["IL", "GENE_OR_GENE_PRODUCT", 338, 340], ["MethodsPlates", "SIMPLE_CHEMICAL", 438, 451], ["TMB", "SIMPLE_CHEMICAL", 497, 500], ["competitive swine antibody", "PROTEIN", 119, 145], ["horseradish peroxidase conjugate", "PROTEIN", 286, 318], ["swine", "SPECIES", 131, 136], ["horseradish", "SPECIES", 286, 297], ["swine", "SPECIES", 131, 136], ["a 1:40,000 dilution", "TREATMENT", 16, 35], ["the antibody detection mixture", "TREATMENT", 39, 69], ["the microtiter plate", "TREATMENT", 83, 103], ["The plates", "TREATMENT", 209, 219], ["high sensitivity", "PROBLEM", 255, 271], ["streptavidin-horseradish peroxidase conjugate (Pierce, Rockford, IL)", "TREATMENT", 273, 341], ["the microtiter plate", "TREATMENT", 368, 388], ["MethodsPlates", "TREATMENT", 438, 451], ["PBST", "TREATMENT", 477, 481], ["TMB", "TREATMENT", 497, 500]]], ["After approximately15 min, color development progressed until the negative control attained a standard OD of approximately 2.0 and was subsequently stopped using 2 N H2SO4.", [["N H2SO4", "CHEMICAL", 164, 171], ["H2SO4", "CHEMICAL", 166, 171], ["2 N H2SO4", "TREATMENT", 162, 171], ["progressed", "OBSERVATION_MODIFIER", 45, 55]]], ["Colorimetric development was quantified spectrophotometrically at 450 nm with an ELx800 microplate reader (BioTek Instruments Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories, Westbrook, ME).", [["an ELx800 microplate reader (BioTek Instruments", "TREATMENT", 78, 125]]], ["The raw data was normalized and transformed into a Excel spreadsheet, and the percent inhibition (PI) ratio was calculated using the following formula: PI = 1-{(OD of sample - OD of buffer)/(OD of negative control \u2013 OD of buffer)} X 100.Preparation of PEDV-NP coupled microspheres for the FMIA ::: Ethics Statement ::: MethodsA two-step carbodiimide coupling procedure was used to couple NA PEDV-NP protein to Luminex\u2122 microspheres.", [["carbodiimide", "CHEMICAL", 337, 349], ["carbodiimide", "CHEMICAL", 337, 349], ["PEDV", "SIMPLE_CHEMICAL", 252, 256], ["carbodiimide", "SIMPLE_CHEMICAL", 337, 349], ["Luminex\u2122 microspheres", "SIMPLE_CHEMICAL", 410, 431], ["NA PEDV-NP protein", "PROTEIN", 388, 406], ["The raw data", "TEST", 0, 12], ["the percent inhibition (PI) ratio", "TREATMENT", 74, 107], ["PI", "TEST", 152, 154], ["sample", "TEST", 167, 173], ["MethodsA two-step carbodiimide coupling procedure", "TREATMENT", 319, 368], ["NP protein to Luminex\u2122 microspheres", "TREATMENT", 396, 431]]], ["Briefly, the coupling of fluorescent microsphere was performed by washing 3.125 \u00d7 106 microspheres twice with 250 \u03bcl activation buffer (0.1MNaH2PO4, pH6.2) and sonicating them for 60 s after each wash.", [["MNaH2PO4", "CHEMICAL", 139, 147], ["MNaH2PO4", "SIMPLE_CHEMICAL", 139, 147], ["fluorescent microsphere", "TEST", 25, 48]]], ["Microspheres were activated for 20 min at 20\u201322 \u00b0C in 500 \u03bcl activation buffer containing 2.5 mg N-hydroxysulfosuccinimide (sulfo-NHS) and 2.5 mg N-(3- dimethylaminopropyl)-N-ethylcarbodiimide (EDC) (Pierce Chemical, Rockford, IL).", [["N-hydroxysulfosuccinimide", "CHEMICAL", 97, 122], ["sulfo-NHS", "CHEMICAL", 124, 133], ["N-(3- dimethylaminopropyl)-N-ethylcarbodiimide", "CHEMICAL", 146, 192], ["EDC", "CHEMICAL", 194, 197], ["N-hydroxysulfosuccinimide", "CHEMICAL", 97, 122], ["sulfo-NHS", "CHEMICAL", 124, 133], ["N-(3- dimethylaminopropyl)-N-ethylcarbodiimide", "CHEMICAL", 146, 192], ["EDC", "CHEMICAL", 194, 197], ["Microspheres", "SIMPLE_CHEMICAL", 0, 12], ["N-hydroxysulfosuccinimide", "SIMPLE_CHEMICAL", 97, 122], ["sulfo-NHS", "SIMPLE_CHEMICAL", 124, 133], ["N-(3- dimethylaminopropyl)-N-ethylcarbodiimide", "SIMPLE_CHEMICAL", 146, 192], ["EDC", "SIMPLE_CHEMICAL", 194, 197], ["Microspheres", "TREATMENT", 0, 12], ["N-hydroxysulfosuccinimide (sulfo-NHS)", "TREATMENT", 97, 134], ["N-ethylcarbodiimide (EDC)", "TREATMENT", 173, 198]]], ["Activated microspheres were washed twice with PBS and sonicated.", [["Activated microspheres", "TREATMENT", 0, 22], ["PBS", "TREATMENT", 46, 49]]], ["Coupling was initiated by the addition of 12.5 \u03bcg of recombinant NA PEDV-NP protein, brought to a final volume of 500 \u03bcl with PBS and incubated in the dark for 3 h at 20\u201322 \u00b0C with rotation.", [["NA", "CHEMICAL", 65, 67], ["recombinant NA PEDV-NP protein", "PROTEIN", 53, 83], ["recombinant NA PEDV", "TREATMENT", 53, 72], ["PBS", "TREATMENT", 126, 129]]], ["Coupled microspheres were washed once with 1 ml of PBS plus 0.05 % NaN3 and 1.0 % bovine serum albumin (PBS-NB).", [["serum", "ANATOMY", 89, 94], ["NaN3", "CHEMICAL", 67, 71], ["NaN3", "CHEMICAL", 67, 71], ["NaN3", "SIMPLE_CHEMICAL", 67, 71], ["bovine", "ORGANISM", 82, 88], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["albumin", "GENE_OR_GENE_PRODUCT", 95, 102], ["PBS-NB", "SIMPLE_CHEMICAL", 104, 110], ["bovine", "SPECIES", 82, 88], ["bovine", "SPECIES", 82, 88], ["Coupled microspheres", "TREATMENT", 0, 20], ["PBS", "TREATMENT", 51, 54], ["0.05 % NaN3", "TREATMENT", 60, 71], ["serum albumin", "TEST", 89, 102], ["PBS", "TEST", 104, 107]]], ["Next, the microspheres were blocked with 1 ml of PBS-NB for 30 min to reduce nonspecific binding.", [["PBS-NB", "SIMPLE_CHEMICAL", 49, 55], ["the microspheres", "TREATMENT", 6, 22], ["PBS-NB", "TREATMENT", 49, 55], ["nonspecific binding", "PROBLEM", 77, 96], ["nonspecific binding", "OBSERVATION", 77, 96]]], ["Microspheres were then washed twice with PBS-NB and resuspended in PBS-NB to a final concentration of 2.0 \u00d7 106 antigen-coupled microspheres/ml.FMIA ::: Ethics Statement ::: MethodsA 96-well hydrophilic membrane filter plate was blocked for 2 min with 150 \u03bcl of PBS-NB, and then the liquid was aspirated via vacuum manifold.", [["NB", "ANATOMY", 71, 73], ["Microspheres", "ORGANISM_SUBSTANCE", 0, 12], ["PBS-NB", "SIMPLE_CHEMICAL", 67, 73], ["Microspheres", "TREATMENT", 0, 12], ["PBS-NB", "TREATMENT", 41, 47], ["MethodsA", "TEST", 174, 182], ["well hydrophilic membrane filter plate", "TREATMENT", 186, 224], ["PBS", "TREATMENT", 262, 265], ["NB", "TREATMENT", 266, 268]]], ["The plates were wetted with 20 \u03bcl of PBS-NB buffer to prevent drying.", [["The plates", "TREATMENT", 0, 10], ["PBS", "TREATMENT", 37, 40], ["NB buffer", "TREATMENT", 41, 50], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["Next, 50 \u03bcl of serum (diluted 1:50 in PBS-NB) was added to duplicate wells of the filter plate along with 50 \u03bcl of PBS-NB containing 2.5 \u00d7 103 antigen-coupled microspheres.", [["serum", "ANATOMY", 15, 20], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["PBS-NB", "SIMPLE_CHEMICAL", 38, 44], ["PBS-NB", "SIMPLE_CHEMICAL", 115, 121], ["PBS-NB)", "TREATMENT", 38, 45], ["the filter plate", "TREATMENT", 78, 94], ["PBS-NB", "TREATMENT", 115, 121], ["filter", "OBSERVATION", 82, 88]]], ["Since the microspheres and reporter moieties are light sensitive, all incubations were performed in the dark by sealing the plate with foil.", [["the microspheres and reporter moieties", "TEST", 6, 44], ["all incubations", "TEST", 66, 81]]], ["Subsequently, the FMIA plate was incubated at 20\u201322 \u00b0C for 1 h on a plate shaker rotating at 600 rpm.", [["the FMIA plate", "TREATMENT", 14, 28], ["a plate shaker rotating", "TREATMENT", 66, 89]]], ["The plate was washed 3 times with 200 \u03bcl of PBST.", [["The plate", "TREATMENT", 0, 9], ["PBST", "TREATMENT", 44, 48], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["Next, 50 \u03bcl of anti-swine, biotinylated IgA (heavy & light chain, diluted in PBS-NB; Bethyl Laboratories) or IgG-FC specific polyclonal antibodies (diluted 1:2,000 dilution in PBS-NB; Bethyl Laboratories) were added to the filter plate and incubated at 20\u201322 \u00b0C for 1 h.", [["anti-swine", "ANATOMY", 15, 25], ["anti-swine", "SIMPLE_CHEMICAL", 15, 25], ["IgA", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgG-FC", "SIMPLE_CHEMICAL", 109, 115], ["anti-swine", "PROTEIN", 15, 25], ["biotinylated IgA", "PROTEIN", 27, 43], ["heavy & light chain", "PROTEIN", 45, 64], ["IgG", "PROTEIN", 109, 112], ["FC specific polyclonal antibodies", "PROTEIN", 113, 146], ["anti-swine", "TREATMENT", 15, 25], ["biotinylated IgA (heavy & light chain", "TREATMENT", 27, 64], ["PBS", "TEST", 77, 80], ["Bethyl Laboratories", "TEST", 85, 104], ["IgG", "TEST", 109, 112], ["polyclonal antibodies", "TEST", 125, 146], ["the filter plate", "TREATMENT", 219, 235]]], ["NP IgM and IgG isotype-specific antibody levels were detected using PEDV-NP coated microspheres, but speciated by means of individual and separate IgM and IgG-specific secondary antibodies.", [["NP IgM", "GENE_OR_GENE_PRODUCT", 0, 6], ["IgG", "GENE_OR_GENE_PRODUCT", 11, 14], ["IgM", "GENE_OR_GENE_PRODUCT", 147, 150], ["IgG", "GENE_OR_GENE_PRODUCT", 155, 158], ["IgM", "PROTEIN", 3, 6], ["IgG isotype-specific antibody", "PROTEIN", 11, 40], ["IgM", "PROTEIN", 147, 150], ["IgG", "PROTEIN", 155, 158], ["secondary antibodies", "PROTEIN", 168, 188], ["NP IgM", "TEST", 0, 6], ["IgG isotype-specific antibody levels", "TEST", 11, 47], ["PEDV-NP coated microspheres", "TREATMENT", 68, 95], ["separate IgM", "TEST", 138, 150], ["IgG", "TEST", 155, 158], ["secondary antibodies", "OBSERVATION", 168, 188]]], ["Since validation was performed using serum, and because IgA is present in very low amounts, IgA specific secondary antibodies were not used at this step.", [["serum", "ANATOMY", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["IgA", "GENE_OR_GENE_PRODUCT", 56, 59], ["IgA", "GENE_OR_GENE_PRODUCT", 92, 95], ["IgA", "PROTEIN", 56, 59], ["IgA", "PROTEIN", 92, 95], ["secondary antibodies", "PROTEIN", 105, 125], ["serum", "TEST", 37, 42], ["IgA", "TEST", 56, 59], ["very low amounts", "PROBLEM", 74, 90], ["IgA specific secondary antibodies", "PROBLEM", 92, 125]]], ["After incubation with the secondary antibodies, 50 \u03bcl of streptavidin phycoerythrin (2.5 \u03bcg/ml in PBS-NB, Molecular Probes) was added to each well and incubated for 30 min at 20\u201322 \u00b0C with shaking.", [["streptavidin phycoerythrin", "CHEMICAL", 57, 83], ["streptavidin phycoerythrin", "SIMPLE_CHEMICAL", 57, 83], ["secondary antibodies", "PROTEIN", 26, 46], ["streptavidin phycoerythrin", "PROTEIN", 57, 83], ["the secondary antibodies", "TREATMENT", 22, 46], ["streptavidin phycoerythrin", "TREATMENT", 57, 83], ["Molecular Probes", "TREATMENT", 106, 122], ["shaking", "PROBLEM", 189, 196]]], ["The supernatant was aspirated, and the plate was washed 3 times with PBST.", [["supernatant", "ANATOMY", 4, 15], ["the plate", "TREATMENT", 35, 44], ["PBST", "TREATMENT", 69, 73], ["aspirated", "OBSERVATION", 20, 29]]], ["Finally, the microspheres were resuspended in 125 \u03bcl of PBST per well and transferred to a clear 96-well polystyrene optical plate.", [["polystyrene", "CHEMICAL", 105, 116], ["the microspheres", "TREATMENT", 9, 25]]], ["Coupled microspheres were analyzed through a dual-laser Bio-Rad Bio-Plex 200 instrument.", [["Coupled microspheres", "TREATMENT", 0, 20], ["a dual-laser Bio-Rad Bio", "TREATMENT", 43, 67]]], ["The median fluorescent intensity (MFI) for 100 microspheres corresponding to each individual bead analyte was recorded for each well.", [["each individual bead analyte", "TREATMENT", 77, 105]]], ["All reported MFI measurements were normalized via F - F0, where F0 was the background signal determined from the fluorescence measurement of a test sample in uncoated beads and F was the MFI for a serological test sample using antigen-coated beads.Establishment of serological reference standards for ELISA and FMIA development ::: Ethics Statement ::: MethodsFour serological reference serum sets were constructed as standards termed high, medium, low and negative to serve as internal quality control standards and to mathematically normalize individual samples for objective comparisons between testing platforms.", [["sample", "ANATOMY", 148, 154], ["sample", "ANATOMY", 214, 220], ["serum", "ANATOMY", 387, 392], ["serum", "ORGANISM_SUBSTANCE", 387, 392], ["MFI measurements", "TEST", 13, 29], ["the fluorescence measurement", "TEST", 109, 137], ["a test sample", "TEST", 141, 154], ["a serological test sample", "TEST", 195, 220], ["antigen-coated beads", "TREATMENT", 227, 247], ["ELISA", "TEST", 301, 306], ["Methods", "TEST", 353, 360], ["Four serological reference serum sets", "TEST", 360, 397], ["objective comparisons", "TEST", 568, 589], ["testing platforms", "TEST", 598, 615]]], ["The high-labeled standard was designed to generate an OD above 2.0 for the iELISA and bELISA and an MFI of approximately 25,000 for the FMIA.", [["an MFI", "TEST", 97, 103], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["The high standard was used exclusively for the mathematical determination of the serological response (S/P ratio) of samples used for test validation.", [["samples", "ANATOMY", 117, 124], ["the serological response", "PROBLEM", 77, 101], ["test validation", "TEST", 134, 149], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["The medium standard generated a response of between 1.5 and 2.0 OD for the two ELISAs and approximately 10,000 MFI for the FMIA.", [["the two ELISAs", "TEST", 71, 85], ["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["The low standard was designed to deliver a signal slightly above threshold level for all 3 tests, and the negative serum generated an OD or MFI to a background level of less than 0.2 OD for the ELISAs and 600 MFI for the FMIA.Validation methods for the determination of diagnostic sensitivity, specificity, repeatability and threshold cutoff level ::: Ethics Statement ::: MethodsTo accurately assess the diagnostic sensitivity and specificity of the assays, samples of known serostatus for PEDV were used.", [["serum", "ANATOMY", 115, 120], ["samples", "ANATOMY", 459, 466], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["PEDV", "ORGANISM", 491, 495], ["PEDV", "PROTEIN", 491, 495], ["PEDV", "SPECIES", 491, 495], ["all 3 tests", "TEST", 85, 96], ["the ELISAs", "TEST", 190, 200], ["diagnostic sensitivity", "TEST", 270, 292], ["specificity", "TEST", 294, 305], ["repeatability", "TEST", 307, 320], ["threshold cutoff level", "TEST", 325, 347], ["Methods", "TREATMENT", 373, 380], ["the diagnostic sensitivity", "TEST", 401, 427], ["the assays", "TEST", 447, 457], ["PEDV", "PROBLEM", 491, 495], ["low standard", "OBSERVATION_MODIFIER", 4, 16]]], ["This included sera from multiple animal populations including experimentally infected animals and serum samples submitted to the South Dakota ADRDL.", [["sera", "ANATOMY", 14, 18], ["serum samples", "ANATOMY", 98, 111], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["animals", "ORGANISM", 86, 93], ["serum samples", "ORGANISM_SUBSTANCE", 98, 111], ["multiple animal populations", "PROBLEM", 24, 51], ["experimentally infected animals", "PROBLEM", 62, 93], ["serum samples", "TEST", 98, 111]]], ["PEDV negative sample sets included samples from selected high biosecurity herds with no history of PEDV and archived serum samples collected prior to the emergence of PEDV in the U.S., including samples testing positive for the related swine coronaviruses TGEV and PRCV.", [["samples", "ANATOMY", 35, 42], ["serum samples", "ANATOMY", 117, 130], ["samples", "ANATOMY", 195, 202], ["PEDV", "CHEMICAL", 167, 171], ["serum samples", "ORGANISM_SUBSTANCE", 117, 130], ["swine", "ORGANISM", 236, 241], ["coronaviruses", "ORGANISM", 242, 255], ["TGEV", "ORGANISM", 256, 260], ["PRCV", "CANCER", 265, 269], ["swine", "SPECIES", 236, 241], ["TGEV", "SPECIES", 256, 260], ["PEDV", "SPECIES", 99, 103], ["PEDV", "SPECIES", 167, 171], ["swine coronaviruses TGEV", "SPECIES", 236, 260], ["PRCV", "SPECIES", 265, 269], ["PEDV", "TEST", 0, 4], ["sample sets", "TEST", 14, 25], ["samples", "TEST", 35, 42], ["PEDV", "PROBLEM", 99, 103], ["archived serum samples", "TEST", 108, 130], ["PEDV", "PROBLEM", 167, 171], ["samples testing", "TEST", 195, 210], ["the related swine coronaviruses TGEV", "PROBLEM", 224, 260], ["PRCV", "TREATMENT", 265, 269], ["coronaviruses TGEV", "OBSERVATION", 242, 260]]], ["Known positive samples were collected from pigs that were naturally infected at least 3 weeks prior to collection and were previously positive by PCR.", [["samples", "ANATOMY", 15, 22], ["pigs", "ORGANISM", 43, 47], ["pigs", "SPECIES", 43, 47], ["pigs", "SPECIES", 43, 47], ["Known positive samples", "PROBLEM", 0, 22], ["collection", "TEST", 103, 113], ["PCR", "TEST", 146, 149], ["positive", "OBSERVATION_MODIFIER", 6, 14], ["samples", "OBSERVATION", 15, 22]]], ["The negative-testing sample population (uninfected animals) consisted of maximally 980 PEDV negative serum samples, while the positive-testing (infected) population was composed of 516 serum samples.", [["serum samples", "ANATOMY", 101, 114], ["serum samples", "ANATOMY", 185, 198], ["serum samples", "ORGANISM_SUBSTANCE", 101, 114], ["serum samples", "ORGANISM_SUBSTANCE", 185, 198], ["PEDV", "SPECIES", 87, 91], ["serum samples", "TEST", 101, 114], ["serum samples", "TEST", 185, 198]]], ["Receiver operating characteristic (ROC) analysis was calculated for each assay to assess diagnostic performance, which included determination of sensitivity, specificity and threshold cutoff using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium).Validation methods for the determination of diagnostic sensitivity, specificity, repeatability and threshold cutoff level ::: Ethics Statement ::: MethodsThe repeatability of each assay was assessed by running the same internal quality control serum standards in multiple replicates within the same run or between runs.", [["serum", "ANATOMY", 506, 511], ["serum", "ORGANISM_SUBSTANCE", 506, 511], ["ROC) analysis", "TEST", 35, 48], ["each assay", "TEST", 68, 78], ["diagnostic performance", "TEST", 89, 111], ["sensitivity", "TEST", 145, 156], ["specificity", "TEST", 158, 169], ["threshold cutoff", "TEST", 174, 190], ["MedCalc version", "TEST", 197, 212], ["diagnostic sensitivity", "TEST", 306, 328], ["specificity", "TEST", 330, 341], ["repeatability", "TEST", 343, 356], ["threshold cutoff level", "TEST", 361, 383], ["Methods", "TREATMENT", 409, 416], ["each assay", "TEST", 437, 447]]], ["For the iELISA and the bELISA, the intra-assay repeatability was calculated for 48 replicates on 3 separate plates, then repeated over a 3-day period for inter-assay repeatability assessment.", [["the intra-assay repeatability", "TEST", 31, 60], ["inter-assay repeatability assessment", "TEST", 154, 190]]], ["The values for each assay were expressed as a mean, standard deviation and percent coefficient of variation (CV%) for repeated measure.Measurement of statistical testing agreement ::: Ethics Statement ::: MethodsMultiple comparison, inter-rater agreement (kappa measure of association) was calculated among all four tests (bELISA, iELISA, FMIA and IFA) using IBM, SPSS version 20 software (SPSS Inc., Chicago, IL).", [["The values", "TEST", 0, 10], ["each assay", "TEST", 15, 25], ["standard deviation and percent coefficient of variation", "PROBLEM", 52, 107], ["four tests", "TEST", 311, 321], ["bELISA", "TEST", 323, 329], ["iELISA", "TEST", 331, 337], ["IBM", "TEST", 359, 362], ["SPSS version", "TEST", 364, 376]]], ["The sample cohort used was a well-characterized set of serum samples collected from \u201cpositive testing\u201d experimentally infected pigs over time courtesy of Dr. Richard Hesse (n = 158) and from archived experimental control uninfected PEDV \u201cnegative testing\u201d animals.", [["serum samples", "ANATOMY", 55, 68], ["serum samples", "ORGANISM_SUBSTANCE", 55, 68], ["pigs", "ORGANISM", 127, 131], ["pigs", "SPECIES", 127, 131], ["pigs", "SPECIES", 127, 131], ["PEDV", "SPECIES", 232, 236], ["serum samples", "TEST", 55, 68]]], ["The interpretation of kappa can be rated as follows: Kappa less than 0.0, \u201cpoor\u201d agreement; between 0.0 and 0.20, \u201cslight\u201d agreement; between 0.21 and 0.40, \u201cfair\u201d agreement; between 0.41 and 0.60, \u201cmoderate\u201d agreement; between 0.61 and 0.80, \u201csubstantial\u201d agreement; and between 0.81 and 1.0, \u201calmost perfect\u201d agreement [28, 29].FFN ::: Ethics Statement ::: MethodsA PEDV virus neutralization assay using a FFN format was developed for rapid detection of neutralizing antibodies produced in response to PEDV infection.", [["infection", "DISEASE", 509, 518], ["PEDV", "ORGANISM", 504, 508], ["neutralizing antibodies", "PROTEIN", 456, 479], ["PEDV virus", "SPECIES", 368, 378], ["PEDV", "SPECIES", 504, 508], ["Kappa", "TEST", 53, 58], ["MethodsA PEDV virus neutralization assay", "TEST", 359, 399], ["a FFN format", "TEST", 406, 418], ["rapid detection", "TEST", 437, 452], ["neutralizing antibodies", "PROBLEM", 456, 479], ["PEDV infection", "PROBLEM", 504, 518], ["PEDV infection", "OBSERVATION", 504, 518]]], ["The FFN was evaluated using serum samples or rennet treated milk and colostrum samples.", [["serum samples", "ANATOMY", 28, 41], ["rennet", "ANATOMY", 45, 51], ["milk", "ANATOMY", 60, 64], ["colostrum samples", "ANATOMY", 69, 86], ["FFN", "SIMPLE_CHEMICAL", 4, 7], ["serum samples", "ORGANISM_SUBSTANCE", 28, 41], ["rennet", "SIMPLE_CHEMICAL", 45, 51], ["milk", "ORGANISM_SUBSTANCE", 60, 64], ["colostrum samples", "ORGANISM_SUBSTANCE", 69, 86], ["The FFN", "TEST", 0, 7], ["serum samples", "TEST", 28, 41], ["colostrum samples", "TEST", 69, 86]]], ["Heat-inactivated samples were diluted in a 2-fold dilution series starting at 1:10 in MEM plus 1.5 \u03bcg/ml TPCK-treated trypsin in 96-well plates.", [["samples", "ANATOMY", 17, 24], ["MEM", "CHEMICAL", 86, 89], ["TPCK", "CHEMICAL", 105, 109], ["TPCK", "CHEMICAL", 105, 109], ["samples", "CANCER", 17, 24], ["TPCK", "SIMPLE_CHEMICAL", 105, 109], ["trypsin", "SIMPLE_CHEMICAL", 118, 125], ["trypsin", "PROTEIN", 118, 125], ["Heat-inactivated samples", "TREATMENT", 0, 24], ["a 2-fold dilution series", "TREATMENT", 41, 65], ["TPCK", "TEST", 105, 109], ["trypsin", "TEST", 118, 125]]], ["An equal amount of cell culture adapted PEDV stock at a concentration of 100 foci forming units/100 \u03bcl was added to each well and plates incubated for 1 h at 37 \u00b0C. The virus/sample mixture was then added to washed confluent monolayers of Vero-76 cells and incubated for 2 h at 37 \u00b0C. Plates were washed again with MEM/TPCK-trypsin medium and incubated 20\u201324 h to allow for replication of non-neutralized virus.", [["cell", "ANATOMY", 19, 23], ["foci", "ANATOMY", 77, 81], ["sample", "ANATOMY", 175, 181], ["monolayers", "ANATOMY", 225, 235], ["Vero-76 cells", "ANATOMY", 239, 252], ["Vero-76", "CHEMICAL", 239, 246], ["MEM/TPCK-trypsin", "CHEMICAL", 315, 331], ["TPCK", "CHEMICAL", 319, 323], ["cell", "CELL", 19, 23], ["PEDV", "ORGANISM", 40, 44], ["monolayers", "CELL", 225, 235], ["Vero-76 cells", "CELL", 239, 252], ["TPCK", "SIMPLE_CHEMICAL", 319, 323], ["washed confluent monolayers", "CELL_LINE", 208, 235], ["Vero-76 cells", "CELL_LINE", 239, 252], ["PEDV", "SPECIES", 40, 44], ["Vero-76", "SPECIES", 239, 246], ["cell culture", "TEST", 19, 31], ["PEDV stock", "TREATMENT", 40, 50], ["The virus/sample mixture", "TREATMENT", 165, 189], ["Vero", "TEST", 239, 243], ["MEM/TPCK-trypsin medium", "TREATMENT", 315, 338], ["non-neutralized virus", "PROBLEM", 389, 410], ["equal", "OBSERVATION_MODIFIER", 3, 8], ["amount", "OBSERVATION_MODIFIER", 9, 15], ["cell culture", "OBSERVATION", 19, 31], ["virus", "OBSERVATION", 169, 174]]], ["Plates were then fixed with 80 % acetone and stained with FITC conjugated mAb SD6-29 to allow visualization of infected cells.", [["cells", "ANATOMY", 120, 125], ["acetone", "CHEMICAL", 33, 40], ["SD6-29", "CHEMICAL", 78, 84], ["acetone", "CHEMICAL", 33, 40], ["FITC", "CHEMICAL", 58, 62], ["acetone", "SIMPLE_CHEMICAL", 33, 40], ["FITC", "SIMPLE_CHEMICAL", 58, 62], ["cells", "CELL", 120, 125], ["FITC conjugated mAb SD6-29", "PROTEIN", 58, 84], ["infected cells", "CELL_TYPE", 111, 125], ["Plates", "TEST", 0, 6], ["80 % acetone", "TREATMENT", 28, 40], ["FITC conjugated mAb SD6", "TEST", 58, 81], ["infected cells", "PROBLEM", 111, 125], ["infected cells", "OBSERVATION", 111, 125]]], ["Endpoint neutralization titers were determined as the highest serum, milk or colostrum dilution resulting in a 90 % or greater reduction in fluorescent foci relative to controls.Expression of recombinant PEDV-NP antigen ::: ResultsAs shown in Fig. 1, the purity of the recombinant protein was assessed via SDS-PAGE and gave a band that migrated corresponding to the expected molecular mass of 51 kDa upon staining with Coomassie brilliant blue R250.", [["serum", "ANATOMY", 62, 67], ["milk", "ANATOMY", 69, 73], ["colostrum", "ANATOMY", 77, 86], ["foci", "ANATOMY", 152, 156], ["Coomassie brilliant blue", "CHEMICAL", 419, 443], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["milk", "ORGANISM_SUBSTANCE", 69, 73], ["colostrum", "ORGANISM_SUBSTANCE", 77, 86], ["PEDV-NP antigen", "GENE_OR_GENE_PRODUCT", 204, 219], ["Coomassie brilliant blue R250", "SIMPLE_CHEMICAL", 419, 448], ["PEDV", "PROTEIN", 204, 208], ["NP antigen", "PROTEIN", 209, 219], ["recombinant protein", "PROTEIN", 269, 288], ["Coomassie brilliant blue R250", "SPECIES", 419, 448], ["Endpoint neutralization titers", "TEST", 0, 30], ["colostrum dilution", "TEST", 77, 95], ["greater reduction in fluorescent foci", "PROBLEM", 119, 156], ["ResultsAs", "TEST", 224, 233], ["the recombinant protein", "TEST", 265, 288], ["a band", "TREATMENT", 324, 330], ["greater", "OBSERVATION_MODIFIER", 119, 126], ["reduction", "OBSERVATION_MODIFIER", 127, 136], ["fluorescent foci", "OBSERVATION", 140, 156], ["mass", "OBSERVATION", 385, 389], ["51 kDa", "OBSERVATION_MODIFIER", 393, 399]]], ["The protein yield of the IPTG induced E. coli culture was calculated to be approximately 11 mg PEDV-NP/liter of 2XYT medium with a purity of greater than 95 %.", [["IPTG", "CHEMICAL", 25, 29], ["IPTG", "CHEMICAL", 25, 29], ["IPTG", "SIMPLE_CHEMICAL", 25, 29], ["E. coli", "ORGANISM", 38, 45], ["E. coli", "SPECIES", 38, 45], ["E. coli", "SPECIES", 38, 45], ["The protein", "TEST", 0, 11], ["the IPTG", "TREATMENT", 21, 29], ["E. coli culture", "TEST", 38, 53], ["2XYT medium", "TREATMENT", 112, 123]]], ["The identity of the protein was further characterized by Western blot using convalescent swine serum, an anti-His mAb and an anti-PEDV-NP mAb (Fig. 2).Diagnostic sensitivity, specificity, repeatability and threshold cutoff level ::: ResultsTo optimize the serologic assays, various antigen and serum dilutions were used to determine optimum concentrations.", [["serum", "ANATOMY", 95, 100], ["serum", "ANATOMY", 294, 299], ["swine", "ORGANISM", 89, 94], ["serum", "ORGANISM_SUBSTANCE", 95, 100], ["serum", "ORGANISM_SUBSTANCE", 294, 299], ["anti-His mAb", "PROTEIN", 105, 117], ["anti-PEDV", "PROTEIN", 125, 134], ["NP mAb", "PROTEIN", 135, 141], ["swine", "SPECIES", 89, 94], ["swine", "SPECIES", 89, 94], ["convalescent swine serum", "TEST", 76, 100], ["an anti", "TREATMENT", 102, 109], ["His mAb", "TREATMENT", 110, 117], ["an anti-PEDV-NP mAb", "TREATMENT", 122, 141], ["Diagnostic sensitivity", "TEST", 151, 173], ["specificity", "TEST", 175, 186], ["repeatability", "TEST", 188, 201], ["the serologic assays", "TEST", 252, 272], ["various antigen", "TEST", 274, 289], ["serum dilutions", "TEST", 294, 309]]], ["All 3 tests were optimized in a checkerboard fashion to maximize signal-to-noise ratios.", [["All 3 tests", "TEST", 0, 11]]], ["It was determined by antigen titration that the optimal coating of Luminex\u2122/FMIA microspheres was achieved at a concentration of 12.5 \u03bcg protein per 3.125 \u00d7 106 microspheres.", [["Luminex\u2122", "CHEMICAL", 67, 75], ["Luminex\u2122", "SIMPLE_CHEMICAL", 67, 75], ["FMIA microspheres", "SIMPLE_CHEMICAL", 76, 93], ["antigen titration", "TREATMENT", 21, 38], ["Luminex\u2122/FMIA microspheres", "TREATMENT", 67, 93]]], ["Similarly, the optimum coating of both the iELISA and bELISA plates was achieved at a concentration of 250 ng/well.", [["iELISA", "SIMPLE_CHEMICAL", 43, 49], ["bELISA plates", "TREATMENT", 54, 67], ["optimum", "OBSERVATION_MODIFIER", 15, 22], ["coating", "OBSERVATION_MODIFIER", 23, 30]]], ["In addition, to determine the optimum serum dilution for each of the testing platforms, a well-characterized PEDV \u201chigh\u201d positive serum standard was serially diluted in a log2 titration against antigen coated microspheres (FMIA) or antigen coated ELISA wells at a fixed concentration.", [["serum", "ANATOMY", 38, 43], ["serum", "ANATOMY", 130, 135], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["PEDV", "ORGANISM", 109, 113], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["antigen coated microspheres", "SIMPLE_CHEMICAL", 194, 221], ["FMIA", "SIMPLE_CHEMICAL", 223, 227], ["PEDV", "SPECIES", 109, 113], ["the optimum serum dilution", "TEST", 26, 52], ["the testing platforms", "TEST", 65, 86], ["PEDV", "TEST", 109, 113], ["a log2 titration", "TREATMENT", 169, 185], ["antigen coated microspheres", "TREATMENT", 194, 221], ["antigen coated ELISA wells", "PROBLEM", 232, 258], ["a fixed concentration", "TREATMENT", 262, 283]]], ["Figure 3 shows concentration-dependent OD or MFI signals of various serum standards.", [["serum", "ANATOMY", 68, 73], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["Figure", "TEST", 0, 6], ["dependent OD", "PROBLEM", 29, 41], ["various serum standards", "TEST", 60, 83], ["dependent OD", "OBSERVATION_MODIFIER", 29, 41]]], ["Overall, sample absorbance increased inversely proportional to the serum dilution.", [["sample", "ANATOMY", 9, 15], ["serum", "ANATOMY", 67, 72], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["sample absorbance", "TEST", 9, 26], ["the serum dilution", "TEST", 63, 81]]], ["However, based upon the highest signal-to-noise ratio, it was determined that the optimal serum dilution for the bELISA was 1/3, while the iELISA and FMIA each demonstrated an optimum dilution of 1/50 as indicated by arrows (Fig. 3).Diagnostic sensitivity, specificity, repeatability and threshold cutoff level ::: ResultsROC analysis to determine sensitivity, specificity and threshold cut-off levels was performed using large numbers of swine serum samples and demonstrated excellent agreement (>0.91 kappa scores) between assays with good intra and inter assay repeatability (Table 1).", [["serum", "ANATOMY", 90, 95], ["serum samples", "ANATOMY", 445, 458], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["swine", "ORGANISM", 439, 444], ["serum samples", "ORGANISM_SUBSTANCE", 445, 458], ["swine", "SPECIES", 439, 444], ["swine", "SPECIES", 439, 444], ["the optimal serum dilution", "TEST", 78, 104], ["the bELISA", "TEST", 109, 119], ["an optimum dilution", "TEST", 173, 192], ["Diagnostic sensitivity", "TEST", 233, 255], ["specificity", "TEST", 257, 268], ["repeatability", "TEST", 270, 283], ["ResultsROC analysis", "TEST", 315, 334], ["sensitivity", "TEST", 348, 359], ["specificity", "TEST", 361, 372], ["threshold cut-off levels", "TEST", 377, 401], ["swine serum samples", "TEST", 439, 458], ["kappa scores", "TEST", 503, 515], ["assays", "TEST", 525, 531]]], ["None of the known positive TGEV or PRCV samples tested was shown to cross-react.Diagnostic sensitivity, specificity, repeatability and threshold cutoff level ::: ResultsThe optimal cutoff values and corresponding sensitivity and specificity of each individual test are presented in Fig. 4.", [["PRCV samples", "ANATOMY", 35, 47], ["TGEV", "ORGANISM", 27, 31], ["PRCV samples", "CANCER", 35, 47], ["TGEV", "SPECIES", 27, 31], ["PRCV", "SPECIES", 35, 39], ["the known positive TGEV", "PROBLEM", 8, 31], ["PRCV samples", "TEST", 35, 47], ["Diagnostic sensitivity", "TEST", 80, 102], ["specificity", "TEST", 104, 115], ["repeatability", "TEST", 117, 130], ["The optimal cutoff values", "TEST", 169, 194], ["corresponding sensitivity", "TEST", 199, 224], ["each individual test", "TEST", 244, 264], ["positive", "OBSERVATION_MODIFIER", 18, 26], ["TGEV", "OBSERVATION", 27, 31]]], ["Specifically, ROC analysis for the iELISA and bELISA showed similar sensitivity and specificity of 97.9 and 97.6 %; and 98.2 and 98.9 %, respectively.", [["ROC analysis", "TEST", 14, 26], ["the iELISA", "TEST", 31, 41], ["specificity", "TEST", 84, 95]]], ["The ROC analysis for the FMIA showed estimated sensitivity and specificity of 98.2 and 99.2 %, respectively.", [["The ROC analysis", "TEST", 0, 16], ["the FMIA", "TEST", 21, 29], ["specificity", "TEST", 63, 74]]], ["Although the FMIA showed an identical sensitivity as the bELISA, it demonstrated the highest degree of specificity of all three assays at 99.2 %.", [["FMIA", "SIMPLE_CHEMICAL", 13, 17], ["FMIA", "DNA", 13, 17], ["the FMIA", "TEST", 9, 17], ["all three assays", "TEST", 118, 134]]], ["This observation was not surprising given that FMIA technology inherently imparts greater sensitivity and a larger dynamic range than the ELISA platform [30].Diagnostic sensitivity, specificity, repeatability and threshold cutoff level ::: ResultsIn addition to determining cutoff values, sensitivities and specificities, multiple comparison tests were performed to calculate the degree of agreement among the ELISA, FMIA and IFA tests.", [["FMIA", "SIMPLE_CHEMICAL", 47, 51], ["the ELISA platform", "TEST", 134, 152], ["Diagnostic sensitivity", "TEST", 158, 180], ["specificity", "TEST", 182, 193], ["repeatability", "TEST", 195, 208], ["cutoff values", "TEST", 274, 287], ["sensitivities", "TEST", 289, 302], ["multiple comparison tests", "TEST", 322, 347], ["the ELISA", "TEST", 406, 415], ["IFA tests", "TEST", 426, 435]]], ["Specifically, the Kappa test demonstrated all diagnostic platforms had kappa values greater than 0.91, which demonstrates that all 4 tests are in \u201calmost perfect\u201d agreement with each other.Assessment of repeatability ::: ResultsThe iELISA and bELISA demonstrated slightly lower %CVs than the FMIA with 3.7 %, 6.8 %, 10.7 % intra-assay variability for bELISA, iELISA and FMIA respectively.", [["the Kappa test", "TEST", 14, 28], ["kappa values", "TEST", 71, 83], ["all 4 tests", "TEST", 127, 138], ["The iELISA", "TEST", 228, 238], ["bELISA", "TEST", 243, 249], ["slightly lower %CVs", "PROBLEM", 263, 282], ["the FMIA", "TEST", 288, 296], ["intra-assay variability", "TEST", 323, 346], ["bELISA", "TEST", 351, 357], ["iELISA", "TEST", 359, 365], ["slightly", "OBSERVATION_MODIFIER", 263, 271], ["lower", "OBSERVATION_MODIFIER", 272, 277]]], ["Inter-assay %CVs were 5.0, 5.6 and 7.7 % for the bELISA, iELISA and FMIA respectively.", [["Inter-assay %CVs", "TEST", 0, 16], ["the bELISA", "TEST", 45, 55]]], ["Nonetheless, all the CVs were 10.7 % or less, which demonstrated that the tests were highly repeatable in a diagnostic application.Evaluation of a kinetic PEDV antibody response ::: ResultsAs shown in Fig. 5, a mean antibody response to PEDV-NP could be detected as early as 9 DPI for both the iELISA and bELISA.", [["PEDV-NP", "CHEMICAL", 237, 244], ["PEDV-NP", "SIMPLE_CHEMICAL", 237, 244], ["PEDV antibody", "PROTEIN", 155, 168], ["PEDV", "PROTEIN", 237, 241], ["PEDV", "SPECIES", 237, 241], ["all the CVs", "TEST", 13, 24], ["the tests", "TEST", 70, 79], ["Evaluation", "TEST", 131, 141], ["a kinetic PEDV antibody", "TEST", 145, 168], ["ResultsAs", "TEST", 182, 191], ["a mean antibody response", "TEST", 209, 233], ["PEDV", "TEST", 237, 241], ["Fig", "OBSERVATION", 201, 204]]], ["The FMIA detected PEDV-NP antibodies slightly earlier at 6 DPI.", [["DPI", "CHEMICAL", 59, 62], ["FMIA", "SIMPLE_CHEMICAL", 4, 8], ["FMIA", "PROTEIN", 4, 8], ["PEDV", "PROTEIN", 18, 22], ["NP antibodies", "PROTEIN", 23, 36], ["PEDV", "SPECIES", 18, 22], ["The FMIA", "TEST", 0, 8], ["PEDV", "TEST", 18, 22], ["NP antibodies", "TEST", 23, 36]]], ["All 3 tests detected the duration of antibody out to the 43 DPI time-point in this study but demonstrated a decline in detectable antibody after 21 DPI.Application of the FMIA to isotype PEDV-NP specific antibodies ::: ResultsHigh levels of PEDV-NP specific IgM antibodies were observed at 7 DPI compared to IgG (Fig. 6).", [["DPI", "CHEMICAL", 148, 151], ["DPI", "CHEMICAL", 292, 295], ["FMIA", "SIMPLE_CHEMICAL", 171, 175], ["PEDV-NP", "GENE_OR_GENE_PRODUCT", 241, 248], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 258, 272], ["FMIA", "PROTEIN", 171, 175], ["isotype PEDV-NP specific antibodies", "PROTEIN", 179, 214], ["PEDV", "PROTEIN", 241, 245], ["IgM antibodies", "PROTEIN", 258, 272], ["IgG", "PROTEIN", 308, 311], ["PEDV", "SPECIES", 241, 245], ["All 3 tests", "TEST", 0, 11], ["antibody", "TEST", 37, 45], ["this study", "TEST", 78, 88], ["a decline in detectable antibody", "PROBLEM", 106, 138], ["the FMIA", "TREATMENT", 167, 175], ["ResultsHigh levels", "TEST", 219, 237], ["PEDV", "TEST", 241, 245], ["NP specific IgM antibodies", "TEST", 246, 272], ["IgG", "TEST", 308, 311]]], ["However, the IgM antibodies decreased to barely detectable levels by 20 DPI.", [["DPI", "CHEMICAL", 72, 75], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 13, 27], ["IgM antibodies", "PROTEIN", 13, 27], ["the IgM antibodies", "TEST", 9, 27]]], ["IgG continued to increase linearly to 20 DPI.", [["DPI", "CHEMICAL", 41, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "PROTEIN", 0, 3], ["IgG", "TEST", 0, 3]]], ["There is a concomitant appearance of neutralizing antibodies by 14 DPI.FFN ::: ResultsThe FFN assay was initially evaluated using sequential serum samples from experimentally inoculated piglets.", [["serum samples", "ANATOMY", 141, 154], ["DPI", "CHEMICAL", 67, 70], ["serum samples", "ORGANISM_SUBSTANCE", 141, 154], ["piglets", "ORGANISM", 186, 193], ["neutralizing antibodies", "PROTEIN", 37, 60], ["piglets", "SPECIES", 186, 193], ["neutralizing antibodies", "TREATMENT", 37, 60], ["The FFN assay", "TEST", 86, 99], ["sequential serum samples", "TEST", 130, 154], ["concomitant", "OBSERVATION_MODIFIER", 11, 22], ["neutralizing antibodies", "OBSERVATION", 37, 60], ["inoculated piglets", "OBSERVATION", 175, 193]]], ["Additional evaluation was conducted using 250 serum samples from known PEDV na\u00efve herds and 250 samples from herds with documented PEDV exposure, collected at least 3 weeks after initial PCR diagnosis and whole herd feedback.", [["serum samples", "ANATOMY", 46, 59], ["samples", "ANATOMY", 96, 103], ["PEDV", "CHEMICAL", 131, 135], ["serum samples", "ORGANISM_SUBSTANCE", 46, 59], ["PEDV", "SPECIES", 71, 75], ["PEDV", "SPECIES", 131, 135], ["Additional evaluation", "TEST", 0, 21], ["serum samples", "TEST", 46, 59], ["initial PCR diagnosis", "TEST", 179, 200]]], ["Experimentally inoculated piglets demonstrated detectable seroconversion by 14 DPI (Fig. 6).", [["DPI", "CHEMICAL", 79, 82], ["piglets", "ORGANISM", 26, 33], ["piglets", "SPECIES", 26, 33]]], ["Essentially all samples from PEDV na\u00efve animals had serum FFN endpoint titers of <1:20 while most samples from the PEDV positive set had endpoint titers ranging from 1:40 to 1:1280 (data not shown).", [["samples", "ANATOMY", 16, 23], ["serum", "ANATOMY", 52, 57], ["samples", "ANATOMY", 98, 105], ["PEDV", "ORGANISM", 29, 33], ["animals", "ORGANISM", 40, 47], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["FFN", "SIMPLE_CHEMICAL", 58, 61], ["PEDV", "SPECIES", 29, 33], ["PEDV", "SPECIES", 115, 119], ["all samples", "TEST", 12, 23], ["PEDV na\u00efve animals", "TEST", 29, 47], ["serum FFN endpoint titers", "TEST", 52, 77], ["the PEDV", "TEST", 111, 119], ["endpoint titers", "TEST", 137, 152]]], ["Further evaluation of the FFN included serum, milk and colostrum samples from 27 sows from a herd that had experienced an acute PEDV outbreak 6 to 7 weeks prior to farrowing.", [["serum", "ANATOMY", 39, 44], ["milk", "ANATOMY", 46, 50], ["colostrum samples", "ANATOMY", 55, 72], ["FFN", "CHEMICAL", 26, 29], ["FFN", "SIMPLE_CHEMICAL", 26, 29], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["milk", "ORGANISM_SUBSTANCE", 46, 50], ["colostrum samples", "ORGANISM_SUBSTANCE", 55, 72], ["sows", "ORGANISM", 81, 85], ["FFN", "PROTEIN", 26, 29], ["PEDV", "SPECIES", 128, 132], ["Further evaluation", "TEST", 0, 18], ["the FFN", "TEST", 22, 29], ["serum", "TEST", 39, 44], ["colostrum samples", "TEST", 55, 72], ["an acute PEDV outbreak", "PROBLEM", 119, 141], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["PEDV", "OBSERVATION", 128, 132]]], ["All animals were exposed to live virus twice within the first week of the outbreak, followed by one dose of Harrisvaccines Porcine Epidemic Diarrhea Vaccine, RNA (Harrisvaccines, Inc., Ames, IA) at 1 week pre-farrow.", [["Harrisvaccines", "CHEMICAL", 108, 122], ["Diarrhea", "DISEASE", 140, 148], ["Porcine", "SPECIES", 123, 130], ["Harrisvaccines Porcine Epidemic Diarrhea Vaccine", "TREATMENT", 108, 156]]], ["Serum and colostrum samples were tested at the time of farrowing, followed by serum and milk samples at 1 week and 2 weeks later.", [["Serum", "ANATOMY", 0, 5], ["colostrum samples", "ANATOMY", 10, 27], ["serum", "ANATOMY", 78, 83], ["milk samples", "ANATOMY", 88, 100], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["colostrum samples", "ORGANISM_SUBSTANCE", 10, 27], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["milk samples", "ORGANISM_SUBSTANCE", 88, 100], ["Serum and colostrum samples", "TEST", 0, 27], ["serum and milk samples", "TEST", 78, 100], ["colostrum", "ANATOMY", 10, 19], ["farrowing", "OBSERVATION", 55, 64]]], ["As shown in Fig. 7, mean colostrum titers were approximately 4-fold higher than serum titers at the time of farrowing.", [["colostrum", "ANATOMY", 25, 34], ["serum", "ANATOMY", 80, 85], ["colostrum", "ORGANISM", 25, 34], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["mean colostrum titers", "TEST", 20, 41], ["serum titers", "TEST", 80, 92], ["Fig", "OBSERVATION", 12, 15], ["titers", "OBSERVATION_MODIFIER", 35, 41], ["farrowing", "OBSERVATION", 108, 117]]], ["At later time-points, serum and milk titers were similar in magnitude, although substantial animal to animal variation was apparent.DiscussionOverall, this repertoire of assays is useful for initial identification and efficient, high throughput quantitation of PEDV antibodies.", [["serum", "ANATOMY", 22, 27], ["milk", "ANATOMY", 32, 36], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["milk", "ORGANISM_SUBSTANCE", 32, 36], ["PEDV antibodies", "GENE_OR_GENE_PRODUCT", 261, 276], ["PEDV antibodies", "PROTEIN", 261, 276], ["PEDV", "SPECIES", 261, 265], ["serum and milk titers", "TEST", 22, 43], ["assays", "TEST", 170, 176], ["PEDV antibodies", "PROBLEM", 261, 276], ["substantial", "OBSERVATION_MODIFIER", 80, 91]]], ["We evaluated all three diagnostic platforms against a well characterized IFA and compared the individual serum IgM and IgG kinetic antibody responses in an FMIA to the appearance of neutralizing antibody as detected by the FFN assay.", [["serum", "ANATOMY", 105, 110], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["IgM", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgG", "GENE_OR_GENE_PRODUCT", 119, 122], ["serum IgM", "PROTEIN", 105, 114], ["IgG kinetic antibody", "PROTEIN", 119, 139], ["neutralizing antibody", "PROTEIN", 182, 203], ["FFN", "PROTEIN", 223, 226], ["a well characterized IFA", "TEST", 52, 76], ["the individual serum IgM", "TEST", 90, 114], ["IgG kinetic antibody responses", "TEST", 119, 149], ["neutralizing antibody", "TEST", 182, 203], ["the FFN assay", "TEST", 219, 232], ["neutralizing antibody", "OBSERVATION", 182, 203]]], ["Each of the antibody-capture assays was validated using a large number of serum samples (n >1100) based upon the assay validation methods of Jacobson, which is supported by the Office International des Epizooties [25].DiscussionSince PEDV was first identified in the U.S. in May 2013, it has spread rapidly to at least 33 states (www.aasv.org) and has been reported in Mexico and Canada [31].", [["serum samples", "ANATOMY", 74, 87], ["serum samples", "ORGANISM_SUBSTANCE", 74, 87], ["antibody", "PROTEIN", 12, 20], ["the antibody", "TEST", 8, 20], ["serum samples", "TEST", 74, 87], ["large", "OBSERVATION_MODIFIER", 58, 63]]], ["The virus causes severe gastroenteritis, destroying villus enterocytes in pigs of all ages, and is characterized by vomiting and diarrhea, leading to subsequent dehydration, high mortality rates and economic losses, particularly in nursery piglets [3, 32].", [["villus enterocytes", "ANATOMY", 52, 70], ["gastroenteritis", "DISEASE", 24, 39], ["vomiting", "DISEASE", 116, 124], ["diarrhea", "DISEASE", 129, 137], ["dehydration", "DISEASE", 161, 172], ["villus enterocytes", "MULTI-TISSUE_STRUCTURE", 52, 70], ["pigs", "ORGANISM", 74, 78], ["pigs", "SPECIES", 74, 78], ["pigs", "SPECIES", 74, 78], ["The virus", "PROBLEM", 0, 9], ["severe gastroenteritis", "PROBLEM", 17, 39], ["villus enterocytes", "PROBLEM", 52, 70], ["vomiting", "PROBLEM", 116, 124], ["diarrhea", "PROBLEM", 129, 137], ["subsequent dehydration", "PROBLEM", 150, 172], ["high mortality rates", "PROBLEM", 174, 194], ["economic losses", "PROBLEM", 199, 214], ["virus", "OBSERVATION", 4, 9], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["gastroenteritis", "OBSERVATION", 24, 39], ["villus enterocytes", "OBSERVATION", 52, 70], ["vomiting", "OBSERVATION", 116, 124], ["diarrhea", "OBSERVATION", 129, 137], ["dehydration", "OBSERVATION", 161, 172], ["high", "OBSERVATION_MODIFIER", 174, 178], ["mortality", "OBSERVATION_MODIFIER", 179, 188], ["rates", "OBSERVATION_MODIFIER", 189, 194], ["economic losses", "OBSERVATION", 199, 214]]], ["A variety of serological tests have been developed against PEDV, but they vary by antigen used and in the degree of validation.", [["PEDV", "ORGANISM", 59, 63], ["PEDV", "SPECIES", 59, 63], ["serological tests", "TEST", 13, 30], ["PEDV", "PROBLEM", 59, 63]]], ["In addition, few have used North American NP based antigens or compared the array of serologic assays described here.", [["North American NP based antigens", "PROTEIN", 27, 59], ["serologic assays", "TEST", 85, 101], ["few", "OBSERVATION_MODIFIER", 13, 16]]], ["In the current study, four tests (IFA, bELISA, iELISA, FMIA) showed strong correlation.", [["the current study", "TEST", 3, 20], ["four tests", "TEST", 22, 32], ["IFA", "TEST", 34, 37], ["bELISA", "TEST", 39, 45], ["iELISA", "TEST", 47, 53]]], ["In addition, newly developed NP mAbs were used in the bELISA and for expediting FFN testing in the detection of neutralizing antibodies.DiscussionIn the development of the ELISAs and FMIA, the full length NA PEDV-NP gene was amplified directly from RNA extracted from PEDV-infected ileal tissue.", [["ileal tissue", "ANATOMY", 282, 294], ["FFN", "CHEMICAL", 80, 83], ["FFN", "SIMPLE_CHEMICAL", 80, 83], ["PEDV", "GENE_OR_GENE_PRODUCT", 268, 272], ["ileal tissue", "TISSUE", 282, 294], ["NP mAbs", "PROTEIN", 29, 36], ["FFN", "PROTEIN", 80, 83], ["neutralizing antibodies", "PROTEIN", 112, 135], ["FMIA", "DNA", 183, 187], ["NA PEDV-NP gene", "DNA", 205, 220], ["PEDV", "SPECIES", 268, 272], ["NP mAbs", "TREATMENT", 29, 36], ["expediting FFN testing", "TEST", 69, 91], ["neutralizing antibodies", "PROBLEM", 112, 135], ["the ELISAs", "TEST", 168, 178], ["the full length NA PEDV", "TREATMENT", 189, 212], ["NP gene", "TREATMENT", 213, 220], ["PEDV", "PROBLEM", 268, 272], ["infected ileal tissue", "PROBLEM", 273, 294], ["mAbs", "OBSERVATION", 32, 36], ["neutralizing antibodies", "OBSERVATION", 112, 135], ["infected", "OBSERVATION", 273, 281], ["ileal tissue", "ANATOMY", 282, 294]]], ["Multiple sequence alignment analysis showed that the amplified NP gene shared a 100 % nucleotide homology with that of the US Colorado strain isolated in 2013 (Genbank accession no. 13\u2013019349).", [["nucleotide", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 86, 96], ["amplified NP gene", "DNA", 53, 70], ["Multiple sequence alignment analysis", "TEST", 0, 36]]], ["Several authors confirm that the NP carries multiple antigenic determinants that are conserved among the Coronaviridae [33, 34].", [["multiple", "OBSERVATION_MODIFIER", 44, 52], ["antigenic", "OBSERVATION", 53, 62]]], ["However, we performed one-way cross-reactivity testing using serum from TGEV and PRCV, and no antibody cross-reactivity was detected within any of our assays.", [["serum", "ANATOMY", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["TGEV", "ORGANISM", 72, 76], ["PRCV", "CANCER", 81, 85], ["TGEV", "SPECIES", 72, 76], ["PRCV", "SPECIES", 81, 85], ["cross-reactivity testing", "TEST", 30, 54], ["serum from TGEV", "TEST", 61, 76], ["PRCV", "TEST", 81, 85], ["antibody cross-reactivity", "PROBLEM", 94, 119], ["our assays", "TEST", 147, 157], ["no", "UNCERTAINTY", 91, 93]]], ["In addition to being highly conserved among various PEDV variants, the NP is the most abundant viral protein expressed in PEDV infected cells, making it an attractive target antigen [12, 13].", [["cells", "ANATOMY", 136, 141], ["PEDV", "GENE_OR_GENE_PRODUCT", 52, 56], ["NP", "GENE_OR_GENE_PRODUCT", 71, 73], ["PEDV", "CELL", 122, 126], ["cells", "CELL", 136, 141], ["PEDV variants", "DNA", 52, 65], ["viral protein", "PROTEIN", 95, 108], ["PEDV infected cells", "CELL_TYPE", 122, 141], ["PEDV", "SPECIES", 122, 126], ["various PEDV variants", "PROBLEM", 44, 65], ["PEDV infected cells", "PROBLEM", 122, 141], ["PEDV variants", "OBSERVATION", 52, 65], ["infected cells", "OBSERVATION", 127, 141]]], ["Using Western blotting experiments, we confirmed the finding of Hou et al. [19], in which they observed the level of expression of NP protein to be significantly higher than the level of the spike protein.", [["NP", "GENE_OR_GENE_PRODUCT", 131, 133], ["NP protein", "PROTEIN", 131, 141], ["spike protein", "PROTEIN", 191, 204], ["NP protein", "PROBLEM", 131, 141], ["the spike protein", "PROBLEM", 187, 204]]], ["Our study demonstrated that it is possible to achieve a protein yield of over 10 mg per liter of culture with a purity of greater than 95 %.DiscussionThe recombinant NP has previously been identified as a useful antigen in other ELISAs developed to detect antibodies in pigs located in China and Korea [19].", [["pigs", "ORGANISM", 270, 274], ["antibodies", "PROTEIN", 256, 266], ["pigs", "SPECIES", 270, 274], ["pigs", "SPECIES", 270, 274], ["Our study", "TEST", 0, 9], ["culture", "TEST", 97, 104], ["a useful antigen in other ELISAs", "PROBLEM", 203, 235], ["antibodies", "PROBLEM", 256, 266]]], ["In a study by Hou et al. [19], the authors showed similar sensitivities and specificities of their iELISA compared to the iELISA described in this study.", [["a study", "TEST", 3, 10], ["this study", "TEST", 142, 152]]], ["However, smaller numbers of known positive and negative samples were evaluated than in the current study.DiscussionSince no test has 100 % specificity, a bELISA was developed that is useful for confirmatory testing due to its higher inherent specificity than the iELISA [35].", [["samples", "ANATOMY", 56, 63], ["smaller numbers of known positive and negative samples", "PROBLEM", 9, 63], ["the current study", "TEST", 87, 104], ["test", "TEST", 124, 128], ["confirmatory testing", "TEST", 194, 214], ["smaller", "OBSERVATION_MODIFIER", 9, 16], ["numbers", "OBSERVATION_MODIFIER", 17, 24], ["positive", "OBSERVATION_MODIFIER", 34, 42], ["negative samples", "OBSERVATION_MODIFIER", 47, 63]]], ["Blocking or competitive ELISAs have been constructed using monoclonal antibodies in PEDV serodiagnosis, and the specific methodology can affect the overall specificity and performance of the assay.", [["monoclonal antibodies", "PROTEIN", 59, 80], ["PEDV", "SPECIES", 84, 88], ["Blocking or competitive ELISAs", "PROBLEM", 0, 30], ["monoclonal antibodies", "TREATMENT", 59, 80], ["PEDV serodiagnosis", "TEST", 84, 102], ["the assay", "TEST", 187, 196]]], ["Our method was based upon coating plates with highly purified NA PEDV-NP, then using a combination of two separate NA, anti- PEDV-NP specific, biotinylated, monoclonal antibodies as the blocking/competitive detection step.", [["NA", "CHEMICAL", 115, 117], ["NA", "SIMPLE_CHEMICAL", 115, 117], ["PEDV", "PROTEIN", 125, 129], ["NP specific, biotinylated, monoclonal antibodies", "PROTEIN", 130, 178], ["anti- PEDV", "TREATMENT", 119, 129], ["monoclonal antibodies", "TREATMENT", 157, 178]]], ["This allows the capture of anti-NP antibodies at higher quantities and those with a greater range of antigen specificities.", [["anti-NP antibodies", "GENE_OR_GENE_PRODUCT", 27, 45], ["anti-NP antibodies", "PROTEIN", 27, 45], ["anti-NP antibodies", "TREATMENT", 27, 45]]], ["The analytical specificity of the NP-based bELISA is also dependent on the affinity of the mAbs used.", [["bELISA", "DNA", 43, 49], ["mAbs", "PROTEIN", 91, 95], ["the mAbs", "TREATMENT", 87, 95]]], ["The antibodies used in this study are directed against conserved epitopes on the nucleocapsid protein without any evidence of cross-reactivity to any other genera of Alphacoronavirus tested.", [["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 166, 182], ["antibodies", "PROTEIN", 4, 14], ["conserved epitopes", "PROTEIN", 55, 73], ["nucleocapsid protein", "PROTEIN", 81, 101], ["The antibodies", "TREATMENT", 0, 14], ["this study", "TEST", 23, 33], ["the nucleocapsid protein", "TEST", 77, 101], ["cross-reactivity", "PROBLEM", 126, 142], ["Alphacoronavirus tested", "PROBLEM", 166, 189]]], ["A previous assessment of antigenic cross-reactivity was performed using these same mAbs against different strains of PEDV and TGEV [7].", [["PEDV", "CELL", 117, 121], ["TGEV", "ORGANISM", 126, 130], ["mAbs", "PROTEIN", 83, 87], ["PEDV", "SPECIES", 117, 121], ["TGEV", "SPECIES", 126, 130], ["A previous assessment of antigenic cross-reactivity", "TEST", 0, 51], ["these same mAbs", "TREATMENT", 72, 87], ["PEDV", "PROBLEM", 117, 121]]], ["In that study, the authors reported that both mAbs used in the bELISA reacted with all PEDV strains tested, namely the homologous US isolate PC22A and the heterologous strains S INDEL IOWA 106, S 197DEL PC177 and CV777, at similar titers.", [["S 197DEL PC177", "CELL", 194, 208], ["mAbs", "PROTEIN", 46, 50], ["bELISA", "DNA", 63, 69], ["PEDV", "SPECIES", 87, 91], ["S 197DEL PC177", "SPECIES", 194, 208], ["that study", "TEST", 3, 13], ["both mAbs", "TREATMENT", 41, 50], ["all PEDV strains", "PROBLEM", 83, 99], ["the homologous US", "TEST", 115, 132], ["S 197DEL PC177", "TEST", 194, 208]]], ["Neither of the PEDV-NP mAbs cross-reacted with either the TGEV Miller or Purdue strains.", [["TGEV", "ORGANISM", 58, 62], ["PEDV", "PROTEIN", 15, 19], ["NP mAbs", "PROTEIN", 20, 27], ["TGEV", "SPECIES", 58, 62], ["the PEDV", "TEST", 11, 19], ["PEDV", "OBSERVATION", 15, 19]]], ["Not only were the bELISA mAbs tested for heterologous cross-reactivity, but all three diagnostic platforms were evaluated in their ability to capture antibody against TGEV and PRCV, and there was no cross-reactivity to either heterologous virus.DiscussionSerology testing with IFA, iELISA, bELISA or FMIA is useful in determining whether pigs were previously infected with PEDV, or if piglets have acquired antibodies through colostrum (eg. passive antibody transfer).", [["colostrum", "ANATOMY", 426, 435], ["TGEV", "ORGANISM", 167, 171], ["PRCV", "CANCER", 176, 180], ["FMIA", "SIMPLE_CHEMICAL", 300, 304], ["pigs", "ORGANISM", 338, 342], ["piglets", "ORGANISM", 385, 392], ["colostrum", "ORGANISM_SUBSTANCE", 426, 435], ["bELISA mAbs", "PROTEIN", 18, 29], ["pigs", "SPECIES", 338, 342], ["piglets", "SPECIES", 385, 392], ["TGEV", "SPECIES", 167, 171], ["PRCV", "SPECIES", 176, 180], ["pigs", "SPECIES", 338, 342], ["PEDV", "SPECIES", 373, 377], ["the bELISA mAbs", "TEST", 14, 29], ["heterologous cross-reactivity", "PROBLEM", 41, 70], ["diagnostic platforms", "TEST", 86, 106], ["TGEV", "PROBLEM", 167, 171], ["PRCV", "TEST", 176, 180], ["cross-reactivity", "PROBLEM", 199, 215], ["heterologous virus", "PROBLEM", 226, 244], ["DiscussionSerology testing", "TEST", 245, 271], ["IFA", "TEST", 277, 280], ["PEDV", "PROBLEM", 373, 377], ["piglets", "PROBLEM", 385, 392], ["acquired antibodies through colostrum", "PROBLEM", 398, 435], ["passive antibody transfer", "TREATMENT", 441, 466]]], ["However, tests that evaluate the functionality of the antibodies such as the FFN are needed to determine if the detected immune response could be helpful in providing protection to nursing piglets.", [["FFN", "GENE_OR_GENE_PRODUCT", 77, 80], ["piglets", "ORGANISM", 189, 196], ["antibodies", "PROTEIN", 54, 64], ["FFN", "PROTEIN", 77, 80], ["tests", "TEST", 9, 14], ["the antibodies", "TEST", 50, 64], ["the FFN", "TEST", 73, 80]]], ["Neutralizing antibodies may be protective through actions including blocking uptake of the virus into cells, preventing virus binding to receptors on cells, preventing uncoating of the virus genomes in endosomes and/or causing aggregation of virus particles.", [["cells", "ANATOMY", 102, 107], ["cells", "ANATOMY", 150, 155], ["endosomes", "ANATOMY", 202, 211], ["cells", "CELL", 102, 107], ["cells", "CELL", 150, 155], ["endosomes", "CELLULAR_COMPONENT", 202, 211], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["Neutralizing antibodies", "TREATMENT", 0, 23], ["blocking uptake of the virus into cells", "PROBLEM", 68, 107], ["virus binding", "PROBLEM", 120, 133], ["the virus genomes in endosomes", "PROBLEM", 181, 211], ["aggregation of virus particles", "PROBLEM", 227, 257], ["virus particles", "OBSERVATION", 242, 257]]], ["For enveloped viruses, such as PEDV, lysis of the virus may also occur when antiviral antibodies and serum complement disrupt the viral membrane.", [["serum", "ANATOMY", 101, 106], ["membrane", "ANATOMY", 136, 144], ["PEDV", "GENE_OR_GENE_PRODUCT", 31, 35], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["viral membrane", "CELLULAR_COMPONENT", 130, 144], ["antiviral antibodies", "PROTEIN", 76, 96], ["serum complement", "PROTEIN", 101, 117], ["PEDV", "SPECIES", 31, 35], ["enveloped viruses", "PROBLEM", 4, 21], ["PEDV", "PROBLEM", 31, 35], ["lysis", "TREATMENT", 37, 42], ["the virus", "PROBLEM", 46, 55], ["antiviral antibodies", "TEST", 76, 96], ["serum complement", "TEST", 101, 117], ["viruses", "OBSERVATION", 14, 21], ["viral membrane", "OBSERVATION", 130, 144]]], ["For these reasons, an FFN-based virus neutralization assay was developed to assess levels of PEDV neutralizing antibodies in serum, milk or colostrum samples.", [["serum", "ANATOMY", 125, 130], ["milk", "ANATOMY", 132, 136], ["colostrum samples", "ANATOMY", 140, 157], ["FFN", "CHEMICAL", 22, 25], ["FFN", "SIMPLE_CHEMICAL", 22, 25], ["PEDV", "GENE_OR_GENE_PRODUCT", 93, 97], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["milk", "ORGANISM_SUBSTANCE", 132, 136], ["colostrum samples", "ORGANISM_SUBSTANCE", 140, 157], ["PEDV neutralizing antibodies", "PROTEIN", 93, 121], ["milk", "SPECIES", 132, 136], ["PEDV", "SPECIES", 93, 97], ["an FFN-based virus neutralization assay", "TEST", 19, 58], ["PEDV neutralizing antibodies", "TEST", 93, 121], ["serum", "TEST", 125, 130], ["colostrum samples", "TEST", 140, 157]]], ["The FFN provides a more rapid determination of neutralizing antibody levels than is possible with traditional virus neutralization assays that rely on visualization of virus-induced CPE after three or more days incubation to allow for full development of PEDV CPE.", [["FFN", "CHEMICAL", 4, 7], ["PEDV", "CHEMICAL", 255, 259], ["FFN", "SIMPLE_CHEMICAL", 4, 7], ["PEDV", "ORGANISM", 255, 259], ["FFN", "PROTEIN", 4, 7], ["PEDV", "SPECIES", 255, 259], ["neutralizing antibody levels", "TEST", 47, 75], ["traditional virus neutralization assays", "PROBLEM", 98, 137], ["virus", "PROBLEM", 168, 173], ["CPE", "PROBLEM", 182, 185], ["PEDV CPE", "PROBLEM", 255, 263], ["PEDV", "OBSERVATION", 255, 259]]], ["The direct observation of fluorescent stained infected cells, or lack of stained infected cells in the case of virus neutralization, allows for simple endpoint determination.", [["cells", "ANATOMY", 55, 60], ["cells", "ANATOMY", 90, 95], ["cells", "CELL", 55, 60], ["cells", "CELL", 90, 95], ["fluorescent stained infected cells", "CELL_TYPE", 26, 60], ["stained infected cells", "CELL_TYPE", 73, 95], ["fluorescent stained infected cells", "PROBLEM", 26, 60], ["stained infected cells", "PROBLEM", 73, 95], ["virus neutralization", "TREATMENT", 111, 131], ["simple endpoint determination", "TEST", 144, 173], ["infected cells", "OBSERVATION", 81, 95]]], ["This feature is particularly valuable when dealing with a fastidious, trypsin-dependent virus such as PEDV where CPE-based endpoints may not be obvious or may be confused with trypsin-induced CPE in the cell monolayer.", [["cell monolayer", "ANATOMY", 203, 217], ["trypsin", "GENE_OR_GENE_PRODUCT", 70, 77], ["PEDV", "GENE_OR_GENE_PRODUCT", 102, 106], ["trypsin", "GENE_OR_GENE_PRODUCT", 176, 183], ["cell monolayer", "CELL", 203, 217], ["trypsin", "PROTEIN", 70, 77], ["trypsin", "PROTEIN", 176, 183], ["PEDV", "SPECIES", 102, 106], ["a fastidious, trypsin-dependent virus", "PROBLEM", 56, 93], ["PEDV", "PROBLEM", 102, 106], ["CPE", "PROBLEM", 113, 116], ["confused", "PROBLEM", 162, 170], ["trypsin", "TEST", 176, 183], ["cell monolayer", "OBSERVATION", 203, 217]]], ["Although neutralizing antibodies present in the serum would not be expected to provide direct protection from a strictly enteric infection such as PEDV, our data suggest a correlation between detectable neutralizing antibody levels in the serum and those present in milk and colostrum of previously exposed or vaccinated sows.DiscussionSome correlation between PEDV neutralization results and ELISA results exists as described in the literature.", [["serum", "ANATOMY", 48, 53], ["serum", "ANATOMY", 239, 244], ["milk", "ANATOMY", 266, 270], ["colostrum", "ANATOMY", 275, 284], ["enteric infection", "DISEASE", 121, 138], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 239, 244], ["milk", "ORGANISM_SUBSTANCE", 266, 270], ["colostrum", "ORGANISM_SUBSTANCE", 275, 284], ["sows", "ORGANISM", 321, 325], ["neutralizing antibodies", "PROTEIN", 9, 32], ["neutralizing antibody", "PROTEIN", 203, 224], ["PEDV", "PROTEIN", 361, 365], ["PEDV", "SPECIES", 147, 151], ["neutralizing antibodies", "TEST", 9, 32], ["direct protection", "TREATMENT", 87, 104], ["a strictly enteric infection", "PROBLEM", 110, 138], ["PEDV", "PROBLEM", 147, 151], ["detectable neutralizing antibody levels", "PROBLEM", 192, 231], ["the serum", "TEST", 235, 244], ["PEDV neutralization", "TEST", 361, 380], ["ELISA results", "TEST", 393, 406], ["infection", "OBSERVATION", 129, 138]]], ["One study performed a comparative analysis between a whole-virus antigen ELISA and a serum neutralization test for the serodiagnosis of PEDV [21].", [["serum", "ANATOMY", 85, 90], ["serum", "ORGANISM_SUBSTANCE", 85, 90], ["PEDV", "SPECIES", 136, 140], ["One study", "TEST", 0, 9], ["a comparative analysis", "TEST", 20, 42], ["a whole-virus antigen ELISA", "TEST", 51, 78], ["a serum neutralization test", "TEST", 83, 110], ["the serodiagnosis", "TEST", 115, 132], ["PEDV", "PROBLEM", 136, 140]]], ["The presence of antibodies was confirmed by each test, and an overall testing agreement of 84.2 % was demonstrated using 1024 field serum samples.", [["serum samples", "ANATOMY", 132, 145], ["serum samples", "ORGANISM_SUBSTANCE", 132, 145], ["antibodies", "PROTEIN", 16, 26], ["an overall testing agreement", "TEST", 59, 87], ["1024 field serum samples", "TEST", 121, 145]]], ["Furthermore, a pairwise correlation was performed that showed corrected cutoff values between the ELISA OD and SN titers having an R value of 0.837, indicating that the CPE-based neutralization test had roughly the same reliability as the ELISA test [21].DiscussionNewer technologies such as the FMIA are useful for the detection of antibodies against multiple antigens simultaneously for surveillance purposes.", [["FMIA", "SIMPLE_CHEMICAL", 296, 300], ["antibodies", "PROTEIN", 333, 343], ["a pairwise correlation", "TEST", 13, 35], ["corrected cutoff values", "PROBLEM", 62, 85], ["the ELISA", "TEST", 94, 103], ["SN titers", "TEST", 111, 120], ["an R value", "TEST", 128, 138], ["the CPE", "TEST", 165, 172], ["based neutralization test", "TEST", 173, 198], ["the ELISA test", "TEST", 235, 249], ["the detection", "TEST", 316, 329], ["antibodies", "PROBLEM", 333, 343], ["multiple antigens", "PROBLEM", 352, 369], ["surveillance purposes", "TEST", 389, 410]]], ["FMIA are bead based assays for simultaneous high throughput detection of antibodies to multiple antigens.", [["FMIA", "SIMPLE_CHEMICAL", 0, 4], ["antibodies", "PROTEIN", 73, 83], ["bead based assays", "TEST", 9, 26], ["antibodies to multiple antigens", "PROBLEM", 73, 104]]], ["The FMIA differs from the ELISA since it involves a fluid incubation step with \u201cbeads suspended in solution, which allows for higher surface area exposure in 3 dimensions\u201d [30].", [["fluid", "ANATOMY", 52, 57], ["surface area", "ANATOMY", 133, 145], ["FMIA", "SIMPLE_CHEMICAL", 4, 8], ["FMIA", "PROTEIN", 4, 8], ["the ELISA", "TEST", 22, 31], ["a fluid incubation step", "TREATMENT", 50, 73], ["\u201cbeads", "TREATMENT", 79, 85], ["fluid", "OBSERVATION", 52, 57]]], ["Therefore, there is a shorter diffusion path to antibody binding sites on the antigen coated beads resulting in rapid reaction times.", [["antibody binding sites", "PROTEIN", 48, 70], ["a shorter diffusion path to antibody binding sites", "PROBLEM", 20, 70], ["the antigen coated beads", "TREATMENT", 74, 98], ["rapid reaction times", "PROBLEM", 112, 132], ["shorter", "OBSERVATION_MODIFIER", 22, 29], ["antibody binding", "OBSERVATION", 48, 64], ["rapid", "OBSERVATION_MODIFIER", 112, 117], ["reaction times", "OBSERVATION", 118, 132]]], ["Instead of a method using an enzymatic reaction such as with the ELISA, the FMIA detection is with laser technology, which results in a shorter detection time.", [["FMIA", "SIMPLE_CHEMICAL", 76, 80], ["a method", "TREATMENT", 11, 19], ["an enzymatic reaction", "PROBLEM", 26, 47], ["the ELISA", "TEST", 61, 70]]], ["This PEDV antigen specific bead set can be \u201cmixed\u201d with additional coated beads to other antigens, such as SIV, PCV2, PRRSV or other pathogens, for simultaneous detection of antibodies to these antigens.", [["PEDV antigen", "GENE_OR_GENE_PRODUCT", 5, 17], ["SIV", "ORGANISM", 107, 110], ["PCV2", "ORGANISM", 112, 116], ["PRRSV", "ORGANISM", 118, 123], ["PEDV antigen", "PROTEIN", 5, 17], ["antigens", "PROTEIN", 89, 97], ["antibodies", "PROTEIN", 174, 184], ["antigens", "PROTEIN", 194, 202], ["SIV", "SPECIES", 107, 110], ["PCV2", "SPECIES", 112, 116], ["PRRSV", "SPECIES", 118, 123], ["This PEDV antigen", "TEST", 0, 17], ["additional coated beads", "TREATMENT", 56, 79], ["SIV", "PROBLEM", 107, 110], ["PCV2", "PROBLEM", 112, 116], ["PRRSV", "PROBLEM", 118, 123], ["other pathogens", "PROBLEM", 127, 142], ["simultaneous detection", "TEST", 148, 170], ["antibodies", "PROBLEM", 174, 184]]], ["In addition, an FMIA could be developed for differentiation of wild-type infected vs vaccinated animals (DIVA) if proteins used in the vaccine were different from those produced in a wild-type infection.DiscussionIndividual kinetic serum IgG and IgM levels were measured by FMIA in experimentally infected animals over time.", [["serum", "ANATOMY", 232, 237], ["FMIA", "CHEMICAL", 16, 20], ["infection", "DISEASE", 193, 202], ["FMIA", "CHEMICAL", 274, 278], ["FMIA", "SIMPLE_CHEMICAL", 16, 20], ["serum", "ORGANISM_SUBSTANCE", 232, 237], ["IgG", "GENE_OR_GENE_PRODUCT", 238, 241], ["IgM", "GENE_OR_GENE_PRODUCT", 246, 249], ["FMIA", "SIMPLE_CHEMICAL", 274, 278], ["serum IgG", "PROTEIN", 232, 241], ["IgM", "PROTEIN", 246, 249], ["wild-type infected vs vaccinated animals", "PROBLEM", 63, 103], ["proteins", "PROBLEM", 114, 122], ["the vaccine", "TREATMENT", 131, 142], ["a wild-type infection", "PROBLEM", 181, 202], ["Individual kinetic serum IgG", "TEST", 213, 241], ["IgM levels", "TEST", 246, 256], ["infection", "OBSERVATION", 193, 202], ["infected", "OBSERVATION", 297, 305]]], ["The appearance of the IgM subclass is considered an immunological parameter of early infection and generally appears prior to the appearance of IgG, and this was confirmed in our study.", [["infection", "DISEASE", 85, 94], ["IgM", "GENE_OR_GENE_PRODUCT", 22, 25], ["IgG", "GENE_OR_GENE_PRODUCT", 144, 147], ["IgM subclass", "PROTEIN", 22, 34], ["IgG", "PROTEIN", 144, 147], ["the IgM subclass", "TEST", 18, 34], ["early infection", "PROBLEM", 79, 94], ["IgG", "TEST", 144, 147], ["our study", "TEST", 175, 184], ["IgM subclass", "OBSERVATION", 22, 34], ["early", "OBSERVATION_MODIFIER", 79, 84], ["infection", "OBSERVATION", 85, 94]]], ["This was in contrast to the data of Woo et al. [36], which was unable to detect IgM antibodies using their NP-based indirect ELISA.", [["IgM antibodies", "GENE_OR_GENE_PRODUCT", 80, 94], ["IgM antibodies", "PROTEIN", 80, 94], ["IgM antibodies", "TEST", 80, 94]]], ["IgG antibodies may be more easily detected as they are characterized by higher antigen affinity but lower avidity than IgM [37].", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 0, 14], ["IgG antibodies", "PROTEIN", 0, 14], ["IgM", "PROTEIN", 119, 122], ["IgG antibodies", "TEST", 0, 14], ["higher antigen affinity", "PROBLEM", 72, 95], ["IgM", "TEST", 119, 122]]], ["Further understanding of various antibody profiles will provide important information on the ability of vaccines to stimulate a protective immune response.ConclusionsThese well-validated NA PEDV iELISA, bELISA, FMIA and FFN assays are useful for a range of serological investigations.", [["PEDV", "SPECIES", 190, 194], ["various antibody profiles", "PROBLEM", 25, 50], ["vaccines", "TREATMENT", 104, 112], ["bELISA", "TEST", 203, 209], ["FFN assays", "TEST", 220, 230], ["serological investigations", "TEST", 257, 283]]], ["They can serve as a complement to nucleic acid detection and determine the PEDV status of asymptomatic individuals for cost-effective tools in management strategies and monitoring virus exposure within the herd.", [["nucleic acid", "CHEMICAL", 34, 46], ["herd", "ORGANISM_SUBDIVISION", 206, 210], ["nucleic acid detection", "TEST", 34, 56], ["asymptomatic individuals", "PROBLEM", 90, 114], ["management strategies", "TREATMENT", 143, 164], ["monitoring virus exposure", "TREATMENT", 169, 194]]], ["The FMIA will be useful for isotyping the antibody responses and in multiplexing for determining exposure to multiple pathogens simultaneously.", [["FMIA", "SIMPLE_CHEMICAL", 4, 8], ["isotyping the antibody responses", "PROBLEM", 28, 60], ["multiple pathogens", "PROBLEM", 109, 127], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["pathogens", "OBSERVATION", 118, 127]]], ["In addition, the FFN is useful for determining whether the antibodies measured are providing a biological function of blocking virus infectivity.", [["FFN", "SIMPLE_CHEMICAL", 17, 20], ["FFN", "PROTEIN", 17, 20], ["antibodies", "PROTEIN", 59, 69], ["the FFN", "TEST", 13, 20], ["the antibodies", "TEST", 55, 69], ["blocking virus infectivity", "PROBLEM", 118, 144]]], ["Work is ongoing to further validate these assays on other sample matrices such as milk and colostrum for measuring passive transfer of antibodies and oral fluids for pen-based surveillance.", [["milk", "ANATOMY", 82, 86], ["colostrum", "ANATOMY", 91, 100], ["oral", "ANATOMY", 150, 154], ["milk", "ORGANISM_SUBSTANCE", 82, 86], ["colostrum", "ORGANISM_SUBSTANCE", 91, 100], ["oral", "ORGANISM_SUBDIVISION", 150, 154], ["antibodies", "PROTEIN", 135, 145], ["these assays", "TEST", 36, 48], ["other sample matrices", "TREATMENT", 52, 73], ["milk and colostrum", "TREATMENT", 82, 100], ["passive transfer of antibodies", "TREATMENT", 115, 145], ["oral fluids", "TREATMENT", 150, 161]]]], "PMC7482054": [["COVID-19 and the impacts on social protection and the labour market ::: IntroductionThe pandemic arrived with devastating effects.", [["COVID", "TEST", 0, 5]]], ["Data from the Ministry of Economy show a negative balance of more than 1 million formal jobs between March and April.", [["negative", "OBSERVATION", 41, 49]]], ["In total, there was an increase of 4.9 million in the numbers of unemployed persons.", [["persons", "ORGANISM", 76, 83], ["persons", "SPECIES", 76, 83], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["4.9 million", "OBSERVATION", 35, 46]]], ["Furthermore, until May 26, working hours and wages were reduced for 8.1 million workers under a special programme for the formal labour market.1 More than half of these labour agreements were for the complete suspension of employment contracts.COVID-19 and the impacts on social protection and the labour market ::: IntroductionThe official unemployment rate in May was 10.1%, slightly smaller than in January and February.", [["the formal labour market", "TREATMENT", 118, 142], ["COVID", "TEST", 244, 249], ["The official unemployment rate", "TEST", 328, 358], ["slightly", "OBSERVATION_MODIFIER", 377, 385], ["smaller", "OBSERVATION_MODIFIER", 386, 393]]], ["However, if we also take into account the contingent of people who couldn\u2019t search for a job specifically due to the pandemic (and the social distancing policies),2 that number rises to 25.4%.", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62]]], ["If there had not been any government assistance whatsoever, household per capita income would have dropped by R$66 (5.0%) and the poverty rate would have risen from 18.7 to 21.9% of the population (Barbosa and Prates 2020).COVID-19 and the impacts on social protection and the labour market ::: IntroductionThe Emergency Basic (EBI) Income Programme eased the impact on the average income of informal workers and the poorest families.", [["the poverty rate", "TEST", 126, 142], ["COVID", "TEST", 223, 228]]], ["However, situations of poverty involve a multitude of dimensions not fully captured solely by income: bad housing conditions, lack of access to public services, more exposure to violence and crime, insecure jobs, etc. These dimensions are not tackled by a short-term cash transfer.", [["poverty", "DISEASE", 23, 30], ["violence", "DISEASE", 178, 186], ["a short-term cash transfer", "TREATMENT", 254, 280]]], ["And the money received certainly does not make up for the deaths from COVID-19, greater among the poorest.", [["deaths", "DISEASE", 58, 64], ["COVID", "TEST", 70, 75]]], ["In other words, poverty rates, measured as income insufficiency, become less correlated to and an inadequate proxy for the real multidimensional poverty.", [["insufficiency", "DISEASE", 50, 63], ["poverty rates", "TEST", 16, 29], ["income insufficiency", "PROBLEM", 43, 63]]], ["We should also heed warning of the transient or temporary nature of these transfers: after the emergency benefit ends, we immediately return to the desolate scenario created by the pandemic.COVID-19 and the impacts on social protection and the labour market ::: IntroductionWhile the EBI is an essential measure, it leaves out a large share of the population located in the \u201cmiddle\u201d of the income distribution.", [["COVID", "TEST", 190, 195], ["large", "OBSERVATION_MODIFIER", 329, 334], ["population", "OBSERVATION", 348, 358], ["middle", "ANATOMY_MODIFIER", 375, 381], ["income distribution", "OBSERVATION", 390, 409]]], ["Some of these individuals are constantly transiting between formality and informality, going in and out of poverty: any static photograph would categorically place them on one side or the other (however, like Schr\u00f6dinger\u2019s cat, they live in a quantum superposition of states).", [["individuals", "ORGANISM", 14, 25]]], ["Another group is the category we call the \u201cnew vulnerable\u201d: formal workers who, under usual conditions (or even in crises), would not be at risk, but were hit hard by economic downturns and/or wage reduction agreements.COVID-19 and the impacts on social protection and the labour market ::: IntroductionAs a result, it is possible that this unprotected middle class has been enduring losses without any compensation.", [["COVID", "TEST", 219, 224]]], ["A possible counterintuitive consequence may be the reduction of income inequality: the economically impacted middle class becomes more similar to the poorest strata.", [["possible", "UNCERTAINTY", 2, 10], ["reduction", "OBSERVATION_MODIFIER", 51, 60], ["economically", "OBSERVATION_MODIFIER", 87, 99], ["impacted", "OBSERVATION", 100, 108], ["middle", "ANATOMY_MODIFIER", 109, 115]]], ["We have seen this happen before in Brazil in the early 1990s, albeit on a smaller scale.", [["a smaller scale", "TREATMENT", 72, 87]]], ["Inequality has always been a serious problem, but its solution cannot strive towards \u201cequality in poverty\u201d.COVID-19 and the impacts on social protection and the labour market ::: IntroductionThe consequences of the crisis will be felt for a long time.", [["a serious problem", "PROBLEM", 27, 44], ["COVID", "TEST", 107, 112], ["the crisis", "PROBLEM", 211, 221], ["serious", "OBSERVATION_MODIFIER", 29, 36]]], ["If we do not implement a minimum income policy, broader than the current Bolsa Fam\u00edlia, we run the risk of pushing a large share of people back into poverty and vulnerability: both those who had been temporarily shielded by the EBI, and the \u201cmiddle\u201d segment of the income distribution\u2014the old and the new vulnerable.COVID-19 and the impacts on social protection and the labour market ::: IntroductionIn any case, the EBI has had positive impacts on economic circulation, even amidst a pandemic.", [["poverty", "DISEASE", 149, 156], ["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138], ["COVID", "TEST", 316, 321], ["middle", "ANATOMY_MODIFIER", 242, 248], ["segment", "ANATOMY_MODIFIER", 250, 257], ["income distribution\u2014", "OBSERVATION", 265, 285], ["new", "OBSERVATION_MODIFIER", 301, 304], ["vulnerable", "OBSERVATION", 305, 315]]], ["Freire et al. (2020) argue that the benefit paid to the poorest population spreads, by way of consumption, to other families and income brackets\u2014meaning it generates economic momentum during the crisis and allows for the collection of consumption and production taxes, feeding back into public finances.", [["the crisis", "PROBLEM", 191, 201], ["production taxes", "TREATMENT", 251, 267]]], ["Without the EBI, Brazilian GDP would have plummeted even more in 2020.COVID-19 and the impacts on social protection and the labour market ::: IntroductionThe unavoidable need for social distancing to contain the disease sabotaged the ill-fated plans for growth and adjustment in 2020.", [["GDP", "CHEMICAL", 27, 30], ["GDP", "SIMPLE_CHEMICAL", 27, 30], ["COVID", "TEST", 70, 75], ["the disease", "PROBLEM", 208, 219]]], ["Furthermore, social isolation policies in Brazil were extremely uncoordinated between the central government and the states (Barberia et al. 2020).", [["social isolation policies", "TREATMENT", 13, 38]]], ["On the one hand, President Jair Bolsonaro has never admitted the seriousness of the pandemic and has openly boycotted social isolation measures, going as far as contradicting the recommendations of the Ministry of Health.", [["social isolation measures", "TREATMENT", 118, 143]]], ["On the other hand, state governors have adopted more or less erratic measures, depending on their political alignment with the president.COVID-19 and the impacts on social protection and the labour market ::: IntroductionAt the international level, the initiatives towards regional integration throughout the 2000s have been shattered by the new right-wing governments in Latin America, less prone to south\u2013south cooperation.", [["COVID", "TEST", 137, 142], ["shattered", "OBSERVATION", 325, 334], ["new", "OBSERVATION_MODIFIER", 342, 345], ["right", "ANATOMY_MODIFIER", 346, 351]]], ["Institutions created to reinforce and promote regional integration in the 2000s, such as CELAC (Community of Latin American and Caribbean States), are being left to their own devices (Prates and Lages [forthcoming]).", [["regional integration", "OBSERVATION", 46, 66]]], ["And Brazil, as the continent\u2019s largest country, played a central role in this process, which ultimately stalled coordinated efforts between countries and aggravated the spread of the virus in the region.", [["Brazil", "TREATMENT", 4, 10]]], ["On the Brazilian side, collective actions to tackle the pandemic have been negatively affected both internally (the central government does not coordinate with the states), as well as at the international level, thus clearly hindering their effectiveness.COVID-19 and the impacts on social protection and the labour market ::: IntroductionThe truth remains that Brazil has done very little to contain the pandemic, and the consequences are devastating.", [["COVID", "TEST", 255, 260], ["the pandemic", "PROBLEM", 401, 413], ["devastating", "OBSERVATION_MODIFIER", 440, 451]]], ["The death toll has reached far higher levels than necessary, even though Brazil\u2019s public health system is renowned worldwide for its breadth, capillarity, and competence to deal with similar situations.3 It is no accident that the country has been extremely successful in fighting HIV, malaria, and the Zika virus.", [["death", "DISEASE", 4, 9], ["malaria", "DISEASE", 286, 293], ["HIV", "ORGANISM", 281, 284], ["Zika virus", "ORGANISM", 303, 313], ["HIV", "SPECIES", 281, 284], ["HIV", "SPECIES", 281, 284], ["Zika virus", "SPECIES", 303, 313], ["The death", "PROBLEM", 0, 9], ["fighting HIV", "PROBLEM", 272, 284], ["malaria", "PROBLEM", 286, 293], ["the Zika virus", "PROBLEM", 299, 313], ["no", "UNCERTAINTY", 210, 212]]], ["However, by undermining the central role of doctors, specialists, and scientists, President Jair Bolsonaro has transformed the Ministry of Health into no more than an adjunct in the fight against the pandemic.COVID-19 and the impacts on social protection and the labour market ::: IntroductionReopening the economy is not a solution.", [["COVID", "TEST", 209, 214], ["a solution", "TREATMENT", 322, 332]]], ["Abandoning containment measures prematurely may result in even greater damage; not to mention more deaths, of course.", [["deaths", "DISEASE", 99, 105], ["Abandoning containment measures", "TREATMENT", 0, 31]]], ["Unfortunately, there is no magic bullet.", [["magic bullet", "PROBLEM", 27, 39], ["no", "UNCERTAINTY", 24, 26], ["magic bullet", "OBSERVATION", 27, 39]]], ["Extra domo nullasalus\u2014\u201coutside the home there is no salvation\u201d\u2014nor without basic income.The Pandemic and Beyond in Developing CountriesWe find ourselves in a unique opportunity to debate more solid basic income programmes; if not universal, at least broader.", [["Pandemic", "DISEASE", 92, 100], ["salvation", "PROBLEM", 52, 61], ["no", "UNCERTAINTY", 49, 51], ["Pandemic", "OBSERVATION", 92, 100]]], ["Income transfers focused solely on extreme poverty (such as Bolsa Fam\u00edlia in Brazil), disregards the income volatility that affects almost two thirds of the population\u2014a problem that has never been addressed by any social policy; a wound that reopens with each new instability.", [["wound", "ANATOMY", 232, 237], ["wound", "PATHOLOGICAL_FORMATION", 232, 237], ["a wound", "PROBLEM", 230, 237], ["each new instability", "PROBLEM", 256, 276], ["wound", "ANATOMY", 232, 237], ["new", "OBSERVATION_MODIFIER", 261, 264], ["instability", "OBSERVATION", 265, 276]]], ["However, the \u201cusual\u201d situation in middle-income countries\u2014such as Brazil, India, South Africa, and many other Latin American, African, and Asian countries\u2014remains deeply characterized by unjustifiable social ills, impelling us towards a permanent basic income.The Pandemic and Beyond in Developing CountriesA broader income programme, however, cannot replace other welfare and social policies\u2014especially health, education, and social assistance services provided by the State.", [["Pandemic", "DISEASE", 264, 272], ["Pandemic", "OBSERVATION", 264, 272]]], ["Otherwise, it would just mean a \u201cvoucherization\u201d of social protection.", [["social protection", "TREATMENT", 52, 69]]], ["On the contrary, it must be integrated into a broad social protection system to address the challenges imposed by the legacy of the pandemic, the impact of digitization on the labour market, and new forms of informality.The Pandemic and Beyond in Developing CountriesIn this regard, we emphasize the vertiginous growth of the so-called \u201cindependent workers\u201d all over the world.", [["Pandemic", "DISEASE", 224, 232], ["a broad social protection system", "TREATMENT", 44, 76], ["digitization on the labour market", "TREATMENT", 156, 189], ["informality", "PROBLEM", 208, 219], ["new", "OBSERVATION_MODIFIER", 195, 198], ["Pandemic", "OBSERVATION", 224, 232]]], ["Unlike traditional informal and autonomous workers, \u201cindependents\u201d undertake activities that are intermediated through the so-called on-demand platforms.The Pandemic and Beyond in Developing CountriesThe International Labour Organization (ILO) has consistently reiterated that the platform economy can negatively affect the realization of the Fundamental Principles and Rights at Work laid out in 1998.", [["Pandemic", "OBSERVATION", 157, 165]]], ["But neither the consumers nor the \u201corganizers\u201d of the platforms recognize a labour relationship that would imply accountability for the workers\u2019 social security.The Pandemic and Beyond in Developing CountriesThe effects of digitalization on labour and its regulation were already underway before the pandemic (Paus and Ford 2018).", [["Pandemic", "DISEASE", 165, 173], ["digitalization on labour", "PROBLEM", 223, 247], ["Pandemic", "OBSERVATION", 165, 173]]], ["Either way, the pandemic has unveiled potentialities but also limits to digitalization.The Pandemic and Beyond in Developing CountriesThe unfolding scenario for the post-pandemic world is fraught with uncertainties.", [["Pandemic", "DISEASE", 91, 99], ["The unfolding scenario", "PROBLEM", 134, 156], ["Pandemic", "OBSERVATION", 91, 99]]], ["However, we must acknowledge that the promotion of well-being inevitably calls for solutions that coalesce the previous challenges posed to the future of labour (ILO) with the potential social tragedy that the pandemic has in store for us.", [["solutions", "TREATMENT", 83, 92]]]]}